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“A chemist dabbling in his lab 
Felt his project was a little drab 
 
So embarked to discover fluorescent weed 
Citing a greater scientific need 
 
Soon had friends with glowing lips 
Funded his life on their grateful tips 
 
Checked his spectra, in disbelief 
When his friends got no relief 
 
He made an error in his reaction 
That gave his friends no satisfaction 
 
In desperation he hid away 
Improving his creation day by day 
 
His project done, his girlfriend’s plea 
Was to write it up as a PhD 
 
This is what I submit to you 
To read, to marvel, to hold as true” 
 
- A. S. Yates 
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Abstract 
 
An increased understanding of the peripheral cannabinoid receptor (CB2) is required 
due to the CB2 receptor’s emerging involvement in a number of disease states. New 
fluorescent technologies are capable of generating information about the CB2 receptor 
systems that has been unachievable us ing existing pharmacological methods i.e. 
radioisotope techniques.  
Our work, to develop fluorescently labelled CB2 receptor ligands, will provide 
cannabis researchers a unique pharmacological tool to use in conjunction with these 
emerging fluorescent technologies.  This will aid the understanding of cellular actions 
of cannabinoids and accelerate the discovery of novel CB2 selective drugs. 
We report on the design, synthesis, and biological evaluation of novel fluorescent 
ligands targeted towards the CB2 receptor. The fluorescent ligands were designed and 
synthesised by conjugating recognized high affinity selective CB2 ligands (JTE2-3, 
JTE2-6 & JWH015) to appropriate fluorescent dyes via a chemical linker. Positioning 
of the fluorescent dye upon the pharmacophore was guided using established SAR 
data and supplemented by in-house molecular modelling experiments. 
Our results showed that modification of JTE2-3 and JTE2-6 with dansyl and 
BODIPY fluorophores resulted in fluorescent ligands which displayed poor affinity 
to the CB2 receptor and consequently were unsuccessful when used in fluorescent 
confocal microscopy experiments.  Furthermore, our studies revealed important 
species selectivity, associated with JTE2-3, which was previously unrecognised. 
Using de novo drug design on JWH015, we synthesised and tested a 3-naphthyl 
modified fluorescent conjugate, 3-Gly-NBD-JWH015. The compound retained 
limited affinity to the CB2 receptor, but fluorescent confocal microscopy did not 
reveal specific receptor membrane binding.  Further experiments using 3-naphthyl 
precursor compounds, displaying less bulky 3-substituents, demonstrated that limited 
modification to the 3-naphthyl position of JWH015 was tolerated and provided a first 
insight to the SAR at this position. 
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1. Introduction 
 
There are currently a limited number of in-vitro assays available to study receptor-
ligand interactions. The techniques that are used, such as radioligand binding and 
reporter-gene assays, are not ideal due to the speed, cost and technical implications 
associated with these assays. We are interested in developing an emerging technique 
which can be used to study receptor- ligand interactions using fluorescent- labelled 
ligands. Fluorescent ligands with specificity towards GPCRs are promising to be 
extremely useful tools in the field of pharmacology and drug discovery1-3. They offer 
advantages to most of the problems associated with existing techniques; however few 
fluorescent GPCR ligands are known, which presently restricts the use of this 
technique. Our group is interested in studying the peripheral cannabis receptor (CB2), 
which is a member of the GPCR class of receptors. We aim to develop novel 
fluorescent ligands that act at the peripheral cannabis receptor (CB2), for use in both 
fluorescent-based biological experiments and in the screening of novel synthetic 
cannabinoids from combinatorial chemical libraries. Thus potentially providing data 
on both the cellular actions of cannabinoids and providing a tool to enhance the 
opportunity of discovering new selective cannabinoids. 
Cannabis and the active pharmacological agents acting at the cannabis 
receptors, the cannabinoids, have long been of interest to scientists who wished to use 
the compounds in alleviating suffering caused by human disease. From its beginnings 
as a crude preparation used in China 2000 B.C., through to its current clinical trials in 
the United Kingdom by the company GW Pharmaceuticals, the use of cannabis for 
medicinal purposes has long been the subject of controversy. Primarily, this has been 
the result of an association of cannabis with a ‘drug of abuse’, compounded by the 
lack of scientific data available on how cannabis elicits its effects. The recent 
discovery in 1993 of the peripheral cannabis receptor (CB2)4, which is unrelated to the 
psychoactive effects of cannabis, in conjunction with a general softening of societies’ 
attitudes to the use of cannabis*, has provided cannabis research groups a unique 
opportunity of providing quality scientific data and novel synthetic cannabinoid 
compounds which may provide relief to suffering patients.  
                                                 
* The licensing of UK clinical trials for cannabis medicines and the downgrading of cannabis to a class 
C drug under the Misuse of Drugs Act 1971 are viewed by the author as a ‘softening of attitudes’ 
towards the use of cannabis. 
 2
1.1 Fluorescent labelled ligands as a tool to study G-protein 
coupled receptors 
 
G-protein coupled receptors (GPCR) are widely expressed in the body and play a 
fundamental role in the physiology and the pathophysiology of disease (see section 
1.3.1 for further details of GPCRs). Agonists and antagonists towards the GPCRs are 
the most successful class of drugs, in terms of therapeutic benefit and commercial 
sales, with GPCR ligands accounting for 50% of the modern drug arsenal5, and 
approximately 9% of total global pharmaceutical sales worth $23.5 billion dollars in 
20006. An example of some of the best selling therapeutics targeted at GPCRs, 
demonstrating the diversity in receptors and indications that GPCR agonists and 
antagonists can be used to treat are shown in Table 1-1. 
 
Trade name 
(generic name) 
GPCR targeted 
Agonist or 
Antagonist 
Indication Company 
Claritin® 
(Loratidine) 
Histamine H1 Antagonist Rhinitis or allergy Eli Lilly 
Imigran™ 
(sumatriptan) 
Serotonin 5-HT1B/1D Agonist Migraine Glaxosmithkline 
Cozaar® 
(Irbesartan) 
Angiotensin AT2 Antagonist Hypertension Merck and Co. 
Serevent® 
(Salmeterol) 
β2 Adrenoreceptor  Agonist Asthma Glaxosmithkline 
Singulair® 
(Montelukast) 
Leukotriene BLT1 Antagonist Asthma Merck and Co. 
Table 1-1 Selection of the best selling therapeutics targeted at GPCRs in 2000. Adapted from reference 6 . 
 
Despite their importance as drug targets, techniques to investigate the pharmacology 
surrounding the ligand-receptor interactions are limited to studying the interactions of 
the receptor with radioactively labelled receptor-specific- ligands or analyzing 
‘downstream processes’ of receptor activation, such as reporter genes, GTP-γ-S and 
cAMP assays. 
Studying the receptor using a radioactively labelled ligand has been the 
primary and most established method for studying ligand-receptor interactions. Use of 
a 3H or 125I radioactive ligand specific to the receptor of interest can be used to 
determine the dissociation constant (Kd) of the radioactive ligand and the binding site 
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density (Bmax) when saturation binding experiments are used7. Alternatively 
competition experiments are capable of determining the equilibrium constant for a 
competitive inhibition of the receptor (Ki) when studying the displacement of the 
radiolabelled ligand by a non-radioactive ligand7. The technique can be extended to 
mapping the distribution of receptors in a section of tissue by using a technique called 
autoradiography (see section 1.3.4.1). Use of radioligand techniques suffer from a 
number of problems. The technique relies on equilibrium between free ligand and 
receptor bound ligand and is not capable of easily studying binding kinetics. 
Equilibration takes time to achieve and this is mirrored in the relatively long assay 
times associated with radioligand binding techniques. Separation of the bound and 
free ligand, using filtration or centrifugation, is another time consuming step in the 
assay, and finally the filtered matter (representing the bound ligand component) must 
be allowed to incubate with scintillation fluid long enough for the tritium to diffuse 
out and interact with the scintillator. Therefore the process of using a radioligand to 
study ligand-receptor interactions takes a significant amount of time which is a 
serious problem for users of this technique wishing to perform thousands (high 
throughput screening (HTS)) and up to a one hundred thousand (ultra highthroughput 
screening (uHTS)) assays a day screening new chemical entities for receptor 
affinity8,9. Finally the assay produces significant quantities of radioactive and 
flammable scintillation effluent which has an associated high cost for its disposal. 
Other techniques using radioactive reporter elements, such as intracellular cAMP and 
GTP-γ-S binding, are able to give information on the efficacy of a ligand upon 
binding to a GPCR. These techniques, specifically GTP-γ-S binding, have been 
developed into a HTS assay format i.e. Scintillation proximity assay (SPA) beads or 
Flashplates®10. However the technique still employs radioactive substances and 
suffers from sensitivity problems discussed in section 1.3.4.3.  
Development of non-radioactive, homogenous, miniaturized assays for 
GPCRs has been slow11. Recently, however, reporter-gene systems for the study of 
GPCRs have offered an alternative to biochemical and binding assays12. The reporter-
gene is a sequence of DNA whose product is synthesized in response to a cellular 
change occurring within the cell, i.e. an increase in cAMP. Examples of the reporter 
elements produced include enzymes, and Luciferase (a luminescing compound)12. By 
choosing the correct promoter and reporter elements the assays can; allow the ligand-
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receptor interaction to be studied and quantified in living cells, can elucidate 
signalling pathways associated with the receptor and can be used in HTS 
applications12. However the assays’ drawbacks are the need to stably transfect a cell 
line with the appropriate genetic code, and the 4-6 hour incubation required to express 
the reporter gene product12.  Therefore new techniques to study ligand-receptor 
interactions avoiding some of the problems stated above would be a welcome 
development in the pharmacology and HTS laboratories. 
The use of fluorescent ligands to study GPCRs interactions promises to be a 
valuable addition to the techniques discussed above in the field of pharmacology and 
drug discovery1-3. Fluorescence assays offer the advantages of high sensitivity, 
reduced sample volumes, low effluent disposal costs, fast assay times and an ability to 
detect a wealth of biological phenomena in a real time aqueous environment1-3,13. The 
development of fluorescent ligands with affinity towards a specific GPCR of 
emerging importance, the CB2 receptor (see section 1.3.4), will allow this system to 
be interrogated with all of the advantages fluorescence assays offer. 
1.1.1 Principles of fluorescence 
 
 Fluorescence is described as the emission of light energy as a molecule relaxes from 
an excited electronic state to a lower energy state14,15. A fluorescent dye is capable of 
absorbing a discreet package of energy (Eabs), in the form of electromagnetic 
radiation, which can promote an electron from the ground state (S0) up to a first 
excited singlet state (S1). The emission phase of fluorescence is represented by the 
loss of energy from S1 to S0 (Eem), typically over a lifetime of 10-8s. Due to loss of 
energy within the S1 state, via non-radiative pathways, the emitted fluorescence will 
be of lower energy and hence longer in wavelength than that of the electromagnetic 
energy absorbed. This phenomenon is described as the red or Stoakes shift and allows 
the user to detect the emitted light over the background of the light source used to 
excite the fluorescent dye14. 
Competing with emission is a number of other mechanisms which are capable of 
transferring the energy from S1 to S0 through non-radiative pathways. 
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• Internal conversion occurs from the S1 of one molecule to the S1 of another 
molecule. Quenching of fluorescence by this mechanism can occur over 
relatively long distances of up to 10 nM14-16. 
• Intersystem crossing involves the formation of a triplet state. Magnetic 
perturbations caused by environmental factors such solvent, paramagnetic ions 
and atoms with a large atomic radius (heavy atom effect) are capable of 
changing the direction of spin of the electron in S114. The resulting triplet state 
is of lower energy than the corresponding S1 and possesses a much longer 
lifetime (10-2-102 s)15. This stability makes it vulnerable to loss of energy 
through non-radiative processes such as collisions with solvent and the 
quenching of triplet states in the solution phase is always observed. 
• Photobleaching may occur in susceptible dyes if a high energy excitation 
light source (i.e. Laser) is used. The flurophore undergoes a chemical reaction, 
which is usually initiated from the triplet state and is free radical in nature, to 
yield a non-fluorescent product17,18. 
 
These quenching effects are measured as the fluorescent dyes quantum yield (q), and 
are important factors when choosing the fluorescent dye that will be conjugated to the 
biological ligand. Many of the sensitive fluorescent techniques used with fluorescent 
ligands are negatively affected if the dyes are subject to these quenching mechanisms.   
 
1.1.2 Fluorescent techniques 
 
We intend to use our novel fluorescent CB2 ligand in a number of different 
fluorescent applications which will be considered briefly below. 
 
1.1.2.1 Confocal microscopy 
 
Fluorescent labelled ligands have found use in confocal microscopy experiments 
reporting on biological functions such as intra-cellular binding events19, uptake 
mechanisms and subsequent cell storage20, and receptor localization, internalization 
and density measurements21-25. The optical principles are outside the scope of this 
report but for futher information readers are directed towards two excellent 
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references16,26. Confocal microscopy confers advantages over conventiona l wide field 
light microscopy by only reporting on a small percentage of the total fluorescence 
observed. Thus confocal microscopy is capable of providing information on thin 
slices (0.5 µm) of a cellular structure under investigation resulting in increased 
resolution compared to wide field microscopy whose depth of field is between 2-3 
µm16. An important consideration in designing fluorescent ligands for confocal 
application is that due to the optical principles behind the technique large excitation 
energies from laser sources must be used which can increase the photobleaching of 
the ligands used26. Visualization of fluorescent derivatives of the α1 adreno-receptor 
agonist prazosin21, the D1 dopamine antagonist SCH 2339022, the β-adrenorecptor 
antagonist CGP 1217723, the adenosine antagonist XAC24 and the adenosine agonist 
N6-aminobutyladenosine25 by confocal microscopy have been used by researchers to 
comment upon the localization, distribution and internalization of receptors at the 
single cell level. 
 
1.1.2.2 Single molecule detection 
 
Single molecule detection (SMD) is a term used to describe a number of different 
techniques, which are capable of distinguishing fluorescence bursts caused by a 
molecule of interest and background fluorescence. In contrast to bulk fluorescent 
techniques (such as confocal microscopy) which studies the average values generated 
from a system over time, SMD techniques are capable of studying fluctuating systems 
under equilibrium by generating very small detection volumes (sub-femtolitre (10-15 
L)) and using small concentrations of fluorophore (sub-nanomolar (<10-9 M))27,28. 
SMD is therefore an ideal approach to reducing the amounts of scarce and expensive 
materials used in biomedical research (such as enzymes, receptors, cells, solvent and 
ligands) which makes it a powerful tool in both biological assays and HTS28. 
There are several different methods for studying time-dependant fluorescence 
fluctuations and the following is a brief introduction concerning their application in 
studying fluorescent receptor ligands. 
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1.1.2.2.1 Fluorescence correlation spectroscopy  
 
The philosophy and experimental realisation of fluorescence correlation spectroscopy 
(FCS) was first published in the early 1970s29,30, but it is only recently through 
advantages in laser technology and confocal microscopy that the technique is gaining 
influence in biological chemistry28. The in-depth principles of FCS are outside the 
scope of this thesis and readers are directed to comprehensive reviews on this 
topic28,31,32. In brief, however, FCS is capable of generating information on the 
rotational and translational diffusion and the life time of the excited state of a 
flurophore by deciphering the random fluctuations of fluorescence observed using 
autocorrelation mathematics28,32. FCS can therefore give information upon the bind ing 
state of a fluorescent ligand without the need for physical separation. FCS has been 
used in conjunction with fluorescent derivatives of the 5HT3 receptor antagonist 
GR119566 to show the binding constants of the fluorescent ligand, the stoichiometry 
of the ligand-receptor interaction and the mass of a 5HT3 receptor 33. This 
methodology has also been used to demonstrate that 5HT3 receptors are found in 
different environments within a cell membrane34. It has subsequently been shown by 
our research group that the interactions of a fluorescent adenosine agonist and 
antagonist with the adenosine A1 receptor can be studied using FCS to provide data on 
receptor environment within the membrane 24,25. Taken together it is clear that FCS 
can provide useful biological information on receptor- ligand interactions occurring 
dynamically upon live cells when combined with a fluorescent ligand specific to the 
receptor being studied. The experimental conditions and the process of autocorrelation 
mathematics used in FCS demand that the fluorescent dyes used have a high quantum 
yield33, high photostability34, do not form triplet states easily33 and exhibit an 
emission wavelength which is far separated from the background cellular 
autofluorescence34. 
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1.1.2.2.2 Other single molecule detection techniques 
 
The application of other SMD methods for biological monitoring is beginning to be 
used; however most of these techniques have not yet been used with fluorescent 
receptor ligands to date. The following SMD methods have been reported to have the 
potential to be used to study ligand-receptor interactions using a fluorescent labelled 
ligand. 
 
• Dual colour fluorescence cross-correlation spectroscopy (DC-FCCS) is a 
technique designed to study two spectrally separated fluorophores (i.e. green 
and red dyes) interacting in the same confocal detection volume35. Thus, we 
can envisage labelling the CB2 receptor with Green Fluorescent Protein36 and 
labelling a CB2 ligand with a red fluorescent dye and detecting the binary 
species, as would occur in ligand-receptor binding. DS-FCCS confers 
advantages over FCS as the simplified data analysis of this technique allows 
for high confidence millisecond determination of a binary species, occurring 
within the detection volume making it highly suitable as a high throughput 
screening assay37,38. 
 
• Image correlation spectroscopy combines confocal scanning microscopy 
with FCS measurements. This method generates high-resolution images, 
which can be used to characterize a variety of cell features of both dynamic 
and structural nature. Thus, the numerical data extracted from FCS 
measurements can be overlaid onto a real image of the structure under study to 
allow easier interpretation of the data39. 
 
• Fluorescence intensity distribution analysis (FIDA) is a technique that 
discriminates between different fluorescent species according to their specific 
molecular brightness. It is a development of the analysis performed on the data 
from a classical FCS experiment. In classical FCS, the system under 
investigation requires large changes in the molecular weight of the 
fluorescence species to influence the observed diffusion coefficient (a 
doubling of the diffusion coefficient requires an 8-fold increase in molecular 
weight). The diffusion coefficient can then be used to determine parameters 
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such as bound versus unbound ligand concentrations. However the emission 
characteristics of the fluorophore can also change upon binding or when 
several ligands aggregate together giving rise to bright species which dominate 
the autocorrelation curves. These problems are overcome when using FIDA 
analysis, which is capable of distinguishing fluorescent molecules on the basis 
of their molecular brightness. FIDA analysis has been used successfully to 
study the binding of a fluorescent 5HT receptor ligand to an unspecified 5HT 
receptor over expressed in E. Coli 40. This method was capable of 
demonstrating that the addition of the high affinity 5HT1A ligands 8-hydroxy-
DPAT (agonist) and NAN-190 (antagonist) inhibited the binding of the 
fluorescent ligand, shown as a reduction in the number of “bright spikes” 
observed40. Thus, FIDA appears capable of generating “yes” or “no” decisions 
on whether an unlabelled ligand is capable of competing with a fluorescent 
ligand for occupancy at a receptor, something that is of great interest to 
researchers in high throughput screening laboratories looking to discover new 
receptor ligands. 
 
1.1.2.3 High throughput screening applications 
 
One of the main aims of this research was to design a fluorescent CB2 ligand which 
could be used in a fluorescent-based HTS assays, enabling screening of new lead 
compounds with affinity to the CB2 receptor. HTS is the primary engine driving lead 
discovery in most pharmaceutical companies and currently involves performing 
several million assays per year1. The testing of vast numbers of synthetic and natural 
compounds against a receptor target of therapeutic interest imposes great demands for 
both faster and smaller volume assays without compromising data quality1,11. SMD 
based HTS addresses each of these requirements by offering fast (0.2 – 0.4 seconds 
per scan) and low volume (often limited by liquid handling capabilities) assays, which 
are still capable of being highly sensitive and quantitative13,41. The low assay volume 
required allows cost savings on the amounts of test compounds, biological materials 
and solvent required for each assay. The non-radioactive nature of the tests also 
reduces the cost per assay due to the decreased cost of waste disposal. Various 
research groups have demonstrated SMD to be applicable to HTS1,13,33,37,38,40,42. 
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1.2 Cannabis 
 
Cannabis is a collective term for a series of preparations derived from the plant 
Cannabis sativa. There are many regional or colloquial names for the preparations of 
cannabis but the two most commonly referred to in the United Kingdom are 
marijuana and hashish (cannabis resin). Marijuana consists of the dried leaves and 
female flower heads and hashish is the plant secretions compressed into blocks. These 
preparations can either be heated and the vapour inhaled, or eaten to afford adsorption 
of the active pharmacological agents present within cannabis; the cannabinoids. 
The term cannabinoid was originally used to describe the family of 
approximately sixty, 21-carbon structures present within the preparations of cannabis. 
Of these, the most significant in terms of both quantity and psychoactive efficacy, is 
the compound ∆9-tetrahydrocannabinol (∆9-THC 1, Figure 1-1)43. Recently the term 
cannabinoid has been used to describe any compound that has activity at the cannabis 
receptors including synthetic and endogenous compounds. 
 
1.2.1 Historical overview of cannabis   
 
Cannabis, and hence, the cannabinoids have enjoyed a long history of use as a 
medicinal agent. Cannabis had its first entry in the worlds oldest Pharmacopoeia, the 
Chinese Shen-nung pen-ts’ao ching which was compiled in the first or second century 
A.D). The list of over 100 ailments which ma (cannabis) was used to treat includes 
many which cannabis is currently prescribed or undergoing clinical trials for i.e. anti-
emetic, pain relief, and rheumatism44. Following its first recorded use in China 
approximately 5000 years ago, cannabis has enjoyed many centuries of medicinal use; 
which have included the treatment of pain, asthma and dysentery, the promotion of 
sleep, the suppression of nausea and vomiting and the abolition of convulsions and 
spasms45. Within the United Kingdom doctors could legally prescribe cannabis until 
1971, and cannabis still had an official entry in the Pharmaceutical Codex until 1949. 
Cannabis cannot be introduced without considering its potential use as a ‘drug 
of abuse’. Although a thorough review of this subject is outside the scope of this 
work, the reader is directed to a review of cannabis misuse46. The fact that cannabis is 
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used as an intoxicating drug has been a factor in its prohibition as a medicinal agent. 
Within the United Kingdom cannabis is the most widely used of the illicit drugs with 
an estimated 1,503,000 users between 16-24 years old using the drug in 199947. 
Cannabis is used recreationally because of the euphoria it produces. The adverse 
physiological effects it produces include psychomotor and cognitive impairment, 
anxiety, panic attacks, acute psychosis and paranoia. In 1971 this led to its 
reclassification as a controlled drug, placing it within Schedule 1 of the Misuse of 
Drugs Act 1971 (drugs without therapeutic value), where it still remains today, 
hampering its use or evaluation as a medicine. 
A thorough scientific understanding regarding cannabis as a drug has only 
recently started to be compiled. The following discoveries have been fundamental to 
the current understanding of how cannabis exerts its pharmacological actions. 
 
• 1964 Gaoni and Mechoulam first elucidated the structure of the major 
psychoactive compound (∆9-THC 1, Figure 1-1) in cannabis resin43. 
• 1982 Pfizer Central Research synthesised and patented CP 55, 940 2 (Figure 
1-1)48. This compound demonstrated that the core three ring structure (A, B 
& C) of the natural cannabinoids could be simplified to two rings (A & C) 
and still retain potent cannabinoid pharmacology49.  
• 1990 Matsuda et al. provided the first definitive poof of a central 
cannabinoid receptor (CB1) by isolating the cDNA of a cannabinoid receptor 
from a rat brain and expressing it in Chinese Hamster Ovary (CHO) cells50. 
The central CB1 receptor has been shown to be responsible for the euphoric 
and psychotropic effects of  ∆9-THC 1 51. 
• 1991 Stirling Research Group discovered a new chemical class of 
cannabinoid ligand, the indole cannabinoids52. These compounds showed no 
chemical resemblance to the tri or bicyclic classical cannabinoids. The potent 
cannabinoid Win 55212-2 3 (Figure 1-1) was developed through this research 
program53.  
• 1992 Devane et al. isolated and characterised the first endogenous ligand to 
the cannabis receptor. Anandamide 4 (Figure 1-1) was extracted from the 
lipophillic fraction of porcine brain extracts and was shown to bind to 
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membranes derived from rat brain homogenate (the standard test for CB1 
receptor binding)54. 
• 1993 Munro et al. discovered a second cannabinoid receptor which was 
isolated from human myeloid cells4. The finding of a second cannabinoid 
receptor named the peripheral CB2 receptor was evidence that some of the 
beneficial therapeutic uses of cannabis are derived from a non-psychoactive 
pathway. 
• 1994 Sanofi introduced the first selective CB1 antagonist SR141716 5 
(Figure 1-1) which has proved a useful investigative tool into the in vivo and 
in vitro functions of the endogenous cannabinoid system55,56. Under the trade 
name Rimonabant® it is now under investigation as a drug in a number of 
medical conditions. 
• 1998 Sanofi introduced the first selective CB2 antagonist SR144528 6 
(Figure 1-1) which has proved to be a powerful tool in investigating the in-
vitro and in-vivo actions and effects of the CB2 receptor57. 
 
This selected chronology showing the major scientific discoveries associated with 
cannabis highlights that it has only been in the last decade that scientists have been 
able to relate cannabis pharmacology to two different receptor sub-types (CB1 and 
CB2), each capable of binding a diverse range of chemical ligands.  Researchers are 
now beginning to exploit this information in developing new treatment strategies for 
disease. It is envisaged that the addition of a fluorescent labelled ligand, selective to 
the CB2 receptor, will give scientists a new tool capable of exploring the less well 
characterized CB2 receptor, at a level of detail which is not available using current 
pharmacological ligands. The renaissance surrounding the use and testing of 
cannabis in the United Kingdom has arisen since positive recommendations towards 
medicinal cannabis were made in reports by the House of Lords select committee on 
Science and Technology58,59. The committee, after studying the available literature 
and taking statements from eminent scientists, were favourable towards medicinal 
cannabis as long as a careful scientific approach to its use was adopted.  A key 
conclusion from the 1998 report was that “clinical trials of cannabis for multiple 
sclerosis (MS) and chronic pain should be mounted as a matter of urgency”58; a 
reflection of the potential benefits that are being ignored by cannabis’s continued 
prohibition. 
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Figure 1-1 The chemical structure of a number of selected cannabinoid ligands. 
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This recommendation has led to both the Medical Research Council (MRC) and a 
privately owned company, GW Pharmaceuticals, being granted Home Office 
licenses enabling them to conduct a large clinical trial into cannabis based medicines 
for the relief of symptoms in MS and pain control. The full results of these trials are 
still awaited. However, GW Pharmaceuticals have already made their first 
submission to the UK’s regulatory authority, the Medicines and Healthcare Products 
Regulatory Agency (MHRA), for their standardised cannabis extract product 
Sativex® to be used in patients with MS and neuropathic pain60. 
One of the key reasons cannabis has returned to a status as a drug of medicinal 
value has been that quality scientific evidence, amassed by cannabis researchers over 
the last half a century, has become impossible for governmental bodies to ignore. 
However, further research into cannabis and its actions is essential, if cannabinoids 
are to find approval with politicians, regulatory authorities and the general public, as 
an effective therapeutic agent. 
1.2.2 Therapeutic use of cannabis 
 
Cannabis’s use as a “cure all” for nearly 5000 years has led to it being evaluated as a 
medicine in literarily hundreds of diseases. Thus, cannabis has been used as an 
analgesic, anti-spasmodic, anticonvulsant, anti-emetic and hypnotic throughout 
ancient China, the Middle East, Southern Africa and South America, and was still 
advocated up until the 19th century by eminent doctors such as W. B. O’Shaughnessy 
(the medic who discovered the pathology of Cholera) and Russell Reynolds (Queen 
Victoria’s personal physician)61. Indeed Reynolds wrote “Indian hemp, when pure and 
administered carefully, is one of the most valuable medicines we possess”62. 
In recent years the evidence base to support cannabis as a medicinal product 
has grown and the prospect of a cannabis-based product is now real. Following the 
House of Lords Committee report in 1998, cannabis trials are currently underway and 
reporting on the use of standardized cannabis preparations or synthetic ∆9-THC 1 
(Figure 1-1) for use in MS and pain. Cannabinoids have also been evaluated in a 
number of other conditions and the individual conditions that cannabis is currently 
being used for as a potential therapy will now be considered. 
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1.2.2.1 Multiple Sclerosis 
 
Multiple Sclerosis (MS) is the most common disabling nervous system disease of 
young adults, with an estimated 85,000 people suffering with the condition in the 
United Kingdom. MS is a progressive, degenerative disease, in which the brain and 
spinal cord nerves are damaged by the gradual destruction of myelin, the protective 
insulating layer of fatty tissue that normally coats nerve fibres. Although the precise 
cause of the disease is unknown, it is thought to represent an auto- immune condition 
whereby the body’s own defences attack and break down the myelin leading to the 
major symptoms of muscle spasticity (90%), urinary tract dysfunction (90%), tremor 
(80%) and pain (50%)63. Anecdotal reports of the beneficial use of cannabis to 
alleviate the suffering caused by MS have arisen primarily because individuals with 
MS constitute the biggest users of illicit cannabis for medicinal purposes64. Controlled 
clinical trials have tried to establish a product license for cannabis medicines by 
showing them to be efficacious and safe. 
A review of the literature up until 1997 indicates that there have been 15 
reported trials conducted into cannabis usage and MS 45. The total number of subjects 
in the trials however was extremely low; a total of approximately 174 people 
throughout all the trials. The trials broadly showed that cannabis was generally well-
tolerated and patients showed improvement in the subjective assessment of their 
symptoms, but did not show improvement in their objective assessment of spasticity 
and tremour.  A summary of the details and results of the three largest clinical trials 
are shown in Table 1-2. 
More recently two larger trials using orally dosed ∆9- THC 1 (Figure 1-1) or 
cannabis extract have also proved inconclusive in their support for use of cannabis 
based medicines in MS65,66. Both trials showed that there was significant 
improvement in subjective spasticity and pain but there was no significant difference 
when analysis of the objective assessment of disease markers, such as spasticity, was 
considered. In both trials cannabis side effects caused by the medication where rated 
as mild and well-tolerated. In summary, cannabis has not been shown to conclusively 
provide measurable benefit in MS when trialed in humans. However, patients did 
report a perceived benefit from the cannabis-based medicines, and many more 
regularly use illicit forms of cannabis to self-medicate. A major problem in the trials 
is that the ∆9- THC 1 or cannabis extract have been dosed orally. Cannabis absorption 
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from the gut is variable and slow and this is problematic when finding a correct dose 
within its small therapeutic window, which if exceeded, results in psychotropic side 
effects45. GW Pharmaceuticals appear to have overcome this problem by formulating 
the cannabis extract into a sublingual spray. Their medicinal product, Sativex®, is now 
awaiting regulatory approval for use in MS. 
Another approach to avoiding the psychotropic side effects of cannabis is to 
target the non-psychotropic CB2 receptor. It has recently been established that the 
peripheral cannabis receptor (CB2) is responsible for some of the therapeutic actions 
of cannabinoids in animal models of MS, possibly through an immunoregulatory 
pathway67-69. If this evidence of CB2 receptor involvement can be shown in human 
MS patients it would enable the development of a non-psychoactive therapy, targeted 
to the CB2 receptor, which may be suitable for long-term use. 
1.2.2.2 Analgesia 
 
Pain is one of the most common medical symptoms requiring drug treatment. 
Although the arsenal of analgesics available is extensive, there are certain painful 
conditions for which conventional analgesics fail to treat effectively. Chronic 
neuropathic pain arising from damage to neural tissue is usually unresponsive to 
established analgesic medication. A need for a new effective analgesic to combat 
neuropathic pain is therefore needed70. The results from trials involving pain are 
mixed. A systematic review by Campbell et al. of nine human trials involving 
cannabis as an analgesic concluded that cannabinoids are no more effective than 
codeine in controlling pain, but with the disadvantage of increased central nervous 
system (CNS) side-effects71. A summary of the three largest trials are shown in Table 
1-2. It was proven that ∆9-THC 1 and the synthetic cannabinoid levonantradol 7 
(Figure 1-1) had an analgesic effect, but at the expense of drowsiness and CNS side-
effects. The authors do however concede that new and effective agonists at the 
cannabinoid receptors could reduce the CNS side-effects and that these should be 
evaluated as an analgesic in neuropathic pain and spasticity. A recent discovery that 
the CB2 receptor is implicated in neuropathic pain pathways has made the idea of a 
cannabinoid analgesic, free from CNS side effects, more of a reality72,73. It is 
interesting to note that GW Pharmaceuticals product Sativex® is currently awaiting 
licensing for use in neuropathic pain. A recently published trial using Sativex® 
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showed that the sublingual formulation was able to significantly reduce pain in 
patients suffering from a mixture of intractable neurogenic symptoms when assessed 
by Visual Analogue Scoring assessment74. Although the cannabis treatment group had 
significantly increased side effects the authors concluded that these were generally 
well-tolerated. 
 
1.2.2.3 Nausea and vomiting 
 
Nausea and vomiting are the only indications that presently have a cannabinoid 
containing medicine available to patients. These are the orally administered synthetic 
cannabinoids Dronabinol (Marinol) and Nabilone 8 (Cesamet, Figure 1-1). 
Dronabinol is the trade name for synthetic ∆9-THC 1 and is licensed in the United 
States for nausea and vomiting associated with cancer chemotherapy and as an 
appetite stimulant to overcome the devastating cachexia often observed in AIDS and 
cancer patients. For a thorough analysis on the uses, efficacy and side effects of 
Dronabinol, readers are directed to the clinical review by Plasse et al.75.  
Nabilone 8 is a synthetic cannabinoid that was developed by scientists at the 
Eli Lilly Company, who were looking to modify the natural cannabinoids (i.e. ∆9-
THC 1) to have improved separation of the desired therapeutic effects from the 
psychotropic side effects. Although it still possessed a psychotropic side-effect 
profile, it was thoroughly tested in clinical trials and received a license in the United 
Kingdom for use in nausea and vomiting caused by cytotoxic chemotherapy 
unresponsive to conventional anti-emetics. A thorough review of the clinical trials 
involving Nabilone 8 was conducted by Ward and Holmes76. 
 
1.2.2.4 Appetite modification 
 
Anecdotal evidence and early published work on the effects of cannabis have reported 
that users show an increase in appetite77. Cannabis agonists such as ∆9-THC 1 
(Dronabinol, Figure 1-1) are used as an appetite stimulant and can significantly 
reverse the weight loss observed in cancer and AIDS, with 47% of the patients trialed 
reporting a subjective increase in appetite75.  Recent evidence has shown that the 
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endogenous cannabinoid system e.g. anandamide 4 (Figure 1-1) may tonically 
activate the CB1 receptor, maintaining food intake78. The same authors of this study 
showed that if the CB1 receptor antagonist SR141716 5 (Figure 1-1) was administered 
to mice it reduced their food intake. This has led the company, Sanofi-Synthelabo, to 
trial SR141716 5 (Rimonabant®), which is currently in worldwide phase III trials, as 
an anti-obesity agent. This is the first example that we are aware of where a cannabis 
antagonis t is undergoing a clinical evaluation and demonstrates that synthetic 
cannabinoids are beginning to find uses in clinical settings 
1.2.2.5 Other therapeutic areas 
 
Cannabis has also been evaluated as a medicine in a number of other disease states. 
For example, epilepsy, glaucoma, asthma, mood disorders and as a sedative. These 
conditions are likely to derive their benefit from activation of CB1 receptors, and there 
is no current evidence to suggest any CB2 receptor involvement and readers are 
directed to some excellent reviews on the trials already conducted45,61,79.  As the scope 
of this thesis wishes to examine the usefulness in directing research towards the 
peripheral CB2 receptor these therapeutic areas will not be examined in any further 
detail.  
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Reference 
77 
78 
79 
80 
81 
82 
Results
i 
Significant subjective improvement in spasticity 
at doses of 7.5mg ∆9-THC 1 and above, but no 
change in objective measurements of weakness, 
spasticity, coordination, gate or reflexes. Side 
effects in 12 patients on ∆9-THC 1 and 5 
patients on placebo. 
Cannabis impaired posture and balance in all 
subjects, causing greater impairment in MS 
patients. No other objective neurological 
changes but subjective improvement in some 
patients. “High” experienced with cannabis. 
Improvement in muscle spasms and pain, 
depression, tremor, anxiety, paraesthesiae, 
weakness, balance and constipation. No 
information on adverse effects. 
Significant pain relief with 15 and 20mg ∆9-
THC 1 compared to placebo. Drowsiness and 
mental clouding common 
∆9-THC 1 20mg and codeine 120mg gave 
equivalent and significant pain relief compared 
with placebo.  ∆9-THC 1 caused sedation and 
mental clouding. 
Significant pain relief with both doses of 
levonantradol 7 compared with placebo. 
Drowsiness common with levonantradol 7. 
Type of study 
Double blind, placebo 
controlled 
Double blind, placebo 
controlled 
Questionnaire survey  
Double blind, placebo 
controlled 
Double blind, placebo 
controlled 
Double blind, placebo 
controlled 
Drug and dose 
Oral  ∆9-THC 1 2.5-15mg 
once or twice a day 
Smoking cannabis. 1.54% 
∆9-THC 1  per cigarette 
single dose 
Smoking cannabis - dosage 
not known 
Oral ∆9-THC 1  5, 10, 15, 
20mg in random order 
Oral ∆9-THC 1  10 and 
20mg vs oral codeine 
Intra-muscular 
levonantradol 7 (a synthetic 
cannabinoid) 1.5-3mg 
Number of 
subjects 
13 patients with MS 
10 patients with MS 
10 normal controls 
112 patients with MS 
10 patients with cancer 
pain  
36 patients with cancer 
pain  
56 patients with post-
operative pain 
Indication 
MS 
MS 
MS 
Pain 
Pain 
Pain 
T
a
b
le 1
-2
 A
 sum
m
ary of som
e of the m
ajor hum
an clinical trials involving M
S
 or pain sym
ptom
s. i) sum
m
ary of 
results w
as taken from
 reference 45. 
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1.3 The cannabis receptors 
 
Two cannabis receptors have been identified and cloned, the central CB1 and the 
peripheral CB2 receptor 80. Both of these receptors belong to the larger super family of 
the Guanosine Binding Protein Coupled Receptors (GPCR). In order to appreciate the 
complexity and importance of the cannabinoid receptor, it is important to understand 
the nature and workings of the GPCR family to which it belongs. 
1.3.1 GPCR receptors 
 
The GPCR super family has a common protein structure embedded within the 
phospholipid membrane. The distinguishing feature of the GPCR is that the protein 
chain winds back and forth through the membrane seven times - hence GPCRs are 
also know as seven transmembrane (TM) receptors. The receptor comprises of 7 α-
helices that are lipophilic on their outside face, which transverse the lipid membrane, 
connected by intra-cellular and extra-cellular loops (Figure 1-2). The α helices are 
numbered from 1 (I) through to 7 (VII) and are clustered together in a barrel type 
structure. 
 
GPCRs are difficult to study at the molecular level due to their intrinsic association 
with the cell membrane. They are difficult to purify due to the reliance upon the lipid 
membrane encasing the receptor to stabilize their structure and hence cannot be 
crystallised. These difficulties have partially been overcome recently by using a 2.8 Å 
X-ray crystal structure of a related 7-TM protein called Bovine Rhodopsin (BR) as a 
template for the individual amino acid sequence of the GPCR81. Evidence that the 
crystal structure of BR is a satisfactory model for the GPCRs has been generated by a 
number of researchers82-84. 
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Figure 1-2 A cartoon description of a GPCR receptor. 
 
The 3D structure of the GPCR is important as it dictates how an external ligand 
interacts with the receptor and how the receptor translates this stimulus into a cellular 
event. Ligand binding to the GPCR can occur either in a deep binding pocket within 
the TM regions (type A); to the top of the TM regions (type B); or involve interaction 
with the extra-cellular loops (type C)85.  
When a ligand binds to the GPCR a cascade of events are initiated that result 
in a signal being passed from the extra-cellular surface to the intra-cellular domain 
where cell processes can be regulated. Upon activation with an agonist ligand the 
GPCR undergoes a conformational change allowing a membrane bound protein, 
called a G-protein, to bind to the receptor ligand complex. G-protein coupling is the 
first level in the signalling cascade (see Figure 1-3). The coupling event is able to 
propagate the signalling process due to the heterotrimeric structure of the G-protein 
which consists of three separate subunits (α, β , and γ). When un-coupled from the 
receptor the α subunit binds guanosine diphosphate (GDP 9, Figure 1-4). Upon ligand 
induced receptor coupling, the α subunit changes conformation and its guanyl binding 
pocket now preferentially binds guanosine triphosphate (GTP 10, Figure 1-4) instead 
of GDP 9.  The expulsion of GDP 9 by GTP 10 causes further conformational 
changes in the G-protein trimer and causes it to separate into an α subunit binding 
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GTP 10 and a βγ complex. The activated receptor- ligand complex is capable of 
activating several G-proteins in this way, leading to signal amplification. 
 
 
 
Figure 1-3 A cartoon description of the events following the agonist stimulation of a GPCR. 
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Figure 1-4 Guanyl nucleotide analogues GDP 9, GTP 10, and GTP-γ-S 11 
 
A further consequence of receptor activation of a GPCR, which adds to the difficulty 
in studying these receptors in any intimate depth, is the possibility that activation of 
the receptors leads to desensitisation or internalization, via the action of a cellular 
protein β-Arrestin86. As a consequence of this there may be decreased receptor 
availability or desensitisation of the receptor to the ligand, resulting in the reduction 
of the signal amplification process.  
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However for a functioning GPCR, activation yields both an α-GTP complex and a βγ 
complex which form the second level in the signalling cascade. The α, β , and γ 
subunits are not homogeneous in any single cell system. There are at least twenty 
different α (i.e. αs, αi/o, αq,), five β , and six γ subunits that have been described87. A 
receptor can only couple to certain G-proteins available within the cell, and thus 
activate specific α, β , and γ subunits exclusive to the receptor type.  It is the type of 
subunit which is activated that determines the cellular effect of the receptor. The 
effects of G-protein cell signalling is an extremely large field of biology and will not 
be explored in depth, instead readers are directed towards excellent reviews on this 
topic87-89. However an example will be given of the mechanisms by which the αi 
subunit affects cell function in-order that the reader has an understanding of the 
cellular actions of activation of the cannabinoid receptor which couples to αi/o G-
proteins (Gi/o)80,90. 
1.3.2 Gi/o Cell signalling 
 
The active αi/o subunit, formed, by the GTP 10 replacing bound GDP 9, has a finite 
lifetime in which it can carry out signalling duties91. This is due to an intrinsic 
GTPase activity of the α subunit which cleaves the terminal phosphate group of GTP 
10 generating GDP 9 which returns the α subunit to its inactive form in which it can 
recombine with a βγ unit to form the original trimeric G-protein (see Figure 1-3 and 
Figure 1-5). An interesting observation, that forms the basis of a functional GPCR 
assay, is that when synthetic GTP analogues, such as GTP-γ-S 11 (Figure 1-4), are 
present the GTPase function within the α subunit is unable to hydrolyse the guanyl 
analogue and the α unit is trapped in the active state 89 (Figure 1-5). Within the 
lifetime of its activation, the Gi/o protein is capable of eliciting a number of responses 
within the cell. The action of the α subunit with secondary effector systems has been 
studied in the greatest depth and it is these effects that will be considered further. Free 
βγ subunits are also emerging as possessing an important role in the cell signalling 
following GPCR activation but will not be considered in this report92. 
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The first discovered and most studied response of the αi/o subunit was its ability to 
inhibit the membrane bound enzyme Adenylate Cyclase (AC), which catalyses the 
conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate 
(cAMP). Thus activation of an αi/o protein leads to a decrease in the intra-cellular 
cAMP levels in the cell (Figure 1-6). The secondary messenger cAMP is responsible 
for the activation of another cellular enzyme, Protein Kinase A (PKA), which causes 
phosphorylation of further cell specific enzymes leading to a cellular response. The 
αi/o unit is also capable of attenuating ion channels located within the cell membrane 
causing an increase in K+ (via GIRK channels) and a decrease in Ca2+ entry  (via N-
type channels) into the cell 89,93 (Figure 1-6). This leads to a reduced neurotransmitter 
release through reduced intra-cellular Ca2+ and a hyperpolarized membrane potential 
resulting in a higher depolarizing stimulus required for the cell to “fire”. Thus the 
overall effect of activating a GPCR which is coupled to a Gαi/o protein is to apply a 
biochemical “brake” to the functions of the cell. 
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Figure 1-6 The main cellular effects of activation of a GPCR linked to an αi/o containing G-protein. 
AC adenylate cyclase, cAMP cyclic adenylate monophophate, PKA Protein Kinase A, MAP Mitogen-
Activated Protein, PLC Phospholipase C. 
 
1.3.3 The CB1 receptor system 
 
As the focus of our work is dedicated to the development of CB2 selective fluorescent 
ligands only a brief introduction, regarding the role of the CB1 receptor system will be 
given. Readers who wish to understand the CB1 receptor system in further depth are 
directed to two excellent reviews on the subject51,80.  The central cannabis receptor 
was the first cannabis receptor to be discovered in 199050. It is named the central 
receptor as it is mainly located within the central nervous system (CNS), although 
Northern blot analysis of CB1 mRNA has found evidence of the receptor in many 
peripheral tissues, including the heart, liver, kidney, spleen, small intestines, testes 
and ovaries51. The distribution of the CB1 receptor in the CNS is not homogenous and 
is most densely located within the cerebellum, basal ganglia, hippocampus, and the 
cerebral cortex80. The CB1 receptor is a type A GPCR receptor which couples to Gαi/o 
proteins leading to the expected cellular responses explained in section 1.3.2. (i.e. a 
decrease in cellular cAMP etc). The human CB1 receptor contains 472 amino acids94 
and the mouse and rat CB1 receptor contains 473 amino acids50,95. Overall these three 
receptors have a high amino acid sequence homology of between 97-99%.80. The 
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pharmacology of the CB1 receptors has been extensively studied. In-vitro assays can 
be performed on membrane homogenates derived from rat or mouse whole brain and 
on transfected cell lines expressing the CB1 receptor (human or rat). It is noteworthy 
to comment that when using a transfected cell line, the preparation will only contain 
the CB1 receptor, however this is not necessarily the case when using primary tissues 
that express dense populations of the CB1 receptor such as the brain. This is because 
the CB2 receptor, expressed on microglia73,96, and possibly a new type of cannabinoid 
receptor yet to be identified may also be present within the brain97. The different in 
vitro assays available for CB1 receptors are also the same tests used to investigate the 
CB2 systems and will be covered in section 1.3.4.3.  
The complex array of behavioral effects exhibited by the cannabinoids acting 
at the CB1 receptor have been characterized in numerous animal species, including 
humans. Drug discrimination tests, dog static ataxia, mouse tetradmodels and many 
others have been used in order to demonstrate the psychoactive effects of the CB1 
cannabinoids. Table 1-3 describes the main observations and outcomes of the in-vivo 
bioassays used in CB1 pharmacology. These assays are evidence that the CB1 receptor 
is responsible for the bizarre and complex psychoactive effects of the cannabinoids as 
blockade using the CB1 antagonist SR141716 5 negates the effect. 
It is notable that the bulk of the cannabinoid literature has focused ultimately 
on the CB1 receptor and its pharmacological responses51,80. This has been a result of a 
number of factors. Primarily since the discovery of ∆9-THC 1 in 1964 the activity of 
cannabis has been associated with the psychoactive effects it produces. With the 
discovery of the CB1 receptor in 1990 and its expression throughout the CNS, 
scientists were able to quantify the effects of cannabis to this receptor and much work 
was, and still is, being undertaken on this system. The discovery in 1993 of the CB2 
receptor gave scientists a new avenue of exploration in cannabinoid research. Since 
the discovery of the CB2 receptor, the literature has remained heavily biased towards 
the understanding and exploitation of the CB1 receptor. For example, an ISI Web of 
Science database search under the search terms “CB1” or “CB2” afforded results from 
1993-2003 of 1570 and 569 papers respectively†. This bias towards CB1 research is 
despite the fact that the CB1 receptor by its very nature gives rise to the detrimental 
                                                 
† Web of Science search (http:wok.mimas.ac.uk) conducted on 22nd December 2003  
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psychoactive side effects which have caused problems in the use of cannabis 
medicines as detailed in section 1.2.2. 
 
 
Name of 
test 
Description Observations 
Evidence of CB1 
receptor 
involvement 
Reference 
Dog static 
ataxia 
A range of 
cannabinoids and other 
CNS acting drugs are 
administered 
Psychoactive cannabinoids 
produce an effect where the 
dog weaves to and fro whilst 
remaining in one spot. This is 
not repeated when other CNS 
active drugs are used. 
SR141716 5 a potent 
CB1 antagonist blocks 
ataxia effects of ∆9-
THC 1. 
98 
Mouse 
tetradmodel 
A range of 
cannabinoids and other 
CNS acting drugs are 
administered. The test 
is also know as the 
Billy Martin test after 
the Professor who 
discovered the 
response. 
Psychoactive cannabinoids 
produce sedation, hypothermia, 
anti-nociception and catalepsy. 
Other CNS acting drugs 
produce these effects but not in 
the same dose range.  
SR141716 5 blocks the 
tetrad effect for most 
cannabinoids indicating 
CB1 involvement.  
99 
Rat drug 
discrimination 
Rats are trained to 
press a lever for a food 
reward when under the 
influence of a 
psychoactive 
cannabinoid (∆9-THC 
1 etc). They are then 
administered a range of 
cannabinoids and other 
CNS acting drugs. 
If fed an investigational drug 
that is perceived by the animal 
to be a psychoactive 
cannabinoid the animal pushes 
the lever to indicate this to the 
investigator. 
When rats trained on 
CP 55,940 2 or ∆9-THC 
1 were co-administered 
SR141716  5 and a 
psychoactive 
cannabinoid the lever 
pushing reaction was 
blocked. 
100 
Human assay Humans volunteers are 
administered 
cannabinoids and 
asked to rate how they 
feel under the 
influence of the drug 
(i.e using visual scale 
analogues) 
Pyscoactive cannabinoids such 
as ∆9-THC 1 were described as 
giving a“drug high”, getting 
them “stoned” and volunteers 
were able to assess the “drug 
strength” and distinguish 
placebo. 
Doses of 90mg of oral 
SR141716  5 produced 
∼40% reduction in the 
visual analogue ratings 
of the high experience 
using  inhaled cannabis. 
101 
Table 1-3 A summary of in vivo bioassays used to determine the activity of compounds at the CB1.  
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1.3.4 The CB2 receptor system 
 
The peripheral CB2 receptor was discovered in 1993 by Munro et al. 4 and is the 
second and last cannabinoid receptor discovered to date. Being the newest of the 
cannabinoid receptors the CB2 receptor system has been subject to less investigation 
than the CB1 system. However the CB2 system is emerging as an attractive target for 
drug therapy 102,103.  
The peripheral CB2 receptor was discovered by accident during work to 
identify novel GPCRs expressed in human myeloid cells (human promyelotic 
leukaemic line HL60). One of the receptors discovered was 44% homologous (rising 
to 68% in the transmembrane regions) to the previously discovered CB1 receptor4. 
The sequence identity although significantly lower than the usual 70-80% homology 
observed in other GPCR families, was enough to lead to the discovery of the second 
cannabinoid receptor. The receptor is mainly located in the peripheral cells of the 
immune system and has led to the speculation that the CB2 receptor is implicated in 
immunological control4,51,80. The cellular distribution (and the methods used to 
determine this) of the CB2 receptor will be discussed in section 1.3.4.1. Following its 
discovery in human tissue, the CB2 receptor has been cloned from the mouse 
(mCB2)104 and the rat (rCB2)105 106. The sequence homology between the mouse and 
human CB2 is only 82% and the homology between rat and human is lower at 81%105, 
or 57%106 in the more recent model. There is obviously a discrepancy between these 
two rCB2 receptor clones. The differences are believed to be derived from the 
different primers used in the Polymerise Chain Reaction (PCR) amplification step 
used to generate the cDNA. Griffin et al. generated a receptor that contained 360 
amino acids (the same number as in the human CB2 receptor and 81% homologous) 
which when cloned in Human Embryonic Kidney (HEK) cells bound the specific CB2 
antagonist SR144528 6, and other non-specific agonists (i.e. Win 55212-2 3 and ∆9-
THC 1) and showed a decrease in cAMP production upon agonist stimulation105. The 
other receptor generated by Brown et al. contained 410 amino acids ( and was 57% 
homologous to human CB2 receptor) and when transfected in CHO cells was 
stimulated by Win 55212-2 3 to produce an increase in MAP Kinase106 (Figure 1-6). 
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 They further demonstrated that their cloned receptor was expressed in native 
rat spleen. Brown explained the discrepancy between the two cloned rat receptors was 
due to Griffin using a PCR primer that was expressed from an intron piece of rat 
cDNA. As a result the receptor expresses 18 amino acids not actually present, and is 
missing 54 amino acids that arise from an exon piece of DNA located upstream. The 
disparity between the two rat sequences occurs in the carboxyl tail of the receptor 
which is not involved in ligand binding; hence both receptors are capable of binding 
cannabinoids. The carboxyl tail of the human CB2 receptor is involved in the process 
of receptor desensitisation through a mechanism of phosphorylation of a terminal 
serine residue (residue 352) promoting β  arrestin internalisation107. 
 From this observation it was noted that the rat receptor having a different 
carboxyl tail may act differently to the human receptor and researchers should be 
wary of extrapolating data from a rat model to human systems. Indeed, we report in 
chapter 5 that we found large differences in binding affinity between the rat and 
human CB2 towards a particular cannabinoid ligand. 
1.3.4.1 The distribution of the CB2 receptor 
 
The original work of Munro et al. assayed different organs of the rat for the CB2 
receptor and showed the presence of a cannabinoid receptor that was located on cells 
and tissues of the immune system. Their techniques involved Northern blot analysis 
of the mRNA expressed within a tissue and in-situ hybridisation of CB2 DNA. The 
hybridisation was achieved using a β  emitting radioactively labelled oligonucleotide 
(containing 35S-dATP) complementary to CB2 receptor DNA, followed by 
autoradiography (exposure of the tissue slice to a β  sensitive film). Both of these 
experiments showed that the CB2 receptor is located in the spleen; the 
autoradiography gave spatial information identifying CB2 receptors in the macrophage 
containing marginal zone of the spleen. Just after Munro et al. published their ground 
breaking work, Lynn and Herkenham published work confirming the presence of a 
cannabinoid receptor in multiple lymphoid organs of the rat immune system including 
the spleen108. The technique they used was to equilibrate a β  emitting radioactively 
labelled non-selective cannabinoid ligand [3H] CP 55,940 with a tissue of interest. 
The tissue was then subjected to autoradiography which highlighted areas of 
lymphatic tissue that bound CP 55,940 2 in a dose responsive and blockable manner. 
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The conclusion of their work was that binding was confined to organs that were rich 
in B lymphocyte cells i.e. the marginal zone of the spleen, lymph nodes and Peyers 
patches. These techniques and other similar published experiments106,109 are extremely 
useful in establishing the presence of the CB2 receptor and its location within a piece 
of tissue. However, in order to examine the location of the CB2 receptor on individual 
immune cells, fluorescent based immunocytochemistry experiments have been 
conducted96,110,111. In these experiments antibodies were raised in rabbits against the 
carboxyl terminus end (intra-cellular) of the rCB2 receptor (known as rabbit anti-rat 
CB2 antibodies). These antibodies were then labelled with a fluorescently labelled 
secondary antibody raised against the primary rabbit antibodies, and fluorescent 
confocal imaging (section 1.1.2.1) was used to visualise and quantify the CB2 
receptors (Figure 1-7). 
 
Figure 1-7 Immunocytochemistry to visualize the rat CB2 receptor. Cells are permeabilised to allow 
the large Mw antibodies to gain access to the intracellular side of the receptor. CB2 receptors are 
visualized by using primary antibodies raised against the rat CB2 receptor terminal carboxylic acid 
sequence (these antibodies are collected by injecting rabbits with a peptide sequence corresponding to 
the terminal carboxyl amino acid sequence) and secondary labelling using fluorescently conjugated 
antibodies raised against a rabbit. 
 
Using this immunocytochemistry approach Carayon et al. were able to identify that 
the CB2 receptor was located in tonsil tissue and was restricted to areas of the tonsil 
that expressed B-cells. They were also able to estimate (from the fluorescence per 
cell) that there were approximately two thousand CB2 receptors per B-cell110. Walter 
et al. demonstrated, using the same technique, that CB2 receptors were located in the 
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lamellipodia of activated microglial cells (an immune cell) of the CNS which was the 
first reported detection of CB2 receptors within the CNS96. It has been shown by both 
authors that the use of fluorescence visualization of the CB2 receptor can give much 
more detailed information on the location and abundance of the receptor than can be 
obtained using any other technique. 
The disadvantage of this technique is that the antibodies against the CB2 
receptor are difficult to produce. Rabbits must be injected with the carboxyl tail 
antigen for many months before they produce the CB2 receptor antibody. The other 
disadvantage of using antibodies is that they are large molecular weight 
immunoglobulins (IgG) and cells must be fixed and permeablised in-order for them to 
gain access to the carboxyl terminus of the receptor. Therefore the technique is unable 
to detect real time processes (such as receptor re- location or internalisation) in living 
cells. 
Our approach of designing a fluorescent ligand to the CB2 receptor would 
overcome these problems and would combine the same ease of  conducting an 
autoradiography experiment using [3H] CP 55, 940  “out of a bottle”,  with the 
sensitivity of immunocytochemistry experiments on living cells/tissue. 
Many different techniques have been used to determine the location of the CB2 
receptor. A summary of CB2 receptor tissue distribution is shown in Table 1-4 and it 
can be seen that the locations are exclusively cells and tissues involved in immune 
regulation. 
 
Cell type/Tissue Species Reference 
B lymphocytes Human 110,111 
Macrophages Human 111 
Microglia Rat 96 
Natural Killer cells Human 111 
Peripheral mononuclear cells Human 111 
CD4 lymphocytes Human 111 
CD8 lymphocytes Human 111 
Lymph nodes Human 111 
Peyer’s patches Rat 108 
Spleen Human, rat 4,108,111 
Tonsils Human 111 
Thymus Human 111 
Table 1-4 Location of the CB2 receptors in immune cells and tissues. 
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The immune distribution of the CB2 receptor has lead to its immunological effects 
being studied and will be discussed in the following section.  
1.3.4.2 Immune functions of the CB2 receptor 
 
Having established that the CB2 receptor is located on the cells and tissues of the 
immune system it is hardly surprising that many investigations into the immune 
effects of the cannabinoids have been conducted. It is outside the scope of this report 
to detail the exact mechanisms involved in CB2 immune regulation, other than to 
comment that many authors have concluded that the action of cannabinoids acting at 
the CB2 receptor induce changes in the levels of important signalling molecules. Thus 
cytokines (TNF-α, IL-2 etc), nitrous oxide and prostanoid production have all been 
shown to be attenuated by the action of cannabinoids and this results in downstream 
changes in immune function102,103. 
Three selected examples from the literature demonstrate the link between the CB2 
system and immune regulation. 
 
• CB2 knockout mice have been used to show that CB2 receptors are involved 
in immuno-regulation. It was demonstrated that the non-specific agonist ∆9-
THC 1 (Figure 1-1) inhibited helper T-cell activation in wild type mice, but 
did not inhibit T-cells derived from the CB2 knockout mice109.  
• Increased cytokine levels in human MS patients being treated with 
cannabis extract and ∆9-THC 1 has been reported112. The likely mechanism 
of action of cannabinoids in treating MS is via attenuating immune function 
(MS is an autoimmune disease – see section 1.2.2.1). A small study of 16 
patients demonstrated that cannabis based treatment significantly increased 
levels of TNFα and IL-12 in whole blood and plasma respectively compared 
to control. Although no direct involvement of the CB2 system was shown (i.e. 
using CB2 selective antagonists) it was suggested by the authors that changes 
in cytokine levels observed were due to cannabinoid activation of the CB2 
receptors located on immune cells112. This evidence is supported by other 
investigations using murine models of MS. These investigations show CB2 
selective agonists alter immune function by altering cytokine production, 
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immune cell recruitment and pathohistology, all dir ect markers in MS disease 
control68,69. 
• CB2 selective agonists are effective in reducing pain
72,113. The mechanism 
of action remains unclear but it is postulated that it is dependant upon the 
ability of CB2 agonists to alter inflammatory states, such as Nerve Growth 
Factor induced mast cell degranulation, neutrophil accumulation in 
inflammatory models113, and cytokine release from activated microglia in 
neuropathic pain73. This evidence is included to draw the reader’s attention 
towards a common problem – the lack of any definitive mechanisms available 
for CB2 mediated immune regulation. Both Zhang et al. 73 and Nackley et al. 
113 make reference to exploring the phenotype of cells expressing the CB2 
receptor as crucial to elucidating the mechanism of action. However “due to 
the low CB2 mRNA levels and the lack of specific CB2 antibodies, it is not 
possible to perform double labelling experiments to identify conclusively the 
phenotype of nerve injury- induced CB2 expressing cells”73. A selective CB2 
fluorescent ligand would allow researchers to achieve CB2 labelling and 
generate further evidence on the mechanism in which CB2 receptors 
participate in immune function. 
 
1.3.4.3 In-vitro bioassay systems    
A number of well established and defined in-vitro assays are available to test 
experimentally whether a compound has affinity and activity at the CB2 receptor. 
1.3.4.3.1 Binding assays 
 
The classical displacement binding assay is capable of determining to what degree a 
know concentration of a test compound is capable of displacing a know concentration 
of radiolabelled cannabinoid from a preparation containing CB2 receptors. The most 
widely used commercially available radiolabelled cannabinoid is [3H] CP 55, 940 
(Figure 1-13) and has approximately equal affinity for both CB1 and CB2 receptors (it 
is also the probe of choice in CB1 binding assays)80. It is noteworthy that there is no 
radiolabelled CB2 selective agonist or antagonist currently commercially available. 
Due to the unspecific nature of CP 55, 940 2 the membrane used for binding must 
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contain only CB2 receptors. For this reason the spleen (see 1.2.4.1) is chosen when 
using primary tissue or transfected cell lines can be used that express a specific 
species (i.e. rat or human) of CB2 receptor. Common cell types for this purpose are 
Human Embryonic Kidney (HEK)105,114 or Chinese Hamster Ovary (CHO) cells106. 
 
1.3.4.3.2 [
35
S] Guanosine-5’-O-(3-thiotriphosphate) binding 
 
The [35S] Guanosine-5’-O-(3-thiotriphosphate) ([35S] GTP-γ-S) bioassay exploits the 
coupling of CB2 receptors to G-proteins (section 1.3.1). It relies on the increase in G-
protein affinity for GTP 10 (and hence GTP-γ-S 11, Figure 1-4) that is triggered by 
agonist occupation of the CB2 receptors. The measured response is the net agonist-
stimulated [35S] GTP-γ-S 11 binding to the G-protein10. The assay, when investigating 
CB2 receptors, is performed on membrane homogenates from transfected cells (CHO 
or HEK) expressing high levels of receptor. GTP-γ-S 11  binding for the CB1 receptor 
can be performed on brain homogenate115 or using whole brain tissue sections (giving 
spatial information of receptor localization via autoradiography)116 to determine CB1 
receptor activation in primary tissue. However, there are no documented literature 
examples where spleen (or any immune tissue) membrane homogenate or tissue 
sections have been used to determine GTP-γ-S binding for the CB2 receptor in 
primary tissue. 
1.3.4.3.3 Inhibition of cyclic AMP production 
 
The decrease in cellular cAMP production can be exploited for the quantitative, 
functional bioassay of cannabinoids in-vitro51. CB2 receptor assays are performed 
using transfected cell lines expressing the CB2 receptor clone. Cells expressing CB2 
receptors naturally (e.g. mouse spleen cells and human lymphocytes) are relatively 
insensitive to cannabinoid induced inhibition of cAMP production80. 
 
1.3.4.3.4 Practical difficulties  
 
One practical difficulty in conducting assays using cannabinoid compounds is their 
high lipophillicity and low water solubility. As such compounds first have to be 
dissolved in either ethanol or dimethyl sulphoxide (DMSO) to give a stock solution, 
which can be diluted in the final aqueous test solutions containing Bovine Serum 
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Albumin (BSA) which acts as a solubilising agent and reduces non-specific binding of 
the cannabinoids. 
1.3.4.4 Therapeutic indications of the CB2 receptor 
 
As previously discussed in section 1.2.2 the CB2 receptor has emerging importance in 
a number of disease states. These disease states and the evidence of CB2 involvement 
will be briefly introduced. 
 
1.3.4.4.1 Pain 
 
It is well documented that cannabinoid agonists exert antinociceptive effects (section 
1.2.2.2 and Richardson et al.117). The majority of these effects are thought to be 
mediated by CB1 receptors as the effect can be blocked by CB1 selective 
antagonists117. Recently, new experiments have shown that analgesic nociception is 
additionally mediated via CB2 receptors. Mice deficient in CB1 receptors display a 
hypoalgesic state when treated with ∆9-THC 1 (Figure 1-1)118 and the analgesic 
effects of the endogenous cannabinoid ligand Palmitoylethanolamide can be blocked 
using the CB2 selective antagonist SR144528 6 (Figure 1-1)119. The work on CB2 
participation in pain control has recently been accelerated by the discovery of the 
selective CB2 agonist AM1241 58, (Figure 1-21). This agonist has been demonstrated 
to inhibit experimental neuropathic pain (spinal cord ligatures)72,73, and experimental 
inflammatory pain (carrageenan evoked thermal and mechanical stimuli)113,120 without 
producing the problematic CNS effects associated with non-specific cannabinoids120. 
 
1.3.4.4.2 Multiple Sclerosis 
 
As discussed in chapter 1.2.2.1 cannabinoids are being trialed for the treatment of 
multiple sclerosis (MS). Two recent discoveries have indicated that by selectively 
targeting the CB2 receptor system disease symptoms and underling pathology may be 
controlled. The debilitating symptoms of MS, such as tremor and spasticity, were 
shown to be decreased in an autoimmune disease model of MS by using the CB2 
selective agonist JWH 133 27 (Figure 1-12)121 and increased when the animals were 
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treated with SR144528 6 (which indicated that the endogenous cannabinoid system 
has tonic activity in MS)67. Using a different autoimmune model of MS, Arévalo-
Martin et al. demonstrated that the selective CB2 agonist JWH015 53 (Figure 1-21)122 
was able to significantly improve neurological defects in a long lasting manner69. 
Improvements in the neurological defects observed were mirrored in an improvement 
in motor function. 
1.3.4.4.3 Immunomodulation 
 
The location of CB2 receptors on immune cells combined with evidence that 
cannabinoids can suppress the immune system serve as strong indicators that they 
may be a useful target for novel immunomodulatory drugs103. Direct evidence of non-
specific cannabinoids (i.e. ∆9-THC 1) causing immunosuppression has been 
demonstrated by the increased susceptibility towards the herpes simplex virus in 
mice123,124. Whilst susceptibility to herpes virus is not a positive effect, there are many 
disease states that do require management using immunosuppressive therapy e.g. 
rheumatoid arthritis, psoriasis, organ transplant patients etc. Recent evidence has 
shown that the CB2 receptor can be targeted to give clinical effects of 
immunosuppression. A key paper that demonstrated the link between immune 
regulation and CB2 receptors described the use of CB2 receptor knockout mice 
previously discussed in section 1.2.4.2. The use of CB2 selective ligands for 
investigating clinically relevant immune regulation has been lacking. However, 
Iwamura et al. has recently shown that the CB2 selective ligand JTE 907 66 (Figure 
1-22) and SR144528 6 were capable of reducing the swelling associated with 
carrageenan- induced mouse paw edema in a dose dependant manner125. Furthermore 
many of the patents protecting novel CB2 selective ligands are purported to be useful 
as anti- inflammatory, anti-allergic and immunoregulator agents126-129.  
 
1.3.4.4.4 Cancer 
 
Following the discovery that anandamide 4 inhibits the proliferation of human breast 
cancer cell lines in vitro, via a CB1 receptor mediated mechanism130, researchers have 
become interested in exploiting cannabinoids as novel anticancer agents. The first 
reported CB2 mediated anti-tumor activity was reported by Sánchez et al.131. They 
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were able to show that the highly aggressive glioma tumor could be inhibited by intra-
tumourally administered JWH 133 27 (Figure 1-12), and this effect was blocked by 
SR144528 6 but not by SR141716 5. They also demonstrated a correlation of the 
severity of biopsied human tumours with CB2 receptor expression within the tumor, 
using immunofluorescence techniques discussed in 1.3.4.1. The authors comment that 
that the CB2 receptor might serve as a diagnostic marker of glial cell 
proliferation/malignancy. Hence any fluorescent ligand generated via our own 
research could be evaluated for this role. Further work using the selective CB2 agonist 
JWH015 53 (Figure 1-21) in treating cancers of the immune system (i.e. leukemia and 
lymphomas) has shown that it was effective at causing significant apotosis in these 
immune cell lines132. The non-specific agonist  ∆9-THC 1 (Figure 1-1), which also 
caused apotosis, was partially blocked by the co-administration of SR144528 6 
(Figure 1-1) adding evidence that the effect was mediated at least partially via CB2 
receptors. Others have demonstrated that the over expression of the CB2 receptor in 
leukemic cell lines acts as an oncoprotein and postulate that further work into the role 
of the CB2 receptor may open new ways into the treatment of acute myloid 
leukemia133. Although the evidence is sparse and the mechanisms unclear the 
potential of the CB2 receptor mediated anticancer actions is an area worthy of further 
exploration. 
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1.4 Ligands for the cannabis receptors 
 
In considering a suitable CB2 selective ligand that can be successfully labelled with a 
fluorescent dye it is necessary to consider the cannabinoids that already exist, and 
review them in terms of their suitability for conjugation with a large molecular weight 
fluorescent dye. The final construct should also retain a high affinity to the CB2 
receptor, retain selectivity towards the CB2 over the CB1 receptor, and be chemically 
suitable in terms of the conditions employed in the in-vitro biological environment. 
The consideration for the fluorescent dye will be considered in section 2.2.4. 
 
 
To fit these criteria the CB2 selective ligands were considered for their following 
properties. 
 
• High affinity towards the CB2 receptor (i.e. Ki ≤ 20 nM) 
• High CB2/CB1 selectivity (≥ 20) 
• Chemically stable to hydrolysis, light and enzymatic degradation 
• Structure Activity Relationship (SAR) that provides evidence that the ligand 
can tolerate molecular extension and bulky substituents 
• Structure that allows its synthesis outside the Misuse of Drugs Act 
 
There are a number of different chemical types of ligands that have affinity towards 
the cannabinoid receptor and some of these chemicals have been mentioned 
previously (1 –8, Figure 1-1). For the purposes of this review it is useful to segregate 
cannabinoids into one of five chemical classes using a method modified from 
Khanolkar et al.134 which is illustrated in Figure 1-8 using some examples of drugs 
already discussed. 
For each class of compound the principal ligands will be introduced, general 
SAR will be discussed and the CB2 selective ligands will be considered in greater 
detail with a view for modification with fluorescent dyes. For a more thorough review 
of CB1 selective ligands cannabinoid readers are directed towards some excellent 
review articles134-140. 
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Figure 1-8 Chemical classes of cannabinoids showing the numbering systems employed.  
 
1.4.1 Nomenclature    
 
The naming of cannabinoid compounds can be extremely confusing, as often 
historical trivial names are used over the systematic IUPAC‡ names and many of the 
chemical ligands with biological activity are known by codes (i.e SR144528 6) given 
by their discovering inventor/company.  
The naming of compounds in this report will use the common trivial and code 
names most often found in the majority of the scientific literature, as even the IUPAC 
itself concedes that trivial names “…are useful, and in many cases indispensable”141. 
Some examples of the complexity of the systematic name and their trivia/code name 
equivalent are given in Table 1-5. 
 
 
                                                 
‡ International Union of Pure and Applied Chemistry. 
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Trivial/code name IUPAC name 
∆9-THC 1 
(6aR)-6,6,9-trimethyl-3-pentyl-(6ar,10at)-6,7,8,10a -tetrahydro-6H-
benzo[c]chromen-1-ol 
Win 55212-2 3 
(R)-(+)-{2,3-dihydro-5-methyl-3[(4-morpholinyl)methyl]pyrrolo(1,2,3-de)-1,4-
benzoxazin-6-yl}(1-naphthalenyl)methanone 
 
SR144528 6 
N-[(1S)-endo-1,3,3-trimethyl bicyclo[2.2.1] heptan-2-yl]-5-(4-chloro-3-
methylphenyl)-1-(4-methylbenzyl)-pyrazole -3-carboxymide 
 
Table 1-5 Examples of trivial and code names and their systematic equivalent. The systematic name 
was obtained by searching for the structure of the compound in the Beilstein  database BS0304AE and 
using the systematic IUPAC name found. 
 
The similarity between abbreviated coded names only relates to the discovering 
inventor/company and not to the chemical or pharmacological class of compound. 
Thus JWH015 (53, Figure 1-21) is a member of the indole class whilst JWH133 27 
(Figure 1-12) is a member of the classical cannabinoid class. Similarly SR141716 5 is 
a CB1 antagonist whilst SR144528 6 is a CB2 antagonist. A list of the common 
abbreviations and their origins are given in Table 1-6. 
 
 
Abbreviation AM CP HU JTE JWH O SR Win  
Description 
Alexandros 
Makriyanis, 
University 
of 
Connecticut, 
Storrs, USA 
Central 
Pfizer 
Hebrew 
University, 
Jerusalem, 
Israel 
Japan 
Tobacco 
Inc. 
Japan 
John W. 
Huffman, 
Clemson 
University, 
South 
Carolina, 
USA 
Organix 
Inc. USA 
Sanofi 
Recherche. 
Later Sanofi 
Winthrop now 
Sanofi- 
Synthelabo 
Stirrling 
Winthrop Inc. 
 Later Sanofi-
Winthrop now 
Sanofi-
Synthelabo 
Table 1-6 Common abbreviations used to name cannabinoid compounds and the explanation of the 
abbreviation.  
 
The numbering of cannabinoid compounds is shown in Figure 1-8 and is used as an 
important descriptor when describing the SAR of a compound. In this report a semi 
systematic approach is taken when dealing with derivatives of known compounds. For 
example the addition of a nitro group to the 3’ of Win 55212-2 3 would result in a 
compound named 3’-nitro-Win 55212-2 12 (Figure 1-9). 
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3'-nitro-Win 55212-2 12  
Figure 1-9 Example of a semi-systematic approach to nomenclature 
  
Finally in cannabinoid medicinal chemistry a term which is frequently employed in 
the literature and within this report in discussing compounds, is the notion of North 
(being at the top of the page) and South (being at the bottom of the page) to describe 
certain functional groups or ring systems within a compound. Thus in CP 55, 940 2 
(Figure 1-13 A) the secondary hydroxyl at position 1 is known as the North Aliphatic 
Hydroxyl (NAH) and the primary hydroxyl terminating the propyl chain is known as 
the Southern Aliphatic Hydroxyl (SAH)137. 
1.4.2 Classical cannabinoids 
 
The classical cannabinoids (CC) are based around the core tricyclic dibenzopyran 
structure, shown by the rings A B and C of ∆9-THC 1 (Figure 1-10). Other common 
examples of CC compounds include ∆8-tetrahydrocannabinol (∆8-THC 13) and 
HU210 14 (Figure 1-10). 
 
O
OH
O
OH
O
OH
HO
∆9-THC 1 ∆8-THC 13 HU210 14
               CB1 receptor       35 - 80                                      47                                         0.06 - 0.73
Ki (nM)
               CB2 receptor        4 - 75                                       39                                         0.17 - 0.52
AB
C
 
Figure 1-10 Structures of common classical cannabinoids and their Ki values (or ranges of Ki values 
reported)80. 
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These CC are not selective ligands and show nanomolar affinity to both CB1 and CB2 
receptors. Researchers concur that the SAR of  the CC can be dealt with by 
considering three key sites upon the pharmacophore80,137,138. 
 
• The C3 alkyl side chain domain. 
• The C1 phenolic group domain. 
• The C9 methyl group domain. 
 
Each will be considered separately with particular reference given to modifications 
that increase CB2 affinity or involve a large bulky subsistent (mimicking a fluorescent 
dye). It should be noted that analogues of ∆8-THC 13  will be considered due to their 
ease of synthesis and enhanced stability relative to their ∆9-isomers142 which is an 
important consideration when extrapolating the data for intended synthetic purposes. 
 
1.4.2.1 The side chain  
 
The hydrophobic alkyl side chain is a key pharmacophore in the CC.  An alkyl chain 
of between 3 to 7 carbon units is required for activity138. The addition of dimethyl 
groups (located at position (1’,1’) or (1’,2’)) on a heptyl chain is optimal for overall 
activity, although no selectivity between CB1 and CB2 receptors is gained143. This is 
clearly demonstrated in the case of 3-(1’,1’-dimethylheptyl)-∆8-THC 16 where the Ki 
falls from 22 to 0.49 for the unsubstituted heptyl compound 15 at the CB1 receptor144 
(Figure 1-11). Other approaches to modify the side chain are detailed below and in 
Figure 1-11. 
 
• Halogenated alkyl chains , such as a 5’- iodopentyl chain 17 have led to 
modest increase in affinity to CB1 receptors145. 
• Unsaturated bonds and 1’ substituents have been used to conformationally 
define the alkyl chain. Thus, Papalatis et al. have shown that dithiolane at 1’ 
18, and later a 1’cyclopropane derivative of 3-heptyl-∆8-THC increased the 
affinity to both the CB1 and CB2 receptors but showed no enhancement of 
selectivity.146,147. Dithiolane at position 1’ also increased affinity to the 
cannabinoid receptors when pentyl derivatives of ∆8-THC were assessed148. 
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Although the derivatives were synthesised to impart rigidity to the side chain, 
the increased cannabinoid affinity observed maybe due to 1’ steric bulk 
interacting with a binding domain present within both receptors147. 
• Constraining the side chain, using two or three carbon bridges to lock C1’ or 
C2’ of the side chain to C2 or C4 of the  phenolic ring, lead to a decrease in 
activity at both CB1 and CB2  receptors and gave no selectivity towards either 
receptor149,150. 
• Replacement of the alkyl chain with bulky cyclic groups  has been 
demonstrated to increase receptor affinity, whilst producing a moderate 
increase in CB2 selectivity148,151. Use of a cycloheptyl group 19148 or a phenyl 
group 20151 gave a 4 fold and 13 fold selectivity towards the CB2 receptor 
respectively. 
 
In conclusion, side chain manipulations often result in compounds with enhanced 
affinity towards both cannabinoid receptors. The most promising modification, with 
respect to finding a lead compound with CB2 selectivity, incorporates a bulky 
substituent (mimicking a fluorescent dye), comes from compounds 19 and 20. 
However, to date only simple hydrocarbon groups have been evaluated and not larger 
heterocycles (of which most fluorescent dyes are chemically similar to – section 
2.2.4), and the resulting CB2 selectivity is not as large as would make the compounds 
useful for our purposes. 
 
1.4.2.2 The phenolic group 
 
Use of the 3-(1’,1’-dimethylheptyl) group provides the “magic bullet”137 for 
improving receptor affinity and therefore the majority of phenolic modifications have 
been conducted upon 1’,1’-dimethylheptyl-∆8-THC 15 analogues.  
Until recently it was thought that the phenol group at C1 was essential for 
cannabimimetic activity80. It is now accepted that the phenol group can be removed 
(in 1-deoxy analogues) or masked as the ether/ester and still retain an affinity towards 
the cannabinoid receptors, often with increased affinity towards the CB2 receptor137. 
Gareau et al. demonstrated that the 1-methoxy and 1-deoxy analogues of 1’,1’-
dimethylheptyl-∆8-THC (21 & 23, Figure 1-11) displayed less affinity to the 
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cannabinoid receptors but enhanced selectivity towards the CB2 receptor (1-methoxy 
21 Ki CB1=16 µM & CB2=20 nM and 1-deoxy 23 Ki CB1=250 nM & CB2=21 nM)144. 
Larger groups such as the diacetoxyphosphate ester 22 (Figure 1-11) however lowered 
the affinity at the CB2 receptor. At around the same time Huffman et al. reported that 
1-deoxy versions of HU210 14 and 3-(1’,1’-dimethylheptyl)-∆8-THC 15 also 
exhibited CB2 selectivity. Further work by, Song and Bonner, and Huffman et al., 
used 3D molecular modelling to postulate that the residue Lys192, present in TM 3, of 
the CB1 receptor forms important interactions with the phenol group present in CC 
and non-classical cannabinoids (section 1.4.3) and if this residue is mutated, or the 
phenol group is removed or masked, then the binding to the CB1 receptor is 
reduced152,153. The analogous lysine residue in the CB2 receptor (Lys109) has been 
shown by mutational analysis not to be involved in important interactions with the 
phenolic group of the CC and hence the compounds still show high affinity to this 
receptor154. The application of modifying the phenol group to produce selective CB2 
ligands will be discussed in 1.4.2.4. Modifications to the phenol group introducing 
bulky substituents have been published155. Derivatives of ∆8-THC include biphenyl 
24, aminoalkyl chains 25 and morpholinoalkyl ethers 26 (Figure 1-11). Work was 
carried out in 1991, before existence of the CB2 receptor was confirmed and hence the 
compounds were assayed only against the CB1 receptor (using rat brain homogenate). 
All of the compounds suffered large decreases in binding affinity with EC50 
(concentration of compound capable of displacing 50% of the radiolabelled CP 55, 
940 2) in the µM range. To the best of our knowledge the compounds have never been 
assayed in CB2 receptor assays.  
 
1.4.2.3 The 9-methyl group 
 
The main observation relevant to this report is that when the 9-methyl group present 
in ∆9 or ∆8-THC is oxidized to the hydroxymethyl group (as occurs during human 
metabolism of ∆9-THC 1)  the affinity of the resulting compound is increased80. The 
most common demonstration of this effect is with the compound HU210 14 (11-
hydroxy-(1’,1’-dimethylheptyl)-∆8-THC). 
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Figure 1-11 SAR of ∆8-THC analogues modifying the C1, C3 and C9 position. Abbreviations - a ref. 
80 b ref. 156 c ref. 144 d ref. 134 e ref. 146 f ref. 148 g ref. 151 h ref. 155 ND not determined. 
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It incorporates the “magic bullet”137 of the 1’, 1’ dimethylheptyl side chain and gains 
increased affinity to both the CB1 and CB2 though the hydroxyl group at C11 (range 
of reported Ki CB1 0.06-0.73 & CB2 0.17-0.52 nM)137. Further oxidation of the 
methylene to the aldehyde abolishes all cannabinoid activity137. 
 
1.4.2.4 CB2 selective classical cannabinoids 
 
The work generated by Gareau et al. and later by Huffman et al. showed that ∆8-THC 
analogues devoid of a C1 phenol group led to compounds with high CB2 selectivity 
and good CB2 affinity144,153. The compound 3-(1’,1’-dimethylheptyl)-1-methoxy-∆8-
THC (L759633, 21) (Figure 1-11 & Figure 1-12) displayed the best CB2 profile with a 
Ki of 15850 & 20 nM at CB1 & CB2  respectively144.  The actual Ki and large 
selectivity shown by L759633 21, has been disputed by other authors, where lower 
CB2 affinity and selectivity have been reported (Ki CB1 941 & CB2 65 nM121 and Ki 
CB1 713 & CB2 57 nM157), however they have all demonstrated that it was CB2 
selective compound.  
Work by Huffman and co-corkers to further exploit these findings led them to 
synthesise a number of 1-deoxy-(1’,1’dimethylalkyl)-∆8-THC analogues to explore 
the nature of the side chain requirements to improve CB2 affinity121. This study 
revealed that short alkyl chain lengths decreased CB1 binding at little or no expense to 
CB2 binding affinity whilst the opposite was true for longer alkyl chain lengths121. 
The optimum compound for affinity and selectivity was found to be 3-(1’,1’-
dimethylbutyl)-1-deoxy-∆8-THC (JWH133, 27, Figure 1-12) which displayed a Ki of 
677 & 3.4 nM at CB1 & CB2 receptors respectively121.  In a later study Huffman 
assessed the effect of introducing C11 hydroxyls (known to increase cannabinoid 
affinity – section 1.4.2.3) and masking the C1 hydroxyl group of 3-(1’,1’-
dimethylalkyl)-∆8-THC157. The resulting 11-hydroxy analogues gave higher affinity 
compounds at both CB1 and CB2 receptors as expected, but with no overall gain in 
terms of CB2 affinity versus selectivity157. Again side chain SAR demonstrated that 
shorter alkyl chains were optimum for CB2 affinity. The optimum compound selected 
from the 16 different analogues was 3-(1’,1’-dimethylpentyl)-1-methoxy-∆8-THC 
(JWH229, 28, Figure 1-12) which exhibited a Ki at the CB1 receptor of 3134 nM and 
at the CB2 receptor of 18 nM157. 
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It was shown that in both of these studies affinity and selectivity for the CB2 receptor 
could not be quantitatively assessed by opting for a specific C3, C1 and C9 
substituent, but rather each of these groups affected the other. As Huffman himself 
comments in his thorough review of this topic “…development of preliminary SAR 
for 1-deoxy-cannabinoids, was achieved, although to a limited extent”135. 
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O O
OCH3
L759633 21 JWH133 27 JWH229 28
 
Figure 1-12 The structures of selective CB2 classical cannabinoids 
 
The evidence presented highlights that CC’s attain a high selectivity and affinity 
towards the CB2 receptor with analogues containing short C3 alkyl side chains and 
simple C1 deoxy- or methoxy- motifs. There is little evidence to convince us that a 
large bulky fluorescent dye could be incorporated onto a CC to produce a CB2 
selective ligand. Combined with the need to acquire a Home Office license (and the 
associated strict working guidelines) for working with ∆8-THC it was felt that the CC 
template would be unsuitable for the initial work into generating fluorescent CB2 
ligands. 
1.4.3 Non-classical cannabinoids 
 
The Non-Classical cannabinoids (NCC) are a group of CC like compounds that lack 
the pyranoid B ring (Figure 1-1). In their quest for improving the analgesic properties 
of cannabinoid compounds, scientists at Pfizer started to modify the dihydropyran 
ring of THC type compounds.  The resultant compound, Levonantradol (CP 50,556, 
7, Figure 1-1), which entered into human clinical trials (section 1.2.2.2), demonstrated 
that the pyran ring of THC was not required for cannabinoid activity. Subsequently 
the Pfizer group synthesized a number of compounds lacking the pyranoid B ring48. 
Two compounds emerged from their endeavors that are of interest; CP 55,940 2 and 
CP 47,497 29 (Figure 1-13 A). CP 47,497 29 represents the prototypical compound of 
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the A-C bicyclic series and CP 55,940 2 (in its tritiated form – see Figure 1-13 B) is 
the most widely used radiolabelled cannabinoid used to study CB1 and CB2 receptor 
binding.  
It is well established that CP 55,940 2 (and its radiolabelled counterpart) have 
high affinity at both the CB1 and CB2 receptor with Ki values of between 0.5-5.0 and 
0.69-2.8 nM respectively51,80. However despite extensive SAR studies conducted on 
analogues of CP 55,940 2 and CP 47,497 29 concerning in-vitro and in-vivo CB1 
pharmacology the ability of the these analogues to interact with CB2 receptors 
remains to be established80,158. 
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Figure 1-13 (A) The structures of two typical NCC. NAH Northern Aliphatic Hydroxyl. SAH Southern 
Aliphatic Hydroxyl. (B) The synthesis of tritiated CP 55,940, the most common radiolabelled 
cannabinoid159. 
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The SAR conducted on NCCs for the CB1 receptor shows very similar trends to those 
found for CC ligands (see - 1.4.2). 
 
• C4’ 1’,1’-dimethyl substituted side chain of between 5 and 7 carbon units is 
optimal for CB1 binding158. 
• The 2’-deoxy analogues still retain affinity at the CB1 receptor although it is 
decreased by ∼40 fold158. 
• The NAH at C1 can be removed with the compound retaining cannabinoid 
activity in-vivo158. 
• Other SAR explored the cyclohexanol ring size and the substituent at C4 of 
CP 47,497 29 analogues. Of the 26 analogues examined, CP 55,940 2 
remained the most potent analogue, however ring sizes up to cyclooctanol and 
C4 short chain alkyl groups (up to a butyl chain), with or without 
functionalized termini (ether, 1° amine, amide, hydroxylamine), were all well 
tolerated with little affect upon CB1 affinity (all analogues retained CB1 
affinity of  <15 nM)158.   
 
To the best of our knowledge, the effect of modifying NCCs with bulky substituents 
has not been published, however it is prudent to comment that due to the NCCs 
exhibiting structural and SAR similarities to the CC the placement of bulky 
substituents on an NCC is likely to have similar effects to those shown by the CC 
(section 1.4.2). The stereochemical requirements for the NCC are the same as for the 
CC with the natural stereochemistry of ∆9-THC (6aR, 10aR) being required in NCCs 
(3R, 4R) to give optimum CB1 binding 80,158. A further stereochemical requirement 
that is present within the NCC pharamacophore is the requirement of the NAH to be β  
to the cyclohexane ring134. The likely biological binding conformation of CP 55,940 2 
(and conformationally restricted analogues of it), determined by NMR and 
computational studies, has been postulated to have the NAH, the SAH and the phenol 
hydroxyl all on the upper face of the conformer giving the molecule an amphipathic 
nature (Figure 1-14)160,161. Therefore to be on the same face as the other two 
hydroxyls the NAH must be in the equatorial conformation.  
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Figure 1-14 A ligand-membrane-receptor hypothesis model for CP 55,940 2 binding to the 
cannabinoid receptor adapted from reference 160. 
 
1.4.3.1 CB2 selective non-classical cannabinoids. 
 
The first report of a CB2 selective NCC ligand appeared in the literature in 1999 from 
the Mechoulam group based at Hebrew University162. The compound, code-named 
HU308 (30, Figure 1-15), showed agonist properties at the CB2 receptor with a Ki of 
23 nM. HU308 30 exhibited little affinity to the CB1 receptor (Ki >10 µM). The 
compound was first synthesized 9 years previously as part of the group’s 
investigations into the stereochemistry requirements/synthesis of ∆8-THC 
derivatives163. Thus, their rational for designing this type of compound to be CB2 
selective is not included in the 1999 report other than to say that the dimethoxy 
groups in HU308 30 are based on the increase in CB2 selectivity shown by the methyl 
ether derivatives of CC such as L759633 (21  Figure 1-12); a CB2 selective ligand. 
Later Huffman et al. synthesized a pyridone analogue of CP 47,497164. The resulting 
distereoisomers of the pyridone analogue 31 and 32 (Figure 1-15) were found to have 
similar high affinities at the CB2 receptor (31 56 & 32 50 nM) and lower affinities at 
the CB1 receptor (31 973 & 32 1054 nM). This result was surprising as it was known 
that an α-NAH in NCCs does not bind as well as the β  conformation and yet both of 
these compounds (31 and 32) bound equally well (section 1.4.3). This result may be 
explained by these novel compounds adopting a different binding confirmation to that 
of CP 55,940 2 and CP 47,947 29 in the receptor. The CB2 selectivity of 31 & 32 
described may be attributed to them being equivalent of 1-deoxy-∆8-THC analogues 
such as JWH133 (27, Figure 1-12) and posess selectivity for similar reasons as 
described in section 1.4.2.4. 
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Figure 1-15 The structure and in-vitro  binding affinity of CB2 selective NCC. a ref.162, b ref. 164, c 
ref. 165. 
 
One large study into the SAR of NCC at the CB2 receptor used phenol and resorcinol 
benzenoid rings with various carbo/heterocyclic moieties to generate 41 analogues 
which were subjected to pharmacological testing165. The two examples shown in 
Figure 1-15 are the potent CB2 selective compound O1966A 34 and its phenol 
equivalent O1826 33. The authors acknowledge, for compound 34, that there was a 
mixture of distereoisomers but gave no further details. These two compounds convey 
the main findings of this study, i.e. masking of the phenol groups as methoxy ethers 
34 had the biggest effect on CB2 selectivity. Of the range of carbo/heterocyclic groups 
assessed, the cyclohexane ring with a methyl group at C3 and a hydroxyl at C1 
(compound 34) gave the optimum compounds with respect to CB2 affinity and 
selectivity132. 
Overall the NCCs show a similar SAR to those observed for the CC ligands 
(section 1.4.2). It is therefore with similar reasoning that we feel that this class of 
compound is not suitable to modify with bulky fluorescent dyes to generate high 
affinity CB2 selective ligands.  
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1.4.4 Arachidonic acid derivatives 
 
Arachidonic acid derivatives are the natural ligands for the cannabis receptor. 
Anandamide 4 (Figure 1-16) was isolated and discovered in 1992 and was shown to 
be the first of the endogenous ligands to the cannabis receptors54. Subsequently a 
further four arachidonic acid based natural ligands, 2-arachidonoylglycerol 35166, 2-
arachidonylglyceryl ether (Noladin ether, 36)167, Virodhamine 37168, and N-
Arachidonoyldopamine 38169,  have been postulated as endogenous cannabinoid 
ligands (Figure 1-16). The roles, biosynthesis and deactivation of this family of 
endocannabinoids is outside the scope of this thesis and readers are directed to an 
excellent review on these topic170. All of the endocannabinoids are ligands at both the 
CB1 and CB2 receptors with a preference of affinity towards the CB1 receptor80. The 
published literature concerning synthetic analogues of arachidonic acid have all 
reported compounds which show selectivity towards the CB1 receptor171-175. 
Combined with the fact that anandamide is photolabile§ this class of compound is not 
suitable for labelling with fluorescent dyes to generate CB2 selective fluorescent 
ligands. 
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Figure 1-16 Chemical structures of arachidonicAcid cannabinoid ligands. 
 
                                                 
§ Although no experiments investigating the photodegradation of Anandamide have been published the 
commercial suppliers of Anandamide (Tocris) advise in their summary of Product Characteristics 
“Protect from light”. This appears prudent advise when considering that Polyene systems such as 
Anandamide are well known for their ability to absorb light (i.e. the pigments Retinal & β Carotene)   
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1.4.5 Pyrazole cannabinoids 
 
The pyrazole class of cannabinoids exhibits the only known antagonist/inverse agonist 
behavior upon binding to the cannabinoid receptors80. The prototypical members of 
this class are the Sanofi compounds SR141716 555, a potent CB1 ligand, and 
SR144528 657 a potent CB2 ligand (Figure 1-17 A & C). SAR studies on the pyrazole 
pharmacophore, using SR141716 5 as the lead structure, have been extensive, 
concentrating on CB1 receptor binding, and have concluded the following points: 
 
• 3° amides, like compound 43 (Figure 1-17, B), and the replacement of amide 
functionality by other H-bonding acceptors/donors strongly decrease CB1 
binding affinity compared to 2° amides such as displayed by compound 
42176,177. 
• The optimum group at N1 is 2’’,4’’-dichlorophenyl. Replacement of this 
group with cycloalkanes178, 4’-alkylphenyl moieties177, or monochlorinated 
phenyls 39176 diminishes CB1 binding (see Figure 1-17, A). 
•  The C3 amido group can tolerate replacement of the N-piperidine group 
present in SR141716 with related 5-7 membered rings or cyclohexane without 
altering binding affinity. Replacement of cyclic groups with linear alkyl chains 
led to a decrease in affinity in one study177 but did not alter CB1 binding in 
another179. 
• A bulkier substituent than hydrogen (i.e. methyl, bromine or iodine) increases 
CB1 affinity in position C4176,177. 
• Para (4’) substituted alkyl- or halo- phenyl groups all give enhanced CB1 
binding when positioned at C5176 (Figure 1-17 A & B). However 4’-nitro, 4’-
amino and 2’-substituted phenyls at C5 all lead to a decrease in affinity176. The 
potent CB1 antagonist AM251 41 was prepared by a simple replacement of the 
4’-chlorophenyl group of SR141716 5 with a 4’- iodophenyl moiety176. This 
useful analogue allows the inclusion of radioactive forms of iodine (I-123) 
into the synthesis of AM251 41 which can be used for in-vivo imaging.  
 
Unfortunately there are no published SAR studies on the CB2 selective ligand 
SR144428 to date. We are therefore left with relatively little information to the nature 
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of the CB2 affinity/selectivity exhibited by SR144528 6 and this will be explored in 
section 1.4.5.1. 
 
1.4.5.1 CB2 selective pyrazoles 
 
The current knowledge of the limited SAR for the CB2 receptor is as follows: 
 
• 3° amides decrease CB2 affinity ( Figure 1-17 B)176. 
• N1 substituents consisting of 4’’-monosubstituted phenyl 6 and 3’’-
methylcyclohexyl 40 rings show an increase in CB2 binding and a decrease in 
CB1 binding176 (Figure 1-17, A & C). This observa tion is shown in the 
structure of SR144528 6 with a 4’’-methylbenzyl group replacing the 2’’, 4’’-
dichlorphenyl of SR141716 5. 
• Hydrogen at position C4 is optimal for CB2 binding as shown in the structure 
of SR144528 6. However it has recently been shown that a methylene bridge 
connecting C4 to the neighbouring aromatic residue at C5 significantly 
increases CB2 affinity and selectivity180. This is likely to be due to increased 
rigidity within this molecule, rather than steric factors (see below)180. 
 
The SAR for the CB2 selective pyrazole cannabinoids has been extremely sparse. 
There have been no published accounts of any modifications which have incorporated 
bulky groups or alkyl linker chains. The most interesting set of compounds that 
incorporated these features, required in fluorescent dye conjugation, were 
unfortunately not tested with CB2 receptors177. 
The most important discovery since SR144528 6, was published in 2003 by 
Mussinu et al. after we had concluded our own studies180. Their group reported the 
synthesis and pharmacological testing of a number of novel 1,4-dihydroindenol[1,2-
c]pyrazole based CB2 selective ligands (Figure 1-17 D). They used a common 
medicinal chemistry approach of introducing a conformational restriction into 
analogues of SR141716 in an attempt to permit the ligand to bind with high affinity 
and selectivity to a desired receptor181.  
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Figure 1-17 The structure and in-vitro  pharmacology of the pyrazole cannabinoids. A) The effect of 
the N1 substitution. B) The effect of amide substitution and halogen exchange. C) The prototypic CB2 
ligand SR144528. D) The novel 1,4-dihydroindenol[1,2-c]pyrazole CB2 selective cannabinoids. a. ref 
176 b. ref 178 c. ref 57 d. ref 180. 
 
Their discoveries were evidence that the rigid 1,4-dihydroindenol derivatives showed 
extensive selectivity towards the CB2 receptor even when the substituents at N1, C3 
and C5 were previously thought to confer CB1 selectivity. Thus the rigid analogue of 
SR141716 44 has  >6000 fold CB2 selectivity with a sub-nanomolar Ki of 0.34 nM 
and their 6-methyl analogue 45 is the most potent and selective CB2 ligand described 
to date (Figure 1-17 D). Unfortunately molecular modelling studies undertaken with 
SR144528 6 showed that the 1,4-dihydroindenol methylene bridge would be located 
deep within CB2 receptor binding pocket, pointing down towards the intra-cellular 
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side182. This is an unsuitable locus for manipulation since the fluorescent dye should 
be located away from the receptor (i.e. on the extracellular face) so as to minimise 
perturbation of ligand-receptor interactions. According to Gouldson’s model the site 
with most potential for modification would be the 4’’-benzylic methyl group of 
SR144528 which lies towards the top of the receptor pocket182.    
However, up until we concluded our studies, the lack of CB2 receptor SAR for 
the pyrazoles meant that using the template of SR144528 6 as a lead compound for 
conjugation with a fluorescent dye would be difficult in regards to fluorescent dye 
placement. 
 
1.4.6 Indole based cannabinoids 
 
The indoles were the first class of cannabimimetics that were not structurally related 
to ∆9-THC. Researchers at Stirling Winthrop reported a new family of indoles which 
possessed cannabinoid properties52. Constrained analogues of the non-steroidal anti-
inflammatory drug Pravadoline 46 (Figure 1-18) were synthesized which exhibited 
reduced inhibition of the cyclo-oxygenase enzyme but increased affinity to the CB1 
receptor53. R-(+)-Win 55212-2 3 (Figure 1-18) has been the most studied compound 
arising from this program. It displays high stereospecific affinity for both the CB1 and 
CB2 receptor with a Ki range of 1.89-123 nM and 0.28-39.3 nM respectively80. Most 
studies show that Win 55212-2 3 exhibits a modest selectivity in favour of the CB2 
receptor80. The key structural features necessary for high CB1 binding have been 
summarized by the authors in a large SAR study which evaluated 125 non-constrained 
analogues of Win 55212-2 3 3183. They concluded; 
 
• A bicyclic (preferably 1-naphthoyl) substituent is required at C3 of the indole. 
• A small substituent (or better no substituent) is required at C2 of the indole. 
• An aminoethyl (preferably morpholinoethyl) substituent is required at N1 of 
the indole which lead to the early generic name for this series of compounds to 
be aminoalkylindole (AAI). 
 
Compound 47 (Figure 1-18) is the resultant compound which has nanomolar 
displacement values at the CB1 receptor. 
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However this model SAR has now been superceded by other developments which 
have shown that the N1 aminoethyl group can be replaced with simple n-alkyl 
chains184 such as JWH007 48 and the indole structure can be simplified to a pyrrole 
49185 or an indene 50 186 structure with the compounds retaining cannabinoid 
properties (Figure 1-18). 
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Figure 1-18 The structures and in-vitro  pharmacology of indole based cannabinoids. a ref. 187 b range 
of values given ref. 80 c ref. 122 d ref. 188 e ref. 189. NR not reported. 
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1.4.6.1 Modeling studies on indoles 
 
The intimate ligand-receptor interactions of the indole cannabinoids has been studied 
to a greater depth than for any other class of compound and this makes them an 
interesting class of cannabinoids to interrogate using molecular modelling to guide the 
choice of fluorescent dye placement. A short summary of the modelling studies 
performed to date will be considered.  
Early studies simply superimposed the AAI pharmacophore over the structure 
of ∆9-THC by aligning the naphthyl ring of the AAI over rings B & C of ∆9-THC, the 
carbonyl group of the AAI over the C1 phenol of ∆9-THC, and the N1 substituent of 
the AAI was aligned with the C3 side chain of ∆9-THC, illustrated in Figure 1-19. 
From the proposed model, indole analogues with simple N1 n-alkyl chains instead of 
aminoalkyl chains and simplified pyrrole analogues were synthesized and screened 
and showed that binding to the CB1 receptor was retained184,188. 
 
O
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O  
Figure 1-19 The suggested alignment of CCs with  indole based cannabinoids proposed by Huffman et 
al
184. 
  
Later receptor mutational152 and docking190 studies indicated that there could be 
divergence within the binding site of Win 55212-2 3 from that of other classes of 
cannabinoid ligand, therefore the structural superimposition of AAI with ∆9-THC 
giving rise to the cannabimimetic 1-n-alkly indoles and the pyrrole series may have 
been serendipitous.  
The binding conformation and the amino acid residues involved in indole-
receptor interactions have been reported. The bioactive conformation of the indole 
cannabinoids was determined in one study by Reggio et al. to be in the s-trans form. 
The s-trans form results in the aryl system lying close the indole C2 and the carbonyl 
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oxygen lying near to the indole C4 (Figure 1-20).They demonstrated that the rigid 
AAI mimic (E)-Naphthylideneindene (which is the rigid s-trans form of Win 55212-2 
3) bound with greater affinity to the CB1 and CB2 receptors  than the (Z)- isomer189 
(Figure 1-20).  
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s-trans Win 55212-2 (E)-naphthylideneindene s-cis Win 55212-2 (Z)-naphthylideneindene  
Figure 1-20 Relationship between the s -trans and s -cis conformers of Win 55212-2 and the respective 
rigid E and Z indenes. 
 
Directly contrasting this result was a later publication by Xie et al. which used 2D 
NMR and molecular dynamics experiments to demonstrate that the low energy 
conformation of Win 55212-2 3 in solution was in fact the s-cis form191 (Figure 1-20). 
We will report in chapter 6 our findings concerning the binding conformation of Win 
55212-2 3 obtained from molecular modelling studies. 
Many independent studies have demonstrated that the indoles bind to the 
cannabinoid receptors primarily by aromatic stacking interactions. SAR 
determinations detailed in 1.4.6 show that 3-naphthoyl indoles c.f. 3-benzoyl indoles 
and indoles c.f. pyrroles exhibit increased binding to the cannabinoid receptor 
mirroring the increase in aromatic character exhibited by these compounds183,188. 
Further SAR studies involving the (E)-Naphthylideneindene186,189 and the completely 
hydrocarbon based 1-pentyl- indene192 demonstrate that the major interactions of 
binding at the cannabinoid receptor are aromatic and Van Der Waals. Molecular 
modelling has also been used to show the type and location of the interactions taking 
place between the indole cannabinoids and the receptor. Chin et al. was able to 
determine that TM 3 plays an important role in the selectivity of some of the indole 
cannabinoids for the CB2 receptor by generating a hybrid CB1 receptor that contained 
TM 3 of the CB2 receptor. These hybrid receptors were capable of binding the indoles 
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Win 55,212-2 3 and JWH015 (53, Figure 1-21) with greater affinity than the wild type 
CB1 receptor193. A single point mutation experiment which altered a non-conserved 
CB2 Phenylalanine residue (F197) to the corresponding CB1 amino acid Valine 
demonstrated through computer modelling analysis, that F197, as part of an aromatic 
cluster in TM 3-4-5, was crucial in the selectivity of Win 55212-2 for the CB2 
receptor194. Molecular modelling experiments using the global minimum energy 
conformations of several 3-Indolyl-1-naphthylmethanes and 3-(1-naphthoyl)indole 
compounds, into an activated CB1 receptor model, have also shown that these 
molecular structures bind by aromatic stacking interactions with residues present in 
TM 3-4-5-6192. 
In summary, molecular modelling and SAR techniques have been used by a 
number of independent researchers to give a model of the indole cannabinoids binding 
to the cannabinoid receptor. The models show that 3-substituted indoles bind 
primarily through aromatic stacking interactions with residues within TM 3-4-5-6. In 
addition, the CB2 selectivity of these compounds may be inferred by a phenylalanine 
residue (F197) only present in the CB2 receptor which can form an extra aromatic-
aromatic interaction with the indole structure. 
 
1.4.6.2 CB2 selective indoles 
 
The first indole cannabino id ligand which showed significant CB2 selectivity was the 
prototypical compound Win 55212-2 3135. Although most published data 
demonstrates that Win 55212-2 3 is selective towards the CB2 receptor, the results 
also show that the compound has high affinity for the CB1 receptor80,135. Further 
exploitation of the SAR generated two compounds L768242 51 and JWH015 53 
(Figure 1-21) which demonstrated high affinity and selectivity for the CB2 receptor. 
Gallant et al. generated several compounds of the L768242 51 type by switching the 
substitution pattern of the aroyl and morpholino groups from the established 3-aroyl-
1-aminoalkyl to 1-aroyl-3-aminoalkyl195. They demonstrated that the N1-(2, 3-
dichlorobenzoyl) group had as high an affinity to the receptors as N1 naphthoyl 
substitution, suggesting that the dichlorophenyl was isosteric to the naphthyl system. 
The Huffman group synthesized JWH015 53 (Figure 1-21) in 1994 based on the 
alignment of indole with ∆9-THC shown in Figure 1-19, however it was only shown 
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to be CB2 selective in 1996 when it was first tested in membranes containing CB2 
receptors196. SAR of this type of N-alkylindole has been extensive; however no bulky 
substituents have been evaluated for effects on the pharmacophore scaffold. The SAR 
on this type of compound can be summarized as follows: 
 
• The optimum N1 substituent for CB2 selectivity is n-propyl. Smaller alkyl 
groups abolish binding at both receptors, whilst extending the chain length up 
to n-hexyl increases CB2 affinity but at the expense of selectivity122. This can 
be shown in the compounds 48, 52, and 53 (Figure 1-21). Heptyl chains, as in 
55, start to decrease affinity at both receptor types. This trend fits the 
hypothesis that the nitrogen of the indole is equivalent to the C3 side chain of 
CC as shown in Figure 1-19, as in the CC a short C3 side chain is optimum 
for CB2 selectivity (see - 1.4.2.4). 
• Methyl substitution at C2 of the indole leads to compounds with increased 
affinity at the CB2 receptor122. This is illustrated by the difference between 
JWH015 53 and compound 54 which lacks the methyl group and shows a 10 
fold loss in CB2 affinity (Figure 1-21). Larger n-alkyl chains and branched 
alkyls at C2 however attenuate binding at both receptors135. 
• Substitutions on the 3-naphthoyl moiety (4-methoxy- & 7-methyl-1-naphthoyl 
substituents were evaluated) gave compounds with similar selectivity and 
affinity to the unsubstituted naphthoyl analogues122,135.  
 
Other CB2 selective indoles have recently been published in the literature. Bristol 
Myers Squibb developed a range of 3-amido substituted indoles based on evidence of 
CB2 selectivity shown by the indole cannabinoids and the amide containing Japan 
Tobacco cinnamides126. Their studies produced a number of CB2 selective ligands 
shown in Figure 1-21 and generated some interesting SAR for the purposes of 
designing fluorescent labelled CB2 ligands197. 
 
• The C3 amido aromatic amino acid of 56 could be replaced with non-aromatic 
amide groups retaining CB2 affinity (although CB1 affinity was not 
reported)197. 
 62
• Chiral discrimination was observed in compound 56 as its enantiomer showed 
minimal CB2 binding197.  
• Inclusion of a C7 methoxy group in 56 increased CB2 affinity from 250 nM to 
8 nM197. 
• The C3 amido functionality was further developed to contain the bulky (S)-
fenchyl group (as used in SR144528 6, Figure 1-17). Compound 57 
demonstrated that the molecular space within the receptor at C3 was able to 
accommodate large bulky substituents197 (Figure 1-21). 
• Derivatives of 57 where the substitution at N1 was varied indicated that 
simple n-pentyl chain gave the highest CB2 affinity (5 nM), CB1 binding was 
not reported as the compound showed little activity in an in-vivo 
inflammatory model197. 
• C2 derivatives of 57 showed that the methyl or hydrogen substituent was 
optimal for CB2, with larger alkyl groups reducing CB2 affinity197. 
 
An interesting CB2 selective indole AM1241 58 (Figure 1-21), with in vivo activity, 
has recently been reported in a patent198 and in subsequent pharmacological 
papers72,73,113,120. The compound has shown promising results in various pain models 
when used in vivo (see - 1.3.4.4.1). The compound has a bulky 2- iodo-5-nitrobenzoyl 
substituent at C3 and utilizes a N-methylpiperidinyl group at N1. In order to retain 
CB2 binding the stereochemistry of the N1 substituent must retain the R configuration 
which is also a requisite in Win 55212-2 3198.   
Overall the indole cannabinoids represent an excellent class of compounds for 
our purposes of conjugation to fluorescent dyes. Indole based cannabimimetics have 
nanomolar affinity and appear to show a natural selectivity towards the CB2 receptor. 
They are chemically simple and stable, and appear to tolerate bulky substituents in the 
C3 position. We planned to exploit the established knowledge regarding ligand-
receptor interactions to build an in-silico model which can be interrogated to provide 
guidance in the synthesis of novel CB2 selective fluorescent ligands and will report 
our results in chapter 6.  
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Figure 1-21 The CB2 selective indoles. a ref. 195, b ref. 122, c ref. 197, d ref. 113. 
 
1.4.7 Japan Tobacco ligands 
 
This set of compounds consisting of benzamides, cinnamides and heterocylic 
structures (Figure 1-22) are set aside from the other categories of cannabinoid ligand 
due to their chemical structure not fitting any of the other cannabimimetic classes 
detailed in section 1.4. First reported in 1997, 391 compounds, mainly consisting of 
substituted aromatic amides were cited. Pharmacological data demonstrating high CB2 
selectivity and affinity was reported for 32 of these compounds126. The patent gives 
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limited pharmacology data but includes Ki binding values from rat cerebellum and 
spleen membranes. Detailed pharmacology on compound JTE907 (66, Figure 1-22), 
which is similar in structure to compounds from their original patent, was reported 
elsewhere in which JTE907 66 was shown to have inverse agonist properties at the 
CB2 receptor. In addition, it displayed a variable Ki value in human, mouse and rat 
CB2 receptors of 36, 1.6, and 0.4 nM respectively125. Independent testing of the 
binding affinity of one other member of the Japan Tobacco compounds was reported 
by the Bristol Myers Squibb company in 2002. Compound 61 (R=OH) exhibited a 
100 fold increase in Ki value in their human CB2 receptor assay compared to the Ki 
obtained from the rat CB2 receptor reported in the original patent (Figure 1-22)197. 
These patterns of receptor species differences in the Japan Tobacco compounds were 
not evident when we embarked on our investigations however we will be reporting on 
these differences in chapters 4 and 5. 
The Japan Tobacco compounds possessed excellent diversity in the chemical 
structures and groups tolerated whilst retaining high CB2 selectivity and affinity. The 
compounds still remain today the most selective and high affinity ligands to the CB2 
receptor reported. The key SAR to these compounds can be summarized as follows: 
 
• Amide type functionality attached either directly to a benzenoid ring (as in 62-
65, Figure 1-22) or positioned through a 2 carbon linker which allows 
conjugation between the amide and benzenoid ring (as in cinnimides 59-61, & 
66, Figure 1-22) is observed in each of the compounds. 
• An n-pentyl chain which is meta to the amide connection to the benzene ring 
is observed in all of the active compounds. The n-pentyl chain is connected to 
the benzene ring through a heteroatom (O, N and S). 
• The position para to the amide connection to the benzene ring can 
accommodate long chain alkyls attached to the ring through a heteroatom. 
• An N -ethylaromatic moiety is a preferred substituent on the amide group. The 
aromatic group observed was mainly tyramine based although in compounds 
60, 61 (R=H), 65, and 66 show that the phenol group is not essential for 
binding.  
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The Japan Tobacco compounds represent a lead set of compounds for derivatisation 
with fluorescent dyes. Their large CB2 affinity and selectivity should allow 
modifications with fluorescent dyes resulting in fluorescent CB2 ligands. The SAR 
they display shows tolerance to long alkyl chains on the benzamide ring as 
demonstrated by compound 62 and 65, and they can tolerate a wide range of structural 
diversity on the N-amide substituent as demonstrated in compounds 61, 64, 65, and 
66. It is for this reason that the Japan Tobacco compounds represent the class of 
compounds that we feel most likely to tolerate modifications to allow conjugation to 
fluorescent dyes and we will report on our investigations in chapters 2, 4 and 5. 
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              59                               400                  1.8a
              60                              3700                 44a
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                                                5700               120b (human receptors)
              61 (R = H)               >1000                 86b (human receptors) 
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JTE907 66                              2370                  36c (human receptors)
                                               1060                  1.6c (mouse receptors)
                                               1050                  0.4c (rat receptors)  
Figure 1-22 The structure and in-vitro  pharmacology of the Japan Tobacco ligands. a. ref 126, b ref. 
197, c ref. 125. 
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1.5 Research aims 
 
We aim to design and synthesize novel CB2 ligands which are conjugated to 
fluorescent dyes making them suitable for use in confocal microscopy and SMD 
applications. By using both classical SAR and molecular modeling approaches we 
will interrogate cannabinoid lead structures in-order that we can locate the fluorescent 
dye upon the pharmacophore whilst retaining cannabinoid activity.  From our 
extensive literature search conducted on the cannabinoid ligands we will be using the 
Japan Tobacco ligands and the indole cannabinoids as lead structures for conjugation 
to fluorescent dyes. We will report the design, synthesis and pharmacology of these 
ligands in subsequent chapters. As the nature of our work is directed towards the 
greater understanding of the CB2 receptor we will also be reporting serendipitous 
results, relating to ligand-receptor binding at the CB2 receptor, obtained through our 
molecular modelling and pharmacology findings. These specifically rela te to an 
unusual species selectivity encountered with a Japan Tobacco compound and a 
hypothesis to how it occurs. 
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2 Fluorescent CB2 ligand based on a modification to the 
benzamide ring of a Japan Tobacco Compound. 
 
2.1 Background to designing a GPCR fluorescent ligand. 
 
A review of the literature quickly determined that only one fluorescent cannabinoid 
ligand, SK-4-45-1 67, had previously been reported20. The ligand was a fluorescently 
labelled derivative of anandamide and displayed no detectable binding to the CB1 
receptor (Figure 2-1)20. SK-4-45-1 67 was however recognised by the anandamide 
transporter system and was subsequently used to track the re-uptake of anandamide 
into intracellular compartments. 
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Figure 2-1 The structure of SKM 4-45-1 67. A substrate for the anandamide transmembrane carrier  
 
Due to the inability of SKM 4-45-1 67 to bind to the cannabinoid receptor, and the 
reported photo- instability and CB1 selectivity of anandamide derivatives previously 
discussed in section 1.4.4 it became obvious that a novel approach to designing a 
fluorescent CB2 ligand was required. 
Several fluorescent ligands which bind to GPCRs have previously been 
reported, alongside their pharmacological data and use in various fluorescent assays. 
A short discussion of adenosine and serotonin fluorescent ligands will be given to 
introduce the reader to the concepts and decisions taken during the work described.  
2.1.1 Fluorescent adenosine agonist ligands 
 
The adenosine receptors are a class of three (A1, A2, A3) GPCR receptors that have 
important roles in physiology and the pathology of disease199. They are therefore 
important receptors to understand and as a result selective adenosine fluorescent 
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ligands have been designed for use in fluorescent applications. Original work by 
Macchia et al. was able to show that attachment of a Dansyl fluorescent dye, via an 
alkyl linker, to N6 of the adenosine agonist NECA 68 (Figure 2-2) proceeds with 
retention of A1 receptor binding200. The rational in attaching the fluorescent dye in 
this way came from previous SAR which demonstrated that alkyl linkers, terminating 
in a bulky substituent at N6 led to compounds with high affinity and selectivity at the 
A1 receptor199,201. Macchia et al. assessed the effect of different alkyl chain lengths 
(from C3 to C12) used to tether the Dansyl molecule to the NECA ligand (69a-f, 
Figure 2-2). They found that the C6 alkyl cha in 69c was optimum for A1 binding 
affinity with a Ki of 27 nM determined using radioligand binding. Chain lengths of C3 
69a and C4 69b gave compounds with a Ki  of < 100 nM, but increasing the alkyl 
chain length above C6 led to incremental decreases in binding affinity; with the C12 
linker compound 69f having a binding affinity of 3400 nM. The group were able to 
use 69c to visualize the A1 receptor in rat cerebellar cortex using fluorescence 
microscopy. As an extension to their work they acknowledged in a subsequent 
publication that the Dansyl-NECA ligands could be improved by altering the 
fluorophore to one with a longer λabs202. The short λabs (340 nm) necessary to excite 
the Dansyl dye is known to cause problems in biological experiments due to cells and 
tissues autofluorescing at this wavelength203. Their solution was to substitute the 
Dansyl dye with the longer λabs dye 7-Nitrobenzofurazan (NBD, λabs 465 nm) to give 
compounds 70a-e (Figure 2-2). By changing the dye the reported pharmacological 
profile of the compounds surprisingly changed from being A1 selective using Dansyl 
to A3 selective using NBD (see table in Figure 2-2). This result was not commented 
upon by the authors, but it does suggest that the choice of fluorescent dye can 
significantly affect the pharmacology of the conjugated ligand. An alternative 
explanation was that the binding assay used to determine the Ki of the NBD ligands 
70a-e utilised a radiolabelled antagonist instead of a radiolabelled agonist, which was 
used for the Dansyl compounds 69a-f. Antagonists are known to switch A1 receptors 
to their low affinity binding state204 resulting in the lower Ki observed. The NBD 
series also demonstrated that increasing alkyl linker length resulted in compounds 
with increased binding affinity towards the A3 receptor. This is opposite to the Dansyl 
series and may be due to differing modes of binding mechanism displayed by the two 
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differing fluorophores. The NBD ligand 70d was used to visualise the A3 receptor in 
CHO cells using confocal microscopy.  
Our research group was interested in generating fluorescent adenosine agonists 
that were more suitable for use with SMD applications. Using the N6 alkyl NECA 
compounds 69 & 70 discussed above as a lead molecule the boron containing 
fluorophore BODIPY® 630/650 was chosen as a substitute dye for Dansyl or NBD. 
The BODIPY® 630/650 dye was chosen as it has an λabs of 633nm producing much 
lower levels of cellular autofluorescence203. It also displays high molecular brightness, 
is subject to low photobleaching rates and has a low percentage of triplet states; 
important factors in SMD (section 1.1.2.2.1)205. Commercially available BODIPY® 
630/650 is only available with a C6 alkyl chain already incorporated onto the dye206, 
therefore a short alkyl linker of 4 carbon units was incorporated at the N6 position and 
conjugated to the BODIPY® 630/650 dye to produce 71207. This ligand was shown in 
a reporter gene efficacy assay, quantified through Luciferase expression, to have 
equivalent potency to the high affinity A1 agonist N6-cyclopentyl adenosine (CPA)207. 
Initial displacement binding studies on this ligand at the A1 receptor has shown it to 
have a biphasic binding curve with a detectable low affinity binding Ki of 22 µM. 
This is 100 fold less potent than NECA, but due to the antagonist radioligand binding 
assay used it is likely to be reporting on the binding to A1 receptors in the low affinity 
binding state - in a similar way to the results from the NBD series of drugs. The 
BODIPY-NECA compound 71 has been successfully used in SMD and single cell 
applications207.  
We have successfully applied the same methodology used for 71 to 
fluorescently label the endogenous ligand adenosine25. Thus adenosine was modified 
with a N6 aminobutyl tether and conjugated to BODIPY® 630/650 to give 72 (Figure 
2-2). This ligand shows similar efficacy to the agonist NECA 68 using a cAMP 
sensitive secreted placental alkaline phosphatase (SPAP) reporter gene assay25. 
Agonist activity of adenosine was retained and the results from radioligand 
competition binding studies are awaited. The BODIPY-adenosine ligand 72 has been 
used in confocal microscopy and FCS experiments to report on the location and 
function of the A1 receptor25.  
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compound n Ki (A1, nM) Ki (A2, nM) Ki (A3, nM)
68 N/A 200a 15a 8.2a
69a 3 42a 4300a 1800a
69b 4 70a 9500a 2000a
69c 6 27a 4300a 3600a
69d 8 111a >10000a 252a
69e 10 234a >10000a 1100a
69f 12 3400a >10000a 2500a
70a 2 >10000b 6750b 56b
70b 4 >10000b >10000b 381b
70c 6 >10000b 6083b 24b
70d 8 3476b 5096b 7.4b
70e 10 6350b 6100b 28b
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Figure 2-2 The structure and Ki values of fluorescent adenosine agonists. a ref. 200, b ref. 202, c ref. 208 
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2.1.1.1 Synthetic strategy used for fluorescent adenosine agonists 
 
Compounds 69-71 were synthesised by an amine substitution of a common 6-
chloropurine 73 intermediate. The differences in the synthesis of the Dansyl, NBD 
and BODIPY® ligands relate to when the fluorescent dye was introduced into the 
molecule as shown in Scheme 2-1. 
In the synthesis of the Dansyl ligands the Dansyl dye was pre-conjugated with 
the alkyl linker and the amine group of the alkyl linker was reacted with the 6-
chloropurine 73 to give the acetonide intermediate. The acetonide was hydrolysed 
using aqueous acid to yield the final ligands 69a-f (Scheme 2-1, A). The disadvantage 
of this technique is that in-order to displace the 6-chloropurine 73 the fluorophore is 
exposed to the forcing conditions of refluxing in EtOH. Also this method relied upon 
deprotecting the acetonide using acid hydrolysis in the presence of the fluorophore. 
This method is inappropriate for labelling with labile fluorophores. 
The methodology used to synthesise the NBD ligands 70a-e overcame the 
synthetic flaw of exposing the dye to forcing chemical conditions by using mono-Boc 
protected diaminoalkyl linkers. The linker was installed without the fluorophore, and 
de-protection of the Boc group exposed the1° amine which was conjugated to the 
NBD fluorophore(74, Scheme 2-1, B). The acetonide protection was kept in place 
during the conjugation as NBD-Cl can react with hydroxyl functional groups. 
Acetonide de-protection, was carried out in the presence of the NBD fluorophore, 
however this procedure would affect acid sensitive fluorophores if they had been 
used. 
The synthesis of the BODIPY® ligand 71 (Figure 2-2) utilised methodology 
that produced intermediate 75, which was suitable for conjugation with any amine 
reactive fluorescent dye and avoided the need for further chemical manipulation (i.e. 
de-protection) once the fluorophore was installed. By using the commercially 
available BODIPY® 630/650 activated as the succinimidyl ester (OSu) we were able 
to label selectively at the 1° amine without affecting the free hydroxyl groups present 
on the molecule209,210.  Compound 71 was purified by preparative TLC. Similar 
methodology was also employed successfully in the synthesis of the fluorescent 
adenosine ligand 72 (Figure 2-2)25.  
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Scheme 2-1 The different synthetic methodology used to install the fluorescent dye onto the NECA 
based fluorescent adenosine agonists. 
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2.1.2 Fluorescent Serotonin ligands 
 
Various fluorescent agonists and antagonists have been prepared against 3 of the 14 
known Serotonin (5HT) GPCRs. The methodology used in both the design and the 
synthesis of these 5HT ligands is very similar to that used in the synthesis of the 
fluorescent adenosine agonists (section 2.1.1) i.e. a 1° amine terminating alkyl chain 
is installed at a position upon a 5HT ligand known to tolerate molecular extension and 
conjugated to an appropriate fluorescent dye in the final synthetic step. 
Wohland et al. was able to label an experimental Glaxo Wellcome 5HT3a 
antagonist GR-119566X 76 (Figure 2-3) which already possessed an aminopropyl 
chain installed in the drug molecule33. They simply reacted GR-119566X 76 with 
different fluorophores and following purification, tested the ligands for affinity at the 
5HT3 receptors. GR-119566X 76 was labelled with 4 different dyes, fluorescein (λabs 
494 nm, λEm 518 nm) 77a, NBD (λabs 465 nm, λEm 535 nm), Rhodamine 6G (λabs 556 
nm, λEm 578 nm) 77b and Cy5 (λabs 649 nm, λEm 670 nm) 77c, which spanned a range 
of absorption and emission wavelengths (Figure 2-3)33. They reported that ligands 77a 
& b both exhibited sub-nanomolar Kd values whilst the Cy5 containing ligand 77c 
had an increased Kd of 18 nM, which they attributed to the increased steric hindrance 
of the dye.33. The authors went on to use these fluorescent ligands in Fluorescence 
Correlation Spectroscopy experiments and were therefore able to comment upon the 
suitability of the 4 fluorescent dyes evaluated  in this SMD application33,34. They 
concluded that the Cy5 and the Rhodamine dyes were the most suitable for SMD 
applications due to the high count rate, high photostability, and high signal to noise 
ratio of the dyes. Finally the group concluded with a statement that should be 
considered when designing fluorescent ligands suitable for SMD work “…a suitable 
ligand for FCS has to weigh between the higher accuracy of a high count fluorophore 
and the presumed disturbance of the ligand-receptor interaction by this label”33. 
A separate group utilised SAR data from a series of benzopyran based 5HT1A 
ligands211 to design fluorescent 5HT1A agonists212. They employed an aminobutyl 
linker, previously shown to tolerate bulky aromatic substituents, in order to 
fluorescently label the ligand (78, Figure 2-3). 
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Figure 2-3 The structures of fluorescent 5HT agonist and antagonists. 
 
 
 
 75
They chose to label the ligand with both commercially available NBD dye and a novel 
“in-house” coumarin based dye which exhibited higher λEm (550 nm) wavelengths. 
The NBD labelled ligand 78 actually had an increased affinity and selectivity towards 
the 5-HT1A receptor when compared to the non-fluorescent ligands from the original 
SAR study. Ligand 78 was successfully used in a FIDA based experiment40. 
The final set of fluorescent serotonin ligands to be considered were designed 
using the 5HT4 antagonist ML10302 (79, Ki = 1 nM, Figure 2-3) as a template213. By 
utilising a computational based model of ML10302 79 docked into the 5HT4 receptor 
they were able to predict areas upon the pharmacophore that would tolerate 
attachment of a fluorescent dye. Their hypothesis was that the piperidine of ML10302 
79 was in the vicinity of the top of the receptor binding pocket and that alkyl tethers 
conjugated to this ring would place the fluorescent dye in a position favourable for 
binding. By analogy this placed the aromatic ring of ML10302 79 at the bottom of the 
5HT4 receptor binding pocket where it was not expected to tolerate a bulky 
fluorescent dye. 
Compounds 80-83 are some examples from their study which helps to clarify 
their hypothesis (Figure 2-3). A short C1 linker installed at position 4 on the 
piperidine moiety and coupled to Dansyl, NBD and a naphthalimide derivative gave 
compounds 80, 81, and 82 which bound to 5HT4 receptors with 7, 7.5, and 64 nM 
affinities respectively. Compound 82 was used to highlight 5HT4 receptors on C6 
glial cells and report on subcellular localisation213. As a negative control to their 
computational model hypothesis they labelled the aniline nitrogen of ML10302 with 
NBD and Dansyl dyes as in compound 83. These compounds exhibited no affinity 
towards the 5HT4 receptors proving that the dye needed to be positioned away from 
the binding pocket in-order to retain receptor affinity and supporting their original 
hypothesis. 
2.1.1 Summary of the design and synthesis requirements of 
fluorescent ligands 
 
The series of serotonin and adenosine fluorescent ligands have shown that it is 
possible to fluorescently label a selection of selective high affinity receptor ligands 
with a large fluorescent dye, and still retain the high selectivity and receptor affinity 
exhibited by the non-fluorescent ligand. The key requirements to successfully 
generating a fluorescent ligand can be summarised as follow;  
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• The use of an alkyl linker to separate the fluorophore from the pharmacophore. 
• The positioning of the alkyl linker must be on an area of the pharmacophore 
known to tolerate molecular extension using previously elucidated SAR. 
• The use of a 1° amine as an attachment point for the fluorescent dye. 
• Careful selection of suitable fluorophore is required to control both the 
pharmacology and the fluorescent application of the ligand. 
 
These parameters have not only been used successfully to generate fluorescent 
adenosine and Serotonin ligands but when applied to small ligands to other receptor 
types have generated useful fluorescent ligands for the Histamine H1214 and H2215, the 
Muscarinic M1216, the Opioid Mu217, and the β23 and α121 adrenergic receptor types. 
We wish to apply these same principles into the design and synthesis of a fluorescent 
cannabinoid CB2 ligand. 
 
2.2 Designing a fluorescent cannabinoid CB2 ligand 
 
From the principles applied in section 2.1 we designed the ligand using the following 
criteria. 
 
• Selection of a suitable CB2 selective ligand. 
• Selection of an appropriate site within the chosen CB2 ligand to be modified 
for fluorescent dye conjugation. 
• Choice of length and terminating chemical group employed upon the alkyl 
linker. 
• The fluorescent dye to be conjugated to the CB2 ligand. 
• The synthetic strategy to be utilised in building the fluorescent CB2 ligand. 
 
Each of these will be considered separately and the rational of our choices are 
discussed. 
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2.2.1 Selection of a suitable CB2 ligand 
 
A thorough review of the available cannabinoid ligands was completed in section 1.4. 
We concluded that no single CB2 selective ligand possessed every parameter which 
was required for successful conjugation with a fluorescent dye i.e. 
 
• A high affinity towards the CB2 receptor (i.e. Ki ≤ 20 nM). 
• A high CB2/CB1 selectivity (≥ 20). 
• Chemical stability to hydrolysis, light and enzymatic degradation. 
• SAR data providing evidence that the ligand can tolerate molecula r extension 
and bulky substituents. 
• Has a structure that allows its synthesis outside the Misuse of Drugs act.  
 
We therefore selected a CB2 ligand which demonstrated as many of the required 
parameters as possible. As discussed in section 1.4.6 the series of Japan Tobacco 
compounds were chosen as our primary lead compounds. From this selection of 
ligands the compound JTE2-6 63 (Figure 2-4) demonstrated a high CB2 selectivity (> 
455 fold) and affinity (Ki = 1.1 nM) whilst incorporating different chemical 
functionalities allowing a selective chemical synthesis. Therefore JTE2-6 63 was 
selected as a lead molecule to be conjugated to a fluorescent dye. 
 
2.2.2 Selection of a suitable site upon JTE2-6 for conjugation 
 
The successful fluorescent ligands, encountered in section 2.1, each incorporated an 
alkyl linker that acted as both a spacer and tether to the fluorescent dye. Therefore we 
planned to incorporate a similar linker onto JTE2-6 63. The alkyl linker needed to be 
carefully position upon JTE2-6’s pharmacophore in-order that the compound’s CB2 
receptor affinity was retained. The pharmacophore of JTE2-6 was interrogated by 
considering which parts of the structure were communal within all of the active Japan 
Tobacco ligands (see Figure 2-4). 
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Figure 2-4 A breakdown of the SAR data available for the key functional groups of JTE2-6 63. 
 
Considering the structure of JTE2-6 63 from Figure 2-4 it was clear that the 
functionality which demonstrated an ability to tolerate molecular extension with alkyl 
chains was position 4 upon the benzamide ring. Structures similar to JTE2-3 63 have 
been shown to tolerate extension with pentyl chains and still retain excellent affinity 
and selectivity towards the CB2 receptor (i.e. compounds 62 & 65, figure 1-22)126. 
Other groups present on JTE2-6 63 such as the phenol, amide and aniline 
functionality that could also be used to conjugate the fluorescent dye were not 
considered for derivatisation due to the lack of previous evidence demonstrating 
extension upon these positions.  
 
2.2.3 Determining a suitable linker 
 
Two strategies were considered regarding the length of the linker. The first strategy 
involved a SAR approach, synthesising a number of ligands with differing alkyl 
lengths, and testing the pharmacology of all of these ligands conjugated to a single 
fluorophore to determine an optimum length. This approach was adopted by Macchia  
et al. in their synthesis of the NECA  based adenosine ligands 69 and 70200,202. The 
second approach involved using one alkyl chain length and conjugating this ligand to 
different fluorescent dyes and testing the pharmacology of these compounds. This 
approach has been more extensively used in other receptor systems such as 
serotonin33,212 and histamine214,215 ligands. The advantage of the latter technique is 
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that it has been shown that the fluorescent dye may alter the pharmacology and the 
application of the fluorescent ligands and is therefore more important to evaluate than 
the length of the alkyl linker alone. Also the Japan Tobacco compounds have shown 
previous evidence that molecule extension is tolerated at position 4, however there is 
no evidence that a bulky substituent will be tolerated at the terminal end of the alkyl 
chain. Thus, it was felt that a short length alkyl chain linker coupled to different 
fluorescent dyes would determine quickly if this type of derivatisation would be 
tolerated by the CB2 receptor. Optimisation of the linker length would be considered 
at a later date.  
From section 2.1 it was observed that each of the fluorescent ligands discussed 
incorporated a 1° amine group which was conjugated with the fluorescent dye. This is 
advantageous as the high reactivity of 1° amines and the number of commercially 
available amine reactive dyes will allow for a simpler synthesis. We therefore planned 
to incorporate a short alkyl linker (between C4 – C8) terminating in a 1° amine 
functionality at position 4 of JTE2-6 63 (Figure 2-4).  
 
2.2.4 Selection of a fluorophore 
 
The choice of fluorophore which is to be used for the CB2 ligand is of critical 
importance, if the fluorescent ligand is to retain potent pharmacology and find use in 
fluorescence confocal microscopy and SMD applications. Previous work discussed in 
chapter 2.1 evaluated many different types of fluorophore in similar ligands to those 
we wish to produce. In general, smaller molecular weight dyes were preferred such as 
Dansyl 84 and NBD 85, presumably chosen for their small steric impact upon the 
ligand causing less ligand-receptor perturbations (Figure 2-5). The small fluorophores 
Dansyl 84 and NBD 85 were successfully utilised in a number of GPCR ligands 
having activity at the adenosine200,202, serotonin33,212,213, and histamine214,215 receptors. 
These dyes have advantages of being small, and cheap to purchase, however their 
spectral properties are not ideal for biological applications. The absorption and 
fluorescence emission spectra and quantum yields of the Dansyl 84 and NBD 85 dyes 
are markedly dependant on solvent, in particular both dyes suffer from very low 
(<0.01) quantum yields in water218. The short excitation wavelengths of Dansyl (λabs = 
340-350 nm)218 and NBD (λabs = 470 nm)218 are also problematic for biological 
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applications due to the high energy radiation necessary for excitation, damaging cells 
and promoting autofluorescence.  These factors make them less suitable for SMD 
applications although both probes have been used successfully in confocal 
microscopy applications200,202. 
Two red-absorbing dyes have been evaluated in fluorescent receptor ligands. 
The BODIPY® and Cyanine (Cy) dyes (86  & 87, Figure 2-5) have both found use in 
fluorescent ligands for SMD applications25,33. The BODIPY® dyes have been used 
extensively in our own adenosine ligands24,25,207 as well as in other receptor ligands 
such as the muscarinic M1216, the opioid µ217 and β  adrenergic23 receptors. The 
reasons cited for using this unusual boron containing fluorophore include high 
quantum yield (approaching unity), photostability, low pH dependence and low 
percentage of triplet states25,217. A disadvantage of the BODIPY dyes commonly 
cited is a very small Stoakes shift which can cause problems with internal conversion 
quenching (section 1.1.1) between two dye molecules in close proximity of each 
other218. However this is only a problem observed when there is the potential to multi-
label a molecule with more than one fluorophore (i.e labelling large proteins) and is 
not a problem in the work we are conducting. The Cyanine dyes also have an 
excellent λabs for SMD applications with little autofluorescence observed218. However 
due to their structure containing trans double bonds, trans-cis photo induced 
isomerization is a problematic factor in FCS experiments205 They also have a 
considerably smaller quantum yield (∼ 0.3) than the BODIPY® fluorophores33. 
The BODIPY® dyes are available from Molecular Probes and have a number 
of spectral properties219. Depending on its structure, a wide range of emission 
wavelengths can be obtained ranging from 510 to 665 nm. In our previous work with 
the adenosine receptor ligands BODIPY® 630/650 86 (the dyes are named BODIPY® 
λabs/λem) was chosen, as its spectrum was optimal for the excitation source (633 nm 
He-Ne laser) and matched a common optical filter (LP650) of the in-house FCS and 
confocal microscopy equipment. The long excitation wavelength also resulted in less 
cellular autofluorescence and damage25,205. 
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Figure 2-5 The structures of the amine reactive fluorescent dyes that were evaluated for use in the CB2 
fluorescent ligands. Supply information is given when the dye is sold exclusively by one company. 
Spectral data is given for amine conjugates of the dye as NBD-F and Dansyl chloride are non-
fluorescent. 1. ref.218, 2. ref. 205. 
 
 
For this work we have opted to conjugate our CB2 ligand with the small and cheaper 
Dansyl dye 84, and utilise the BODIPY® 630/650 86 dye to produce CB2 ligands for 
confocal microscopy and SMD applications. 
 
2.2.5 Synthetic strategy  
 
A synthetic strategy, enabling the factors discussed in sections 2.2.1 to 2.2.4 to be 
incorporated into the target molecule, needed to be established. The target molecule 
was designated fluorophore-JTE2-6 i and was subjected to a retrosynthesis analysis 
shown in Scheme 2-2. 
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Scheme 2-2 The retrosynthesis of the target molecule fluorophore-JTE2-6. 
 
From Scheme 2-2 two disconnections, A and B, were possible. The fluorophore is 
required to be conjugated to the ligand in the last step, as this protects it from any 
chemical and light degradation inflicted by being introduced too early in the 
synthesis, whilst allowing a ‘generic’ molecule to be synthesised which can be 
conjugated to a choice of fluorophores. Disconnection A confers more advantages to 
the synthesis than B due to factors discussed in section 2.1.1.1.  Disconnection A 
allows the commercially available fluorophores Dansyl-Cl 84 and BODIPY 630/650 
X OSu 86 (represented by synthon iii) to be installed under mild conditions during the 
final step. Disconnection B is less efficient and requires the fluorophore to be pre-
conjugated with the linker (represented by synthon v) which would expose the 
fluorophore to the chemical conditions required for conjugation via an ether linkage. 
Compound ii can be subjected to further retrosynthesis as shown in Scheme 
2-3.  Disconnection E is not a valid pathway as it leads to chemoselectivity problems 
with three nucleophilic groups present in compound x (2 x phenol, 1 x amine). 
Disconnection C and D are both lead to accessible compounds; vi, vii (tyramine) and 
viii. The 1° amine group will be protected with a suitable protecting group in order 
that the chemical steps remain selective. Compounds vi and viii from disconnections 
C and D will be further analysed in Scheme 2-4. 
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Two routes were planned for synthetic evaluation from compounds vi and viii 
converging with a common intermediate xi.   
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Scheme 2-4 Retrosynthetic analysis on compounds vi and viii. PG = protecting group. FGI = functional 
group interconversion 
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The common intermediate xi can be broken down to commercially available 4-
hydroxy-3-nitrobenzoic acid xii and a protected aminoalkyl synthon xiii. Evaluation 
of compounds that would give access to the synthon xiii showed that the aminoalkyl 
alcohols were commercially available. Protection with the acid labile tert-
Butoxycarbonyl (Boc) protecting group followed by in situ activation of the alcohol 
employing Mitsunobu conditions would be used to generate synthon xiii. Considering 
which aminoalkyl alcohols were commercially available we found that they were 
restricted to 3-aminopropan-1-ol, 4-aminobutan-1-ol, 5-aminopentan-1-ol, and 6-
aminohexan-1-ol. 6-Aminohexan-1-ol 88 was chosen for this synthesis as it fulfilled 
all of the requirements discussed in section 2.2.3. 
 
2.3 Chemistry results 
 
N-Benzyloxycarbonyl-6-aminohexan-1-ol 89 was synthesised in high yield according 
to a published procedure using Boc2O in aqueous dioxane220 (Scheme 2-5). The 
alcohol 89 was activated in situ using standard Mitsunobu conditions221 of PPh3, 
diethylazodicarboxylate (DEAD) and coupled to the commercially available methyl 4-
hydroxy-3-nitrobenzoate to afford ester 90. Saponification using LiOH revealed the 
benzoic acid 91. 
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Scheme 2-5 Reagents, conditions and yields: (i) Boc2O, dioxane, NaHCO3, water, rt, 2h, (99%); (ii) 
methyl 4-hydroxy -3-nitrobenzoate, DEAD, PPh3, THF, rt, 5h, (66%); (iii) LiOH, MeCN, H2O, 50 °C, 
30min, (100%). 
 
The carbamate N-H proton of compound 91 displayed an unusual NMR spectrum 
involving a splitting of its peak between the usual upfield position of 4.64ppm (70% 
split) and a downfield position of 6.30ppm (30% split) in CDCl3 (Figure 2-6). The 
proton could be brought into 100% of its normal field alignment (4.64ppm) by the 
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addition of D2O (result not shown). The splitting was observed on different 
concentrations and batches of the acid 91.  This effect was also observed in 
aminobenzoic acid derivatives 92 and 93 (Scheme 2-6) but was not observed with the 
precursor methyl ester 90 (results not shown). 
 
 
The benzoic acid derivative 91 was used in two different competing routes towards 
the target molecule as discussed in the retrosynthetic analysis in section 2.2.5 (route F 
and G, Scheme 2-4). Following route F the nitro group was reduced using hydrogen 
and Pd catalysis to afford the aniline 92 in good yield (Scheme 2-6). Reductive 
alkylation to the substituted aniline 93 with pentanal and NaCNBH3 proceeded in low 
yield (24%). Peptide coupling of 93 with tyramine was attempted using a number of 
coupling reagents including CDI, DCC, and oxalyl chloride/DMF (Vilsmeier reagent), 
however all attempts to form the peptide bond resulted in complex mixtures and 
corresponding low yielding reactions. 
The alternative route shown by G (Scheme 2-4) involved coupling the nitro-
acid 91 directly with tyramine. Thus activation of the acid 91 with CDI followed by 
tyramine coupling afforded 94 in excellent yield (79%).  
Carboxylic acid 
proton 
Carbamate proton 
6.30ppm (30%) 
Carbamate proton
4.64ppm (70%) 
Figure 2-6 
1H NMR showing the unusual splitting of the carbamate proton of 91. The 
proton could be brought into 100% alignment at 4.64ppm by the addition of D2O. 
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Scheme 2-6 Reagents, conditions and yields: (i) H2, Pd/C, EtOH, rt, 12h, (76%); (ii) pentanal, NaCNBH3, MeOH, 4h, rt, (24%); (iii) CDI, MeCN, tyramine, rt, 24h, (no 
reaction) or oxalyl chloride, DMF, pyridine, DCM, tyramine, rt, 24h, (no reaction) or DCC, DCM, tyramine, rt, 24h, (no reaction); (iv) CDI, MeCN, tyramine, rt, 12h, (79%); 
(v) H2, Pd/C, EtOH, rt, (69%); (vi) pentanal, NaCNBH3, MeOH, rt, 4h, (71%); (vii) AcCl, MeOH, rt, 18h, (65%).
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An alternative coupling using the Vilsmeier reagent formed in situ (oxalyl 
chloride/DMF) to form the acid chloride followed by tyramine coupling was assessed. 
This reaction resulted in a low yield (14%) involving a difficult work-up to isolate the 
product.  
Nitro group reduction of 94 gave aniline 95 which exhibited the expected loss 
of the Nitro IR stretch (1559 & 1391 cm-1) and an upfield shift of the benzamide ring 
protons. Accompanying the change, from the electron withdrawing effects of the nitro 
group to the electron rich aniline, was an alteration of the compounds physical 
properties, such that they exhibited fluorescence under long wave UV light. 
Compound 96 was shown to exhibit a λabs 313 nm and a λem 386 nm. 
Alkylation of aniline 95 was evaluated using 1- iodopentane222 and NaHCO3, 
or reductive alkylation223 using pentanal and NaCNBH3. Alkylation using the alkyl 
halide gave a lower yield (25%) and a more difficult reaction mixture to purify than 
the reductive alkylation reaction (71%) which was used in all subsequent reactions. 
Acidolysis of the Boc protecting group of 96 using methanolic HCl relinquished the 
target congener 97 as its corresponding crystalline dihydrochloride salt. 
2.3.1 Conjugation with amine reactive dyes 
 
The congener 97 was coupled with the amine reactive dyes Dansyl chloride 84 and 
BODIPY® 630/650-X OSu 86 (B, Scheme 2-7). In-order to react with both dyes, the 
free base of congener 97 was generated in situ from the hydrochloride salt. The 
coupling reactions were therefore conducted in a 50:50 MeCN/aqueous sodium 
bicarbonate buffer (pH 8.3) designed to liberate the free base and promote organic 
solubility without generating the phenoxide ion (< 2 % in solution**) which could 
cause problems with chemoselectivity. 
The coupling reaction with Dansyl chloride 84 gave two major fluorescent 
products. Isolation of these, using preparative TLC, and subsequent mass 
spectrometry showed that the mono and bis Dansylated products had been formed 
with molecular weights of 675 and 908 respectively. The desired mono Dansyl 
product Dansyl-JTE2-6 99 was obtained in 19% yield and characterised by 1H NMR 
using reverse phase HPLC analysis to assess purity. 
                                                 
** Calculated using the Henderson-Hasselbalch equation using a pKa of 10.0 for phenol. 
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Chemoselective acylation of the 1° amine of 97 with BODIPY® 630/650-X OSu ester 
86 afforded the target molecule BODIPY-JTE2-6 100 in 63% yield, following 
purification using preparative TLC, verified by mass spectrometry, 1H NMR and 
reverse phase HPLC. 
The chemoselectivity of the 1° amine of 97 towards succinimidyl esters was 
tested in a model reaction. A pseudo fluorophore succinimido 1-naphthaleneacetate 98 
was prepared using DCC coupling of 1-naphthylacetic acid and N-
hydroxysuccinimide (A, Scheme 2-7). The use of the pseudo fluorophore avoided the 
expense and complex NMR spectra associated with BODIPY® 630/650-X OSu 86. 
Full chemical analysis (MS, elemental, 1H & 13C NMR, 1H-1H & 13C-1H COSY 
NMR) of the acylated compound 101 isolated from this reaction confirmed that only 
the desired 1° amine of 97 reacts with succinimidyl esters. 
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Scheme 2-7 A. The synthesis of  succinimido-1-naphthaleneacetate. B. Conjugation reaction of 97 with 
amine reactive fluorophores and pseudo fluorophores. Reagents, conditions and yields: (i) DCC, DCM, 
rt, 12h, (47%); (ii) Dansyl-Cl 84 or BODIPY 630/650-X OSu 86 or 98, NaHCO3 (aq) pH 8.3: MeCN 
1:1, rt, 1-12h, (19-63%). 
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Figure 2-7 
1H-1H COSY NMR spectrum of 101 ran in CDCl3 and D
6-DMSO. The spectrum shows the 
coupling of the 4 exchangeable protons present within the molecule to neighbouring protons. The 
phenol and aniline protons show no coupling patterns whilst amide 1 (6.3 ppm) shows a coupling 
pattern to the phenyl ethyl moity (shown by the red line). Amide 2 (5.7 ppm) shows a coupling pattern 
to the oxygen containing hexyl chain  (shown by the yellow line). 
 
The following data provided evidence that the 1° amine of 97 was reacting with one 
molecule of succinimido 1-naphthaleneacetate under the coupling conditions 
employed. 
 
• Elemental analysis and ES-MS confirmed that only one naphthylacetyl group 
was conjugated in the final product. 
phenol 
Amide 1 
 
Amide 2 
aniline 
N
HO N
H
H
NO
OH
O
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• 
1H-1H COSY coupled with D2O shakes were able to identify each of the 
exchangeable protons present in 101 (Figure 2-7, D2O shake data not shown) 
and an interpretation of the data is as followed:  
 
o 1 phenol proton (singlet, 8.3 ppm) coupled to no other protons. 
o 1 amide proton (triplet, 6.3 ppm) coupled to the phenylethyl moiety. 
o 1 amide proton (triplet, 5.7 ppm) coupled to the oxygen linked hexyl 
chain (five couplings can be observed in the COSY due to two 
methylene protons within the chain occurring at the same chemical 
shift). 
o 1 aniline proton (broad singlet, 4.3 ppm) coupled to no other protons. 
 
 
2.4 Pharmacology results  
 
The pharmacology of Dansyl-JTE2-6 99 and BODIPY-JTE2-6 100 was assessed by 
competitive radioligand displacement of the non-selective cannabinoid [3H] CP55, 
940 from cellular membranes containing human CB2 receptors and was performed as 
previously described by Leggett et al.224. Both Dansyl-JTE2-6 99 and BODIPY-JTE2-
6 100 failed to displace any of the [3H] CP 55,940 from cell membranes prepared 
from CHO cells expressing the human CB2 receptor up to a concentration of 10-4 
mol/L (100 µM) (Figure 2-8). The low affinity of BODIPY-JTE2-6 100 was also 
confirmed using cell membranes prepared from HEK cells expressing the human CB2 
receptor by an independent group at the University of Connecticut, Storrs, USA 
(Figure 2-8). In all experiments it was clear that the IC50, and therefore Ki, values 
were > 10 µM for both Dansyl-JTE2-6 99 and BODIPY-JTE2-6 100. 
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Figure 2-8 Radioligand displacement of [3H] CP 55,940 from cell membranes (CHO & HEK) 
containing human CB2 receptors using Dansyl-JTE2-6 99 and BODIPY-JTE2-6 100.  
 
2.5 Use of Dansyl-JTE2-6 and BODIPY-JTE2-6 in 
fluorescence confocal microscopy. 
 
The two fluorescent ligands Dansyl-JTE2-6 99 and BODIPY-JTE2-6 100 were used 
in confocal experiments to demonstrate whether the ligands had the potential to 
highlight CB2 receptor membrane binding. Known concentrations of fluorescent 
ligand were incubated with CHO cells expressing human CB2 receptors and images 
were recorded at various time courses throughout the experiment. To assess whether 
the fluorescence observed was due to specific CB2 binding, CHO cells were pre-
incubated with a blocking concentration of a non-fluorescent cannabinoid ligand (1 
µM HU210 14) and the fluorescent ligand 99 or 100 was subsequently introduced. 
Images collected from this experiment were compared to those conducted without the 
HU210 14 present, to determine if any fluorescence observed was due to CB2 receptor 
binding. Various concentrations of 99 and 100 ranging from 10 – 400 nM were used 
in these experiments. When concentrations of 200 nM or below were used, the 
fluorescence observed was weak even when laser power and pin-hole aperture was 
increased. Increasing the concentration of the fluorescent ligand to 400 nM showed 
intra-cellular fluorescence after 5 minutes; however, this fluorescence could not be 
blocked or reduced by pre- incubation with HU210 for either Dansyl-JTE2-6 99 or 
BODIPY-JTE2-6 100 (Figure 2-9). Background fluorescence from the CB2 
transfected CHO cells was negligible for both of the excitation wavelengths used 
(i.e.363 nm (Dansyl) and 633 nm (BODIPY) - Result not shown). 
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Figure 2-9 Representative confocal slice images of human CB2 transfected CHO cells incubated with 
Dansyl-JTE2-6 99 (A & B) and BODIPY-JTE2-6 100 (C & D). Images taken at 10 mins after the 
fluorescent ligand was introduced using a Zeiss axiovert 100 with LSM510 confocal. Images A & C 
are for un-treated cells whilst images B & D are of cells that have been pre-incubated with 1µM 
HU210. Fluorescent ligand concentration in each experiment was 400 nM.  Fluorescence was obtained 
for images A & B by using laser excitation at 363 nm through a Plan-apochromat 63x/1.4NA oil 
immersion objective and a LP560 emission filter. Pinhole diameter was 166µm. Fluorescence was 
obtained for images C & D by using laser excitation at 633 nm through a Plan-apochromat 63x/1.3 oil 
immersion objective and a LP650 emission filter. Pinhole diameter was 79µm. 
 
2.6 Discussion 
 
An efficient eight-step synthesis starting from commercially available materials and 
utilising established synthetic techniques was used to generate two target fluorescent 
ligands Dansyl-JTE2-6 99 and BODIPY-JTE2-6 100.  
During the compounds’ synthesis a number of interesting discussion points 
were established and are examined below. 
A B
C D
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The 1H NMR analysis of the benzoic acid derivatives 91, 92 and 93 (Scheme 2-5 & 2-
6) showed an unusual splitting pattern within the spectrum for the carbamate N-H 
proton that deserves further comment (Figure 2-6). Our initial thoughts were that the 
erroneous peak observed at 6.30ppm (0.3 protons) was due to contamination. 
However this peak was consistently observed in the spectrum from a number of 
different analytically pure samples of 91. A D2O shake upon this sample, to identify 
exchangeable protons, simultaneously eliminated the erroneous peak at 6.30ppm and 
increased the area of the peak at 4.64ppm to 1 proton. The peak at 4.64ppm, which is 
the normal shift for a carbamate proton, slowly decayed as the N-H bond was replaced 
with the unobservable N-D bond.  This result is indicative that the carbamate N-H 
proton in anhydrous solution is involved in hydrogen bonding which is destroyed 
upon the addition of D2O. The downfield 6.30ppm shift is likely to represent the 
carbamate N-H proton whilst engaged in hydrogen bonding, most likely to the 
carbonyl oxygen of the acid functionality as depicted in Figure 2-10.  
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Figure 2-10 Postulated intra and inter molecular H-bonding of the carbamate N-H proton in the 
benzoic acid derivative 91. 
  
The precursor methyl ester 90 did not exhibit this carbamate splitting pattern 
presumably due to the ester functionality not being able to align correctly to evoke 
hydrogen bonding. 
Condensation with tyramine was assessed using both the nitro-acid 91 and the 
aniline-acid 93. The latter was associated with complex mixtures and low yields, 
whilst the nitro-acid 91 coupled to tyramine using CDI in high yield. The difference 
between these two reactions lay in the disparity between the electron withdrawing 
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nitro group and the nucleophilic aniline. The aniline was potentially able to react with 
CDI225, the O-Acylisourea formed with DCC, and the acid chloride formed with the 
Vilsmeier reagent and hence reduced yields and complex mixtures were observed. 
The nitro group therefore functioned as a masked amino group, and permitted 
reactions involving the external nucleophile, tyramine, to proceed unhindered giving 
intermediate 94. 
The change accompanying the reduction of the nitro group, to compounds 
possessing fluorescent characteristics was investigated to establish if we could use 
them directly as a fluorescent ligand without the need to label them with a peripheral 
dye. The fluorescent properties of compound 96 was determined and found to be 
unsuitable for use in confocal microscopy or FCS (λabs 313 nm, λem 386 nm). The low 
wavelength λabs would cause problems with cellular autofluorescence, and the small 
stoakes shift (73 nm) would make detecting the fluorescence over the background 
difficult (see section 2.2.4). 
The selectivity of succinimidyl esters to acylate 1° amines over other 
nucleophilic sites was tested in a model reaction between the congener 97 and 
succinimido 1-naphthaleneacetate 98. Although the literature would suggest that this 
reaction is selective to the amine, detailed mechanistic reasoning for amine reactivity 
was sparse, with stronger basicity, lower steric bulk and the hard basic nature of the 
1° amine being shown to increase reactivity with OSu esters210. One report however 
demonstrated that OSu esters, under appropriate conditions can react with serine, 
threonine and tyrosine hydroxyls in peptide structures226. Since 97 displayed three 
potential nucleophilic sites that could potentially react with BODIPY® 630/650-X 
OSu 86, and that the 1H  NMR spectra of the BODIPY® 630/650 conjugate 100 was 
complicated with unresolved protons, the use of the model reaction was necessary and 
justified to provide conclusive evidence of selectivity. The detailed chemical analysis 
of the 1-naphthyl-conjugate 101 confirmed that only the desired 1° amine of 97 
reacted stoichiometrically with succinimido 1-naphthaleneacetate 98. The model 
reaction when combined with reported amine selectivity of OSu esters, a high yield 
(63%), correct Molecular ion mass, and correct 1H NMR spectrum led us to conclude 
that selective acylation of the 1° amine of 97 by BODIPY® 630/650-X OSu 86 was 
achieved. 
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The affinity of Dansyl-JTE2-6 99 and BODIPY-JTE2-6 100 at the human CB2 
receptor was demonstrated to be extremely low. Concentrations of 10-4 mol/L of the 
fluorescent ligands were unable to displace any detectable amount of [3H] CP55, 940 
from membrane homogenates containing CB2 receptors. Any attempt to test 
concentrations of the fluorescent ligands above 10-4 mol/L resulted in precipitation of 
the drug from the assay solution. BODIPY-JTE2-6 100 was also screened for affinity 
towards CB2 receptors in transfected HEK cell lines by an independent group in the 
USA to confirm the low binding affinity. These results indicate that large molecular 
weight dyes located on the terminal end of the 4-alkyl chain abolishes binding to the 
CB2 receptor, in the Japan Tobacco series of ligands. Further work to elucidate a 
position on the Japan Tobacco that will tolerate conjugation to fluorescent dyes was 
therefore required and will be discussed in chapter 3. 
Although the CB2 binding results indicated that the fluorescent ligands did not 
bind to the CB2 receptor with any appreciable affinity, it was necessary to confirm this 
result using a fluorescent based assay. The BODIPY-NECA adenosine agonist 71 
showed very low affinity towards the A1 receptor (Ki = 22000 nM) in radioligand 
binding experiments but has been used successfully in both confocal microscopy and 
FCS experiments (section 2.1.1)25. Therefore, we tested the two fluorescent 
cannabinoid ligands 99 & 100 to determine if they could show selective binding to 
CHO cells expressing the human CB2 receptor. Intra-cellular fluorescence was 
observed for both ligands after 5 minutes at concentrations of 400 nM. This 
fluorescence was not reduced/abolished when the cells were pre- incubated with the 
high affinity cannabinoid agonist HU210 14, demonstrating that the fluorescence 
observed was non-specific. The fluorescence observed is most likely due to leeching 
of the highly lipophilic molecules into the cell through the phospholipid membrane. 
These results indicate that the two ligands 99 & 100 had no appreciable affinity 
towards the human CB2 receptor and were unsuitable as fluorescent CB2 receptor 
ligands. The following chapter will discuss our continued efforts to use our initial 
findings of fluorescently labelling JTE2-6 63, to develop modified strategies leading 
towards a fluorescent CB2 ligand.  
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2.7 Conclusions 
 
• We successfully synthesised a derivative of the CB2 selective ligand JTE2-6 
63, incorporating an alkyl linker which was labelled with the dansyl and 
BODIPY® fluorescent dyes. 
• A model reaction, using a pseudofluorophore, demonstrated that succinimidyl 
esters react preferentially with 1° amines when other nucleophilic sites are 
present. 
• The two fluorescently labelled derivatives of JTE2-6 63 were found to have 
lost extensive binding affinity at the CB2 receptor, establishing that bulky 
substituents at the 4-benzamide position of JTE2-6 63 was not tolerated within 
the CB2 receptor binding pocket. 
• The two fluorescent labelled ligands Dansyl-JTE2-6 99 and BODIPY-JTE2-6 
100 were unable to detect membrane receptor binding in CHO cells expressing 
the CB2 receptor, using fluorescent confocal microscopy detection.  
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3 Molecular modelling of the CB2 receptor and docking of 
JTE2-6  
 
Our initial work outlined in chapter 2, concerned modifications to the benzamide ring 
of JTE2-6 63. This approach led to compounds with little affinity to the human CB2 
receptor. This work was carried out rationally with the knowledge that the Japan 
Tobacco compounds could tolerate molecular extension from the benzamide ring 
(section 2.2). Prior to our work it was not clear whether a bulky substituent (such as a 
fluorescent dye) could be incorporated at the terminal end of the alkyl linkers and still 
retain binding affinity to the CB2 receptor. Our results with Dansyl-JTE2-6 99 and 
BODIPY-JTE2-6 100, led us to believe that the benzamide ring of the Japan Tobacco 
compounds may be positioned deep within the receptor binding pocket when bound 
within the CB2 receptor, resulting in large steric/electrostatic clashes with the 
fluorophore. To test this hypothesis, we embarked on a methodology inspired by 
Berque-Bestel et al. who had designed fluorescent serotonin 5HT4 ligands based on 
ML10302 79. This process successfully employed computer modelling of the ligand-
receptor complex to guide the positioning of the fluorescent dye (section 2.1.2)213. 
 
3.1 Computational modelling a of G-protein coupled receptor 
 
G-protein coupled receptors (GPCRs) are seven transmembrane (TM) proteins 
responsible for the transduction of signals from extra cellular ligands into intra 
cellular secondary messengers (section 1.3.1). The characteristic structure and 
intimate relationship with the cellular membrane, makes determination of their 3D 
structure extremely difficult using standard approaches such as X-ray crystallography 
and NMR. Although over 12000 structures are deposited in the Protein Data Bank 
(PDB) by the year 2000 only one of them belonged to the GPCR family84. 
Computational methods have therefore been employed by scientists who wish to 
study the 3D structure of GPCRs. 
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3.1.1 Crystal structure template 
 
Many of the early techniques used to model GPCRs were based upon the structure of 
Bacteriorhodopsin, a 7TM protein which is not associated with a G-protein, since this 
was the only X-ray crystallography data of a 7TM protein that was ava ilable227!  
Recently a high-resolution (2.8 Å) structure of a genuine G-protein associated protein, 
Bovine Rhodopsin, has been published81,228. Comparison of the 3D structures of 
Bacterio- and Bovine Rhodopsin clearly showed that their 3D structures are 
significantly different84. Some authors have stated that using Bacteriorhodopsin, as a 
3D template for modelling GPCRs, leads to models which are too poor to be used for 
‘rational drug design’227. 
The high-resolution X-ray data of Bovine Rhodopsin used to construct models 
of GPCRs has recently replaced Bacteriorhodopsin as the template of choice when 
modelling GPCRs. This template, based on an actual G-protein coupled receptor, is 
easier to justify as a model and has received positive support in the field of GPCR 
modelling82,83,229, however some authors do remain sceptical to the accuracy of the 
GPCR model generated84,227. Use of homology modelling to the 2.8Å model of 
Bovine Rhodopsin has been demonstrated to yield excellent results in the study of a 
number of GPCR systems including the dopamine D2 & D3 receptors, muscarinic M1 
receptor, and vasopressin V1a receptor82,83,229.  
 
3.1.2 Sequence alignment 
 
The generic procedure for producing a homology protein model based on comparative 
modelling has been described by Andrew Leach230. The specific methods (or 
“…recipe [sic]…”) for homology modelling of GPCRs, using the Bovine Rhodopsin 
template, have been described by Oliveira et al.231, and is depicted in Figure 3-1. In 
brief the primary amino acid sequence of the receptor to be modelled is extracted 
from a sequence data base i.e. Swiss-Prot††. The primary amino acid sequence can 
then be aligned against the sequences of other GPCR family members, including 
Bovine Rhodopsin. The objective of a sequence alignment is to position the amino 
acid sequences so that the matched stretches of amino acids correspond to common 
                                                 
†† http://ca.expasy.org/sprot/ 
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structural or functional features (such as the TM α-helices of GPCRs). Gaps in the 
aligned sequence correspond to regions where polypeptide loops are deleted or 
inserted. Various alignment algorithms may be used to ‘score’ the arbitrary 
alignments and the objective is to ascertain the alignment with the best score. Scoring 
can be derived from a number of different factors. The simplest type of score is the 
percentage sequence identity, which gives a score equal to the number of identical 
matches between the two alignments. This method can be extended by giving positive 
scores to amino acid residues that are topologically equivalent i.e. similar shape, 
electronic, hydrogen-bonding and hydrophobic properties. The more useful and 
complicated sequence alignment algorithms are outside the scope of this work but 
readers are directed to an excellent review of the mathematics behind the 
techniques230. In brief these powerful algorithms use a dynamic programming 
technique based around matrix problem solving methods. The system uses gap 
penalties, which introduces a negative scoring into the alignment when the sequence 
has gaps introduced into it to enhance the sequence identity. To cut down computer 
processing time and to allow for multiple sequence alignments, heuristic search 
methods such as, FASTA, BLAST and CLUSTAL W are commonly used by 
molecular modelling laboratories230,232. These programmes generally work by rapidly 
identifying regions of potential interest using fast look-up methods and then expand 
regions locally to identify the alignment. Alignment of GPCR proteins is made 
slightly easier, over other protein classes, in that they posses a highly conserved 
residue in each of the seven TM α-helices182. Thus highly conserved residues are 
matched up first and then the alignment algorithm is allowed to run. Once a 
satisfactory alignment has been found for the structurally conserved sequences (i.e the 
TM α-helices), the 3D model of Bovine Rhodopsin can be mutated to the amino acids 
present in the GPCR to be modelled. The intra- and extracellular loops can be added 
by searching protein databases for the X-ray coordinates of similar peptide sequences 
to the loop sequence present in the GPCR sequence. Once the model has been 
constructed it is refined by using molecular mechanics and molecular dynamics to 
give an energy minimised representation of the GPCR. 
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Figure 3-1 Cartoon schematic of generating a 3D GPCR model from the X-ray crystallography data 
from Bovine Rhodopsin. 
 
3.1.3 Energy minimisation and molecular dynamics 
 
Energy minimisation techniques use complicated mathematical models to lower the 
potential energy surfaces of macromolecules. Adjusting the internal or Cartesian co-
ordinates of the atoms in the structure reduces the electronic and steric interactions 
occurring within the molecule leading to a lower energy structure. Minimisation 
methods are capable of finding one of the many energy minimums for a structure; 
however the minima located may not be the overall global energy minimum (Figure 
3-2). This is because minimisation algorithms move the energy in a ‘downhill’ 
direction and thus are not capable of surmounting energy barriers to achieve the 
global energy minimum. 
Sequence, of unknown 3D 
structure, of a GPCR 
 
3D structure and 
sequence data for Bovine 
Rhodopsin  
Sequence alignment 
Build loops 
Mutate the structurally 
conserved sequences 
Refine model by energy 
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Figure 3-2 A schematic one-dimensional energy surface. The diagram shows that energy minimisation 
techniques can only move in a ‘downhill’ direction to the nearest energy minimum. Thus A and B will 
both find the same energy minimum but it would only be the starting structure C that could find the 
global energy minimum for this structure . 
 
The actual mathematics used for energy minimisation are outside the scope of this 
work, however for further information readers are directed to Leach’s excellent 
description of the techniques involved233. The main techniques used in energy 
minimisation are: 
 
• Steepest decent – A nonconvergent first-order minimisation. This method uses 
a displacement opposite to the potential energy gradient which is added to the 
coordinates at each step. The step size is increased if a lower energy results; 
otherwise it is decreased.  
• Conjugate gradient – A convergent first-order minimisation. This method 
makes use of the minimisation history, as well as the current gradient to 
determine the next step. 
• Newton-Raphson method – A second-order deriva tive method. A very 
powerful method which uses large amounts of computer memory and is 
therefore a slow computing process. Due to the memory restrictions this 
technique is currently limited to systems with about 200 atoms or less234. 
• Adopted-Basis set Newton-Raphson (ABNR) - A convergent method which 
combines the reduced computing power of first-order techniques with the 
en
er
gy
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increased chance of finding the lowest potential energy state from using the 
more powerful second order methods. 
 
The choice of which energy minimisation method to use is a balance of a number of 
factors, including computer processing time, the robustness of the method employed 
and how far the starting structure is away from the energy minimum. For instance 
steepest descent is extremely useful in producing initial structures that have had most 
of their high-energy interactions reduced, in contrast convergent methods are much 
better once the initial strain has been removed233. The more powerful second-order 
methods such as Newton-Raphson are not suitable for use in GPCR modelling. 
However, the ABNR technique can be used (due to its refinements in its computer 
processing ability) and is the method of choice for most large systems234. Following 
energy minimisation the GPCR model is ready to use, having had the high-energy 
steric and columbic interactions removed. 
The model can now be subjected to computer simulation methods. The 
minimised structure represents an individual minimum energy configuration of a 
system. In the case of macromolecules, such as GPCRs, there are an enormous 
number of minima which are closely separated to the one found through minimisation 
techniques. To study how the receptor behaves as it moves through these phases of 
energy minima, it is necessary to model successive configurations of the system 
generated by applying Newton’s laws of motion to the system: a technique known as 
Molecular Dynamics (MD)235. Newton’s laws can be stated as follows: 
 
1. A body continues to move in a straight line at constant velocity unless a force acts 
upon it. 
2. Force equals the rate of change of momentum. 
3. To every action there is an equal and opposite reaction. 
 
Thus the whole macromolecule may be simplistically reduced to balls, representing 
atoms, and springs, representing bonds. If kinetic energy, in the form of heat (300-
900K is normal), is introduced into the system then the set of balls and springs are set 
in motion. The velocities and atomic coordinates, during MD, must be calculated at 
definitive time points and this is a critical factor in a successful MD. Too small a time 
frame and the trajectory will only cover a limited proportion of the phase space; too 
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large and instabilities may arise due to unrealistic collisions between the atoms. The 
suggested time step for flexible molecules with flexible bonds such as a GPCR is 1.0 
x 10-15 seconds (1 fs)235. Therefore MD simulations comprising even short time 
frames, limited to a few hundred ps, require large amounts of computing power and 
need several days of processor time to complete. During an MD simulation the 
intermediate structures generated can be analysed both in terms of energy functions or 
observed as a 3D movie simulation to study key interactions. Any of the structures 
generated from an MD simulation can be subjected to energy minimisation techniques 
discussed above to give the best possible representation of what the 3D structure of 
the GPCR may look like.  
 
3.1.4 Ligand docking 
 
Once the initial GPCR receptor has been constructed, a ligand can be docked into the 
receptor. The docking of a ligand in a GPCR has been recommended to be done using 
the binding pocket that encases 11-cis-retinal; the covalently bound natural ligand of 
Bovine Rhodopsin84. The retinal molecule, bound in Bovine Rhodopsin, is located 
within the TM regions; specifically interacting with TM 3, 5 and 681,83. It has been 
shown, mainly through site-directed mutagenesis studies, that for other GPCR 
systems the small-molecule binding site is also located within the TM regions84. Thus, 
TM 3, 5, 6 and 7 are known to interact with agonist ligands in the β2-adrenergic 
receptor, TM 3 has been demonstrated to interact with ligands in the 5HT1A receptor, 
and TM 3, 5 and 7 are involved in the antagonist binding of losartan in the 
angiotensin II receptor84. It is clear from this picture that there is not a common 
binding pocket for the GPCRs. However, by using the natural retinal binding pocket 
within Bovine Rhodopsin and using the available site-directed mutagenesis and other 
‘common knowledge’ for a particular ligand-GPCR interaction, it is possible to build 
a useful and predictive model84. It is noteworthy to state that once a ligand has been 
docked into a GPCR, energy minimisation and molecular dynamics can be used to 
generate energy minima structures as discussed in section 3.1.3. 
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3.2 Previous modelling of the CB2 receptor  
 
The CB2 receptor, a member of the GPCR superfamily, has been cloned and 
characterised in human, rat and mouse species4,104-106 (section 1.3.4). To date, like all 
other GPCRs, there is no X-ray crystallography or conclusive NMR data available to 
help elucidate the 3D structure of the CB2 receptors. Knowledge of the 3D structure 
would help researchers understand the intimate ligand-receptor interactions occurring 
within the receptor. Specifically it would allow us to determine the best position to 
locate a fluorescent dye on the Japan Tobacco pharmacophore. 
To allow us to accurately represent the 3D structure of the CB2 receptor we 
considered work previously undertaken by other researchers, who have examined the 
molecular pharmacology of the CB2 receptor using mutagenesis and molecular 
modelling techniques.  
3.2.1 Mutational analysis 
 
Studies using single-point mutations and chimeric receptors have been used to locate 
important binding interactions necessary for selective CB2 binding. A summary of this 
work is shown in Table 3-1.  
In the absence of a 3D-crystal structure, accurate modelling of the integral 
membrane proteins depends heavily on mutational analysis. This technique can afford 
information on the key amino acids and regions of amino acids that are important to 
receptor function. Mutations have concentrated on the suspected binding pockets 
located within the extra cellular loops (EL) and the transmembrane (TM) regions. 
Shire et al., commented that the experimental protocol for mutational analysis of the 
cannabinoid receptors is more difficult than with other GPCRs236. His reasons were 
based on the low amino acid identity between CB1 and CB2 receptors, particularly in 
TM 1, TM 4 and TM 5 (section 1.3.4), and that the cannabinoid subfamily are 
characterised by structural features not found in the majority of GPCRs. Thus, the 
lack of EL 1/TM 3 cysteines, the absence of a highly conserved proline residue in TM 
5, and the unusual 2 cysteine residues found in EL 2 of CB1 and CB2 make 
extrapolation of previous mutations to GPCRs extremely difficult.  
Mutational work has shown there may be different binding pockets for the 
different sub-classes of cannabinoid ligands154,182,194. The aminoalkylindoles (e.g. Win 
55212-2 3), classical cannabinoids (e.g. CP 55, 940 2) and the biarylpyrazole (e.g. SR 
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144528 6) have been shown by mutational analysis to form distinct binding 
interactions with different amino acids within the CB2 receptor. 
 
CB2 
residue 
mutated 
Mutation Effect on Ligand Binding 
Amino 
Acid 
position  
Reference 
Lys 109 Ala CP55,940 (=), Win 55212-2 (=) TM 3 154 
Lys 109 Arg CP55,940 (=), Win 55212-2 (=) TM 3 154 
Ser 112 Gly CP55,940 (-), Win 55212-2 (=) TM 3 154 
Phe 197 Val CP55,940 (=), Win 55212-2 (-) TM 5 194 
Tyr 190a Phe CP55,940 (=), Win55212-2 (=) TM 5 237 
Tyr 190a Ile Abolished binding  TM 5 237 
Trp 172 Phe CP55,940 (=), Win55212-2 (=) TM 4 238 
Trp 172 Ala Abolished binding TM 4 238 
Asp 130 Ala HU-210 (-), Win 55212-2 (-) TM 3 239,240 
Ser 161 Ala CP55,940 (=), Win 55212-2 (=), SR144528 (-) TM 4 182 
Ser 165 Ala CP55,940 (=), Win 55212-2 (=), SR144528 (-) TM 4 182 
Cys 174 Ser Abolished binding TM 4 182 
Cys 179 Ser Abolished binding EL 2 182 
Cys 175 Ser CP55,940 (=), Win 55212-2 (-), SR144528 (-) EL 2 182 
Table 3-1 A summary of the mutational work published on the CB2 receptor, including the amino acid 
residue mutated, the position within the receptor and the reference. (=) binding is not significantly 
different from wild type. (-) binding is significantly reduced from wild type. TM transmembrane. EL 
extra cellular loop. (a) In their publication McAllister et al237.refer to this residue as Tyr 191. This 
was a typographical error confirmed in a personal communication from the authors . 
 
The binding of Win 55212-2 3, a CB2 selective indole cannabinoid (section 1.4.6), to 
the CB2 receptor has been shown to involve important aromatic stacking interactions; 
rather than ionic- or H-bonding interactions194. Experimental evidence for this has 
involved mutation of the unique Phe 197 found in CB2 to a valine resulting in a 14 
fold decrease in Win 55212-2 3 binding194. Other single point mutations of aromatic 
residues (Trp 172 & Tyr 190) to non-aromatic amino acids have also been show to 
significantly reduce the binding of Win 55212-2 3237,238. However, when conservative 
mutation of these residues to the aromatic amino acid Phe was conducted, binding of 
Win 55212-2 3 was unaltered237,238. Further evidence of aromatic stacking interactions 
involving Win 55212-2 3, including SAR data, are discussed in section 1.4.6.1. 
Furthermore, mutations of H-bonding or ionic bonding residues such as Ser 112154, 
Ser 161182, Ser 165182, and Lys 109154 within the CB2 receptor failed to alter the 
binding of Win 55212-2 3. A chimeric receptor generated by replacing the TM 3 
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region of a CB1 receptor with TM 3 of the CB2 receptor, increased the binding of Win 
55212-2 3193. This result demonstrated that subtype selectivity of Win 55212-2 3 for 
the CB2 receptor may be a result of amino acid residues present in TM 3. Further 
work by this group pointed to residue Ser 112 in the CB2 receptor (analogous to Gly 
195 in CB1) as key to the subtype specificity of Win 55212-2 3. This was 
demonstrated by mutating Gly 195 in CB1 to Ser193. The four-fold increase in binding 
of Win 55212-2 3, to this mutant, was attributed to CB2’s Ser 112 being involved in 
crucial interactions with Win 55212-2 3. However, later work, mutating Ser 112 to 
Gly in the CB2 receptor failed to support this argument154. Chimeric work by Shire et 
al. has demonstrated that only TM 4-EL 2-TM 5 (Phe 197 is found in TM 5) of the 
CB2 receptor is necessary for Win 55212-2 3 selectivity236. 
 
Studies to show the effect of certain amino acids in the CB2 receptor on the binding of 
the non-classical cannabinoid CP 55,940 2 have been unclear. It was initially thought 
that hydrogen bonding interactions would play an important role in binding due to the 
number of hydroxyl groups present on CP 55,940 2 (figure 1-13). However mutation 
of Lys 109 (analogous to Lys 192 in the CB1 receptor) to Ala and Arg, had no effect 
on the binding of CP 55,940 2 to the CB2 receptor154. This is in direct contrast to the 
mutation of Lys 192 in the CB1 receptor which was shown to be critical for binding of 
these ligands152. These two results would indicate that H-bond interactions, occurring 
between Lys and hydroxyls in the cannabinoids, are important in the CB1 receptor but 
not required in the CB2 receptor. A separate study showed that a H-bonding 
interaction between CP 55,940 2 and the CB2 receptor was contributing to the ligand-
receptor binding154. They mutated Ser 112 present in TM 3 of the CB2 receptor to Gly 
and reported that this change significantly reduced the binding of CP 55,940. It was 
concluded that hydrogen bond interactions between the NAH (Figure 1-13) and Ser 
112 in TM 3 was important for CB2 binding of CP 55,940 2. 
SAR work with classical and non-classical cannibinoids has probed the 
importance of the phenol group and the NAH function of CP-55,940 2 and similar 
molecules. These studies have clearly shown that the hydroxyl groups present in the 
molecules are not required for CB2 binding (sections 1.4.2.4 & 1.4.3.1) and it is likely 
therefore that hydrogen bonding interactions are not involved in the binding of these 
cannabinoids in the CB2 receptor. 
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Mutational analysis probing the binding interactions of SR 144528 6 has been 
conducted. Initial work by Shire et al. concentrated on replacing regions of the CB1 
receptor, that has essentially no affinity with SR144528 6, with the analogues regions 
from the CB2 receptor and monitoring the binding of SR144528 6 to the chimeric 
receptor236. They demonstrated that TM 4-EL 2-TM 5 of the CB2 receptor was 
responsible for the CB2 selectivity of SR144528 6. Further work by the same group, 
using single point mutations, indicated both Ser 161 and Ser 165 on TM 4 contributed 
to H-bonding interactions with SR144528 6182. Mutation of a non-conserved Cys 175 
residue in CB2’s EL 2 abolished binding of SR144528 6, but did not adversely affect 
CP 55, 940 2 or Win 55212-2 3182. This sulphur-containing residue was postulated to 
form either direct sulphur-pi  interactions, or an undetermined disulphide bridge, which 
are considered important to ligand recognition. Other work has shown that 
independent mutation of Cys 174 and Cys 179 results in receptors that do locate to the 
membrane, but fail to bind any of the cannabinoid ligands tested236. A structurally 
vital disulphide bridge has been proposed between them182. The highly conserved 
DRY motif (Asp 130, Arg 131, and Tyr 132 in the TM 3 of the CB2 receptor) found in 
the majority of GPCRs  has been evaluated for its role in ligand binding. In a CB2 
mutational study it was found that Asp 130 mutations markedly reduced all classical 
and indole cannabinoid binding239. 
 
In summary, these data indicates that there are different binding interactions occurring 
with the different classes of chemical ligands. Specific amino acid changes may affect 
the binding of just one ligand, such as Ser 112 or Phe 197, or may abolish binding for 
all of the cannabinoid classes tested, such as Tyr 190 or Trp 172 (Table 3-1). This 
may be indicative of whether the amino acid involved is associated with key ligand-
receptor interactions or is involved in the overall structure of the TM helix and 
therefore the shape of the binding pocket. The most consistent data discussed regards 
the binding of Win 55212-2 3, for which an aromatic-aromatic ligand-receptor 
binding nature has clearly been established. This has specifically involved the residue 
Phe 197, present in the CB2 receptor, and is thought to confer an extra aromatic 
interaction that results in CB2 selectivity of  Win 55212-2 3. 
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3.2.2 Molecular modelling studies  
 
The first computational model of a cannabinoid receptor, conducted in 1995, was for 
the CB1 receptor153,190. Their methodology aligned the TM regions of the CB1 
receptor with the sequences of 58 other GPCRs, using the highly conserved amino 
acids present in each of the TM helices. TM 5 of the CB1 (and the CB2 receptor) 
which does not contain the highly conserved proline used for alignment, needed to be 
identified using structural alignment based on its hydrophobicity profile. The helices 
were modelled using the ChemProtein module (Chem-X suite) and aligned to the TM 
helix bundle present in the X-ray structure of Bacteriorhodopsin. This original model 
of the CB1 receptor, was then adapted by researchers interested in the CB2 receptor by 
mutating the CB1 residues into corresponding sequence-aligned CB2 residues153,154,194. 
Thus, early modelling of the CB2 receptor was based entirely on a CB1 receptor 
model; which was originally based on the non G-protein associated 
Bacteriorhodopsin. A later CB2 model employed similar methodology used above, but 
mutated a model of the β2-adrenoreceptor to the CB2 receptor based on sequence 
alignment data of the human CB2 receptor aligned to sequences of the β-
adrenoreceptor family182. The original model of the β2-adrenoreceptor was built using 
the crystal structure of Bacteriorhodopsin as a template241. Therefore two different 
methods used to construct the CB2 receptor were both based on the crystal structure 
data of Bacteriorhodopsin, which, as discussed in section 3.1, has limitations and has 
been superseded by Bovine Rhodopsin 227. After we had concluded our own studies, 
Xie et al. published a further model of the CB2 receptor242. They were the first to 
publish a CB2 receptor model based on the 2.8Å crystal structure data from Bovine 
Rhodopsin aligning Bovine Rhodopsin with five cannabinoid receptors (including the 
human CB2 receptor) and four other GPCRs. 
 
3.2.2.1 Results from previous CB2 models 
 
Each of the previous models conformed to the classical shape of a GPCR receptor, 
consisting of seven alpha helical TM regions arranged in a ‘barrel’ formation, which 
were linked by extra and intra-cellular loops. To provide information on the intimate 
interactions occurring within the CB2 receptor binding pocket, three of the CB2 
models were used in ligand-receptor binding simulations with different cannabinoid 
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ligands154,182,194. The data from these studies, suggested that the binding site within the 
CB2 receptor was located within the TM bundles - although the exact combination of 
TM helices involved was ligand dependent. The results from these three studies are 
summarised as follows;  
Song et al. evaluated the binding of Win 55212-2 3194. They proposed 
aromatic stacking interactions, occurring between amino acids present within TM 3, 4 
and 5 and Win 55212-2 3, to be the primary ligand-receptor interactions. They 
reported that selectivity shown by Win 55212-2 3 for CB2 receptors is due to an extra 
aromatic interaction that can be formed between Win 55212-2 3 and Phe 197 on the 
CB2 receptor. Phe 197 is not present in the CB1 receptor and cannot form this extra 
interaction. Other amino acids shown to form ligand interactions are detailed in Table 
3-2. 
CP 55,940 2 was docked in a model generated by Tao et al154. They 
demonstrated that its binding had elements of hydrophobic and hydrogen-bonding 
interactions with the receptor. The most important of these interactions was 
established to be a H-bond between Ser 112 and the NAH of CP 55,940 2. Other 
ligand-receptor interactions associated with amino acids present within TM 3, 6 and 7 
were highlighted in their study but were not discussed. 
SR 144528 6 was docked in a CB2 model generated by the Gouldson group182. 
From their work, they proposed that the interactions of SR 144526 6 with the CB2 
receptor were a mixture of aromatic, hydrophobic and hydrogen bonding. The H-
bonds were formed between the pyrazole nitrogen and the carbonyl group of SR 
144528 6 (figure 1) and the hydroxyl hydrogens of Ser 161 and Ser 165 located in TM 
4. Other contacts made with SR 144528 6 are listed in Table 3-2. The TM helices 
involved in SR144528 6 binding are 3, 4 and 5. Importantly, this model has several 
features in common with the one proposed by Song et al. for Win 55212-2 3 
binding194, especially the importance of aromatic stacking and the involvement of 
common aromatic amino acids namely Phe 197 and Trp 194. The similarity in the two 
models is important, as the two groups produced independent work, and used different 
sequence alignment protocols. In addition both groups had distinct mutagenesis data 
which was used as an initial anchor point for ligand docking.  
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Ligand used to explore 
binding pocket 
Key amino acid residues 
shown to be involved in 
binding 
Type of ligand-receptor 
interaction involved 
TM location of the amino 
acid residue 
Win 55212-2 31 Phe 106 Aromatic 3 
 Phe 117 Aromatic 3 
 Trp 194 Aromatic 5 
 Phe 197 Aromatic 5 
SR 144528 62 Leu 125 Hydrophobic 3 
 Leu 126 Hydrophobic 3 
 Ser 161 H-bond 4 
 Ser 165 H-bond 4 
 Trp 172 Aromatic 5 
 Trp 194 Aromatic 5 
 Phe 197 Aromatic 5 
CP 55, 940 23 Ser 112 H-bond 3 
 Thr 116 H-bond 3 
Solvent-accessible 
methods4 
Phe 117 Aromatic 3 
 Tyr 190 Aromatic 5 
 Phe 197 Aromatic 5 
 Trp 258 Aromatic 6 
Table 3-2 Key amino acid residues implicated in forming important ligand-binding from computational 
modelling studies. 1 ref 194. 2 ref 182. 3 ref 154. 4 ref 242. 
 
The CB2 receptor constructed using the template of Bovine Rhodopsin, published 
after we had concluded our work, did not use a ligand docking experiment to 
investigate the ligand binding pocket242. Instead they used solvent-accessible surface 
approaches to determine the amino acids that could form interactions in a ligand 
binding pocket. The amino acid residues highlighted in their discussion are shown in 
Table 3-2. Their studies showed that the binding site was amphipathic with a 
hydrophilic centre located close to the extracellular loop 2 (shown in blue) and a 
hydrophobic cleft buried deeper in the receptor (shown in yellow) which is ‘framed’ 
with the aromatic residues Phe 117 (TM 3), Phe 197 (TM 5) and Trp 258 (TM 6) 
(Figure 3-10). Overall the helices postulated to be involved with the binding pocket 
were TM 3, 5, 6, and 7. 
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In conclusion the various modelling studies conducted to date have shown that the 
ligand binding pocket is located within the TM helices of the CB2 receptor. The exact 
TM helices and amino acid residues involved in ligand binding is dependent upon the 
cannabinoid that was used in the study. TM 3, 4, 5, 6 and 7 have each been shown to 
be involved in ligand binding. The most consistent interaction demonstrated to be 
important is aromatic-aromatic in nature, with three of the four models specifically 
highlighting Phe 197 as an amino acid crucial to ligand binding. Interestingly, the 
analogous residue to Phe 197 in other GPCRs have also been reported to be an 
important binding residue in the β-adrenoreceptor and serotonin receptors194. The 
binding models proposing TM 4 as a binding helix are unusual in GPCR modelling. 
However previous studies implicating TM 4 in binding have been reported for the 
neuropeptide type receptors i.e. substance P, neurotensin type 1 and neuropeptide Y 
type 1182. The data provided from these studies were used to guide our experimental 
modelling work. 
 
3.3 Experimental results - molecular modelling of the CB2 
receptor  
 
3.3.1 Sequence alignment 
 
The human CB2 receptor was initially sequence aligned against human CB1 and the 
Bovine Rhodopsin (BR) sequences obtained from Swissprot (Swissprot reference 
numbers: P34972 (CB2), P21554 (CB1), and P02699 (BR)) using the sequence 
alignment program ClustalW (Version 1.81)232. Manual alignment of the CB2 
sequence with Bovine Rhodopsin was conducted to locate the homology aligned 
regions. Three different alignments were generated by varying the alignment of TM 5 
of the CB2 receptor with the corresponding Bovine Rhodopsin sequence. TM 5 of the 
CB2 receptor does not contain the usual conserved proline within its sequence and has 
been a difficult issue to resolve for each of the groups conducting modelling of the 
cannabinoid receptors (see section 3.2.2). The three different alignments we used are 
shown in Figure 3-3. 
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Alignment 1 
hCB2 --MEECWVTEIANGSKDGLDSNPMKD--YMILSGPQKTAVAVLCTLLGLLSALENVAVLY 56 
BR   MNGTEGPNFYVPFSNKTGVVRSPFEAPQYYLAEPWQFSMLAAYMFLLIMLGFPINFLTLY 60 
          
hCB2 LILSSHQLRRKPSYLFIGSLAGADFLASVVFACSFVNFHVFHGVDSKAV--FLLKIGSVTMT 116 
BR   VTVQHKKL-RTPLNYILLNLAVADLFMVFGGFTTTLY-TSLHGYFVFGPTGCNLEGFFATLG 120 
                 
hCB2 FTASVGSLLLTAIDRYLCLRYPPSYKALLTRGRALVTLGIMWVLSALVSYLPLMGWT-CC 176 
BR   GEIALWSLVVLAIERYVVVCKPMSNFRFGEN-HAIMGVAFTWVMALACAAPPLVGWSRYI 179 
 
hCB2 PRP--CSELFPLIPNDYLLSWLLFIAFLFSGIIYTYGHVLWKAHQHVASLSGHQDR-QVP 232 
BR   PEGMQCSCGIDYYTPHEETNNESFVIYMFVVHFIIPLIVIFFCYGQLVFTVKEAAAQQQE 239 
 
hCB2 GMARMRLDVRLAKTLGLVLAVLLICWFPVLALMAHSLATTLSDQVKKAFAFCSMLCLINS 292 
BR   SATTQKAEKEVTRMVIIMVIAFLICWLPYAGVAFYIFTHQGSDFGPIFMTIPAFFAKTSA 299 
 
hCB2 MVNPVIYALRSGEIRSSAHHCLAHWKKCVRGLGSEAKEEAPRSSVTETEADGKITPWPDS 352 
BR   VYNPVIYIMMNKQFRNCMVTTLCCGKNPLGD--DEASTTVSKTETSQVAPA--------- 348 
 
hCB2 RDLDLSDC 360 
BR   -------- 
 
Alignment 2 
hCB2 --MEECWVTEIANGSKDGLDSNPMKD--YMILSGPQKTAVAVLCTLLGLLSALENVAVLY 56 
BR   MNGTEGPNFYVPFSNKTGVVRSPFEAPQYYLAEPWQFSMLAAYMFLLIMLGFPINFLTLY 60 
 
hCB2 LILSSHQLRRKPSYLFIGSLAGADFLASVVFACSFVNFHVFHGVDSKAV--FLLKIGSVTMT 116 
BR   VTVQHKKL-RTPLNYILLNLAVADLFMVFGGFTTTLY-TSLHGYFVFGPTGCNLEGFFATLG 120 
                 
hCB2 FTASVGSLLLTAIDRYLCLRYPPSYKALLTRGRALVTLGIMWVLSALVSYLPLMGWT-CC 176 
BR   GEIALWSLVVLAIERYVVVCKPMSNFRFGEN-HAIMGVAFTWVMALACAAPPLVGWSRYI 179 
 
hCB2 PRP—---CSELFPLIPNDYLLSWLLFIAFLFSGIIYTYGHVLWKAHQHVASLSGHQDRQVP 232 
BR   PEGMQCSCGIDYYTPHEETNNESFVIYMFVVHFIIPLIVIFFCYGQLVFTVKEAAAQQ-QE 239 
 
hCB2 GMARMRLDVRLAKTLGLVLAVLLICWFPVLALMAHSLATTLSDQVKKAFAFCSMLCLINS 292 
BR   SATTQKAEKEVTRMVIIMVIAFLICWLPYAGVAFYIFTHQGSDFGPIFMTIPAFFAKTSA 299 
 
hCB2 MVNPVIYALRSGEIRSSAHHCLAHWKKCVRGLGSEAKEEAPRSSVTETEADGKITPWPDS 352 
BR   VYNPVIYIMMNKQFRNCMVTTLCCGKNPLGD--DEASTTVSKTETSQVAPA--------- 348 
 
hCB2 RDLDLSDC 360 
BR   -------- 
 
Alignment 3 
hCB2 --MEECWVTEIANGSKDGLDSNPMKD--YMILSGPQKTAVAVLCTLLGLLSALENVAVLY 56 
BR   MNGTEGPNFYVPFSNKTGVVRSPFEAPQYYLAEPWQFSMLAAYMFLLIMLGFPINFLTLY 60 
   
hCB2 LILSSHQLRRKPSYLFIGSLAGADFLASVVFACSFVNFHVFHGVDSKAV--FLLKIGSVTMT 116 
BR   VTVQHKKL-RTPLNYILLNLAVADLFMVFGGFTTTLY-TSLHGYFVFGPTGCNLEGFFATLG 120 
                 
hCB2 FTASVGSLLLTAIDRYLCLRYPPSYKALLTRGRALVTLGIMWVLSALVSYLPLMGWT-CC 176 
BR   GEIALWSLVVLAIERYVVVCKPMSNFRFGEN-HAIMGVAFTWVMALACAAPPLVGWSRYI 179 
 
hCB2 PRP----CSELFPLIP------NDYLLSWLLFIAFLFSGIIYTYGHVLWKAHQHVASLSGHQDRQVP 232 
BR   PEGMQCSCGIDYYTPHEETNNESFVIYMFVVHFIIPLIVIFFCYGQLVFTVKEAAA-----QQQE-- 239 
 
hCB2 GMARMRLDVRLAKTLGLVLAVLLICWFPVLALMAHSLATTLSDQVKKAFAFCSMLCLINS 292 
BR   SATTQKAEKEVTRMVIIMVIAFLICWLPYAGVAFYIFTHQGSDFGPIFMTIPAFFAKTSA 299 
 
hCB2 MVNPVIYALRSGEIRSSAHHCLAHWKKCVRGLGSEAKEEAPRSSVTETEADGKITPWPDS 352 
BR   VYNPVIYIMMNKQFRNCMVTTLCCGKNPLGD--DEASTTVSKTETSQVAPA--------- 348 
     
hCB2 RDLDLSDC 360 
BR   -------- 
Figure 3-3 The three sequence alignments used to generate the different CB2 receptor models, which 
vary in the alignment of TM 5. The TM helices are highlighted in the following colours: 1 (yellow); 2 
(green); 3 (turquoise); 4 (magenta); 5 (red); 6 (grey); 7 (blue). hCB2 – human CB2 sequence. BR – 
Bovine Rhodopsin sequence. Amino acids represented by standard single letter codes.  
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3.3.2 Homology modelling to Bovine Rhodopsin 
 
The 3D crystal structure of Bovine Rhodopsin (BR) was extracted from the Protein 
Data Bank and imported into Sybyl® (Tripos). The BR model was modified by 
removing the B chain and the glycosylations associated with the molecule. Using 
Mutate Monomers each of the BR helices were mutated to the aligned sequences 
shown in Figure 3-3 to generate the three different alignment models. The remaining 
loop sections of the CB2 model were completed by searching the PDB database using 
the Build Loops function for matching amino acid sequence to the CB2 loop 
sequences. The highest scored loops were inserted into the model and manual 
selection of the best fitting loops was employed. The final models were checked for 
amino acid chirality, proline ring integrity and were finally screened against the 
original CB2 sequence for monomer sequence. The three models were then subjected 
to energy minimisation within Sybyl® using 100 Steepest Descent iterations followed 
by 500 Conjugate Gradient steps using the standard Sybyl® setup for each 
minimisation. The three models, produced by the homology modelling described, are 
shown in Figure 3-4. The amino acid structures displayed in ball and stick style are 
the key amino acids previously shown to be important in ligand-receptor binding (see 
Table 3-1 and Table 3-2). The Ramachandran plots for all three receptors were 
generated using the programme PROCHECK243 and are shown in Figure 3-4. For 
further details on Ramachandran plots, readers are directed to the original paper by 
Ramachandran et al.244. The shaded areas of the plots (red, yellow, pink) correspond 
to the contoured distribution of the φ and ψ torsion angles between amide bonds, 
averaged from the X-ray crystallography data accumulated for 118 protein structures. 
It is clear from these plots that all three structures have amino acid backbones 
conformations that are typically found in many other protein structures. Alignment 3, 
possessed the most favourable conformational space according to the Ramachandran 
analysis with 74.1% of the residues lying in the most favoured region (22.1% in 
allowed regions; 2.2% in generously allowed regions; 1.6% in disallowed regions).   
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Figure 3-4 Representations of the three human CB2 models built by homology modelling to Bovine 
Rhodopsin. 1a Alignment 1 view from top. 1b Alignment 1 view from side. 1c Ramachandran plot of 
Alignment 1.  2a Alignment 2 view from top. 2b Alignment 2 view from side. 2c Ramachandran plot of 
Alignment 2. 3a Alignment 3 view from top. 3b Alignment 3 view from side. 3c Ramachandran plot of 
Alignment 3. Amino acids shown are Phe 117 (Magenta), Tyr 190 (Cyan), Trp 194 (yellow), Phe 197 
(green).  Helix colour: 1, 2, 3, 4, 5, 6, and 7. Ramachandran plot - darker colours represent favourable 
regions of amide bond torsions with black dots representing amino acids from the CB2 receptor model. 
1a 1b 1c
2a 2b 2c
3a 3b 3c
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Alignment 3 also had the key amino acids, implicated in ligand binding, located 
within the TM regions when compared to the other two models. It was therefore 
decided to discard Alignments 1 and 2 and continue only with Alignment 3. The 
model from Alignment 3 was energy minimised using the ABNR minimisation 
algorithm using CHARMM software234, using the protocol: minimise hydrogens only 
(100 steps); minimise side chains only (2000 steps); minimise complete structure 
(25000 steps) until the root-mean-square-derivative (RMSD) reached 0.005 KJmol-1.  
No C or N end-caps were used and a dielectric constant of 4.0 was utilised to mimic 
the phospholipids membrane. This model will now be referred to as Alignment 3.  
3.3.3 Docking JTE2-6 into the CB2 receptor 
 
JTE2-6 63 was constructed using Spartan PCPro (Wavefunction Inc.). Geometry 
optimisation was undertaken using quantum mechanical methods, namely ab initio 
Hartree-Fock calculations at the 3-21G* level. In addition, partial atom charges were 
calculated using the electrostatic surface potential (ESP) method. JTE2-6 63 was 
interactively docked into Alignment 3 using Phe 197 as an anchor point for an 
aromatic-aromatic interaction with the ligand. JTE2-6 63 was docked into the binding 
pocket in both a phenol-up and phenol-down position as shown in Figure 3-5. 
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Figure 3-5 JTE2-6 63 was docked into the CB2 receptor in the (A) phenol-up and (B) phenol-down 
position using Phe 197 as a guiding anchor point. 
 
The ligand-receptor complexes were further optimised using energy minimisation and 
molecular dynamics. In our studies, we applied the CHARMM force field with an 8 Å 
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cut-off for non-bonded interactions to optimize the ligand-receptor model. In order to 
mimic the hydrophobic transmembrane environment we set the dielectric constant to a 
value of 4.0. The molecular dynamics protocol consists of: i) initial minimisation of 
2500 iterations of ABNR conjugate gradients minimisation until the RMSD becomes 
less than 0.005 KJmol-1; ii) MD simulations were performed by placing a harmonic 
constraint on the 7 backbone α-helices, heating the structure to 300K over 1ps, and  
running at constant temperature (300K) for 100 ps with a 1fs time step; iii) quenching 
the structure to 0K over 1 ps, removing all constraints and final minimisation using 
ABNR conjugate gradients (6000 iterations) until the RMSD became less than 0.005 
KJmol-1.   
The energy of the two complexes was monitored throughout the molecular 
dynamics experiment at 0.5 ps time intervals. The plot of the total energy of the 
complex versus time is shown in Figure 3-6.  
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Figure 3-6 Energy profile of JTE2-6 63-CB2 receptor complex over a 0.1 ns molecular dynamic 
simulation performed at 300K using the CHARMM force field. 
 
It is clear from the above graph that the energy of both systems increased rapidly 
during the first ps as the systems were heated from 0K to 300K. Once ‘energised’ 
both systems energy decrease over the first 40 ps. In the phenol-down complex this 
lower energy is continued during the rest of the simulation but in the phenol-up 
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complex the energy is transiently raised at around 40 ps before falling again over the 
remaining period of the simulation. 
The final energy minimised ligand-receptor complexes are shown in Figure 3-7. 
 
 
Figure 3-7 Representations of JTE2-6 63 docked into the human CB2 receptor (Alignment 3). (A) 
Phenol-down model. (B) Phenol-up model. Both these images show the ligand JTE2-6 63 in its final 
binding position/conformation. Model is being viewed with TM 6 front and centre. (C) Overlay of 
phenol-up (magenta) and phenol-down (cyan) bound into the CB2 receptor showing the relative 
positions of the ligand in both models. Model is being viewed with TM 2 front and centre. TM 4 has 
been removed for clarity.  
  
From Figure 3-7 it can be seen that the human CB2 receptor can accommodate JTE2-6 
63 docked in either position. However, the conformation of the ligand and the 
absolute binding position of the ligand changes between both models (Figure 3-7, C). 
The key amino acids involved in ligand-receptor interactions was explored using the 
programme Ligplot for each model245. The results from this analysis are shown in 
Figure 3-8. It can be clearly seen that the amino acids involved in the binding of 
JTE2-6 63 differ between the two docked models. In the phenol-up model the amino 
acids residues involved are residues that have been demonstrated to be involved in the 
binding of other cannabinoid ligands (see Table 3-1 and Table 3-2); notably Phe 117, 
Trp 194, and Phe 197. The residues interacting in the phenol-down model have not 
been implicated in cannabinoid binding in previous studies and include an interaction 
with an amino acid located in TM helix 2 (His 95) which has previously not been 
shown to be involved in cannabinoid binding. 
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Figure 3-8 Ligplot analysis of the amino acid binding interactions occurring with JTE2-6 63 docked in 
the phenol-up and phenol-down position. 
 
3.4 Discussion 
 
The human CB2 receptor was constructed using homology modelling to a high 
resolution X-ray crystal structure of Bovine Rhodopsin in-order to determine the 
probable binding position of the CB2 selective ligand JTE2-6 63. Three different 
sequence alignment models were constructed varying in the alignment of TM 5 with 
the Bovine Rhodopsin sequence. Helix 5 in the CB2 receptor has previously been 
highlighted as a difficult helix to align due to it lacking a conserved proline residue 
within the helix. The three different models constructed were compared using 
conformational space analysis (Ramachandran plots) and visual inspection of four key 
amino acids (Phe 117, Tyr 190, Trp 194, Phe 197) which have all been implicated in 
previous mutational analysis and molecular modelling experiments to be associated 
with TM ligand binding. Alignment 3 was chosen as the best representation of the 
human CB2 model for a number of reasons. The Ramachandran plot showed that 
98.4% of the amino acids were in a conformation that had been observed from real X-
ray crystal structures of 118 other proteins. This was higher than the either alignment 
Phenol-down Phenol-up 
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1 or 2 and represented a ‘high quality model’243. Examination of the residues Phe 117, 
Tyr 190, Trp 194, Phe 197; demonstrated that only in Alignment 3 were all of these 
residues present within the proposed binding pocket located in the TM bundle. In 
Alignment 1 & 2 Trp 190, Trp 194 and Phe 197 were all located either at the top of 
the TM helices or on the extra cellular loops. As previous studies had shown that Phe 
117, Tyr 190, Trp 194, Phe 197  were involved with ligand binding within the TM 
bundle, Alignment 1 and 2 were rejected and further studies were performed on 
Alignment 3.  
After we had completed our studies, the first CB2 receptor model based on 
Bovine Rhodopsin was published242. We took the opportunity to compare the work 
we conducted to their seminal study. The sequence alignment data was compared for 
the seven TM helices of each model with Bovine Rodopsin; the results are shown 
below. 
 
Xie et al.   PQKTAVAVLCTLLGLLSALENVAVLYLIL  Helix 1 
Our study    ---TAVAVLCTLLGLLSALENVAVLYLIL 
BR           WQFSMLAAYMFLLIMLGFPNFLTLYVTVQ 
 
Xie et al.   PSYLFIGSLAGADFLASVVFACSFVNFHVF  Helix 2 
Our study    ---LFIGSLAGADFLASVVFACSFVN---- 
BR           PLNYILLNLAVADLFMVFGGFTTTLYTSLH 
 
Xie et al.   KAVFLLKIGSVTMTFTASVGSLLLTAIDRYLCLR Helix 3 
Our study    ----LLKIGSVTMTFTASVGSLLLTAI------- 
BR           PTGCNLEGFFATLGGEIALWSLVVLAIERYVVVC 
 
Xie et al.   RALVTLGIMWVLSALVSYLPLMGW   Helix 4 
Our study    -ALVTLGIMWVLSALVSYLPLM-- 
BR           HAIMGVAFTWVMALACAAPPLVGW 
 
Xie et al.   IPNDYLLSWLLFIAFLFSGIIYTYGHVLW  Helix 5 
Our study    ---DYLLSWLLFIAFLFSGIIYTYG---- 
BR           NESFVIYMFVVHFIIPLIVIFFQYGQLVF    
 
Xie et al.   RLDVRLAKTLGLVLAVLLICWFPVLALMAHSLA  Helix 6 
Our study    ---------LGLVLAVLLICWFPVLALMAH--- 
BR           KAEKEVTEMVIIMVIAFLIQWLPYAGVAFYIFT 
 
Xie et al.   KAFAFCSMLCLINSMVNPVIYAL   Helix 7 
Our study    -AFAFCSMLCLINSMVNPVIYAL 
BR           IFMTIPAFFAKTSAVYNPVIYIM 
Figure 3-9 Comparison of the TM alignments of Xie et al.242, our study and the Bovine Rhodopsin 
(BR) sequence. 
 
The alignments made in both independent studies matched exactly in the way the CB2 
sequence was aligned to the Bovine Rhodopsin template. The difference in ‘helix 
length’ was due to the two different methods used to determine what residues 
constituted the helix. Xie et al. used a hydrophobicity profile to determine the helices 
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from the sequence alignment242, in contrast our TM regions were based on those 
published for the Bovine Rhodopsin sequence in Swissprot. The amino acids 
proposed to constitute the binding pocket, using solvent accessibility methods, in their 
model were compared to the same amino acids in our model, viewed from a similar 
perspective (Figure 3-10).  
 
 
Figure 3-10 Representations of the conformation and relative position of the amino acid residues 
reported to constitute the binding pocket of the human CB2 receptor
242. (A) shows the amino acid 
alignment from our study of the human CB2 receptor (Alignment 3) binding the ligand JTE2-6 63. The 
backbone amino acids are shown in simple line form and JTE2-6 63 is  not shown for clarity. (B) is 
reproduced from Xie et al. and shows the binding pocket amino acids as determined by solvent–
accessible analysis 242.  
   
The model shown in Figure 3-10 (A) is Alignment 3 of the CB2 receptor binding the 
ligand JTE2-6 63 in the phenol-up position. We chose this model, as the ligand-
receptor interactions present, would induce the amino acids to adopt a conformation 
which best represented their binding conformation. Comparing the two models it can 
be seen that the amino acids shown each occupy the same area of space within both 
receptors. It is extremely interesting to note that the three aromatic amino acids that 
form the hydrophobic cleft at the bottom of the binding pocket are roughly in the 
same conformation in both independent models. 
In conclusion, the model we constructed compares favourably to the published 
model by Xie et al. both in terms of their sequence alignments and the position of key 
A B
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amino acids postulated to form the binding pocket. This comparison, combined with 
our assessment of three different aligned sequences, gave us confidence that our 
model of the human CB2 receptor was built to the highest standard of GPCR 
modelling practice. 
Ligand docking experiments conducted using the human CB2 receptor and the 
Japan Tobacco ligand JTE2-6 63 have shown that the ligand can bind within the 
receptor in at least two different orientations – phenol-up and phenol-down. In both 
experiments, JTE2-6 63 was interactively docked using Phe 197 as an initial anchor 
point and the ligand was docked into the receptor in identical energy minimised 
structural conformation. Thus both models had a similar starting point except that 
they were docked with a 180 degrees rotational difference. After 100 ps of MD 
simulation, the final binding conformations of the two ligands within the models vary 
considerably (Figure 3-7, C). The ligand within the phenol-up model has remained 
generally within its initial docked position, whilst the phenol-down conformation has 
moved away from helix 5 into the centre of the receptor. The conformation of JTE2-6 
63 in the phenol-down model has remained very similar to its initial energy 
minimised conformer. However in the phenol-up system, the phenol ring of JTE2-6 
63 has twisted to form strong aromatic-aromatic interactions with Trp 194 (edge-
edge) and Phe 197 (face-face) in the phenol-up system (Figure 3-11). This is not 
unexpected as both the ligand and the receptor are known to influence each others 
final conformations in the bound state (Koshland’s Theory of Induced Fit181). 
 
 
Figure 3-11 JTE2-6 63 bound in the phenol-up position (shown in magenta) showing the interactions 
with the aromatic amino acids Trp 194, Phe 197 and Phe 117. 
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Phe 197 also forms aromatic interactions (edge-edge) with the benzamide ring as does 
Phe 117 (see Figure 3-11). Examining the energy profile, of the phenol-up complex 
throughout its 100 ps MD simulation, revealed that the complex was stable (Figure 
3-6). The rise in energy at 40 ps was transient and the complex appeared to be 
approaching steady-state at 100 ps. Although its total energy was higher than the 
phenol-down complex this does not imply a less favourable model. The energy 
function is an arbitrary value and can only be used to study events occurring within 
systems and not across systems. The energy profile for the phenol-down model 
achieved a steady-state at around 40 ps and there were no notable fluctuations in the 
profile, also demonstrating that this complex was stable.  The amino acids shown to 
be involved in interactions with JTE2-6 63, in the phenol-down position, have 
previously not been implicated in cannabinoid binding. Notably residue analysis 
showed that TM helix 2 was involved, which is extremely unusual in GPCR ligand 
binding84. The amino acids that were involved in binding JTE2-6 63, in the phenol-up 
position, are residues that have been described to be important in cannabinoid binding 
from many other studies (see Table 3-1 & Table 3-2). We are therefore satisfied that 
we have demonstrated, us ing computational methods, that JTE2-6 63 is likely to be 
bound within the CB2 receptor in a phenol-up position. Although theoretically 
possible to exist, the phenol-down model is not supported by previous experimental 
evidence. Our experimental data had previously demonstrated that modifying the 
benzamide ring, located at the bottom of the binding pocket in the phenol-up model, 
with fluorophores lead to compounds with little affinity to the CB2 receptor (see 
chapter 2). We therefore conclude that JTE2-6 63 is likely to bind in the phenol-up 
orientation. This is the first time binding of this unusual CB2 selective cannabinoid 
has been reported and the utilisation of these results to design a fluorescent CB2 
ligand based on the Japan Tobacco compounds are discussed in the following chapter. 
 
3.5 Conclusions 
 
• We generated a 3D computational model of the human CB2 receptor based on 
homology modelling to the high resolution X-ray crystal structure of Bovine 
Rhodopsin. 
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• Analysis of the model showed excellent correlation between our postulated 
binding pocket and previous experimental data, from molecular modelling and 
single point mutation, including an identical aromatic region within the 
binding pocket which contained the residue Phe 197. 
• The receptor model was used to identify that the likely binding orientation of 
the CB2 receptor ligand JTE2-6 63 was in a phenol-up position, whereby its 
phenol ring is close to the extra cellular surface of the receptor. 
• Computational binding data obtained for JTE2-6 63 will allow us to develop 
novel fluorescently labelled derivatives based on this type of compound. 
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4 Fluorescent CB2 ligand based on a modification to the 
phenol ring of a Japan Tobacco Compound 
 
Our studies, outlined in Chapter 3, concerning the binding of the Japan Tobacco 
compound JTE2-6 63 (Figure 4-2), to the CB2 receptor, demonstrated that it was 
likely to bind in a phenol-up orientation. The work reported below combined this 
modelling data with our previous work described in Chapter 2 to design an alternative 
fluorescent CB2 ligand based on the Japan Tobacco compounds. 
 
4.1 Interrogation of the ‘phenol-up’ JTE2-6-CB2 model 
 
The ‘phenol-up’ model constructed in Chapter 2 was examined to guide our decision 
on where to locate the fluorescent dye upon the Japan Tobacco compounds. The 
phenol ring was clearly shown to lie at the top (extra cellular- face) of the receptor. 
Further interrogation of the structure clearly showed that the phenol ring was in an 
ideal position within the molecule to elaborate a linker for fluorophore attachment. 
This is illustrated Figure 4-1. 
 
 
Figure 4-1 JTE2-6 63 docked into the human CB2 receptor (Alignment 3). (A) Shows the position of 
JTE2-6 63 (magenta) within the receptor. The amino acids shown in green (Ile 186, Pro 187, Tyr 190, 
Ala 270, and Thr 272) form the entrance to the binding pocket. Inter atomic distances between the 
hydroxyl-carbon on the phenol ring (C-OH) to the α-carbon of these amino acids range from 3.40 to 
6.61 Å. The model is viewed with TM helices 5 and 6 to the front. (B) Electrostatic potential surface 
representation of the human CB2 receptor. Red surfaces +ve, blue surfaces –ve, green surfaces are 
amino acids Ile 186, Pro 187, Tyr 190, Ala 270, and Thr 272 forming the entrance to the binding 
bocket. The phenol ring of JTE2-6 63 (magenta) can clearly be observed.  
 
 
A B
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It was envisaged that a carbon linker attached to the JTE2-6’s phenol ring (position 2 
or 6, or 3 or 5 – see Figure 4-2), would readily exit the binding site thereby allowing 
attachment of fluorophores without compromising binding of the ligand.  
The distances between the amino acids forming the entrance to the binding 
pocket (shown in green in Figure 4-1)  and the ligand was calculated to be between 
3.40 and 6.61Å. This equates to between 3 and 7 atomic distances in the linker chain, 
using a C-C and C-N bond length of 1.54 Å and 1.47 Å respectively as a guide246, to 
ensure that the entrance of the binding pocket is avoided by the dye. 
In light of this data, we embarked upon the design and synthesis of a Japan 
Tobacco compound, based on JTE2-6 63, functionalised with a linker covalently 
attached to a carbon atom of the phenol ring. Different fluorophores could then be 
installed in a chemoselective manner using methodologies discussed in Chapter 2 to 
generate compounds for evaluation as fluorescent CB2 selective ligands. 
 
4.2 Designing a fluorescent CB2 ligand based on molecular 
modelling of JTE2-6 docked into the CB2 receptor 
 
The concepts for the design and synthesis of a fluorescent CB2 selective ligand have 
been thoroughly covered in Chapter 2. In brief the key requirements of a lead CB2 
ligand conjugated to a fluorescent dye are: 
 
• A high affinity to the CB2 receptor. 
• A high selectivity to the CB2 receptor versus the CB1 receptor. 
• Modification of the CB2 ligand with a linker, functionalised at the terminus, to 
allow for chemoselective ligation to the fluorescent dye. 
• A suitable fluorescent dye must be chosen balancing the requirements of 
fluorescence spectral properties and the steric size of the dye. 
 
In our initial study the compound JTE2-6 63 was chosen as a lead CB2 ligand, since it 
possessed a chemical structure that allowed a selective chemical synthesis of the 
benzamide ring system to install a functionalised linker at position 4 on this ring. For 
this study we chose to incorporate the functionalised linker onto the phenol ring of the 
ligand and hence chemical selectivity within the benzamide portion of the ligand was 
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not required. It was with this reasoning that we re-examined the range of Japan 
Tobacco ligands available, using a similar selection criteria as stated in section 2.2.1, 
but without the requirement of orthogonal chemical groups on the benzamide portion 
of the ring. The compound JTE2-3 62 was selected as a lead structure due to its 
chemical similarity to JTE2-6 63 (Figure 4-2). This we assumed would mirror similar 
binding conformations in the receptor and we could therefore translate the modelling 
data for JTE2-6 63 and use this for our new lead molecule. However, JTE2-3’s 62 
enhanced CB2 affinity (Ki 0.4 nM) and selectivity (>8250:1) over 63 should increase 
the chance of its fluorescent conjugate remaining a potent CB2 ligand, whilst its 
simple benzamide motif will aid in its chemical synthesis.  
 
O
HN
N
H
O OH
O
O
N
H
O OH
2
3
5
6
JTE2-6 63 JTE2-3 62  
Figure 4-2  Comparison of the Japan Tobacco Ligands JTE2-6 63 and JTE2-3 62. Numbers indicate 
the position on the phenol ring. 
 
We designed a derivative of JTE2-3 62 to incorporate an amine functionalised linker 
at position 2 of its phenol ring. As the entrance to the receptor binding site was 
between 3.40 and 6.61 Å away from the phenol ring, we chose an aminoethyl linker, 
incorporating 3 atomic distances, which should position the dye approximately 4.5 Å 
away from the ligand. This would allow the Dansyl fluorophore, directly coupled to 
the linker, to be favourably positioned to interact with the aromatic residue Tyr 190 
(6.29 Å) (forming the entrance to the binding site) or extend well outside the binding 
pocket using the pre- installed 10 atom linker of BODIPY 630/650 X. These two 
fluorescent dyes were used for identical reasons as discussed in Chapter 2.  
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4.2.1 Synthetic Strategy 
 
A similar strategy to that employed in the synthesis of BODIPY-JTE2-6 100 and 
Dansyl-JTE2-6 99 was instigated for the synthesis of fluorophore-JTE2-3 I (Scheme 
4-1). In brief the key aim of the synthesis was to install the fluorophore in the last 
synthetic step, using chemoselective ligation to the linker-terminating 1° amine 
(retrosynthetic step A, Scheme 4-1). This avoids exposing labile and expensive 
fluorescent dyes (i.e. BODIPY 630/650) to both unnecessary photo- and chemical 
degradation during chemical synthesis and purification. 
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Scheme 4-1 Retrosynthetic strategy from the target molecule fluorophore-JTE2-3 I 
 
The disconnection made at the amide bond in fluorophore-JTE2-3 I (step B, Scheme 
4-1), resulted in two synthons; II, a Protocatechuic acid (3, 4-dihydroxybenzoic acid) 
derivative, and III, a functionalised tyramine. Reagent II was easily accessible from 
commercial Protocatechuic acid but a literature search established that synthon III 
was a novel compound. A synthetic route, starting from tyramine, was investigated 
for III, which would incorporate orthogonal protection for the two aminoethyl 
moieties to aid selective coupling to both II and the fluorophore dye. The 
retrosynthetic strategy shown in Scheme 4-2 begins by breaking the carbon-
heteroatom bond of the additional aminoethyl functionality on tyramine (Scheme 4-2 
step C). The choices of the nitrogen nucleophile V which could be used to create the 
required 1° amine are numerous; and include ammonia; the azide anion; and the 
phthalimide anion as examples. Reagents VI and VII (Scheme 4-2) are equivalent 
reagents to synthon IV with both containing an electrophillic carbon. The leaving 
group (LG) of synthon VII may be a halogen atom, however if one considers it 
instead to be an activated alcohol (i.e. mesylate), then both the aldehyde VI and 
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alcohol precursor to VII can be easily accessed by a functional group interconversion 
(FGI) from the allylic compound VIII using ozonolysis. Compound VIII was 
simplified, by breaking the aromatic-allyl bond, shown in step D, to give the target 
starting material (tyramine IX) and synthon X.  
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Scheme 4-2 Retrosynthetic analysis  for the molecule III. LG = Leaving group. FGI = functional group 
interconversion. 
  
Obviously synthon X could represent the allyl halide, and using Friedel-Crafts 
alkylation the allyl group could be installed. However chemoselectivity and poly-
substitutions were envisaged to be problematic. To avoid these side reactions reagent 
XI was proposed to undergo a [3, 3]-sigmatropic Claisen rearrangement leading to 
mono-substituted 2-allyl product. Reagent XI was easily constructed from tyramine 
and allyl bromide. It should be noted that throughout this synthesis, protecting group 
chemistry would need to be adeptly utilised in-order for the synthesis to proceed 
smoothly and to finish with both of the 1° amines orthogonally protected. It is known 
that the Benzyloxycarbonyl (Cbz) protecting group is both thermo and Lewis acid 
stable247; conditions which are commonly used to evoke the Claisen rearrangement, 
and we planned to utilise this group to protect the amine group of tyramine. With this 
protection present throughout the reactions, we could protect the second amine group 
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orthogonally with the tert-Butoxycarbonyl (Boc) group, which was successfully used 
in the synthesis of BODIPY- and Dansyl-JTE2-6 100 & 99. 
The synthesis of un-modified JTE2-3 62 was also undertaken, enabling us to assess 
the effect of the fluorescent dye conjugation upon the binding affinity. This ligand is 
not commercially available and a synthesis from II (Scheme 4-2) and tyramine 
offered an attractive route to the compound. 
 
4.3 Chemistry results 
 
The Protocatechuic acid derivative 105 was synthesised in high yield from 
commercially available Protocatechuic acid 102 as shown in Scheme 4-3. 
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Scheme 4-3 Synthesis of the Protocatechuic acid derivative. Reagents, conditions and yields: (i) 
MeOH, H+, reflux, 2h, (92%); (ii) 1-bromopentane, K2CO3, DMF, 90 °C, 1h, (72%); (iii) LiOH, 
MeCN, H2O, reflux, 1h, 90% 
 
The 2-aminoethyl tyramine derivative 117 was synthesised in ten steps from 
commercially available tyramine (Scheme 4-4). Following protection of tyramine’s 
amino group to its corresponding benzyl urethane 107, phenolic allylation afforded 
ether 108. The Claisen sigmatropic rearrangement was assessed using thermal and 
Lewis acid catalysed methods. Lewis acid catalysis using AlCl3248 yielded a 
chlorinated product (shown by the distinctive mass spectrum, with a 3:1 ratio of the 
35Cl and 37Cl isotopes in the product249) in overall low yield. Thermal rearrangement 
was tested by heating the allyl ether in refluxing diphenyl ether solvent (b.p. 258 °C) 
and by heating to 280 °C neat in a sealed tube. Both methods yielded the desired 
rearranged product 109 in yields of 56 and 47% respectively. Due to the increased 
yield and the easier experimental protocol, the Claisen rearrangement was carried out 
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in diphenyl ether during subsequent reactions. Benzyl ether protection of the phenol 
110 was used to prevent reaction with functional groups, to be installed in subsequent 
steps, via 5-membered intramolecular reactions. The olefin was oxidised by two 
different routes to the corresponding aldehyde 111 and alcohol 112. Oxidation to the 
1, 2-diol, using catalytic OsO4 and N-methylmorpholine oxide, as a stoichiometric 
oxidant, followed by NaIO4 mediated oxidative cleavage, yielded the aldehyde 111 in 
high yield. Use of the safer polymer bound OsO4250 was also assessed but produced 
poor conversion to the diol. Ozonolysis, using a NaBH4 reductive work-up yielded the 
alcohol 112. Interesting ozonolysis under milder reductive conditions (using 
dimethylsulfide (DMS)) failed to yield the aldehyde 111! 
Various reductive amination methods were tested to assess whether the 
aldehyde 111 could be directly modified to the amine in one-pot. However all 
attempts using ammonia and ammonium salts failed to give any of the desired amine 
115. The amine 115 was successfully accessed by sequential activation of the alcohol 
112 (to the Mesylate 113), substitution by azide and reduction of the resulting azide 
114 using Ph3P and water. Orthogonal Boc protection of this amine to give 116 and 
concomitant hydrogenolysis of the benzyl and Cbz groups yielded the ortho 
substituted tyramine 117 required for coupling. Coupling with the bis-
(pentoxy)protocatechuic acid derivative 105 using CDI proceeded to give 118. 
Formation of the HCl salt of the 2-aminoethyl derivative of JTE2-3 119 was afforded 
by acidolysis of the Boc protecting group of 118 using methanolic HCl. Unlabelled 
JTE2-3 62 was synthesised by coupling 105 with tyramine 106 using CDI in high 
yield (75%) (Scheme 4-5). 
Ligation of 118 with Dansyl-Cl 84 and BODIPY® 630/650 X OSu 86 (Figure 
2.5) was accomplished using methodology used in the successful synthesis of Dansyl- 
and BODIPY-JTE2-6 (99 & 100) (Chapter 2; Scheme 4-5). The free amine of 118 
was liberated and reacted rapidly with the amine reactive fluorescent dyes. The 
fluorescent products from these reactions were confirmed by mass spectrometry, 1H 
NMR and reverse phase HPLC to be the desired structures; Dansyl-JTE2-3 120, and 
BODIPY-JTE2-3 121. 
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Scheme 4-4 Synthesis of 2-aminoethyl derivative of JTE2-3. Reagents, conditions and yields: (i) Benzyl chloroformate, DIPEA, DMF, MeCN, rt, 24h, (57%); (ii) allyl 
bromide, K2CO3, MEK, reflux, 18h, (96%); (iii) Ph2O, reflux, 1h, (56%); (iv) BnBr, K2 CO3, MEK, reflux, 12h, (80%); (v) OsO4, NMO, acetone, H2O, rt. then NaIO4, H2O, 
THF, rt, (79%); (vi) NH3 or NH4
+, NaCNBH3, MeOH, AcOH, H2O, rt, (no reaction); (vii) O3, DCM, MeOH, -78 °C, then NaBH4, rt, 12h; (viii) MsCl, Et3N, DCM, 0 °C; (ix) 
NaN3, DMF, 60 °C, 5h; (x) Ph3P, THF, rt 24h then H2O, rt, 48h; (xi) Boc2O, H2O, dioxane, 0 °C, 1h, (overall for vii-xi 34%); (xii) Pd/C, EtOH, EtOAc, H2 (1atm), rt, 2h 
(54%); (xiii) CDI, MeCN, rt, (20%); (xiv) MeOH, AcCl, rt, 4h, (43%).
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Scheme 4-5 Synthesis of unlabelled and fluorescently labelled JTE2-3. Reagents, conditions and 
yields: (i) CDI, MeCN, rt, 4h, (75%); (ii) Dansyl-Cl 84 or BODIPY 630/650-X OSu 86, NaHCO3 (aq) 
pH 8.3: MeCN 1:1, rt, 1-12h, (70-80%). 
 
4.4 Pharmacology of JTE2-3 and BODIPY-JTE2-3  
 
The pharmacology, of JTE2-3 62 and BODIPY-JTE2-3 121, was assessed by 
competitive radioligand displacement of the non-selective cannabinoid [3H] CP55, 
940 from cellular membranes containing human CB2 receptors and was performed as 
previously described in section 2.4. BODIPY-JTE2-3 121 failed to displace any of the 
[3H] CP 55,940 from cell membranes prepared from CHO cells expressing the human 
CB2 receptor up to concentrations of 10-5 mol/L (10 µM)  (Figure 4-3 A). Surprisingly 
the unlabelled JTE2-3 62 exhibited a much lower affinity than expected, with 
concentrations of 10-5 mol/L (10 µM) displacing only 40% of the bound [3H] CP 
55,940 in the CHO cell membrane assay. The absence of any displacement by 
BODIPY-JTE2-3 121  (no displacement observed at 32 µM) and the lower than 
expected affinity of JTE2-3 62 were corroborated using cell membranes prepared 
from HEK cells expressing the human CB2 receptor by an independent group in the 
USA  (Figure 4-3 B). They determined a Ki value of 3.11 µM for JTE2-3 63 in a HEK 
cellular membrane assay. The results from both the CHO and HEK assays indicated a 
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Ki for BODIPY-JTE2-3 121 of >>32 µM. Binding affinity of Dansyl-JTE2-3 120 was 
not determined due to the poor solubility of the compound and that the other ligands 
tested exhibited such poor binding. 
 
 
Figure 4-3 Radioligand displacement curves for the compounds JTE2-3 62 and BODIPY-JTE2-3 121. 
The curves show the percentage of [3H] CP55, 940 displaced from cellular membranes containing the 
human CB2 receptor. (A) Demonstrates the displacement from cellular membranes made up of CHO 
cells expressing the CB2 receptor (n=3). (B)  Demonstrates the displacement from cellular membranes 
made up of HEK cells expressing the CB2 receptor (n=4). 
 
4.5 Use of BODIPY-JTE2-3 in Fluorescent Confocal 
Microscopy 
 
The fluorescent ligand BODIPY-JTE2-3 121 was used in confocal experiments to 
demonstrate whether the ligand had the potential to highlight CB2 receptor membrane 
binding. Detailed experimental conditions are included in section 2.5 but in brief 
known concentrations of fluorescent ligand were incubated with CHO cells 
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expressing human CB2 receptors and images were recorded at various time courses 
throughout the experiment. To assess whether the fluorescence observed was due to 
specific CB2 binding, fresh CHO cells were pre- incubated with a blocking 
concentration of a non-fluorescent cannabinoid ligand (i.e. 1 µM HU210 14) and the 
fluorescent ligand was subsequently introduced. Images collected from this 
experiment were compared to those conducted without the HU210 14 present, to 
determine if any fluorescence observed was due to CB2 receptor binding. Various 
concentrations of 121, ranging from 10 – 400 nM, were used in experiments. The 
fluorescence observed was weak even when laser power and pin-hole aperture was 
increased. Even at concentrations of 400 nM fluorescence from the CHO cells was 
negligible (results not shown). Background fluorescence from the CB2 transfected 
CHO cells was negligible at the excitation wavelengths used (633 nm) (Result not 
shown). 
 
4.6 Discussion 
 
 
Synthesis to access JTE2-3 62 and its 2-aminoethyl derivatives 119, 120, and 121 was 
successfully carried out. The positioning of the 2-aminoethyl linker was guided by 
molecular modelling results which demonstrated that attachment of a linker at this 
position should not interfere with the binding of the ligand in the receptor binding 
pocket. 
In order to complete the synthesis of the 2-aminoethyl derivatives of JTE2-3 
62 it was necessary to synthesise a novel ortho substituted tyramine derivative 109. 
By careful selection of the thermo stable Cbz protecting group247, we were able to 
access 109 via a thermally induced [3,3]-sigmatropic Claisen rearrangement. 
Oxidation of the olefin using two different oxidants (OsO4 with a NaIO4 cleavage, and 
O3) gave the aldehyde 111 and alcohol 112 respectively. Repeated attempts to 
generate the aldehyde 111 using ozonolysis and DMS failed to give the desired 
product. A literature report detailing this reaction on a similar allylic benzene system 
did not suggest that there were any problems during this step, however only brief 
experimental conditions were reported248. It was obvious that the ozonide of 110 
could be formed, demonstrated by the successful reduction of this complex using 
NaBH4. Therefore, we concluded that the problems observed in our synthesis were 
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due to the DMS reduction step. All attempts to rectify this by altering the conditions 
of the DMS reduction did not resolve the problem and we had to use the alternative 
OsO4 oxidation to generate the aldehyde 111. Unfortunately reductive amination of 
this aldehyde 111 failed to give the amine required. We assessed the use of NH3 and 
NH4Cl, as a source of ammonium ion, and combinations of these together to form the 
imine in-situ and reducing it to the amine using NaCNBH3. However we could not 
detect the 1° amine in any of the attempted reactions. A Beilstein search revealed that 
other reported experiments using ammonia and aldehydes to give 1° amines often 
exhibited lower yields (the highest reported was 40%251) than the corresponding 
reaction used to yield 2° and 3° amines. This is presumably due to the fact that once 
the 1° amine has been formed it is immediately available to react with the aldehyde 
present and form 2° amines. To produce the amine 115 we therefore had to use a more 
convoluted route, involving activation of the alcohol to the mesylate and forming the 
corresponding azide 114. This was reduced under mild conditions using PPh3 and 
water to the corresponding amine 115. Boc protection of the amine resulted in a 
compound that was quantified analytically and we calculated an overall yield from the 
olefin as a respectable 32% for 5 steps; which represents an average yield of 80% for 
each step. The subsequent chemical reactions leading to the two fluorescent 
conjugates Dansyl-JTE2-3 120 and BODIPY-JTE2-3 121 utilised chemistry fully 
discussed in section 2.6. The unlabelled ligand JTE2-3 62 was synthesised to allow us 
to test the effect of conjugation to the fluorescent dye using a radioligand binding 
competition assay discussed below. 
The affinity of JTE2-3 62 and BODIPY-JTE2-3 121 to the human CB2 
receptor was assessed using radioligand competition displacement assays against the 
non-specific cannabinoid [3H] CP55, 940. The membrane homogenates used were 
made up from both CHO and HEK cells stably transfected with the human CB2 
ligand. Concentrations of up to 32 µM of BODIPY-JTE2-3 121 failed to displace any 
of the [3H] CP55, 940 from the receptors. The Ki value of 3.11 µM obtained for the 
unlabelled JTE2-3 62 was much higher than that reported in the literature (0.4 nM)126. 
This represented a difference in affinity to that quoted in the literature of a factor of 
7500. JTE2-3 62 displayed less affinity to the human CB2 than was expected.  
Adulterating JTE2-3 62 with the fluorescent dyes Dansyl and BODIPY effectively 
abolished any of the human CB2 receptor binding ability JTE2-3 62 possessed. This 
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was confirmed in a fluorescent confocal microscopy experiment, because no 
membrane binding was observed at concentrations of 400 nM.  
The significantly lower affinity of JTE2-3 62 observed in our displacement 
experiments, when compared to the literature Ki value, was unexpected and was a 
matter of concern. Initially we checked that the binding assay was generating 
meaningful data by performing a saturation radioligand binding experiment (using 
[3H] CP55, 940) on the CB2 HEK membranes which yielded a Kd of 5.1 nM (results 
not shown), which was well within the reported range of 0.29-7.37 nM for this 
ligand51. The analytical data for the compound JTE2-3 62 was checked against that 
published in the original patent. 1H NMR and m.p. were identical for our synthesised 
compound and the literature values (section 8.1). 13C and ES-MS, which were not 
reported in the patent, were consistent with the structure of JTE2-3 62. Finally a fresh 
stock solution of JTE2-3 62 was made up to check for errors in ligand concentration. 
We obtained the same results with the new stock solution and this result forms part of 
the n = 4 analysis shown in B of Figure 4-3. We had ruled out all experimental error 
in the calculation of the Ki of JTE2-3 62 (3.11 µM) and yet could not explain the 7500 
fold difference to that reported in the patent (0.4 nM)126. Differences between the two 
experimental protocols used to calculate the Ki of JTE2-3 62 were checked. The 
radioactively labelled ligand used and the species of CB2 receptor tested against 
differed between the two protocols. [3H] Win 55212-2 and rat CB2 receptors (derived 
from rat spleenocytes) were used in the Japan Tobacco publication126, where we had 
used  [3H] CP55, 940 and the human CB2 receptor expressed in HEK and CHO cells. 
[3H] Win 55212-2 is not commercially available so we were unable to assess the 
effect of using a different radioligand. However we were able to test the affinity of 
JTE2-3 62 against the rat CB2 receptor and discovered that the difference in the 
different Ki values obtained was due to the species of CB2 receptor used. A full 
discussion of this work is reported in Chapter 5. 
4.7 Conclusions 
 
• We successfully synthesised a derivative of the CB2 selective ligand JTE2-3 
62, incorporating an alkyl linker which we labelled with Dansyl and 
BODIPY® fluorescent dyes.  
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• Computational modelling demonstrated that the optimum position for 
attachment of an alkyl linker was on the phenol ring, as the phenol ring was 
located near to the top of the receptor binding pocket. 
• Development of novel chemistry was established, enabling the synthesis of 
orthogonally protected 2-aminoethyl tyramine, required for the synthesis of 
the fluorescent conjugate. 
• Binding data for the BODIPY labelled compound 121, demonstrated a loss 
of affinity for the CB2 receptor (Ki > 32 µM).  
• Confocal microscopy experiments showed that BODIPY labelled compound 
121 did not bind to human CB2 receptors expressed in live CHO cells. 
• Binding data obtained for the unlabelled lead compound JTE2-3 62, 
demonstrated it had, surprisingly, 7500 times less affinity to the CB2 receptor 
compared to the Ki value reported in the original patent. Thorough analysis of 
this anomaly suggested that the difference between the two results was due to 
the different species (rat and human) of receptor used in the binding assay.   
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5 Species selective nature of JTE2-3  
 
From our investigations in chapter 4, we discovered that the selective CB2 receptor 
ligand JTE2-3 62 displayed a 7500 fold decrease in binding affinity to the human CB2 
(hCB2) receptor compared to the rat CB2 (rCB2) receptor, which was originally 
reported (Ki  hCB2 = 3.11 µM, rCB2 = 0.4 nM)126. This substantial species dependant 
behaviour of the ligand was, to the best of our knowledge, the largest that has been 
reported for any cannabinoid and the details of our work to understand this unusual 
phenomenon are discussed below. 
5.1 The rat and human CB2 receptor 
 
As discussed previously in section 1.3.4 both the human and rat species of CB2 
receptor have been characterised and cloned. The human receptor, first cloned by 
Munro et al., consists of 360 amino acids4, whilst two independent pieces of research 
have deduced that the  rCB2 receptor contains either 360105 or 410106 amino acids 
depending on which polymerase chain reaction (PCR) primer was employed. It is 
extremely difficult to clarify which of the two clones actually represents the rCB2 
receptor amino acid sequence, as no independent studies examining the different 
sequences have been published following the second cloning study. Since being 
published in July 2002, this most recent study by Brown et al., generating the 410 
amino acid containing receptor106, has only been cited 5 times. By comparison, the 
original study by Griffin et al., who generated a 360 amino acid receptor105, has been 
cited by 13 other researchers since July 2002‡‡. This would suggest that to date the 
sequence generated by Griffin et al. has been adopted as the rCB2 receptor of choice 
with more of the cannabis research community. From the two primary studies, both 
groups were able to show that their receptors were able to bind the cannabinoid Win 
55212-2 3, and both studies demonstrated that this agonist binding gave a measurable 
change in a downstream signalling pathway of the GPCR (i.e. decrease in cAMP105, 
and an increase in MAP kinase106). The difference between the sequence lengths is 
related to the carboxyl terminus end (intracellular) of the receptor explaining why the 
Win 55212-2 3 binding capability of these two different receptors is unaltered106. 
                                                 
‡‡ Web of Knowledge (http://wok.mimas.ac.uk) citation search conducted on 17/06/04 
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The sequence homology of the rCB2 receptor with the hCB2 receptor depends upon 
which rat clone is being compared. The 360 amino acid rCB2 clone, is as expected, a 
closer match to the 360 amino acid hCB2 receptor generating a sequence homology of  
81%105. The 410 amino acid clone has a much lower sequence homology to the hCB2 
receptor with only 57% identity retained106. With this level of divergence in 
homology between the two species it is, perhaps, not surprising to discover that 
cannabinoids may have different affinities and efficacies at the rat and human CB2 
receptors. This observation was highlighted by the authors of the two original rCB2 
cloning publications, who both commented in their respective discussions that species 
differences between rat and human could be expected to emerge in future 
studies105,106. Unfortunately, it appears that other researchers in the cannabinoid field 
have failed to recognise this potential pitfall in their studies. This can be demonstrated 
in the relatively few citations that the two rCB2 cloning papers have received (35 in 
total§§) and that studies conducted on the rCB2 receptor are rarely backed up with a 
corresponding hCB2 receptor assay***. Fortunately, for human drug research, the 
advances made in genetic engineering has allowed most new cannabinoid ligands to 
be screened against the hCB2 receptor stably transfected into CHO or HEK cell lines. 
There are a few examples from the literature where cannabinoids have been 
compared using the same assay conditions, against both the rCB2 and the hCB2 
receptor. In the following section we will discuss these examples in terms of their 
relevance to this work. 
5.2 Differences between CB2 ligand binding at the rat and 
human receptor 
 
There are only three studies directly comparing the affinity of cannabinoid ligands to 
both the rCB2 and the hCB2 receptor. They are limited to testing eight different 
cannabinoids57,105,125. Direct comparison of binding affinity is important, as it 
overcomes the experimental error associated with different techniques employed by 
different laboratories performing the binding assay. Comparison of the binding 
affinity of ligands, performed in different independent studies have been reviewed51,80 
but due to the variability of these results it is difficult to draw meaningful 
comparisons from the work. 
                                                 
§§ Web of Knowledge (http://wok.mimas.ac.uk) citation search conducted on 17/06/04 
*** Author’s personal observation. 
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A summary of both the direct and indirect comparative work is shown in Table 5-1. 
Griffin et al. analysed their affinity data for statistical significance between the rCB2 
and hCB2 receptor105. Using this study it was straightforward to determine which of 
the ligands tested showed significant species differences. Their analysis of seven 
different cannabinoids demonstrated that only three, JWH051 (classical cannabinoid), 
Win 55212-2 3, and anandamide 4 had significant differences between the rat and 
human CB2 receptors105. The differences observed for the three cannabinoid ligands 
were a 9, 8, and 32 fold decreased affinity to the rCB2 receptor respectively105.  The 
observation that SR144528 6 exhibited little species selectivity was corroborated in a 
study by Rinaldi-Carmona et al. which reported that the rCB2 and hCB2 affinities 
were similar57, however work by Iwamura et al. was able to show an 8 fold decreased 
affinity to the hCB2 receptor (Table 5-1)125. Iwamura et al. also demonstrated that 
Win 55212-2 3 had a 5 fold decreased affinity towards the rCB2 receptor125, which is 
in agreement with the results generated by Griffin et al.105.  
The results for Win 55212-2 3 and ∆9-THC 1, shown in Table 5-1, highlights 
how difficult interpreting results obtained from different laboratories can be. Using 
Win 55212-2 3 as an example, it can clearly be seen that although two studies both 
examined the same ligand on the rat and human CB2 receptors, they have both 
produced different Ki values for the two receptor species (rCB2 Ki = 10.4 or 1.30 nM 
and hCB2 Ki = 1.19 or 0.29 nM). It was for this reason that where possible we tried to 
compare direct experimental comparisons of Ki values to assess for species’ 
differences.  
The two most significant results relating to our work are for the compounds 
JTE1-22 61 and JTE907 66 (Table 5-1). These Japan Tobacco compounds were 
shown to exhibit large species differences in affinity, between the rat and human CB2 
receptor. The direct comparison conducted by Iwamura et al. of the compound 
JTE907 66 demonstrated that the compound had a 95 fold less favourable binding 
affinity to the hCB2 receptor than to the rCB2 (Ki 35.9 and 0.38 nM respectively)125. 
This interesting result was attributed to the low sequence homology between the rat 
and human receptors and to the novel structure of JTE907 66125. The one indirect 
comparison included in Table 5-1, is of another Japan Tobacco compound, JTE1-22 
61, which is of interest to us. The results, are extracted from the original Japan 
Tobacco patent126 and from a later publication by the Bristol Myers Squibb (BMS) 
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company who were interested in employing the novel structures as a template for their 
own CB2 receptor ligands197. The original patent reported affinity of JTE1-22 61 in rat 
splenocyte membranes whilst workers at BMS screened the compound in the hCB2 
receptor expressed in CHO cells. It is observed, from Table 5-1, that the binding of 61 
at the rat and human receptors differs by a factor of 86. The low Ki observed in the 
rCB2 receptor (1.4 nM) is altered to a moderate Ki value in the hCB2 receptor (120 
nM). Although the BMS workers who tested the compound in human CB2 receptors 
did not comment on the species difference, this second example of a Japan Tobacco 
compound exhibiting a large difference in affinity towards the CB2 receptor is 
noteworthy. Both of the ligand comparisons available for the Japan Tobacco ligands, 
show large differences (86 and 95 fold) in affinity between the rat and human CB2 
receptor, with a higher binding observed at the rCB2 receptor.   
We will be demonstrating, in the remainder of this chapter, our own evidence 
that another of Japan Tobacco’s amide containing cannabinoid also displays a species 
selective binding, with greater affinity observed for the rCB2 receptor. We will also 
extend the use of molecular modelling discussed in chapter 3 to explore the intimate 
nature of ligand-receptor binding to rationalize these findings.  
 
Compound 
Study 
type 
rCB2 Ki (nM) hCB2 Ki (nM) 
hCB2/rCB2 
ratio 
Statistical 
analysis 
Reference (s) 
SR144528 6 Direct 0.30 0.32 1 NS 105 
 Direct 0.24 1.99 8 ND 125 
 Direct 0.30 0.60 2 NS 57 
Win 55212-2 3 Direct 10.4 1.19 0.1 P < 0.05 105 
 Direct 1.30 0.29 0.2 ND 125 
∆9-THC 1 Direct 28.3 44.9 1.6 NS 105 
 Direct 6.80 3.13 0.5 ND 125 
JWH015 53 Direct 269 98.4 0.4 NS 105 
JWH051 Direct 3.16 0.33 0.1 P <0.05 105 
JTE907 66 Direct 0.38 35.9 95 ND 125 
JTE1-22 61 Indirect 1.4a 120b 86 ND a = 197 b = 126 
Table 5-1 Comparisons of the binding affinity (Ki (nM)) of a selection of cannabinoids towards the 
rCB2 and hCB2 receptor. ND not determined. NS not significant. 
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5.3 Pharmacology results 
 
In-order to be able to directly compare human versus rat affinities of JTE2-3 62 it was 
necessary for us to calculate its Ki value at the rCB2 receptor using a radioligand 
displacement assays. From the result obtained we could directly compare the rat Ki 
value to the human Ki obtained in chapter 4. The Ki value is calculated using the 
Cheng and Prussoff equation which uses the Kd value of the radioactive ligand ([3H] 
CP55, 940) being displaced. Therefore a standard curve was first produced in order to 
determine the Kd value of [3H] CP55, 940 in a rat splenocyte assay. A method by 
DeBlasi et al was followed whereby [3H] CP55, 940 is displaced by cold CP55, 940; 
which avoids the use of problematic saturation binding experiments252. Full details of 
the preparation of the rat splenocyte membranes and the binding experiment are given 
in the experimental section (section 8.2) 
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Figure 5-1 Graph used to calculate the Kd of [3H] CP 55, 940, showing the displacement of [3H] CP 
55, 940 from membranes derived from rat splenocytes by cold CP 55, 940 (n=3). 
 
 
 
The displacement graph shown in Figure 5-1 was used to calculate the EC50 of 0.91 
nM. Using the calculation from DeBlasi et al.252, shown below, we calculated the Kd 
of [3H] CP 55, 940 to be 0.59 nM. 
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DeBlasi et al. calculation252: Kd = EC50 – L  
    Kd = 0.91 – 0.32 
    Kd = 0.59 nM 
where: 
L = concentration of radioligand (nM) 
EC50 = concentration of CP 55, 940 that displaces half the specific binding of [3H] CP 
55, 940 (nM) 
Kd = equilibrium dissociation constant for [3H] CP 55, 940 (nM) 
 
Using the calculated Kd value of 0.59 nM for [3H] CP 55, 940 we were able to use the 
Cheng and Prussoff calculations, within GraphPad® Prism3, to determine the Ki of 
JTE2-3 62 using a competitive radioligand displacement of the non-selective 
cannabinoid [3H] CP 55, 940 from rat splenocyte membranes. The displacement of 
[3H] CP 55, 940 by JTE2-3 62 from the rCB2 receptor is shown in Figure 5-2. From 
this curve the Ki value for JTE2-3 62 was calculated to be 5.02 nM (95% confidence 
intervals 0.85 – 29 nM). This value is 600 fold less than the Ki of 3.11 µM calculated 
for the hCB2 receptor in chapter 4. 
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Figure 5-2  Displacement curve of [3H] CP 55, 940 by JTE2-3 62 from membranes derived from rat 
splenocytes (n=3). 
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Due to the species selective nature of JTE2-3 62 (and at least two other Japan 
Tobacco Compounds), it became prudent for us to retest the two BODIPY Japan 
Tobacco fluorescent derivatives synthesised in chapters 2 and 4, against the rCB2 
receptor. Thus Bodipy-JTE2-6 100 and Bodipy-JTE2-3 121 were used in competitive 
displacement assays against [3H] CP 55, 940 using membranes from rat splenocytes. 
The binding curves from these assays are shown in Figure 5-3 
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Figure 5-3 Displacement curve of [3H] CP 55, 940 by Bodipy-JTE2-6 100 (solid) and Bodipy-JTE2-3 
121 (dashed) from membranes derived from rat splenocytes (n=4). 
 
Although the Ki for both Bodipy-JTE2-6 100 and Bodipy-JTE2-3 121 could not be 
calculated from this assay due to maximal [3H] CP 55, 940 displacement not being 
achieved, it could be shown that at concentrations of 1 µM, 44% and 48% of the 
bound [3H] CP 55, 940 could be displaced by Bodipy-JTE2-6 100 and Bodipy-JTE2-3 
121 respectively. This should be compared to no detectable displacement with these 
compounds at concentrations ≥ 32 µM at the hCB2 receptor. 
 
5.4 Molecular modelling results 
 
We explored the nature of the species selectivity using the molecular model of the 
CB2 receptor discussed in chapter 3. In-order to investigate the possible differences 
between the binding of JTE2-3 62 in the rat and human CB2 receptor we first 
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constructed the rCB2 model by homology modelling to the hCB2 previously 
generated. This was achieved by changing the non-conserved sequences in the hCB2 
receptor to the corresponding rCB2 receptor residue, using similar experimental 
protocol detailed in section 3.3.  The rCB2 sequence was sequence aligned against the 
hCB2 and mouse CB2 (mCB2) sequences (Swissprot reference number Q9QZN9 
(rCB2), P47936 (mCB2), P34972 (hCB2) using the alignment program ClustalW 
(Version 1.81)232. The alignment generated is shown in Figure 5-4 
 
rCB2   MEGCRELELTNGSNGGLEFNPMKEYMILSDAQQIAVAVLCTLMGLLSALENVAVLYLILS 60 
mCB2   MEGCRETEVTNGSNGGLEFNPMKEYMILSSGQQIAVAVLCTLMGLLSALENMAVLYIILS 60 
hCB2   MEECWVTEIANGSKDGLDSNPMKDYMILSGPQKTAVAVLCTLLGLLSALENVAVLYLILS 60 
        
rCB2   SQRLRRKPSYLFIGSLAGADFLASVIFACNFVIFHVFHGVDSRNIFLLKIGSVTMTFTAS 120 
mCB2   SRRLRRKPSYLFISSLAGADFLASVIFACNFVIFHVFHGVDSNAIFLLKIGSVTMTFTAS 120 
hCB2   SHQLRRKPSYLFIGSLAGADFLASVVFACSFVNFHVFHGVDSKAVFLLKIGSVTMTFTAS 120 
        
rCB2   VGSLLLTAVDRYLCLCYPPTYKALVTRGRALVALGVMWVLSALISYLPLMGWTCCPSPCS 180 
mCB2   VGSLLLTAVDRYLCLCYPPTYKALVTRGRALVALCVMWVLSALISYLPLMGWTCCPSPCS 180 
hCB2   VGSLLLTAIDRYLCLRYPPSYKALLTRGRALVTLGIMWVLSALVSYLPLMGWTCCPRPCS 180 
        
rCB2   ELFPLIPNDYLLGWLLFIAILFSGIIYTYGYVLWKAHQHVASLTEHLDRQVPGIARMRLD 240 
mCB2   ELFPLIPNDYLLGWLLFIAILFSGIIYTYGYVLWKAHRHVATLAEHQDRQVPGIARMRLD 240 
hCB2   ELFPLIPNDYLLSWLLFIAFLFSGIIYTYGHVLWKAHQHVASLSGHQDRQVPGMARMRLD 240 
        
rCB2   VRLAKTLGLVMAVLLICWFPALALMGHSLVTTLSDKVKEAFAFCSMLCLVNSMVNPIIYA 300 
mCB2   VRLAKTLGLVLAVLLICWFPALALMGHSLVTTLSDQVKEAFAFCSMLCLVNSMVNPIIYA 300 
hCB2   VRLAKTLGLVLAVLLICWFPVLALMAHSLATTLSDQVKKAFAFCSMLCLINSMVNPVIYA 300 
        
rCB2   LRSGEIRSAAQHCLTGWKKYLQGLGSEGKEEAPKSSVTETEAEVKTTTGPGSRTPGCSNC 360 
mCB2   LRSGEIRSAAQHCLIGWKKYLQGLGPEGKEEGPRSSVTETEADVKTT------------- 347 
hCB2   LRSGEIRSSAHHCLAHWKKCVRGLGSEAKEEAPRSSVTETEADGKITPWPDSRDLDLSDC 360 
Figure 5-4 The sequence alignment of the rat, mouse and human CB2 receptors. Highlighted amino 
acids are non-conserved between the rat and human CB2 sequence. 
 
From the sequence alignment shown in Figure 5-4, we mutated the non-conserved 
amino acids highlighted, from the residue contained in the hCB2 receptor, to the 
corresponding residue present in the rat sequence. The rCB2 receptor sequence was 
subjected to energy minimisation within Sybyl® using 100 Steepest Descent iterations 
followed by 500 Conjugate Gradient steps using the standard Sybyl® setup.  
JTE2-3 62 was constructed using Spartan PCPro (Wavefunction Inc). 
Geometry optimisation was undertaken using quantum mechanical methods, namely 
ab initio Hartree-Fock calculations at the 3-21G* level. In addition, partial atom 
charges were calculated using the ESP method. JTE2-3 62 was interactively docked 
into both the rat and human CB2 receptor models using Phe 197 as an anchor point for 
an aromatic-aromatic interaction with the ligand 62 in a similar manor to that depicted 
in figure 3.5. 
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The two ligand-receptor complexes were further optimised using energy minimisation 
and molecular dynamics. In our studies, we applied the CHARMM force field with an 
8 Å cut-off for non-bonded interactions to optimize the ligand-receptor model as 
previously stated in section 3.3.3.  It is clear from Figure 5-5 (A and B) that JTE2-3 
62 in both the human and the rat receptor occupy very similar positions within the 
receptor. The overlay of the bound ligand demonstrates that the phenol ring in the 
hCB2 receptor has rotated into a more planar position relative to the rCB2, which as a 
consequence, has shifted the amide carbonyl group into a different alignment from 
that observed in the rCB2 receptor Figure 5-5 (C). The key amino acids involved in 
ligand-receptor interactions were located using the programme LigPlot for each 
model245. The results from this analysis are shown in Figure 5-6. It is evident that 
JTE2-3 62 bound into the rCB2 receptor is associated with four extra amino acid 
interactions than when bound in the hCB2 receptor. The most striking difference in the 
interactions observed between the two species is that JTE2-3 62 is capable of forming 
a hydrogen bond (H-bond), involving its carbonyl oxygen and the residue Thr 173 in 
the rCB2 receptor but not in the hCB2 receptor. Other contacts made with the ligand, 
in both receptor species, are hydrophobic and aromatic interactions. It is interesting to 
note that Phe 117, Phe 197 and Trp 194, important residues in CB2 receptor binding, 
are shown to form interactions with the ligand in the rCB2 model. 
Investigations into why the ligand adopts a different conformation, in the rCB2 
and hCB2 receptor, initially concentrated on its contacts made with Thr 173. This 
residue, present in both receptor sequences, was highlighted and shown to adopt very 
similar conformations in both receptors (Figure 5-7, A). Investigation of the non-
conserved amino acids, highlighted in Figure 5-4, was unable to detect any significant 
differences in the binding pocket shape which could alter the bound conformations of 
JTE2-3 62 and therefore evoke the hydrogen bond observed in the rCB2 receptor 
(results not shown). 3D visualisation of both models, in which the ligand binding 
amino acids (identified by LigPlot; Figure 5-6) were highlighted, was able to identify 
a difference in the conformation of Glu 8, located in the extra cellular loop (EL) 1, 
between the rat and human species. Glu 8, which makes a contact with JTE2-3 62 in 
the hCB2 receptor, can be seen to adopt a position in the hCB2 receptor that is altered 
from the corresponding residue in the rCB2 receptor (Figure 5-7, B & C). A distance 
of 1.42 Å and 4.79 Å was measured between the carboxylic acid group of Glu 8 found 
within the hCB2 receptor, and the phenol oxygen of JTE2-3 62 in its final bound 
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conformation within the rat and human receptors respectively. Therefore the 
carboxylic acid group of Glu 8, is involved in a clash with the phenol ring of JTE2-3 
62 in the hCB2, but not in the rCB2 receptor.  
 
 
 
Figure 5-5 Representations of JTE2-2 62 docked into the hCB2 and rCB2 receptor. (A) Shows the 
relative position of JTE2-3 62 in its final binding position/conformation in the hCB2 receptor. Model is 
being viewed with TM 5 & 6 front and centre. (B) Shows the ligand JTE2-3 62 in its final binding 
position/conformation in the rCB2 receptor. Model is being viewed with TM 5 & 6 front and centre. (C) 
Stereoview of the overlay of JTE2-3 62 in the bound conformation from the hCB2 (magenta) and rCB2 
(cyan) receptor. The oxygen atoms shown in red are the phenol (top) and the amide carbonyl (lower).  
 
 
A B
C
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Figure 5-6 Ligplot analysis of the amino acid binding interactions occurring with JTE2-3 62 docked in 
the hCB2 (A) and rCB2 (B) receptor. 
 
 
Figure 5-7 Investigation into the binding conformation of JTE2-3 62 in the hCB2 (magenta) and rCB2 
(cyan) receptor. (A) Shows the similar conformation of Thr 173 in the hCB2 and rCB2 receptor. (B) An 
overlay image of the ligand bound in both receptors showing the interactions with EL 1 (Met 1 – Gly 
12); specifically with residue Glu 8. (C) An alternative view of the bound ligand interacting with Glu 8. 
EL 1 of the rCB2 is not shown for clarity. 
 
Thr 173 
Glu 8
JTE2-3 62
A B C
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5.5 Discussion 
 
It has been previously shown, in chapter 4, that the ligand JTE2-3 62 binds to the 
hCB2 receptor with 7500 fold less affinity than the rCB2 receptor. In order to qualify 
these data we have determined the Ki value of JTE2-3 62 in the rCB2 receptor in our 
own laboratories. The assay, using membranes derived from rat splenocytes, was 
validated by determining the Kd value of a known cannabinoid ligand [3H] CP 55, 
940. The calculated Kd value of 0.59 nM was within the reported range of 0.29-7.37 
nM for this ligand51 and we were therefore confident in using the assay to calculate Ki 
values of unknown compounds. Using this assay we determined the Ki value of JTE2-
3 62 at the rCB2 receptor to be 5.02 nM (95% confidence intervals 0.85 – 29 nM). 
Although this value is 12 fold higher than the one reported in the original patent (0.4 
nM)126, it still supports the original hypothesis that a large increase in affinity is 
observed when the ligand is binding to the rCB2 receptor compared to the hCB2 
receptor. Discussion in section 5.2 highlighted work on other cannabinoids, namely 
JWH051, Win 55212-2 3, and anandamide 4, that have statistically shown a species 
preference. Other cannabinoids, particularly the Japan Tobacco compounds JTE1-22 
61 and JTE907 66 also exhibit a strong selectivity towards the rCB2 receptor. The 600 
fold difference in affinity between the rat and human species demonstrated in chapters 
4 and 5 is to the best of our knowledge, the largest species selectivity demonstrated by 
any cannabinoid to date. The authors of the original rCB2 cloning papers, both 
concurred that due to the low sequence homology between rat and human CB2 
sequences, they would anticipate large differences between a ligand’s affinity or 
potency at the rCB2 and hCB2 receptors to be reported in future pharmacological 
studies; and warned researchers of the potential pitfalls in extrapolating data derived 
from the rCB2 receptor into human models105,106. In this study we have demonstrated 
that the cannabinoid ligand JTE2-3 62 does not bind with equal affinity to the rat and 
human CB2 receptor. Extrapolating CB2 data from rat to human models may also have 
proved unpredictable for Japan Tobacco Inc. as they have withdrawn their benzamide 
drug, JTE907 66, from phase II human clinical trials for undisclosed reasons †††.  
In using the Japan Tobacco compounds as lead molecules in designing 
fluorescent CB2 selective ligands (chapters 2 and 4) we did not recognise the 
                                                 
††† Information obtained from the Japan Tobbaco Inc. website (www.jti.co.jp) which shows that 
compound JTE907 did not progress to phase II trials for an anti-allergy compound in May 2003. 
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importance of species selectivity, as very little literature existed to consolidate 
previous work and the species selectivity exhibited were not as large as we 
encountered. Therefore fluorescent conjuagtion of these ligands with fluorescent dyes, 
which is normally associated with a reduction in receptor binding, was unlikely to 
yield high affinity fluorescent ligands for the hCB2 receptor. In order for the 
fluorescent probe to fulfil its potential as a tool in molecular pharmacology and drug 
discovery, discussed in section 1.1, it is highly desirable that the fluorescent ligand 
should have good affinity towards the hCB2 receptor.  
When we retested the two BODIPY® labelled derivatives, Bodipy-JTE2-6 100 
and Bodipy-JTE2-3 121, against the rCB2 receptor they did demonstrate an albeit 
moderate affinity, displacing 44% and 48% of the bound [3H] CP 55, 940 
respectively, at concentrations of 1 µM. This demonstrated to us that the overall 
strategy adopted for fluorescently labelling these cannabinoids, appeared to be 
partially successful. Unfortunately, the CB2 affinity shown was still too poor for use 
in fluorescence experiments and it was decided not to pursue them as novel CB2 
selective ligands. Instead we concentrated our efforts in designing a high affinity CB2 
selective fluorescent ligand with affinity for the hCB2 receptor, and this work is 
discussed in chapter 6.  
Due to the importance and magnitude of the species selectivity exhibited by 
JTE2-3 62 we used computational methods to determine the nature of the species 
difference. Analysis of the ligand-receptor interactions occurring in both the rCB2 and 
hCB2 receptors, demonstrated that a key difference between the two species was the 
presence of a strong H-bonding interaction occurring within the rat receptor and not 
within the human receptor. It is well known that binding interactions occurring 
between a receptor and a ligand are crucial to prevent the ligand drifting in and out of 
the binding site; with stronger binding interactions leading to ligands with higher 
affinity to the receptor. The rCB2-ligand complex crucially has four extra amino acid 
interactions, including a strong H-bond, when compared to the hCB2-ligand complex 
(Figure 5-6). These extra binding interactions, especially the H-bonding, may well 
account for the higher Ki value observed in the rat receptor. The H-bond occurring 
within the rCB2 receptor exists between the amide carbonyl oxygen of JTE2-3 62 and 
the residue Thr 173. The location and conformation of Thr 173 in both species of 
receptor is almost identical and it is therefore the conformation or position of the 
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ligand within the binding site that has determined whether a H-bond can form (Figure 
5-7, A). Figure 5-5 shows that the conformation of JTE2-3 62 is different in both 
receptor types; with the phenol ring in the hCB2 receptor being twisted into a more 
planar conformation. The result of this twist is that the carbonyl oxygen is shifted out 
of the plane necessary to form the crucial H-bond with Thr 173 (1.8 Å, 120°230). The 
receptor interactions that result in the phenol ring twisting in the hCB2 receptor were 
investigated and we hypothesised that this was due to the conserved Glu 8 residue 
located in EL 1. From Figure 5-7 (B & C) it is possible to show that Glu 8 within the 
hCB2 receptor protrudes further into the binding cavity than is observed in the rCB2 
receptor. Although Glu 8 is conserved between both species it is located in an EL loop 
which is only 50% homologous between the two species (Figure 5-4). The different 
conformations of the EL 1, adopted by both species, may result in the Glu 8 positional 
differences observed. The consequence of Glu 8 extending into the binding cavity is 
shown in Figure 5-7 C. One can envisage that when JTE2-3 62 is docked within the 
hCB2 receptor, the close proximity of Glu 8 (1.42 Å), induces a steric interaction 
which forces the phenol ring down into a planar position, thus shifting the amide 
carbonyl into a non-H-bonding position. The Japan Tobacco compounds are by far the 
most species selective of any of the cannabinoids reported in the literature. By using 
the data from our study it is possible to hypothesise that the difference in binding is 
due to the amide group within the structure forming a H-bond in the rat, but not the 
human, receptor. If this evidence is proven by further studies then compounds such as 
the Japan Tobacco benzamide 65 (figure 1-22), containing a conformationally 
restricted amide, may be less susceptible to the species differences. 
It is finally worth stating that the CB2 model we have used to study the binding 
of the Japan Tobacco ligands is a high quality GPCR model, which is comparable to a 
similar peer reviewed model by Xie et al.242. However, GPCR modelling remains in 
its infancy and consequently is still limited in a number of areas; namely that water is 
not present within the molecular dynamics simulation; the template of Bovine 
Rhodopsin represents the receptor in the ‘off (unbound) state’; and the receptor is not 
coupled to the G-protein during the simulation. These limitations are likely to cause 
inaccuracies within any model produced, and may explain why modelling of JTE2-3 
62 in the hCB2 appeared to give positive binding results when in reality the ligand had 
poor affinity to this receptor. There is currently a large interest in overcoming these 
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limitations in GPCR modelling and we hope to use future developments in this area to 
refine our own CB2 model82-84,227,229,253.  
 
5.6 Conclusions 
 
• The Ki value of JTE2-3 62 in the rCB2 receptor was found to be 5.02 nM 
which was 600 fold less than the Ki value obtained for the hCB2 receptor. This 
difference in species selectivity is the largest reported for any cannabinoid. 
• Our use of JTE2-3 62 as a lead molecule for conjugating with fluorescent dyes 
was unable to take account of this largely unrecognised species difference. It 
was therefore not surprising to find that conjugating a fluorescent dye to a 
ligand with low affinity to the hCB2 receptor, relinquished fluorescent 
conjugers with associated poor hCB2 affinity. 
• Retesting the affinity of the fluorescent conjugers BODIPY-JTE2-6 100 and 
BODIPY-JTE2-3 121 in rCB2 receptors, revealed that they were able to 
displace approximately 40% of the radiolabelled [3H] CP 55,940 from the 
receptors, albeit at high concentrations (1 µM). Hence they also mirrored the 
species selectivity pattern as no displacement was observed when they were 
tested at this concentration against the hCB2 receptor. 
• Molecular modelling was used to understand the nature of the species 
selectivity. It was observed that JTE2-3 62 was able to form extra receptor 
interactions, including a strong hydrogen bond, in the rCB2 receptor 
potentially leading to the lower Ki observed.  
• The hydrogen bond interaction was investigated and found to form between 
the carbonyl of JTE2-3 62 and Thr 173 in the rCB2 receptor. The bond could 
not form in the hCB2 receptor due to a steric clash between Glu 8 and the 
phenol ring resulting in the ligand adopting a different binding conformation 
in which the ligand’s carbonyl group was twisted away from Thr 173. 
• Due to the species selectivity exhibited by the Japan Tobacco compounds we 
decided to adopt a new strategy to develop fluorescent CB2 ligands, with 
affinity at the hCB2 receptor.  
.
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6 Fluorescent CB2 ligand based on a modification to JWH015 
 
Our previous studies have concentrated on the synthesis of fluorescent cannabinoids 
based on modifications to Japan Tobacco compounds, which have been demonstrated 
to posses an unusual species preference towards the rat CB2 receptor. As previously 
discussed in chapter 1, our aim for these fluorescent ligands was to give cannabis 
researchers a unique tool which could be used to further our understanding of the CB2 
receptor system and to allow for the fast pharmacological screening of novel 
cannabinoid compounds. To fulfil these requirements, the fluorescent CB2 ligand 
should have an acceptable affinity towards the human CB2 (hCB2) receptor. Our 
attentions were therefore refocused, upon conjugating a CB2 selective ligand with 
proven affinity at the hCB2 receptor to a fluorescent dye. The work reported below 
describes our efforts to design a fluorescent CB2 ligand, using computational de novo 
design on the hCB2 ligand JWH015 53. 
 
6.1 JWH015 
 
JWH015 53 (Figure 6-1), discussed fully in section 1.4.6, was chosen for the lead 
molecule in this study for a number of reasons. Previous discussion, in section 2.2.1, 
outlined the general requirements of a cannabinoid that was required in-order to 
successfully conjugate to a fluorescent dye. JWH015 53 possessed all of these 
requirements - shown below; 
 
• Ki at the hCB2 receptor of 14 nM122 
• 27 fold CB2/CB1 selectivity122 
• Chemically stable, no known light or enzymatic stability issues 
• Comprehensive SAR conducted for the molecule122,135 
• Is not included in the substances listed in the Misuse of Drugs Act 
 
In addition, JWH015 53 had a number of advantages with regards to the specific 
strategy we planned to use in this work; de novo drug design. The molecule is 
structurally similar to Win 55212-2 3 (Figure 6-1), a molecule which had been 
extensively interrogated by molecular modelling and mutational analysis techniques. 
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We therefore envisaged docking Win 55212-2 3 into the hCB2 receptor, generated in 
chapter 3, using previous published data concerning Win 55212-2 3 binding. 
Structural similarities between JWH015 53 and Win 55212-2 3, will be used to 
superimpose common structural motifs (i.e. naphthyl rings) of the two molecules, in-
order to generate an accurate model where JWH015 53 is bound in the hCB2 receptor 
(Figure 6-1). 
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N
O
JWH015 53  
Figure 6-1 Structures of Win 55212-2 3 and JWH015 53. Dashed lines indicate common structural 
motifs used in structural alignment of the molecules in molecular modelling. + indicates a grow point 
used in LigBuilder. Red line indicates a rotatable bond used in conformational analysis. 
 
Using previous SAR data for JWH015 53122,135 and SAR from similar molecules, 
described in detail in section 1.4.6, a number of positions upon JWH015 53 were 
identified that could potentially tolerate extension and bulky substituents. These 
positions were selected as ‘grow points’ on the molecule, in-order that the de novo 
drug design program LigBuilder254 could interrogate them for their ability to tolerate 
bulky fluorescent dyes. 
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6.2 LigBuilder 
 
LigBuilder is a free-ware, multi-purpose programme used for structure-based drug 
design.  The programme utilises a protein structure incorporating a docked ligand to 
‘virtually screen’ a large number of molecules to determine if they are able to fit 
within the binding pocket of the protein. This use of computational methods saves on 
synthetic effort in developing new ligands towards specific targets. Obviously there 
are many other software packages, such as DOCK255, GRID256, LUDI257 etc., which 
are also capable of performing similar analysis, however we chose Ligbuilder due to 
its accessibility, favourable heterocyclic building block library and reliable ‘SCORE’ 
function (used to predict binding affinity)258.  
LigBuilder breaks down the components of de novo drug design into separate 
stages which allows the process to proceed logically from one step to another. Firstly 
the binding pocket is analysed to determine the size and the nature of key binding 
interactions. In order to do this a pre-docked ligand must be present within the 
receptor, so that the programme can identify which area of the protein to probe. The 
programme then calculates the size of the binding pocket and identifies the key 
interactions using probe atoms which include; (1) a positively charged sp3 hybridised 
nitrogen, as a hydrogen bond donor; (2) a negatively charged sp2 oxygen, as a 
hydrogen bond acceptor; (3) a sp3 carbon atom, probing for hydrophobic 
interactions254. Following scoring and refinement, a computer model of the binding 
site is stored for use in the second step. The second step is known as a ‘building up’ 
process. It uses two different fragment-based algorithms that can GROW or LINK 
fragments onto a predefined seed structure within the receptor. The GROW strategy, 
which we employed, uses a pre-placed seed ligand (JWH015 53 in our work) sited 
within the binding pocket. Assigned ‘grow points’ upon the pharmacophore are used 
by LigBuilder to add candidate fragments, from its database, to the selected site upon 
the seed molecule. The LINK algorithm was not be used in this work and readers are 
directed to the original reference for further details254. The GROW algorithm selects a 
hydrogen on the user identified grow points and links it with a candidate fragment to 
form a new bond. The newly formed bond is then rotated using 15° increments and 
the programme calculates the resulting steric energy, between the ligand and binding 
pocket, for each of the 24 conformers. The lowest energy conformations are used in 
the next step. The conformation selected can then be mutated in terms of its carbon, 
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nitrogen and oxygen atoms to other atoms in the same hybridisation state. This 
mutation function is not a random event and takes account of the binding pocket 
analysis performed in the previous step. Thus, if the region of mutation lies within an 
area where H-bond donors are present it would only mutate the atoms to those of a H-
bond acceptor nature. Finally the GROW algorithm has been enhanced by the input 
from synthetic chemists; which prevents the programme from designing unreasonable 
chemical structures. The scoring method used by LigBuilder has been shown in one 
study to be more reliable than that used by other drug design programmes258. The 
SCORE algorithm is a two phase process which takes into account both the energy 
contributions made by ligand binding, and applies ‘Lipinski rules’259 to the algorithm 
to try to prevent non-drug like molecules from being scored highly. Although Lipinski 
rules apply to developing bioavailable drugs rather than in vitro fluorescent ligands, 
our ligands still require good solubility and other ‘drug like’ properties to be used 
successfully in investigating the CB2 system. We felt that adding this scoring system 
to our work would generate enhanced fluorescent ligands. Therefore the SCORE 
algorithm gave each of the tolerated de novo structures a generic score which allowed 
them to be ranked in order of expected affinity to the receptor. LigBuilder has been 
demonstrated, using thrombin and dihydrofolate reductase, to generate chemical 
structures similar to the known ligands for these two enzymes254. It is worth noting 
that LigBuilder treats the protein model as a rigid structure throughout the drug design 
process. This is a disadvantage in computational de novo drug design in GPCRs as 
TM 6 has been postulated to adopt a new conformation upon agonist binding260. This 
inaccuracy in the technique is unavoidable using current computer technology and 
GPCR molecular modelling techniques (see chapter 3), and may lead to the generation 
of antagonist ligands. However, this was not viewed as a significant problem since all 
we required was a high affinity fluorescent ligand (agonist or antagonist) and 
specifically, in the CB2 receptor, studies have demonstrated  that the conformational 
shift of TM 6 is not significant in agonist binding260. 
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6.3 Molecular modelling 
 
Win 55212-2 3 was constructed using Spartan PCPro (Wavefunction Inc) and 
subjected to  a conformational analysis about the four rotatable bonds, highlighted in 
red in Figure 6-1, using the MMFF molecular mechanics forcefield. The lowest 
energy conformation, equivalent to the s-cis conformation, was chosen (see section 
1.4.6.1 and figure 1-20). Geometry optimisation was undertaken using quantum 
mechanical methods, namely ab initio Hartree-Fock calculations at the 3-21G* level. 
In addition, partial atom charges were calculated using the ESP method. The ab initio 
geometry and charges were used to parameterise the CHARMM force field through 
generation of an RTF file. 
Win 55212-2 3 was used in the s-cis form despite a previous SAR study by 
Reggio et al., demonstrating that only the rigid (E)-naphthylidene indene (equivalent 
to s-trans Win 55212-2 3) was the bioactive conformation in the CB2 receptor189 (see 
section 1.4.6.1 for structures and full discussion). This was decided for a number of 
reasons detailed below: 
• The structure of the (E)-naphthylidene indene (figure 1-20) deviates from the 
indole structure of Win 55212-2 3 considerably. The (E)-naphthylidene indene 
posses neither the H-bond acceptor ring nitrogen nor the carbonyl oxygen of 
Win 55212-2 3 and possess extra pi  electrons resulting from its extra double 
bond. 
• The binding data presented for the (E)- and (Z)- naphthylidene indenes shows 
that although the E isomer binds preferentially to the CB2 receptor (Ki = 2.05 
nM), the Z isomer (representing s-cis Win 55212-2 3) also demonstrated 
nanomolar affinity (Ki = 658 nM)189. 
• Another study, published after the work conducted on  the naphthylidene 
indenes, using high resolution NMR and molecular modelling clearly 
established that the favourable conformation of Win 55212-2 3 was s-cis191. 
• Our own geometry optimisation demonstrated that there was a difference in 
energy between the lowest energy state s-cis and s-trans confomers of 2.5 
Kcal mol-1 and 62% of the lowest energy conformers resided in the s-cis form 
(results not shown). 
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Our major concern about refining the s-cis model, obtained through our own 
geometry optimisation studies and supported by previous NMR data191, to the s-trans 
conformation, previously hypothesised by Reggio et al. to be the bioactive conformer, 
was the methodology used in their hypothesis189.  Although (E)-naphthylidene indene 
was clearly shown to have a higher affinity to the CB2 receptor, it included in its 
structure an additional double bond whilst it did not have two H-bond acceptors that 
are present in Win 55212-2 3. Thus; although the indene analogues would suggest that 
the s-trans form of Win 55212-2 3 was the binding conformation, we felt that the two 
structures were too diverse to correlate together. Subsequent to their SAR study, 
Reggio et al. published molecular modelling results which showed that only the s-
trans isomer of Win 55212-2 3 could bind successfully in the CB2 receptor194 and 
concluded that this was proof of their hypothesis that the s-trans conformation being 
bioactive was correct. We will demonstrate below that in our own work, s-cis Win 
55212-2 3 was not only tolerated in the CB2 receptor, but also displayed very similar 
binding interactions to those obtained for the s-trans confomer.  
Win 55212-2 3 was interactively docked into the CB2 receptor (Alignment 3 
as described in section 3.3.) using Phe 197 (see section 3.3.3  for the importance of 
Phe 197) as an anchor point for an aromatic-aromatic interaction with the indole ring 
of Win 55212-2 3, as previously described194. As Win 55212-2 3 was able to dock 
into the binding pocket in both a naphthyl-up and naphthyl-down position (Figure 
6-2) and only limited unsubstantiated evidence existed that the ‘correct’ position was 
naphthyl-up194, we decided to model and assess both possible complexes.   
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Figure 6-2  Win 55212-2 3 docked in the s-cis conformation to the CB2 receptor. (A) naphthyl-down 
and (B) naphthyl-up position using Phe 197 as an anchor point. 
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Both ligand-receptor complexes were optimised using energy minimisation and 
molecular dynamics. In our studies, we applied the CHARMM force field with an 8 Å 
cut-off for non-bonded interactions to optimize the ligand-receptor model. In order to 
mimic the hydrophobic transmembrane environment we set the dielectric constant to a 
value of 4.0. The molecular dynamics protocol consisted of: i) initial minimisation of 
2500 iterations of ABNR conjugate gradient minimisation until the RMSD became 
less than 0.005 KJmol-1; ii) MD simulation, placing a harmonic constraint on the 7 
backbone α-helices and heating the structure to 300 K over 1 ps, conducted at 
constant temperature (300 K) for 100 ps with a 1 fs time step; iii) quenching the 
structure to 0 K over 1 ps and removing all constraints with a  final minimisation 
using ABNR conjugate gradients (6000 iterations) until the RMSD became less than 
0.005 KJmol-1.   
The energy of the two complexes was monitored throughout the molecular 
dynamics experiment at 0.5 ps time intervals. The plot of the total energy of the 
complex vs time is shown in Figure 6-3.  
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Figure 6-3 Energy profile of Win 55212-2 3-CB2 receptor complex over a 0.1ns molecular dynamic 
simulation performed at 300 K using the CHARMM force field. 
 
The above graph demonstrates that once ‘energised’, the energy function of both 
complexes stabilises over the first 60 ps. In the naphthyl-down complex equilibrium is 
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maintained but in the naphthyl-up complex the energy increases at 60 ps and remains 
approximately 200 KJmol-1 higher than the corresponding naphthyl down model. The 
final energy minimised complexes are shown in Figure 6-4.    
 
 
Figure 6-4 Representations of Win 55212-2 3 docked in the s-cis conformer in the hCB2 receptor. (A) 
a naphthyl-up and (B) a naphthyl-down position. Residue shown in yellow is Phe 197. 
 
Figure 6-4 clearly illustrates that the final position of Win 55212-2 3 in the naphthyl-
down model has shifted away from Phe 197; used as the initial anchor point to dock 
the ligand. The naphthyl-up complex retained close interactions between the ligand’s 
indole ring and Phe 197. The ligand in both simulations retained its s-cis 
configuration. 
The key amino acids involved in ligand-receptor interactions were explored 
using the programme Ligplot for each model245. The results from this analysis are 
shown in Figure 6-5. It was demonstrated that as expected, the shift in the position of 
the ligand, shown in Figure 6-4, resulted in markedly different amino acids residues 
that formed interactions with Win 55212-2 3 in the naphthyl-up and naphthyl-down 
model. The ligand, docked in the naphthyl-up position, was shown to form 
hydrophobic and aromatic interactions with a number of residues that have been 
demonstrated, in previous studies, to interact with cannabinoids (see section 3.2); 
notably Phe 117, Trp 194, and Phe 197 (Figure 6-6). Further examination of the 
naphthyl-up model demonstrated that Win 55212-2 3 was located within an aromatic 
A B
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cluster formed by Phe 117, Trp 194, and Phe 197 (Figure 6-6). Phe 117 and Phe 197 
form face-face aromatic interactions with the indoles ring and Trp 194 forms an edge-
edge interaction with the naphthyl ring of Win 55212-2 3 (Figure 6-6). The naphthyl-
down complex included a H-bond interaction and three interactions with the EL 1. 
 
 
 
Figure 6-5 LigPlot analysis of the amino acid binding interactions occurring with Win 55212-2 3 
bound in the hCB2 receptor in the naphthyl-up and naphthyl-down position. 
 
 
In view of the fact that the naphthyl-up model demonstrated many more similarities to 
previously pub lished data of Win 55212-2 binding, such as an interaction with Phe 
197194 and predominately aromatic-aromatic and hydrophobic interactions we decided 
to use this ligand-receptor complex as a template in the de novo molecular design. 
 
naphthyl-up naphthyl-down 
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Figure 6-6 Win 55212-2 3 bound in the s-cis conformation into the binding site of the hCB2 receptor.  
The aromatic residues, shown in yellow, form an aromatic ‘cage’ around the ligand. 
 
Structural alignment, by superimposing the naphthyl, carbonyl and indole ring 
nitrogens of both JWH015 53 and Win 55212-2 3 (Figure 6-1), and further energy 
minimisation using ABNR conjugate gradients (6000 iterations) until the RMSD 
became less than 0.005 KJmol-1, was used to produce a ligand-receptor model where 
JWH015 53 was located within the binding pocket. The ‘growing points’ for JWH015 
53, shown in Figure 6-1, were added and the molecule was subject to de novo design 
using the programme LigBuilder (section 6.2). 
The de novo design results were manually screened for molecules that had 
high scores and chemical structures that resembled known fluorescent molecules. The 
resounding trend, within the molecules generated, was the diversity and size of 
substituents that were tolerated at the 3-naphthyl position of JWH015 53. Figure 6-7 
shows an example of four of the two hundred structures generated. Compounds 122a-
d show a significant diversity in the type of structure that is tolerated at the 3-naphthyl 
position of JWH015 53; with unsaturated alkyl chains 122a; carbocyclics 122b 
&122d; and functionalised branched alkyl chains 122c featuring in the high scoring 
compounds returned.  
 
Phe 117 
Phe 197
Trp 194 
Win 55212-2
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Figure 6-7 An example of the 3-substituted naphthyl (Nap) derivatives of JWH015 that were generated 
by LigBuilder. 
 
Compound 122b was of specific interest to us as the bulky indene group present 
within the structure resembled the fluorescent dye NBD 85 (see Figure 2-5). To test 
whether the indene of 122b could be replaced with NBD, and still bind to the CB2 
receptor, a NBD equivalent of 122b, incorporating an amine linkage necessary for 
chemical synthesis, was modelled. The NBD derivative of 122b was constructed 
using Spartan PCPro (Wavefunction Inc). Geometry optimisation was undertaken 
using quantum mechanical methods, namely ab initio Hartree-Fock calculations at the 
3-21G* level. In addition, partial atom charges were calculated using the ESP method. 
The 2D and 3D structure of this molecule, 3-NBD-JWH015 123, is shown in 
Figure 6-8 (A & B). The molecule was docked into the hCB2 receptor by 
superimposing the naphthyl groups of 3-NBD-JWH015 123 and Win 55212-2 3, 
which had already been docked into the CB2 receptor as described above, and the 
resulting complex was further minimised, using ABNR conjugate gradients (25000 
iterations) until the functional tolerance was less than 0.00001 KJmol-1, to yield a 
ligand-receptor model where 3-NBD-JWH015 123 was located within the binding 
pocket (Figure 6-8, C & D). 
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Figure 6-8 The 2D and 3D structure of 3-NBD-JWH015 123 (A & B). C and D show 3-NBD-JWH015 
123 bound into the solvent accessible surfaces of the hCB2 receptor. C = view from side looking at the 
benzofurazan ring of 123. D = view from the top looking down at the nitro group of 123. 
 
From the ligand-receptor complex generated it was clear that the hCB2 receptor could 
tolerate the proposed ligand 3-NBD-JWH015 123. The NBD fluorescent dye was 
positioned at the top of the receptor binding pocket and was visible when the solvent 
accessible surfaces were viewed (Figure 6-8, B & C). We therefore concluded that 3-
NBD-JWH015 123 could bind to the hCB2 receptor and synthesis of this molecule 
was undertaken. 
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6.4 Chemistry results 
 
Synthesis of the fluorescent conjuger was accomplished using modifications to a 
procedure by Bell et al.52 (Scheme 6-1). N-Propyl-2-methylindole 125 was accessed 
by alkylation at N1 of commercially available 2-methylindole 124 using standard 
methodology. The commercially available 3-nitro-1, 8-naphthalic anhydride 126 was 
selectively decarboxylated via the mercuric salt of its di-acid to give the desired 3-
nitro-1-naphthoic acid261,262. The meta substitution was confirmed by comparative 
m.p. with literature values and 1H NMR, which established the presence of two 
doublets with characteristic meta coupling (J = 2.4 Hz249). The acid was converted to 
its corresponding acid chloride 127 using SOCl2. Lewis acid promoted electrophilic 
substitution at C3 of 2-methyl-1-n-propylindole yielded the 3-nitro derivative of 
JWH015 128. Reduction of the nitro group of 128 to the corresponding amine 129 
was achieved using catalytic hydrogenation. The two low yielding reactions leading to 
the acid chloride 127 (22%) and the 3-aroylindole 128 (19%) are un-optimised and are 
comparable with previous literature preparations52,261.  
During our synthesis we observed that only non-fluorescent derivatives are 
formed when NBD is reacted with aromatic amines, due to an internal quenching 
caused by a photoinduced electron transfer from the aromatic amine to the NBD 
dye263,264. It was therefore necessary to insert a short C2 amide functionalised linker 
between the aniline nitrogen and the NBD dye, which had previously been shown to 
prevent the internal quenching mechanism264. The short linker was chosen after re-
visiting the molecular model of 3-NBD-JWH015 123 and establishing by visual 
inspection that the binding pocket encasing the NBD dye was spacious with no amino 
acid residues within 8 Å of the dye.  
Therefore, established carbodiimide chemistry was used to couple Boc 
protected glycine with the amine of 129. This was the shortest linker available that 
produced the required amide bond and contained a functionalised amine group; 
necessary for conjugation with the dye. Acidolysis of the Boc group of 130 exposed 
the primary amine 131, which when coupled with NBD-F 85 (Figure 2-5) afforded the 
fluorescent conjuger 3-Gly-NBD-JWH015 132. 
An authentic sample of JWH015 53 was prepared using an alternative 
preparation for 3-aroylindoles, also modified from Bell et al.52 (Scheme 6-2). 3-
Naphthoyl-2-methylindole 134 was prepared from the magnesium salt of 2-
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methylindole, prepared in situ, by the action of methylmagnesium bromide on 2-
methylindole 124, and subsequent reaction with 1-naphthoyl chloride 133. N-
Alkylation of 133 using 1-bromopropane under standard conditions yielded JWH015 
53 as an oil. Commercial samples of JWH015 53 have a m.p. supplied with their 
certificate of analysis‡‡‡, however we were unable to crystallise the sample to 
determine a m.p., despite numerous attempts from a number of different solvent 
systems. The JWH015 53 synthesised did however exhibit a 1H and 13C NMR, MS, 
elemental analysis and a TLC Rf  which was consistent with the structure of JWH015 
53. 
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Scheme 6-1 Synthesis of 3-Gly-NBD-JWH015. Reagents, conditions and yields: (i) 1-bromopropane, 
NaH, DMF, rt, 4h, (97%); (ii) (a) NaOH, water, HgO, AcOH, reflux, 3 days, (b) dil. HCl(aq),, reflux, 4h, 
(c) SOCl2, reflux, 4h, (overall 22%); (iii) AlCl3,, DCM, reflux, 30min, (19%); (iv) Pd/C, H2, EtOH, 1h, 
(66%);  (v) Boc-gly, DCC, DMAP, DCM, rt, 12h, (67%); (vi) MeOH, conc HCl(aq), rt, 12h, (50%); (vii) 
NBD-F 85, NaHCO3(aq) pH 8.3: MeCN 1:1, rt, 1h, (46%). 
                                                 
‡‡‡ Information obtained from Tocris Cookson website www.tocris.com/searchframeset.htm  
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Scheme 6-2 Synthesis of JWH015. Reagents, conditions and yields: (i) MeMgBr, EtOEt, 0 °C-reflux, 
2h, (31%); (ii) 1-bromopropane, K2CO3, MEK, reflux, (36%). 
 
6.5 Pharmacology results 
 
6.5.1 Radioligand binding 
 
Compounds 53, 128, 129, 131, and 132 were tested for affinity at the hCB2 receptor 
by competitive radioligand displacement of the non-selective cannabinoid [3H] CP 55, 
940 from CHO cellular membranes containing hCB2 receptors and was performed as 
previously described by Legget et al.224. The results of the binding assay are shown in 
Table 6-1. 
 
Compound identity Ki hCB2 receptor (nM) 
JWH015 53 36 (31-42) (Lita 14 ± 5) 
128 143 (56-364) 
129 191 (59-622) 
131 420 (359-492) 
3-Gly-NBD-JWH015 132 25% displacement at 10 µM 
Table 6-1 Results of a competitive displacement assay at the hCB2 receptor. Results in parentheses are 
95% confidence intervals for three individual experiments ran in triplicate. (a) ref 122.  
 
Each of the compounds, except 3-Gly-NBD-JWH015 132, exhibited nanomolar Ki 
values with respect to the hCB2 receptor. 3-Gly-NBD-JWH015 132 did show an 
affinity towards the CB2 receptor (25% displacement at 10 µM) however we were 
unable to calculate a Ki for this compound as any attempt to increase the 
concentration of the test solution above 10 µM resulted in precipitation in the assay 
tubes. 
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6.5.2 Functional assay 
 
Due to the precursor compounds of 3-Gly-NBD-JWH015 132 exhibiting nanomolar 
Ki values, we decided to test these compounds in a [35S] GTP-γ-S functional assay to 
determine to what extent the agonist activity of the original JWH015 53 lead structure 
had been retained. For further information on the [35S] GTP-γ-S assay in cannabinoid 
research, readers are directed towards section 1.3.4.3.2 and a review by Griffin et 
al.115. The compounds JTE015 53, 3-nitro-JWH105 128 and 3-amino-JWH015 129 
were assayed for their ability to stimulate [35S] GTP-γ-S binding compared to the 
potent cannabinoid agonist HU210 14, previously described by Leggett et al.224. The 
results are shown in Figure 6-9.  
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Figure 6-9 Agonist-potentiated [35S] GTP-γ-S binding to CHO cell homogenates containing the hCB2 
receptor (significance levels *P<0.05, **P<0.01 compared to basal binding (100%)). Error bars 
represent the SEM of three individual experiments ran in triplicate. 
  
From Figure 6-9 it is clear that each of the compounds tested were able to 
significantly increase [35S] GTP-γ-S binding above basal levels when tested at a 
concentration of 1000 nM. Only HU210 14 was able to significantly raise [35S] GTP-
γ-S binding above basal level when used at 10 nM concentrations. Comparison of the 
three indole based compounds tested, 53, 128, and 129, demonstrated that similar 
levels of receptor stimulation were observed, and Anova analysis was unable to detect 
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any significant statistical difference between any of the three compounds at 
concentrations of 1000 nM. 
 
6.6 Confocal microscopy results 
 
The fluorescent ligand 3-Gly-NBD-JWH015 132 was used in a confocal experiment 
to demonstrate whether the ligands had the potential to highlight CB2 receptor 
membrane binding. A known concentration of 3-Gly-NBD-JWH015 132 was 
incubated with live CHO cells expressing human CB2 receptors and images were 
recorded at various time courses throughout the experiment. To assess whether the 
fluorescence observed was due to specific CB2 binding, CHO cells were also pre-
incubated with a blocking concentration of a non-fluorescent cannabinoid ligand (i.e. 
1 µM HU210 14) and the fluorescent ligand was subsequently introduced. Images 
collected from this experiment were compared to those conducted without the HU210 
present, to determine if any fluorescence observed was due to CB2 receptor binding. 
At concentrations of 100 nM, 132 exhibited strong intra-cellular fluorescence after 20 
minutes; however, this fluorescence could not be blocked or reduced by pre-
incubation with HU210 14 (Figure 6-10). Background fluorescence from the CB2 
transfected CHO cells was negligible for the excitation wavelength used for NBD 
(488 nm) – result not shown. 
 
 
Figure 6-10 Confocal slice, taken at 20 min, of the 3-Gly-NBD-JWH015 132 (100 nM) binding to live 
CHO cells expressing the hCB2 receptor in HEPES buffered saline at 22°C. (A) Overlay of fluorescent 
channel (LP 505) and phase contrast with no HU210 14 present; (B) Overlay of fluorescent channel 
(LP 505) and phase contrast with 1 µM of blocking HU210 14 present. Argon laser excitation at 488 
nm. Slice depth 1.1 nm. 
A B
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6.7 Discussion 
 
A fluorescent conjugate of the selective hCB2 ligand JWH015 53 was synthesised in 
seven steps following de novo drug design using the programme LigBuilder which 
suggested that the 3-naphthyl position of JWH015 53 would tolerate bulky 
substituents, such as fluorescent dyes.  
The molecular modelling and subsequent de novo design used a model of 
JWH015 53 docked into the hCB2 receptor, which was based on a molecular model 
generated of a similar indole cannabinoid, Win 55212-2 3, bound in the CB2 receptor. 
Win 55212-2 3 was chosen as the precursor model, having previously been studied by 
molecular pharmacology194, molecular modelling194 and SAR experiments189 
providing information to construct our model and subsequently compare it with. As 
previously discussed in section 6.3, overall evidence supported docking Win 55212-2 
3 in the s-cis conformer, despite the (E)-naphthylidene indene isomer (postulated to 
represent the s-trans form of Win 55212-2 3189) possessing greater affinity at the 
hCB2 receptor. Our molecular modelling results, which evaluated Win 55212-2 3 in 
both the naphthyl-up and naphthyl-down position provided evidence that the s-cis 
form of 3 was tolerated by the hCB2 receptor when bound in the naphthyl-up position. 
Evaluation of the naphthyl-up ligand-receptor complex revealed that the crucial 
aromatic-aromatic interactions at Phe 117, Trp 194 and Phe 197, demonstrated in 
other experiments to be important182,189,242, were all present in our model (Figure 6-6). 
In-fact in our model the ligand’s position, relative to the position of these amino acids, 
was remarkably similar to that of a previous model generated by Song et al. in which 
s-trans Win 55212-2 3 was bound in the hCB2 receptor194  ( Figure 6-11, A). This is 
in contrast to their conclusion that the s-cis form of Win 55212-2 was not tolerated in 
the binding pocket, due to a steric clash with a valine residue in TM 3.  This clash was 
examined in our model, by highlighting the Van Der Waals (VDW) radii of each 
valine residue in TM 3 and checking that there was no overlap with the VDW surface 
of Win 55212-2 3  ( Figure 6-11, B). It is clear that even the closest valine (Val 164) 
does not clash with the structure of Win 55212-2 3 in any way. An explanation of the 
discrepancy between the two results may be due to their hCB2 model being homology 
aligned to the non-G-protein coupled protein BacterioRhodopsin, which as discussed 
in section 3.1.1, has now been superseded by the use of Bovine Rhodopsin (which 
was used in our model) to generate a more accurate GPCR model.   
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Figure 6-11 (A) The proposed position of Win 55212-2 3 and binding amino acids (shown in yellow) 
from the ligand-receptor complex proposed by Song et al.194. F 3.36 = Phe 117, F 5.46 = Phe 197, W 
5.43 = Trp 194. (B) The relationship between the VDW radii for each of the valine monomers (shown 
in green) present in TM 3 and Win 55212-2 3 from our model of Win 55212-2 3 bound to the hCB2 
receptor. 
 
An interesting observation regarding the naphthyl-down complex, was that after 
molecular dynamic simulation, Win 55212-2 3  was ‘bounced’ out of its initial 
interactively docked binding pocket (Figure 6-2)  into a separate binding pocket 
which was located towards the extra cellular surface of the receptor (Figure 6-4). This 
resulted in a lower energy complex, shown in Figure 6-3. However, the amino acids 
binding the ligand have never been demonstrated in any other study to be important in 
cannabinoid binding. This was very similar to the observations encountered when 
JTE2-6 63 was simulated binding in a phenol-down position in the CB2 receptor 
discussed in chapter 2.  
The model of Win 55212-2 3 bound both in its s-cis conformer and naphthyl-
up position was modified to create a model where our lead molecule JWH015 53 was 
positioned within the hCB2 receptor. De novo design using LigBuilder was able to 
determine that bulky substituents were tolerated at the 3-naphthyl position of JWH015 
53. The molecule 3-NBD-JWH015 123 (Figure 6-8), incorporating the fluorescent 
dye NBD at the 3-naphthyl position, was constructed in silico and demonstrated, by 
computational methods, to fit within the binding pocket of the hCB2 receptor. 
A B
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During our synthesis towards 3-NBD-JWH015 123, we found that only non-
fluorescent species are formed when NBD is conjugated to an aromatic amine such as 
123. Literature reports of this behaviour are sparse; however we were able to find two 
studies in which the mechanism of this fluorescence quenching was investigated264,265. 
One study demonstrated that a photoinduced electron transfer (PET) from the donor 
(NBD dye) to the acceptor (aromatic amine) was responsible for the quenching 
observed265. The second study was able to determine that a linker, placed between the 
donor and acceptor prevented PET. The length of the alkyl linker used was inversely 
proportional to the level of quenching, measured as the quantum yield, observed 264. 
Thus; a nonyl chain (C9) was required to totally negate the PET effect. However they 
also claimed that an amide group within the linker prevented PET occurring, even 
when the chain length was reduced to an acetyl (C2) spacer 264. This latter observation 
became important after we interrogated the 3-NBD-JWH015 123-CB2 receptor model 
to determine if a linker could be placed in the molecule. The model illustrated that the 
NBD structure was located in a pocket that could accommodate a short linker of up to 
three atoms (approximately 4.5 Å in length246).  We therefore decided to install an 
amine functionalised acetyl linker to separate the 3-amino-JWH015 129 and NBD 
moieties. This was achieved using the amino acid, glycine, as the linker.   
The synthesis of the molecule incorporating the glycine linker, 3-Gly-NBD-
JWH 132, was achieved in a seven step convergent synthesis from commercially 
available 2-methylindole and 3-nitro-1,8,-naphthalic anhydride starting materials. The 
low yielding reactions leading to 3-amino-JWH015 128 (19%) and 3-nitro-1-
naphthoic acid (22%) were both comparable with previous literature preparations52,261.  
The reaction leading to the 3-nitro-1-naphthoic acid was reviewed due to the 
fact that there were two carboxylic acid groups which could potentially decarboxylate 
to give two different products. The mechanism postulated for this reaction (Pesci 
reaction), by Newman et al., involved the preferential decarboxylation of the acid 
group in the most electron rich environment (i.e position 8 in 3-nitro-1, 8-naphthalic 
anhydride), due to the increased stability of the transition state as the aromatic-
carboxyl bond is broken and the new aromatic-metal bond is formed (Figure 6-12). 
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Figure 6-12 The Pesci reaction. 
 
The intermediate anhydrohydroxymercuric acid formed was then treated with acid to 
afford the desired compound. The compound’s structure was determined using the 
usual analytical techniques including comparative m.p. compared to literature 
reference values; however the most compelling evidence regarding its substitution 
pattern came from the two meta coupled doublets observed in its 1H NMR spectrum, 
as the spectrum for 6-nitro-1-naphthoic acid would contain only one meta coupled 
doublet in its spectum. Following synthesis we were able to test the compounds’ 
pharmacology.  
The fluorescent conjuger 3-Gly-NBD-JWH 132 was found to have low 
affinity towards the hCB2 receptor in a competitive radioligand binding assay (25% 
displacement at 10 µM). This reduction in receptor affinity compared to the original 
unlabelled JWH015 53 was attributed to the addition of the bulky fluorophore and 
linker system causing steric and electronic clashes within the receptor. However it did 
still retain some affinity to the hCB2 receptor and we evaluated its use as a fluorescent 
cannabinoid in a fluorescence confocal microscopy experiment. Unfortunately due to 
the compound’s low receptor affinity, requiring high concentrations of ligand to be 
used, combined with the high lipophillicity of the ligand we were unable to detect 
membrane binding. Instead we observed a non-specific accumulation within the 
cytosol (Figure 6-10).  
The modification to the 3-naphthyl position JWH015 53 was assessed. Having 
discovered that 3-Gly-NBD-JWH 132 retained some of its affinity to the hCB2 
receptor we decided to test three of the 3-naphthyl precursors, 128, 129, and 131 
(Scheme 6-1) to determine if the smaller substituents, nitro, amine, and N-glycyl, also 
retained affinity to the receptor. From the affinity data we obtained it was noted that 
the binding affinity of the nitro 128, amino 129 and N-glycyl 131 decreased, 
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compared to JWH015 53, as the steric bulk of the substituent at the 3-naphthyl 
position increased. Thus the affinity of the smallest substituent, hydrogen 53 exhibited 
the highest binding, with nitro 128 and amino 129 groups showing a 3.9 and 5.3 fold 
loss in affinity, the addition of the larger glycine residue 131 decreased the affinity by 
a factor of 11.6. The glycine-NBD conjugate 132 with the largest substituent at this 
position demonstrated the largest reduction in binding affinity (K i of >10 µM). 
Receptor efficacy studies, measuring agonist stimulated [35S] GTP-γ-S binding, 
comparing JWH015 53 with the two highest affinity compounds, 3-nitro-JWH015 
128 and 3-amino-JWH015 129, established that 3-naphthyl substitution, with nitro 
and amine groups retained agonist activity to similar levels shown by JWH015 53. 
This study, demonstrating the effect of substitution at the 3-naphthyl position of 
JWH015 53, has established that limited modification using small substituents is 
tolerated in terms of receptor affinity and efficacy. This is a notable result for two 
reasons. (i) to the best of our knowledge it is the first report of the effect of 3-naphthyl 
modification of JWH015 53 and will contribute a useful addition to the overall SAR 
surrounding the indole cannabinoids. (ii) the 3-naphthyl modification was chosen 
using data obtained from de novo drug design. Although the computational modelling 
was speculative in the size of group that was tolerated by the hCB2 receptor, it was 
still able to detect an extra binding pocket, in close proximity to the 3-naphthyl 
position, which can be exploited. This strengthened our belief that using molecular 
modelling to study the hCB2 GPCR was justified and was carried out to the highest 
standards current modelling techniques would allow. Following the completion of our 
study, the structure of a novel CB2 selective indole, AM1241 58, was published72 
(Figure 1-21). AM1241 58 has a 3-(5- iodo-3-nitrobenzoyl)indole core structure, 
which adds to the evidence that the 3-aryl position of 3-arylindoles may be an 
important extra binding pocket within the hCB2 receptor. 
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6.8 Conclusions 
 
• A computational model, in which Win 55212-2 3 was bound in its s-cis 
conformer, in the hCB2 receptor, was established. Analysis of it bound in a 
naphthyl-up and naphthyl-down orientation demonstrated that it preferentially 
bound in the naphthyl-up position. 
• Our model of the bound s-cis conformer was in direct contrast to previous 
work which had established that only the s-trans conformer of Win 55212-2 3 
was bioactive. 
• De novo drug design established that the 3-naphthyl position of JWH015 53 
tolerated bulky substituents. 
• Synthesis of 3-Gly-NBD-JWH015 132 was successfully completed. 
• The fluorescent conjuger 132 retained limited hCB2 affinity (25% 
displacement at 10 µM), however the compound was unable to detect receptor 
membrane binding in live CHO cells expressing the hCB2 receptor using 
confocal microscopy. 
• Testing of the two 3-naphthyl precursors, 3-nitro-JWH015 128 and 3-amino-
JWH015 129, in affinity and efficacy assays, demonstrated that limited 
modification to the 3-naphthyl position resulted in compounds with retained 
activity to the hCB2 receptor. Thus; screening by computational methods was 
able to successfully predict an area within the hCB2 binding pocket that would 
tolerate molecular extension; however it was not able to predict correctly the 
size of substituent tolerated. 
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7 Conclusions and future work 
 
This chapter is not intended to replace the individual conclusion sections within the 
previous chapters, but complements them by pulling together the main findings from 
each chapter. It will also set out our plans for future work we intend to perform. 
Overall, this chapter can be divided into three major areas of work: 
 
• Labelling of CB2 ligands with fluorescent dyes 
• Molecular modelling of the CB2 receptor 
• SAR of the indole cannabinoids. 
 
7.1  Labelling of CB2 ligands with fluorescent dyes 
 
7.1.1 Conclusions 
 
We synthesised five novel ligands, Dansyl-JTE2-6 99, BODIPY-JTE2-6 100, Dansyl-
JTE2-3 120, BODIPY-JTE2-3 121 and 3-GLY-NBD-JWH015 132. Unfortunately, 
despite careful design, using established SAR complemented with in-house 
computational modelling none retained sufficient affinity to highlight specific hCB2 
receptor binding in fluorescent experiments. It was probable that the reduction in 
affinity observed was due to increased steric interactions between the ligand and 
receptor. This effect was exacerbated in the Japan Tobacco derivatives, due to the 
preferential rat selectivity associated with these ligands. Although unable to bind to 
the hCB2 receptor, retesting of the BODIPY labelled derivatives 100 and 121 in the 
rCB2 receptor showed that limited affinity was retained (displacement of 44 & 48% of 
bound [3H] CP 55, 940 at 1 µM was observed respectively). This demonstrated that 
the overall strategy we adopted was partially successful. 
The de novo design used in the synthesis of 3-Gly-NBD-JWH015 132 led to a 
compound which was able to displace 25% of the bound radioligand from the hCB2 
receptor when used at a concentration of 10 µM. This is to the best of our knowledge 
the first report of any fluorescent cannabinoid with affinity to the human CB2 receptor 
and represents our lead compound for future development. 
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7.1.2 Future work 
 
The demand for fluorescent ligands with affinity to GPCRs has strengthened during 
the three years we have been conducting this research266. The case for cannabis 
research made in chapter 1 remains unchanged. We therefore feel that the need to 
develop a fluorescent cannabinoid is greater then ever. We plan to use two different 
strategies which will lead to the generation of the first fluorescent cannabinoid. 
• Development of fluorescent conjugates of JWH015 53, using 3-Gly-NBD-
JWH015 132 as a lead structure. We plan to exploit, the identification of the 3-
naphthyl position as a site capable of modification with fluorescent dyes. Our 
initial work utilised a small glycine linker to anchor the NBD fluorophore, in-
order to keep the dye within the binding pocket. In future work we plan to 
extend the length of the linker in an effort to exit the binding pocket and tether 
the fluorescent dye outside of the receptor. This work is envisaged to proceed 
using a classical SAR approach, involving the synthesis of the core scaffold 3-
amino-JWH015 129, which may then be coupled, using established chemistry, 
to an array of N-Boc-aminoalkyl acids. Boc deprotection and conjugation with 
an amine reactive fluorescent dye will give access to a library of compounds 
for testing. This approach has led to selective fluorescent ligands at the 
adenosine receptor25,200,202,207 and we hope to emulate its success for the hCB2 
receptor.  
• We also wish to exploit information regarding the non-selective compound CP 
55, 940 2 that came to light during the writing of this thesis160,161. Discovery of 
a postulated binding conformation of CP 55, 940 2 (figure 1-14), discussed in 
section 1.4.3, led us to believe that it possible, with minimum synthetic effort, 
to selectively label each of its three hydroxyl groups, with fluorescent dyes 
and test the resulting conjugates. Thus by exploiting the chemical differences 
between the phenol and alcohol (1° & 2°) groups present it will be possible to 
selectively mask (by protecting groups) or activate a specific hydroxyl and 
thus conjugate each of the hydroxyls to commercially available acid or halo 
functionalised fluorescent dyes, via an ester or ether linkage. An example of 
this is shown in Scheme 7-1 in which the 1° alcohol is selectively protected as 
the TBDMS silyl ether. The remaining hydroxyls can be orthogonally 
protected as the acetate ester. Selective cleavage of the silyl ether using the 
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fluoride ion exposes the 1° alcohol which can be reacted with a fluorescent 
dye (e.g. NBD-F). We envisage that if the orientation of the hydroxyl groups 
postulated in fig 1-14 is correct, then the fluorescent dye will exit the top of 
the binding pocket, thus avoiding steric clashes within the receptor. Obviously 
the high affinity exhibited by CP 55, 940 2 towards both CB1 and CB2 
receptors, will result in a fluorescent ligand which is non-specific to either 
receptor.  
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Scheme 7-1 Example of selectively labelling the 1° alcohol of CP 55, 940 2 using NBD. Proposed 
reagents: (i) imidazole, DMF. (ii) Ac2O, acidic clay (iii) TBAF, THF (iv) NBD-F (v) LiOH 
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7.2 Molecular modelling of the CB2 receptor 
 
7.2.1 Conclusions 
 
The use of computational modelling of ligand-CB2 receptor interactions, to aid the 
design of CB2 selective ligands, led to useful information about the possible intimate 
ligand-receptor interactions occurring at the CB2 receptor. Examination of our 
model’s structure correlated extremely well with previously published CB2 models 
and mutational studies in terms of the nature and residues located in the binding 
pocket and the TM helices involved in ligand binding. The most important residue 
postulated from previous studies, Phe 197, formed part of an aromatic cleft within our 
model’s pocket and was used to interactively dock subsequent molecules under 
investigation. 
Use of the CB2 model to investigate ligand binding led to a number of conclusions: 
 
• The ligand JTE2-6 63 was shown to be capable of docking into the hCB2 
receptor in a phenol-up and phenol-down orientation. Amino acid residue 
analysis suggested that the likely orientation was phenol-up.  
• JTE2-3 62 exhibited large differences in affinity between the rCB2 and 
hCB2 receptor (Ki = 5.02 nM and 3.11 µM respectively). It was 
demonstrated using ligand-receptor modelling of both species’ receptor that 
the difference in affinity was due to extra interactions, including a strong H-
bond, that could occur within the rCB2 and not the hCB2 receptor. It was 
postulated that Glu 8 in the hCB2 clashes with JTE-3 62 causing the ligand 
to adopt a new binding conformation thus preventing it from forming a H-
bond with Thr 173. 
• Win 55212-2 3 was able to bind to the hCB2 receptor in the s-cis form 
(Figure 1-20) despite previous literature suggesting that only the s-trans 
form was capable of binding189,194. 
• The orientation of bound Win 55212-2 3 in the hCB2 binding pocket was 
determined to be with the naphthalene ring towards the top of the receptor. 
• De novo drug design upon the CB2 selective ligand JWH015 53 
successfully predicted a previously unrecognised cleft within the bind ing 
pocket. The cleft could be accessed by molecular extension at the 3-
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naphthyl position of JWH015 53. However, the size of the 3-naphthyl 
substituent tolerated was overestimated using computational techniques; 
demonstrated by the decreasing affinity towards the CB2 receptor as the size 
of the 3-naphthyl substituent increased. 
• De novo drug design predicted compounds which retained similar agonist 
activity to the original seed structure JWH015 53. This may be indicative 
that our model represents the receptor in the activated state. This result is 
significant as it is generally accepted that GPCR models based on Bovine 
Rhodopsin represent the receptor in the inactive state. 
 
Our results, obtained using GPCR modelling techniques, are in agreement with a 
recent publication in which leading GPCR experts concluded that homology models 
of Bovine Rhodopsin are extremely useful in understanding and exploiting GPCR 
ligand interactions266. However, the limitations of molecular modelling especially 
regarding the low homology and the inactive state of Bovine Rhodopsin compared to 
GPCRs under study are recognised in this work and are highlighted by other 
advocates of this technique227,253,266. 
7.2.2   Future work 
 
We intend to develop the human and rat CB2 receptor models generated by 
performing single point mutations on hCB2 and rCB2 receptor constructs. 
• The hypothesis that Glu 8 in the hCB2 receptor is responsible for JTE2-3 62 
adopting a less favourable binding orientation will be tested by mutating Glu 8 
of the hCB2 to the smaller amino acid Glycine and testing the affinity of JTE2-
3 62 to this Gly 8 mutant. The expected increase in JTE2-3’s 62 affinity to this 
mutant would support the original hypothesis. 
• Thr 173 in the rCB2 receptor, which is postulated to form an important H-bond 
with JTE2-3 62, will be mutated to the isosteric amino acid Valine. Valine’s 
structure would be unable to form a H-bond with the ligand and we anticipate 
that a decrease in the ligand’s Ki will be observed. 
 
The benefit in conducting mutational analysis on the rat and human CB2 receptor will 
provide applied experimental data to a theoretical model. If our hypothesis for the 
species selectivity of JTE2-3 62 is proven by in-vitro pharmacological analysis it will 
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provide researchers a unique understanding of the nature of binding of these unusual 
cannabinoids and provide confidence in the current techniques used for homology 
modelling of GPCRs. 
7.3 SAR of the indole cannabinoids 
7.3.1 Conclusions 
  
We found using computational de novo modelling that the 3-naphthyl position of 
JWH-015 53 tolerated substituents other than hydrogen. It was found that the nitro 
128, amino 129, and 3-glycyl derivative 131 all retained nanomolar affinity and 
agonist efficacy to the CB2 receptor. Introducing the much larger NBD heterocyclic 
resulted in a compound 132 with significantly reduced affinity at the CB2 receptor. 
This work demonstrates that the 3-naphthyl position of JWH-015 can be modified to 
offer compounds with CB2 agonist properties. This is the first report of this 
modification and will contribute a useful addition to the overall SAR of the indole 
cannabinoids. 
7.3.2 Future work 
 
We have recently seen that two licence applications for cannabis medicines, in the 
form of a sublingual cannabis extract (Sativex), and the CB1 antagonist SR141716 5 
(Rimonabant)§§§ have been announced. To the best of our knowledge no CB2 
selective ligand has been evaluated for use as a therapeutic agent in man. We intend to 
exploit our findings concerning the 3-naphthyl position of JWH-015 53 by 
synthesising a number of 3-naphthyl analogues for testing in affinity and efficacy 
assays (in-vitro), at the human CB1 and CB2 receptors. The 3-naphthyl analogues will 
be accessed using established chemistry discussed in section 6.4, coupling 3-
naphthoic acid derivatives with 2-methyl-1-n-propylindole. 3-Naphthoic acid 
derivatives that are not commercially available may be accessed from 3-nitro-1-
naphthoic acid 127 by reduction to 3-amino-1-naphthoic acid, diazotisation and 
replacement with the nucleophile of choice (e.g. Sandmeyer reaction). This approach 
will hopefully lead to many novel 3-naphthyl derivatives of the CB2 selective agonist 
JWH-015 53 that may confer advantages as a CB2 selective ligand in terms of 
selectivity, potency and solubility.  
                                                 
§§§ Personal communication - European Society of Cardiology Munich 30th August 2004 
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8 Experimental 
 
8.1 Chemistry 
 
All m.p. were determined in a glass capillary using a Gallenkamp 3A 3790 melting 
point apparatus and were corrected using p-toluene sulphonamide as a standard (m.p. 
137 oC). FT-infrared spectra were recorded as thin films or KBr discs in the range of 
4000-600 cm-1 using Avatar 360 Nicolet FT-IR spectrophotometer. 1H NMR were 
recorded on a Bruker-AMX 250 operating at 250 MHz. Chemical shifts given in δ 
values are relative to an internal tetramethylsilane standard. The multiplicity of a 
signal is designated by one of the following abbreviations. s, singlet; d, doublet; t, 
triplet; q, quartet; br broad; m, multiplet; dd, doublet of doublets etc. All coupling 
constants, (J values) are given in Hertz. 13Carbon NMR were recorded on a Bruker 
AMX 250 spectrophotometer operating at 62.9 MHz. Electron spray (ES) and 
atmospheric pressure ionization (AP) mass spectrometry were recorded using a 
Micromass VG platform, and Fast atomic bombardment (FAB) mass spectrometry 
were recorded using and a VG Micromass 70E. 
 
Fluorescence data was obtained using a Hitachi F-2500 FL spectrophotometer using a 
1 cm quartz cell. 
 
Microanalytical data were obtained on a Perkin-Elmer 240 D elemental analyzer. 
 
Thin layer chromatography (TLC) was performed using Merck silica gel 60 GF254 
analytical plates. Preparative TLC was performed using Merck silica gel 60 GF254 
coated glass plates (1mm). Flash chromatography was performed using Merck 
Kieselgel 60 (0.040-0.063 mm). 
 
HPLC was performed using a Vydac reverse phase C8 column (150 x 4.6 mm), a flow 
rate of 1 mL/min and UV detection at 254 nm. Linear gradients were used in all 
applications. An injection volume of 50 µL, using a 1 mg/mL sample dissolved in 
HPLC grade MeCN, was used for all samples. 
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Reagents were all SLR grade or above and purchased through the normal suppliers. 
Anhydrous grade DMF and EtOEt were used in reactions. The Bodipy fluorophore 
was obtained via Molecular Probes, Cambridge Bioscience, Cambridge, UK. The 4-
fluoro-7-nitrobenzofurazan (NBD-F) fluorophore was obtained via Fluka, Sigma-
Aldrich Co. Ltd, The Old Brickyard, Gillingham, Dorset. 
 
pH 8.3 NaHCO3 (aq) buffer used in fluorophore coupling was made by making a 0.1 M 
NaHCO3 (aq) solution (0.84 g NaHCO3 & Q.S. 100 mL water) and titrating to pH 8.3 
using 0.1 M Na2CO3 (aq) solution (1.06 g Na2CO3 & Q.S. 100 mL water). 
 
Preparation of tert-butyl 6-
hydroxyhexylcarbamate (88) 
 
A mixture of 6-amino-1-hexanol (2.0 g, 17 mmol) and di-tert-butyl dicarbonate (7.5 
g, 34 mmol) was stirred at 0 °C in dioxane (50 mL) and water (10 mL). The reaction 
was allowed to warm to rt and stirred for 2 h. The reaction was reduced under vacuum 
to a syrup. The residue was dissolved in ~40 mL of EtOAc, and was washed with sat. 
NaHCO3 (2 x 20 mL), and brine (20 mL). The organics were dried (MgSO4) and 
reduced under vacuum to yield ~7 g of yellow oil. Hexane (30 mL) was added to the 
oil and the solution was cooled and triturated to yield white crystals. The suspension 
was filtered and the solid was washed with cold hexane to yield the title compound 
(3.7 g, 99.5%) as a white crystalline ma terial. 
 
m.p. 37-39 °C. Lit 220 39 °C 
 
1H NMR (CDCl3) δ 4.61 (1H, br s, N-H carbamate), 3.62, (2H, q, J 6Hz, CH2-α-O), 
3.11 (2H, q, J 6Hz, CH2-carbamate), 2.25 (1H, t, J 6Hz, O-H), 1.6-1.2 (17H, m, 
C(CH3)3 & CH2 hexyl). 
HO
H
N O
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13C NMR (CDCl3) 156.2 (4°, C=O Boc), 79.1 (4°, C(CH3) Boc), 62.6 (CH2, C-α-O), 
40.4 (CH2, C-carbamate), 32.6 (CH2), 30.1 (CH2), 28.4 (CH3 Boc), 26.4 (CH2), 25.3 
(CH2). 
 
ES-MS MH+ calcd for C11H24NO3 218.3 found 218.4 (MH+). 
 
FTIR: 3403 (O-H), 3367 (N-H Boc), 2984, 2934, 2856, 1686 (C=O Boc), 1533, 1364, 
1288, 1249, 1171, 1061, 998, 869 cm-1 
 
Preparation of tert-butyl 6-(4-
(methoxycarbonyl)-2-
nitrophenoxy)hexylcarbamate (90) 
 
A solution of methyl 4-hydroxy-3-nitrobenzoate (2.0 g, 10 mmol), tert-butyl 6-
hydroxyhexylcarbamate 89 (2.2 g, 10 mmol) and triphenylphosphine (2.7 g, 10 mmol) 
was prepared by dissolving the reactants in 60 mL of THF. The mixture was cooled to 
0 °C, and a solution of diethyl azodicarboxylate (1.6 mL, 10 mmol) in 10 mL of THF 
was added. The reaction was allowed to warm to rt and left for 5 h. The solvent was 
reduced to yield orange oil. The oil was partitioned between CHCl3 (50 mL) and 
water (50 mL). The organic layer was washed with water (50 mL), before drying 
(MgSO4) and reduction in vacuo. Purification using flash chromatography (50% 
EtOAc: 50 % hexane) yielded the title compound as an off white solid (2.6 g, 66%). 
 
m.p. 99-101 °C. 
 
1H NMR (CDCl3) δ 8.48 (1H, d, J 2Hz, 3-H), 8.18 (1H, dd, J 9Hz & 2Hz, 5-H), 7.11 
(1H, d, J 9Hz, 6-H), 4.64 (1H, bs, N-H carbamate), 4.17 (2H, t, J 6Hz, CH2-α-O), 
O
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3.93 (3H, s, OMe), 3.12 (2H, q, J 6Hz, CH2-carbamate), 1.90 (2H, m, CH2 hexyl), 
1.6-1.3 (15H, m, C(CH3)3 & CH2 hexyl). 
 
13C NMR (CDCl3) 165.0 (4°, C=O ester) 156.0 (4°, C=O Boc), 155.6 (4°, C-4), 139.4 
(4°, C-3), 135.2 (C-H, C-6), 127.1 (C-H, C-2), 122.2 (4°, C-1), 113.9 (C-H, C-5), 79.0 
(4°, C(CH3) Boc), 69.9 (CH2, C-α-O), 52.4 (CH3, OMe),  40.4 (CH2, C-carbamate), 
30.0 (CH2), 28.7 (CH2), 28.4 (CH3 Boc), 26.3 (CH2), 25.5 (CH2). 
 
ES-MS MH+ calcd C19H29N2O7 397.5 found 397.4 (MH+) 
 
Anal calcd C19H28O7N2 C, 57.56, H, 7.13, N, 7.07 % Found C, 57.71, H, 7.12, N, 7.05 
% 
 
FTIR: 3290 (N-H Boc), 2972, 2936, 2856, 1719 (C=O ester), 1686 (C=O Boc), 1621, 
1533, 1437, 1364, 1275, 1252, 1174, 1024, 993, 874 cm-1 
 
Preparation of 4-(6-tert-
butoxycarbonylamino-hexyloxy)-3-nitro 
benzoic acid (91) 
 
A biphasic solution of tert-butyl 6-(4-(methoxycarbonyl)-2-nitrophenoxy)hexyl 
carbamate 90  (2.0 g, 5 mmol), LiOH monohydrate (1.1 g, 25 mmol), water (20 mL), 
and MeCN (60 mL) was heated to 50 °C for 30 min. The solvent was removed under 
vacuum, and the residue was taken up into EtOAc (40 mL) and washed with 2M 
KHSO4 (aq) (2 x 40 mL). The combined aqueous layers were re-extracted with EtOAc 
(40 mL). The organics were combined, brine washed (40 mL), dried (MgSO4), and 
reduced under vacuum to yield 2.0 g (quantitative) of a pale yellow solid. 
 
m.p. 100-110 °C. 
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1H NMR (CDCl3) δ 12.0-11.8 (1H, br s, COOH, exchanges D2O), 8.53 (1H, d, J 2Hz, 
2-H), 8.22 (1H, br d, J 9Hz, 6-H), 7.11 (1H, d, J 9Hz, 5-H), 6.3 (0.4H (split), br s, N-
H carbamate, exchanges D2O), 4.64 (0.6H (split), br s, N-H carbamate, increases to 
1H D2O,), 4.18 (2H, t, J 6Hz, CH2-α-O), 3.14 (2H, br d, J 6Hz, CH2-carbamate), 1.90 
(2H, m, CH2 hexyl), 1.6-1.3 (15H, m, C(CH3)3, & CH2 hexyl). 
 
13C NMR (CDCl3) 169.0 (4°, C=O acid) 156.5 (4°, C=O Boc), 155.6 (4°, C-4), 139.9 
(4°, C-3), 136.1 (C-H, C-6), 128.1 (C-H, C-2,), 122.1 (4°, C-1), 114.3 (C-H, C-5), 
79.0 (4°, C(CH3) Boc), 70.3 (CH2, C-α-O), 40.4 (CH2, C-carbamate), 30.3 (CH2), 
29.0 (CH2), 28.8 (CH3 Boc), 26.7 (CH2), 25.8 (CH2). 
 
Anal calcd C18H26O7N2 C 56.52, H 6.87, N 7.33 % Found C 56.47, H 6.81, N 7.33 % 
 
FTIR: 3322 (COOH), 3390 (N-H Boc) 2988, 2940, 2871, 1704 (C=O acid), 1644 
(C=O Boc), 1617, 1534, 1367, 1269, 1164, 842, 684 cm-1. 
 
Preparation of 3-amino-4-(6-tert-
butoxycarbonylamino-hexyloxy)benzoic 
acid (92) 
 
A flask of 4-(6-tert-butoxycarbonylamino-hexyloxy)-3-nitrobenzoic acid 91 (0.5 g, 
1.3 mmol) and Pd/C (50 mg) in EtOH (& 2 drops of AcOH) was stirred at rt under a 
H2 atmosphere (1 atm) for 24 h. The reaction was filtered through a celite pad, 
concentrated in vacuo, and purified by re-crystallisation from EtOAc: Hexane to yield 
the title compound as an off white solid (350 mg, 76%). 
 
m.p. 104-106 °C 
O
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1H NMR (CDCl3) δ  7.52 (1H, dd, J 8.4Hz & 2Hz, 6-H), 7.43 (1H, d, J 2Hz, 2-H), 
6.76 (1H, d, J 8.5Hz, 5-H), 6.37 (3H , br s, NH2 & COOH), 4.64 (1H , br s, N-H 
carbamate), 4.03 (2H, t, J 6Hz, CH2-α-O), 3.14 (2H, br d, J 6Hz, CH2-carbamate), 
1.82 (2H, m, CH2 hexyl), 1.6-1.3 (15H, m, C(CH3)3, & CH2 hexyl). 
 
13C NMR (CDCl3) 172.0 (4°, C=O acid) 156.5 (4°, C=O Boc), 151.6 (4°, C-4), 136.4 
(4°, C-6), 122.4 (4°, C-1), 122.1 (C-H, C-6), 116.4 (C-H, C-2), 110.6 (C-H, C-5), 79.0 
(4°, C(CH3) Boc), 68.7 (CH2, C-α-O), 40.9 (CH2, C-carbamate), 30.3 (CH2), 29.5 
(CH2), 28.8 (CH3 Boc), 26.9 (CH2), 26.1 (CH2). 
 
FTIR: 3347 (COOH & NH2), 2938, 2940, 2871, 1684 (C=O broad), 1617, 1521, 
1310, 1227, 996, 760, 645 cm-1. 
 
Preparation of 4-(6-tert-
butoxycarbonylamino-hexyloxy)-3-
pentylaminobenzoic acid (93) 
 
A solution of 3-amino-4-(6-tert-butoxycarbonylamino-hexyloxy)benzoic acid 92 (250 
mg, 0.68 mmol), valeraldehyde (73 µL, 1.36 mmol), AcOH (79 µL, 1.36 mmol), 
sodium acetate (93 mg, 0.68 mmol), and sodium cyanoborohydride (43 mg, 0.68 
mmol) was stirred in MeOH (10 mL) at rt for 4 h. The solution was evaporated to 
dryness and the residue was partit ioned between water and EtOAc. The aqueous layer 
was extracted with EtOAc (3 x 40 mL) and the organics were combined, washed with 
brine (30 mL) and dried (MgSO4). The organics were reduced in vacuo and the crude 
product was purified using flash chromatography (30% EtOAc: 70% Hexane) to give 
the title compound as an off white solid (68 mg, 24%). 
 
m.p. 96-98 °C 
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1H NMR (CDCl3) δ  7.47 (1H, dd, J 8.4Hz & 2Hz, 6-H), 7.29 (1H, d, J 2Hz, 2-H), 
6.73 (1H, d, J 8.5Hz, 5-H), 6.90 (1H , br s, N-H aniline), 4.61 (1H , br s, N-H 
carbamate), 4.03 (2H, t, J 6Hz, CH2-α-O), 3.20-3.00 (4H, m, CH2-carbamate & CH2-
aniline), 1.85 (2H, m, CH2 hexyl), 1.6-1.3 (19H, m, C(CH3)3, & CH2 hexyl), 0.97 
((3H, t, J 6.7 Hz, CH3-pentyl). 
 
13C NMR (CDCl3) 172.6 (4°, C=O acid) 156.5 (4°, C=O Boc), 150.8 (4°), 138.6 (4°), 
122.4 (4°), 120.3 (C-H), 110.9 (C-H), 109.6 (C-H), 79.0 (4°, C(CH3) Boc), 68.7 (CH2, 
C-α-O), 44.0 (CH2, C-carbamate), 30.3 (CH2), 29.8 (CH2), 29.5 (CH2), 28.8 (CH3 
Boc), 26.9 (CH2), 26.2 (CH2), 22.9 (CH2), 14.5 (CH3). 
 
FTIR: 3390 (COOH & NH2), 2940, 2871, 1689 (C=O two signals), 1599, 1521, 1310, 
1227, 980, 765 cm-1. 
 
 
 
Preparation of tert-butyl 6-(4-(4-
hydroxyphenethylcarbamoyl)-2-
nitrophenoxy)hexylcarbamate (94) 
 
A solution of 4-(6-tert-butoxycarbonylamino-hexyloxy)-3-nitrobenzoic acid 91 (1.01 
g, 2.63 mmol) and 1,1-carbonyldiimidazole (0.45 g, 2.77 mmol) was pre-mixed in 
MeCN (70 mL) for 2 h. Tyramine (0.38 g, 2.77 mmol), was added to the solution. 
Within 5 minutes the solid had dissolved, and the reaction was left stirring for 18 
hours at rt. The reaction was reduced to dryness under vacuum and the residue was 
dissolved in EtOAc (30 mL), this was washed with water (2 x 15 mL), and 2 M 
KHSO4 (aq) (2 x 15 mL). The combined aqueous layers were re-extracted with EtOAc 
(20 mL). The organics were combined, dried (MgSO4) and reduced to yield 1.34 g of 
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an off white solid. The product was purified by flash chromatography (5% MeOH: 
95% DCM) to yield the title compound as a white solid (1.04g, 79%). 
 
m.p. 140-141 °C. 
 
1H NMR (CDCl3) δ 8.18 (1H, d, J 2 Hz, 3-H), 7.90 (1H, dd, J 9 Hz & 2 Hz, 5-H), 
7.03-7.00 (3H, m, phenol H & 6-H), 6.5-6.3 (2H, m, N-H amide & O-H phenol, 
exchanges D2O), 4.70 (1H, br t, N-H carbamate, exchanges D2O), 4.10 (2H, t, J 6 Hz, 
CH2-α-O), 3.62 (2H, q, J 6.5 Hz, CH2-amide, q→ t  D2O) 3.10 (2H, q, J 6.5 Hz, CH2-
carbamate), 2.81 (2H, t, J 7 Hz, CH2-phenol), 1.80 (2H, m, CH2-hexyl), 1.5-1.3 (15H, 
m, C(CH3)3, & CH2-hexyl). 
 
13C NMR (CDCl3) 165.5 (4°, C=O amide) 156.2 (4°) 155.4 (4°, C=O Boc), 154.8 (4°, 
C-OH), 139.2 (4°), 133.2 (C-H), 130.1 (4°), 129.9 (C-H), 126.5 (4°), 124.0 (C-H), 
115.8 (C-H) 114.4 (C-H), 79.0 (4°, C(CH3)3 Boc), 70.0 (CH2, C-α-O), 41.9 (CH2, C-
amide) 40.4 (CH2, C-carbamate), 34.8 (CH2 C-phenol) 30.0 (CH2), 28.8 (CH2), 28.6 
(CH3, Boc), 26.4 (CH2), 25.6 (CH2). 
 
ES-MS MH+ calcd for C26H36O7N3 502.6 found 502.4 (MH+), and 524.3 (MNa+). 
 
Anal calcd C26H35O7N3.0.5 H2O C 61.16, H 7.11, N 8.23 % Found C 61.39, H 6.77, N 
8.22 % 
 
FTIR: 3423, 3320, 2937, 1685, 1654, 1637, 1559, 1391, 1321, 1171 cm-1 
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Preparation of tert-butyl 6-(4-(4-
hydroxyphenethylcarbamoyl)-2-
aminophenoxy)hexylcarbamate (95) 
 
A solution of tert-butyl 6-(4-(4-hydroxyphenethylcarbamoyl)-2-
nitrophenoxy)hexylcarbamate 94 (876 mg, 1.75 mmol) and Pd/C (175 mg) in EtOH 
(20 mL) was stirred at rt under a H2 atmosphere (1 atm) for 6 h. The reaction was 
filtered through a celite pad, concentrated in vacuo, and purified using flash 
chromatography (70% EtOAc: 30% Hexane). The solid was recrystallised from 70% 
EtOAc: 30% Hexane to yield the title compound as a white solid (577 mg, 69%). 
 
m.p. 121-122 °C 
 
1H NMR (DMSO-d6) δ 9.14 (1H, s, O-H, exchanges MeOD), 8.14 (1H, t, J 5.5 Hz, N-
H amide, exchanges MeOD), 7.12 (1H, d, J 2.1 Hz, 3-H), 7.04-6.98 (3H, m, 5-H & 
phenol H), 6.78 (1H, d, J 8.4 Hz, 6-H), 6.71-6.64 (2H, m, phenol H), 4.77 (3H, br s, 
N-H carbamate & aniline, exchanges MeOD), 3.97 (2H, t, J 6.4 Hz, CH2-α-O), 3.33 
(q, J 6.5 Hz, CH2-amide), 2.91 (2H, q, J 6.4 Hz, CH2-aniline, q → t MeOD), 2.67 
(2H, t, J 6.8 Hz, CH2-phenol), 1.75-1.62 (2H, m, CH2 hexyl), 1.5-1.3 (15H, m, 
C(CH3)3, & CH2-hexyl). 
 
13C NMR (MeOD) 170.4 (4°, C=O amide) 158.5 (4°, C=O Boc), 156.9 (4°, C-OH) 
150.9 (4°), 137.9 (4°), 131.4 (4°), 130.8 (CH), 128.1 (4°), 118.9 (CH), 116.2 (CH) 
114.9 (CH), 111.5 (CH) 79.8 (4°, C(CH3)3 Boc), 69.3 (CH2, C-α-O), 42.9 (CH2, C-
amide) 41.2 (CH2, C-carbamate), 35.8 (CH2, C-phenol) 30.9 (CH2), 30.2 (CH2), 28.8 
(CH3 Boc), 27.6 (CH2), 26.8 (CH2). 
 
ES-MS MH+ calcd C26H38N3O5 472.6 found 472.2 (MH+) 
O
HN O
O
NH2
O
H
N
OH
 192
 
Anal calcd C26H37O5N3.H2O C 63.78, H 8.03, N 8.58 % Found. C 63.85, H 7.80, N 
8.28 % 
 
FTIR: 3405, 3300, 2932, 1702, 1677, 1639, 1545, 1228, 1171 cm-1 
 
Preparation of tert-butyl 6-(4-(4-
hydroxyphenethylcarbamoyl)-2-
(pentylamino)phenoxy)hexylcarbamate 
(96) 
 
A solution of tert-butyl 6-(4-(4-hydroxyphenethylcarbamoyl)-2-
aminophenoxy)hexylcarbamate 95  (500 mg, 1.06 mmol), valeraldehyde (113 uL, 
1.06 mmol), sodium acetate trihydrate (144 mg, 1.06 mmol), acetic acid (121 uL, 2.12 
mmol), and sodium cyanoborohydride (67 mg, 1.06 mmol) was stirred in MeOH (10 
mL) at r.t for 18 h. The reaction was reduced in vacuo. The residue was dissolved in 
EtOAc (30 mL), washed with water (3 x 15 mL), and dried MgSO4. After evaporation 
of solvent the resulting oil was purified using flash chromatography (60% EtOAc: 
40% hexane) to yield the title compound as a white solid (411 mg, 71%). 
 
m.p. 159-161 °C 
 
1H NMR (CDCl3) δ 7.07-6.99 (3H, m, phenol Hs & 3-H), 6.89 (1H, dd, J 8.2 & 1.9 
Hz, 5-H), 6.83 (2H, d, J 8.4Hz, phenol H) 6.65 (1H, d, J 8.3 Hz, 6-H), 6.31 (1H, br t, 
J 5.5 Hz, N-H amide, exchanges D2O), 4.65 (1H, br s, N-H carbamate, exchanges 
D2O), 3.97 (2H, t, J 6 Hz, CH2-α-O), 3.63 (2H, q, J 6.5 Hz, CH2-amide), 3.12 (4H, m, 
CH2-carbamate & CH2-aniline), 2.82 (2H, t, J 6.5 Hz, CH2-phenol), 1.82-1.77 (2H, m, 
CH2-hexyl), 1.56-1.53 (2H, m, CH2-pentyl), 1.50-1.35 (19H, m), 0.91 (3H, t, J 6.7 Hz, 
CH3-pentyl) 
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13C NMR (CDCl3) 168.5(4°, C=O amide) 156.3 (4°, C=O Boc), 155.5 (4°, C-OH) 
148.7 (4°), 138.5 (4°), 130.0 (4°), 129.8 (C-H), 127.3 (4°), 115.7 (C-H), 115.0 (C-H) 
109.4 (C-H), 108.5 (C-H) 79.4 (4°, C(CH3), Boc), 68.2 (CH2, C-α-O), 43.6 (CH2, C-
amide) 41.5 (CH2, C-carbamate), 40.6 (CH2, C-aniline) 34.9 (CH2, C-phenol) 30.1 
(CH2), 29.4 (CH2), 29.1 (CH2) 28.8 (CH3, Boc), 26.5 (CH2), 25.8 (CH2), 22.5 (CH2), 
14.1 (CH3, pentyl). 
 
ES-MS MH+ calcd for C31H48N3O5 542.1 found 542.2. 
 
FAB-MS (+ve mode) M+ calcd for C31H47N3O5 541.3516 found 541.3528, MH+ 
calcd for C31H48N3O5 542.3594 found 542.3599. 
 
Anal calcd C31H47O5N3 C 68.73, H 8.74, N 7.76. Found. C 68.46, H 8.85, N 7.81 
 
Fluorescence properties λmax (excitation) 313 nM, λmax (emmision) 386 nM (0.8 mg in 
10 mL MeCN) 
 
FTIR: 3338 (broad), 2931, 2852, 1686, 1585, 1514, 1365, 1261, 1170 cm-1. 
 
Preparation of N-(4-hydroxyphenethyl)-4-(6-
aminohexyloxy)-3-(pentylamino)benzamide 
dihydrochloride (97) 
 
A solution of HCl in MeOH was prepared by the addition of AcCl (400 µL) to MeOH 
(10 mL). To this solution was added tert-butyl 6-(4-(4-hydroxyphenethylcarbamoyl)-
2-(pentylamino)phenoxy)hexylcarbamate (145 mg, 0.268 mmol), and the reaction was 
stirred at rt for 18 h. The residue after evaporation was crystallised from EtOAc: 
EtOH to yield the title compound as a white solid (89 mg, 65%). 
 
m.p. 150 °C 
 
NH2
O
N
H
O
H
N
OH
2HCl
 194
1H NMR (D2O) δ 7.53 (1H, dd, J 2.2 & 8.7 Hz, 6-H), 7.45 (1H, d, J 2.2 Hz, 2-H), 
7.01 (1H, d, J 8.8 Hz, 5-H), 6.81 (2H, d, J 8.8 Hz, phenol H), 6.59 (2H, d, J 8.5 Hz, 
phenol H), 4.00 (2H, t, J 6.5 Hz, CH2-α-O), 3.33 (2H, t, J 6.9 Hz, CH2-amide), 3.12 
(2H, m, CH2-aniline), 2.83 (2H, t, J 7.6 Hz, CH2-amine), 2.57 (2H, t, J 6.8 Hz, CH2-
phenol), 1.68 (2H, q, J 6.9 Hz, CH2-β-O), 1.55-1.09 (12H, m), 0.68 (3H, t, J 7.0 Hz, 
CH3-pentyl) 
13C NMR (D2O) δ 168.7 (C=O amide), 154.5 (4°), 154.3 (4°) 131.4 (4°), 130.6 (C-H), 
130.0 (C-H), 126.7 (4°), 124.0 (4°), 122.6 (C-H) 115.7 (C-H), 113.6 (C-H), 69.8 
(CH2, C-α-O), 51.1 (CH2, C-aniline) 41.6 (CH2 C-amide) 39.8 (CH2, C-amine), 34.1 
(CH2, C-phenol), 28.3 (CH2, C-β-O) 28.1 (CH2), 27.1 (CH2), 25.3 (CH2), 25.1 (CH2), 
21.8 (CH2), 13.4 (CH3, pentyl). 
 
AP-MS MH+ calcd for C26H40N3O3 442.3 found 442.3 (MH+) 
 
FAB-MS (+ve mode) MH+ calcd for C26H40N3O3 442.3070 found 442.3067. 
 
FTIR (nujol) 3342 (NH3), 3232, 2923, 1622, 1513, 1462, 1376, 1295, 838, 721 cm-1 
 
Labeling of N-(4-hydroxyphenethyl)-4-(6-
aminohexyloxy)-3-
(pentylamino)benzamide with dansyl 
chloride (99) 
 
A solution of N-(4-hydroxyphenethyl)-4-(6-aminohexyloxy)-3-
(pentylamino)benzamide dihydrochloride 97 (15.0 mg, 0.03 mmol) and dansyl 
chloride 84 (7.9 mg, 0.03 mmol), was stirred at rt in the dark, in MeCN (1 mL) and 
pH 8.3 NaHCO3 (aq) buffer (1 mL) for 1 h. The reaction was reduced in vacuo and the 
residue was partitioned between water and CHCl3. The aqueous phase was further 
extracted with CHCl3 (3 x 20 mL). The organic layers were combined, dried 
(MgSO4), and reduced. The resulting oil was purified using preparative TLC (50% 
Acetone: 50% pet ether 40-60) to yield the title compound as a green oil (3.8 mg, 
19%). 
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1H NMR (CDCl3) δ 8.53 (1H, d, J 8.4 Hz, 6-H), 8.47-8.22 (2H, m), 7.56-7.48 (3H, 
m), 7.16 (1H, d, J 7.1 Hz), 7.05 (2H, d, J 8.5 Hz), 6.98 (1H, d, J 2 Hz), 6.89 (1H, dd, J 
2 & 8.2 Hz), 6.82-6.77 (2H, m), 6.66 (1H, d, J 10 Hz), 6.12 (1H, br t, J 5.7 Hz, 
amide), 4.72 (1H, br t, J 6 Hz, amide), 3.88 (2H, t, J 6.5 Hz, CH2-α-O), 3.63 (2H, q, J 
6.6 Hz, CH2-amide), 3.11 (2H, t, J 7.2 Hz, CH2-aniline), 2.93-2.80 (8H, m, contains s 
for N(CH3)2), 1.80-1.60 (4H, m), 1.55-1.09 (12H, m), 0.90 (3H, t, J 7.0 Hz, CH3-
pentyl) 
 
ES-MS MH+ calcd for C38H51N4O5S 675.9 found 675.4 (MH+), 338.4 (- dansyl and 
C6 linker). 
 
HPLC – gradient 35% → 100% MeCN in water over 30 min. Rt 16.40 min (72% 
using peak area) 
 
Labeling of N-(4-hydroxyphenethyl)-4-
(6-aminohexyloxy)-3-
(pentylamino)benzamide with 
BODIPY

 630/650-x, SE (100) 
 
A solution of N-(4-hydroxyphenethyl)-4-(6-
aminohexyloxy)-3-(pentylamino)benzamide 
dihydrochloride 97 (2.75 mg, 0.0052 mmol) and 
Bodipy 630/650-x, SE 86 (3.10 mg, 0.0047 mmol), was stirred at rt in the dark, in 
MeCN (0.5 mL) and pH 8.3 NaHCO3 (aq) buffer (0.5 mL) for 1 h. The reaction was 
reduced in vacuo and the residue was partitioned between water and CHCl3. The 
aqueous phase was further extracted with CHCl3 (3 x 20 mL). The organic layers were 
combined, dried (MgSO4), and reduced. The resulting oil was purified using 
preparative TLC (10% MeOH: 90% CHCl3) to yield the title compound as a blue 
solid (2.90 mg, 63%). 
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1H NMR (CDCl3) δ 8.19 (1H, d, J 3.8 Hz, Bodipy), 7.63-7.52 (2H, m), 7.47 (1H, d, J 
5 Hz Bodipy), 7.40-7.19 (2H, m), 7.09-6.81 (14H, m), 6.70 (1H, br t, J 5.7 Hz, 
amide), 6.62 (1H, d, J 8.2 Hz, JTE), 6.15 (1H, br t, J 5.7 Hz, amide), 5.66 (1H, br t, J 
6 Hz, amide), 4.51 (2H, s, benzylic), 4.19 (1H, br s), 3.94 (2H, t, J 6.5 Hz, CH2-α-O), 
3.61 (2H, q, J 6.6 Hz, CH2-amide (β-phenol)), 3.32 (2H, q, J 6.7 Hz), 3.18 (2H, q, J 
6.5 Hz) 3.11 (2H, t, J 7.2 Hz, CH2-analine), 2.09 (2H, t, J 6.8 Hz, Bodipy) 1.80-1.20 
(23H, m), 0.90 (3H, t, J 7.0 Hz, CH3-pentyl) 
 
ES-MS MH+ calcd for C55H66BF2N6O6S 987.5 found 987.6 (MH+) 
 
HPLC – gradient 35% → 100% MeCN in water over 30 min. Rt 16.52 min (98% 
using peak area) 
 
Synthesis of succinimido 1-naphthaleneacetate 
(98) 
 
A suspension of 1-naphthylacetic acid (550 mg, 2.88 mmol), 
N-hydroxysuccinimide (330 mg, 2.88 mmol) and DCC (590 mg, 2.88 mmol) was 
stirred in DCM (25 mL) at rt for 16 h. EtOEt was added to the reaction and the 
precipitate formed was filtered. The mother liquor was reduced in vacuo and the 
residue dissolved in EtOAc. The organic layer was washed NaHCO3 (aq) (2 x 20 mL) 
and brine (20 mL) before drying (MgSO4). The residue after evaporation was purified 
by flash chromatography (50% EtOAc: 50% hexane) to yield the title compound as a 
white solid (380 mg, 47%). 
 
m.p. 92-95 °C 
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1H NMR (CDCl3) δ 7.93 (1H, d, J 8.4 Hz, 2-H), 7.85 (2H, m), 7.62-7.41 (4H, m), 
4.35 (2H, s, CH2-naphthalene), 2.72 (2H, s, CH2-succinimide) 
 
13C NMR (CDCl3) δ 169.1 (C=O, imide), 166.8 (C=O, ester), 133.8 (4°), 131.7 (4°), 
128.9 (C-H), 128.8 (C-H), 128.2 (C-H), 127.8 (4°), 126.8 (C-H), 126.1 (C-H), 125.4 
(C-H), 123.4 (C-H), 35.4 (CH2, C-naphthalene), 25.5 (CH2, C-imide) 
 
ES-MS MH+ & M- In both modes a molecular ion was not detected. 
 
 
Labeling of N-(4-hydroxyphenethyl)-4-(6-
aminohexyloxy)-3-(pentylamino)benzamide 
with succinimido 1-naphthaleneacetate (101) 
 
A solution of N-(4-hydroxyphenethyl)-4-(6-
aminohexyloxy)-3-(pentylamino)benzamide 
dihydrochloride 97 (27.7 mg, 0.05 mmol) and 
succinimido 1-naphthaleneacetate 98 (13.9 mg, 0.05 mmol), was stirred at rt, in 
MeCN (1 mL) and pH 8.3 NaHCO3 (aq) buffer (1 mL) for 12 h. The reaction was 
filtered under vacuum to recover the solid. The solid was re-crystallised from MeOH: 
water to yield the title compound as a white solid (21.8 mg, 73%). 
 
m.p. 149 °C 
 
1H NMR (DMSO-d6) δ 9.02 (1H, s, O-H), 8.20-8.16 (1H, m, naphthalene), 8.03 (1H, 
br t, J 5.5 Hz, amide), 7.93-7.87 (1H, m, naphthalene), 7.82 (2H, dd, J 2 & 7 Hz, 
naphthalene), 7.56-7.40 (4H, m), 7.19-7.12 (2H, m), 7.05 (2H, d, 8.4 Hz, phenol H), 
6.81 (1H, d, J 8.2 Hz, naphthalene), 6.73 (2H, d, J 8.8 Hz, phenol H), 4.61 (1H, br t, J 
5.7 Hz, amide), 4.01 (2H, t, J 6.5 Hz, CH2-α-O), 3.94 (2H, s, CH2-naphthalene), 3.45 
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(2H, q, J 6.1 Hz, CH2-amide (β  phenol), 3.22-3.05 (4H, m), 2.76 (2H, t, J 8.0 Hz, 
CH2-phenol), 1.75-1.31 (15H, m), 0.90 (3H, t, J 7.0 Hz, CH3-pentyl) 
 
13C NMR (DMSO-d6) δ 170.8 (C=O amide), 167.9 (C=O amide), 155.8 (4°), 148.3 
(4°), 142.5 (4°), 139.0 (4°), 133.9 (4°), 132.1 (4°), 129.7 (C-H), 128.8 (C-H), 128.3 
(C-H), 128.2 (C-H), 127.7 (4°), 115.6 (C-H), 114.9 (C-H), 109.2 (C-H), 68.1 (CH2, C-
α-O), 43.5 (CH2 C-naphthalene) 41.1 (CH2) 39.3 (CH2) 34.3 (CH2), 29.3 (CH2), 29.1 
(CH2) 28.9 (CH2), 27.1 (CH2), 26.3 (CH2), 25.6 (CH2), 22.5 (CH2), 14.1 (CH3, 
pentyl). 
 
ES-MS MH+ calcd for C38H48N3O4 610.4 found 610.3 (MH+), 472.9 (M-tyramine) 
 
Anal calcd C38H47O4N3 C 74.85, H 7.77, N 6.89 % Found. C 74.52, H 7.67, N 6.99 % 
 
FTIR: 3423, 3301 (OH), 2928, 2856, 1659 (C=O amide), 1633, 1538, 1512, 1454, 
1266, 1241, 1217, 777 cm-1 
 
Preparation of methyl 3, 4-dihydroxybenzoate (103) 
 
A solution of 3, 4 dihydroxybenzoic acid (2.0 g, 0.013 mol) and 
conc. H2SO4 (5 drops) in MeOH (80 mL) was refluxed for 4 hours and left to stir at 
room temperature for 48 hours. The solvent was reduced in-vacuo and the residue was 
neutralized by the addition of solid NaHCO3. The neutralized residue was dissolved in 
EtOAc and washed with sat. NaHCO3 and brine solutions. The organics were dried 
(MgSO4) and evaporated to yield 2.0 g (92%) of the title compound as a white solid. 
 
m.p. 132-133 °C Lit267 133 °C 
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1H NMR (MeOD) δ 7.46 (1H, d, J 2.1Hz, H2), 7.44 (1H, dd, J 7.1 & 2.1 Hz, H6), 
6.83 (1H, d, J 7.1Hz, H5), 3.86 (3H, s, methyl ester). 
 
ES-MS MH+ calcd for C8H9O4 169.1, found m/z 169.2 (MH+) 
 
FTIR: 2953, 2871, 1716 (C=O), 1599, 1514, 1436, 1391, 1269, 1132, 1007, 764, 645 
cm-1 
 
Preparation of methyl 3,4-bis(pentyloxy)benzoate 
(104) 
 
A suspension of methyl 3, 4-dihydroxybenzoate 103 (1.5 g, 
8.9 mmol), K2CO3 (3.1 g, 22 mmol) and 1-bromopentane (3.9 mL, 31 mmol) were 
heated at 90 °C in DMF (40 mL) for 1 h. The reaction was filtered and the DMF 
reduced in-vacuo. The residue was dissolved in EtOAc, refiltered and washed with 
2M NaOH (3 x 20 mL) and brine (2 x 20 mL). The organics were dried (MgSO4) and 
evaporated. The title compound was purified from the crude product using flash 
chromatography (15% EtOAc: 85% hexane) to afford 2.1 g (76%) of colourless oil. 
 
1H NMR (CDCl3) δ 7.63 (1H, dd, J 8.5 & 2Hz, 6-H), 7.54 (1H, d, J 2 Hz, 2-H), 6.86 
(1H, d, J 8.5Hz, 5-H), 4.04 (4H, t, J 6.6Hz, CH2-α-O) 3.88 (3H, s, methyl ester), 1.83 
(4H, quintet (5), J 7Hz, CH2-β-O), 1.53-1.25 (8H, m), 0.93 (6H, t, J 7Hz, CH3). 
 
13C NMR (CDCl3) δ 167.0 (C=O), 153.2 (4°, C-O aromatic), 148.5 (4°, C-O 
aromatic), 123.6 (C-H, C-6), 122.4 (4°, C-ester), 114.3 (C-H, C-2), 111.9 (C-H, C-5), 
69.3 (CH2, C-O), 69.0 (CH2, C-O), 51.9 (CH3, methyl ester), 28.9 (CH2), 28.8 (CH2), 
28.2 (CH2), 22.5 (CH2), 14.0 (CH3). 
 
ES-MS MH+ calcd for C18H29O4 309.1,found m/z 309.1 (MH+). 
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FTIR (thin film): 2953, 2929, 2857, 1686 (C=O ester), 1601,1523, 1434, 1307, 1226, 
1135, 761, 643 cm-1 
 
Preparation of 3,4-bis(pentyloxy)benzoic acid 
(105) 
 
Methyl 3,4-bis(pentyloxy)benzoate 104 (1.82 g, 5.9 mmol) and LiOH.H2O (2.48 g, 
5.9 mmol) were refluxed for 1 h in 50 mL of 60% MeCN: 40% water. Acidification of 
the reaction (conc. HCl (aq)) yielded a white precipitate. The solid was filtered from 
the reaction and washed with cold water (50 mL) to yield the title compound (1.56 g, 
90%). 
 
m.p. 135-137 °C Lit 268142 °C 
 
1H NMR (CDCl3) δ 7.73 (1H, dd, J 8.5 + 2 Hz, 6-H), 7.59 (1H, d, J 2 Hz, 2-H), 6.89 
(1H, d, J 8.5 Hz, 5-H), 4.07 (2H, t, J 6.6 Hz, O-CH2 (o), 4.06 (2H, t, J 6.6 Hz, O-CH2 
(p), 1.85 (4H, m, CH2 β  to ether), 1.43 (8H, m), 0.94 (6H, t, J 7 Hz, CH3). 
 
13C NMR (CDCl3) δ 172.1 (4°, C=O), 154.0 (4°, C-O aromatic), 148.5 (4°, C-O 
aromatic), 124.5 (C-H), 121.4 (4°, C-1), 114.5 (C-H), 111.8 (C-H), 69.3 (CH2, C-O), 
69.0 (CH2, C-O), 28.8 (CH2), 28.7 (CH2), 28.2 (CH2), 22.4 (CH2), 14.0 (CH3). 
 
ES-MS MH+ calcd for C17H27O4 295.2, found m/z 295.1 (MH+) 
 
FTIR: 3459 (COOH), 3251, 2969, 1688, 1612, 1533, 1443, 1243, 1184, 1099, 984, 
764, 623, 591 cm-1 
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Preparation of N-benzyloxycarbonyltyramine (107) 
 
A solution of tyramine (12.0 g 0.0875 mol) and DIPEA (15.2 mL, 
0.0875 mol) in 70 mL of 70% MeCN: 30% DMF was cooled to 0 
°C. Benzyl chloroformate (10.8 mL, 0.0963 mol) was added 
dropwise, to the tyramine solution, over 30 min. The reaction was 
allowed to warm to rt and stirred at this temperature for 24 h. The resulting 
suspension was filtered. The filtrate was concentrated in-vacuo to yield brown oil. 
The residue was dissolved in EtOAc (100 mL) and washed with 2M HCl (aq) (2 x 50 
mL) and brine (1 x 50 mL). The organics were dried (MgSO4), and reduced in-vacuo 
to yield 18 g of white solid. The solid was re-crystallized from water: EtOH to yield 
the title compound as colourless needle crystals (13 g, 57%). 
 
m.p. 100-102 °C Lit269 100 °C 
 
1H NMR (CDCl3) δ 7.42-7.33 (5H, m, Cbz phenyl), 6.99 (2H, d, J 8.3 Hz, 2-H & 6-
H), 6.75 (2H, d, J 8.3 Hz, 3-H + 5-H), 6.37 (1H, s, OH), 5.09 (2H, s, benzylic), 4.87 
(1H, br t, N-H carbamate), 3.40 (2H, q, J 6.5 Hz, CH2-N), 2.71 (2H, t, J 7 Hz, CH2-
Ph). 
 
13C NMR (CDCl3) δ 157.0 (4°, C-O, C1), 155.1 (4°, C=O), 136.7 (4°, ipso aromatic), 
130.2 (4°, C4), 130.2 (CH, x 2 phenol ring), 128.6 (CH, Cbz phenyl), 128.5 (CH, Cbz 
phenyl), 115.9 (CH, x 2 phenol ring), 67.2 (CH2, benzylic), 42.9 (CH2 α Cbz), 35.5 
(CH2 β  Cbz). 
 
ES-MS MH+ calcd for C16H18N1O3 272.1, found m/z 272.0 (MH+) 194.1 (M – 
phenyl) 
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FTIR: (KBr) 3331 (O-H, N-H), 1686 (C=O), 1612, 1544, 1514, 1268, 1244, 1139, 
824, 746, 695, 528 cm-1. 
 
Synthesis of O-allyl-N-benzyloxycarbonyltyramine 
(108) 
 
A suspension of N-benzyloxycarbonyl tyramine 107 (9.95 g, 0.0367 
mol), allyl bromide (4.2 mL, 0.0458 mol), and potassium carbonate 
(6.33 g, 0.0458 mol) in methyl ethyl ketone (150 mL) was refluxed 
for 18 h. The resulting fine slurry was filtered and reduced in-vacuo. The residue was 
dissolved in EtOAc (100 mL) and washed with 2M HCl(aq) (2 x 30 mL) and brine (30 
mL). The organic layer was dried (MgSO4) and reduced in-vacuo to yield the title 
compound as a white solid (10.9g, 96%). 
 
m.p. 94-95 °C 
 
1H NMR (CDCl3) δ 7.40-7.30 (5H, m, Cbz phenyl), 7.07 (2H, d, J 9 Hz, 2-H & 6-H), 
6.84 (2H, d, J 8. Hz, 3-H & 5-H), 6.05 (1H, ddt, J 17.3, 11.9, 5.3 Hz, C-CH=C), 5.45 
(1H, ddt, J 17.3, 3.0, 1.5 Hz, C=CH trans), 5.28 (1H, ddt, J 11.7, 3.0, 1.5 Hz, C=CH 
cis), 5.09 (2H, s, benzylic), 4.75 (1H, br t, N-H carbamate), 4.50 (2H, m, O-CH2-
C=C), 3.42 (2H, q, J 6.5 Hz, CH2-Cbz), 2.74 (2H, t, J 7 Hz, CH2-Ph). 
 
13C NMR (CDCl3) δ 157.3 (4°, C-O, C1), 156.3 (4°, C=O), 136.6 (4°, ipso aromatic), 
133.4 (CH, CH=), 130.8 (4°, C4), 129.7 (CH, x 2 phenol ring), 128.5 (CH, Cbz 
phenyl), 128.0 (CH, Cbz phenyl), 117.6 (CH2, =CH2), 114.9 (CH, x 2 phenol ring), 
68.8 (CH2, O-C-allyl) 66.6 (CH2, benzylic), 42.9 (CH2 α Cbz), 35.5 (CH2 β  Cbz). 
 
ES-MS MH+ calcd for C19H22N1O3 312.41, found m/z 312.1 (MH+), 334.1 (MNa+) 
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Anal calcd C19H21N1O3.0.25H2O C 72.24, H 6.86, N 4.43 % Found. C 72.39, H 6.58, 
N 4.40 % 
 
FTIR: (KBr) 3323 (N-H), 3061, 3029, 2944 (CH=CH), 1683 (C=O), 1612, 1542, 
1513, 1291, 1244, 1140, 829, 748, 695 cm-1. 
 
Synthesis of 2-allyl-N-benzyloxycarbonyltyramine 
(109) 
 
O-Allyl N-benzyloxycarbonyltyramine 108 (6.44g, 0.0207 mol) and 
diphenyl ether (20 mL) was heated at reflux, under a N2 
atmosphere, for 1 h. The diphenylether was removed using high vacuum distillation. 
Purification by flash chromatography using 30% EtOAc: 70% hexane yielded the title 
compound as a pale oil, which partially crystallized upon standing at 5 °C (3.63g, 
56%). 
 
1H NMR (CDCl3) δ 7.40-7.30 (5H, m, Cbz phenyl), 6.87-6.82 (2H, m, 3-H & 5-H), 
6.70 (1H, d, J 8. Hz, 6-H), 6.69 (1H, br s, OH, exchanges) 5.96 (1H, ddt, J 16.8 & 
10.3 & 6.5 Hz, C-CH=C), 5.14-5.04 (4H, m, benzylic & C=CH2), 4.95 (1H, br t, D2O 
exchange, N-H carbamate), 3.42-3.25 (4H, m, Ph-CH2-C=C & CH2-N), 2.66 (2H, t, J 
7 Hz, CH2-Ph). 
 
13C NMR (CDCl3) δ 156.7 (4°, C=O), 152.9 (4°, C-O, C-1), 139.7 (CH, CH=), 136.3 
(4°, ipso aromatic), 130.5 (CH, C-3), 130.2 (4°, C-4), 128.5 (CH, Cbz phenyl), 128.1 
(CH, Cbz phenyl), 127.6 (CH, Cbz phenyl), 127.5 (CH Cbz phenyl), 127.0 (CH, C-5), 
126.1 (4°, C-2), 116.0 (CH2, =CH2), 115.6 (CH, C-6), 66.8 (CH2, benzylic), 42.5 (CH2 
α Cbz), 35.1 (CH2 β  Cbz) 34.6 (CH2, Ph-C-allyl). 
 
ES-MS MH+ calcd for C19H22N1O3 312.41, found m/z 312.1 (MH+), 251.0 
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Anal calcd C19H21N1O3 C 73.29, H 6.80, N 4.50 % Found. C 73.09, H 6.71, N 4.52 % 
 
FTIR: (thin film) 3341 (O-H, N-H), 3065, 3032, 2939 (CH=CH), 1693 (C=O), 1610, 
1510, 1133, 819, 737, 697 cm-1. 
 
Synthesis of 2-allyl-O-benzyl-N-
benzyloxycarbonyltyramine (110) 
 
2-Allyl-N-benzyloxycarbonyltyramine 109 (1.83g, 5.9 mmol), 
benzyl bromide (0.97 mL, 7.3 mmol), and K2CO3 (1.01g, 7.3 mmol) 
were refluxed in methyl ethyl ketone (50 mL) for 12 h. The reaction 
was filtered and reduced in-vacuo. The residue was taken up into EtOAc (50 mL) and 
washed with 2M NaOH (2 x 30 mL) and brine (30 mL). The organics were dried 
(MgSO4) and reduced to leave a residue, which upon trituration with cold hexane 
yielded the title compound as a white solid after filtration (1.88g, 80%). 
 
m.p. 66-67 °C 
 
1H NMR (CDCl3) δ 7.44-7.30 (10H, m, Cbz phenyl & Bn phenyl), 6.98-6.92 (2H, m, 
3-H & 5-H), 6.83 (1H, d, J 6.2 Hz, 6-H), 5.98 (1H, ddt, J 18.8 & 10.1 & 6.7 Hz, C-
CH=C), 5.14-5.04 (6H, m, benzylic & C=CH2), 4.76 (1H, br t, N-H carbamate, 
exchanges D2O), 3.45-3.37 (4H, m, Ph-CH2-C=C & CH2-N), 2.77 (2H, t, J 6.9 Hz, 
CH2-Ph). 
 
13C NMR (CDCl3) δ 156.3 (4°, C=O), 155.1 (4°, C-O, C-1), 137.4 (CH, CH=), 136.8 
(4°, ipso aromatic), 136.6 (4°, ipso aromatic) 130.8 (4°, C-4), 130.3 (CH, C-3), 129.2 
(4°, C-2), 128.5 (CH, Cbz phenyl), 128.1 (CH, Cbz phenyl), 127.7 (CH, Cbz phenyl), 
127.4 (CH Cbz phenyl), 127.1 (CH, C-5), 115.6 (CH2, =CH2), 111.9 (CH, C-6), 70.0 
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(CH2, benzylic Bn) 66.6 (CH2, benzylic Cbz), 42.4 (CH2 α Cbz), 35.2 (CH2 β  Cbz) 
34.5 (CH2, Ph-C-allyl). 
 
AP-MS MH+ calcd for C26H28NO3 402.20, found m/z 402.3 (MH+) 358.3 (M – allyl) 
 
Anal calcd C26H27NO3 C 77.78, H 6.78, N 3.49 % Found. C 77.87, H 6.74, N 3.44 % 
 
FTIR: (KBr) 3325 (N-H), 3066, 3033, 2950 (CH=CH), 2896, 2861, 1691 (C=O), 
1607, 1541, 1257, 1140, 914, 812, 734, 696 cm-1. 
 
Synthesis of 2-(2-oxoethyl)-O-benzyl-N-
benzyloxycarbonyltyramine (111) 
 
A solution of 2-allyl-O-benzyl-N-benzyloxycarbonyltyramine 110 
(500 mg, 1.25 mmol), N-methylmorpholine oxide (292 mg, 2.49 
mmol), and 0.1M aqueous solution of osmium tetroxide (1 mL, 
0.01 mmol) was stirred at rt in 10 mL of 80% acetone: 20% water  for 2 h. The 
reaction was quenched by adding saturated aqueous sodium sulphite (10 mL). The 
aqueous reaction was extracted with EtOAc (2 x 30 mL), the combined organics were 
washed with brine (20 mL) and dried (MgSO4). The organics were reduced in vacuo 
to afford the diol product, which was used without further purification or 
characterization.  The diol was dissolved in 10 mL of 50% water: 50% THF and 
cooled to 0 °C. Solid NaIO4 (400 mg) was added to the solution and the reaction was 
allowed to warm to rt. The reaction was diluted with water (30 mL) and the reaction 
was extracted with ether (2 x 20 mL). The organics were combined, brine washed (20 
mL) and dried (MgSO4). Evaporation of the ether yielded the title product as yellow 
oil (395mg, 79%). 
 
1H NMR (CDCl3) δ 9.70(1H, t, J 2Hz, aldehyde), 7.40-7.30 (10H, m, Cbz phenyl & 
Bn phenyl), 7.06 (1H, d, J 8 Hz 5-H), 6.97 (1H, s, 3-H), 6.87 (1H, d, J 8 Hz, 6-H), 
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5.09 (2H, s, benzylic) 5.04 (2H, s, benzylic), 4.94 (1H, br t, N-H carbamate, 
exchanges D2O), 3.65 (2H, d, J 2Hz, CH2-CHO),  3.40 (2H, q, J 6.6Hz, CH2-N), 2.70 
(2H, t, J 6.9 Hz, CH2-Ph). 
 
13C NMR (CDCl3) δ 199.9 (CH, CHO), 156.3 (4°, C=O), 155.4 (4°, C-O, C-1), 136.8 
(4°, ipso aromatic), 136.6 (4°, ipso aromatic), 131.8 (C-H), 131.3 (4°, C-4), 129.0 
(CH, Cbz phenyl), 128.6 (CH, Cbz phenyl), 128.5 (CH, Cbz phenyl), 128.1 (CH, Cbz 
phenyl), 128.0 (CH, Cbz phenyl), 127.1 (CH, Cbz phenyl), 121.7 (4°, C-3), 111.9 
(CH, C-6), 70.0 (CH2, benzylic Bn) 66.6 (CH2, benzylic Cbz), 45.5 (CH2, CH2-CHO), 
42.4 (CH2 α Cbz), 35.2 (CH2 β  Cbz). 
 
AP-MS MH+ calcd for C25H26NO4 404.5, found m/z 404.2 (MH+) 360.1 (M – 
CH2CHO) 
 
Synthesis of 2-(2-tert-butoxycarbonylaminoethyl)-O-
benzyl-N-benzyloxycarbonyltyramine (116) 
 
Ozone gas was sparged into a solution of 2-allyl-O-benzyl-N-
benzyloxycarbonyltyramine 110 (1.0 g, 2.5 mmol) in 30 mL of 
30% DCM: 70% MeOH, cooled to -78°C, until TLC showed the 
starting material had been consumed. Sodium borohydride (0.14 g, 
3.7 mmol) was added portion wise, over 5 mins, to the ozonide solution and the 
reaction was allowed to warm to room temperature and stirred for 12 hours. The 
solvent was reduced in-vacuo and the crude oil was purified using flash 
chromatography (60% EtOAc : 40% hexane) to yield 0.9g of a colourless oil 112. The 
oil was used without further characterization or purification in the next step. The oil 
(850mg) and triethylamine (0.32 mL, 2.3 mol) was cooled to 0 °C in DCM (20 mL). 
Mesyl chloride (0.18 mL, 2.3 mol) was added and the reaction was stirred at 0°C for 2 
h. The reaction was washed with 2M HCl(aq) (2 x 10 mL) and sat. NaHCO3 (aq) (1 x 10 
mL), then dried (MgSO4) and evaporated to yield 0.81 g of solid 113 which was used 
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in the next reaction without further purification or characterization. The solid 113 
(0.76 g, 1.6 mmol) and NaN3 (0.15 g, 2.4 mmol) was heated to 60 °C in DMF (15 
mL) for 5 h. The reaction was quenched with iced water and extracted with 
chloroform (3 x 30 mL) The organics were dried and reduced to yield 0.48 g of the 
azide 114 as a solid, which was used in the subsequent reaction without further 
purification or characterization. The azide 114 and triphenylphosphine (0.32g, 1.2 
mol) was dissolved in THF (10 mL), and stirred at room temperature for 24 h. 
Hydrolysis was afforded by the addition of 0.5 mL of water and a further period of 
stirring at rt for 48 h. The reaction was reduced in-vacuo to yield a yellow oil, which 
was dissolved in saturated MeOH: HCl(g). The solvent was reduced in-vacuo and the 
oily residue was triturated in ether to yield a 370mg of the amine 115 as a white 
gummy material. The amine 115 was Boc protected by dissolving the gum in dioxane 
(15 mL) and 1M NaOH (4 mL). The reaction was cooled to 0 °C and di-tert-butyl 
dicarbonate (201mg, 0.922 mmol) was added and the reaction was stirred for 1 h. The 
reaction was reduced in-vacuo and partitioned between water (20 mL) and EtOAc (20 
mL). The aqueous layer was extracted with EtOAc (2 x 20 mL), the organics were 
combined, dried (MgSO4) and evaporated. The solid was purified by flash 
chromatography (40% EtOAc: 60% hexane) to yield the title compound as a white 
solid (350mg, 34% from 2-allyl-O-benzyl-N-benzyloxycarbonyltyramine 110). 
 
m.p. 104-105 °C 
 
1H NMR (CDCl3) δ 7.43-7.22 (10H, m, Cbz phenyl & Bn phenyl), 6.97-6.78 (2H, m, 
3-H & 5-H), 6.80 (1H, d, J 8.7 Hz, 6-H), 5.07-5.01 (5H, m, 2 x benzylic & N-H 
carbamate), 4.77 (1H, br t, N-H carbamate), 3.42-3.33 (4H, m, 2 x CH2-N), 2.80 (2H, 
t, J 6.4 Hz, CH2-Ph) 2.70 (2H, t, J 6.8 Hz, CH2-Ph), 1.39 (9H, s, C(CH3)3). 
 
13C NMR (CDCl3) δ 156.4 (4°, C=O), 155.9 (4°, C-O, C1), 155.4 (4°, C=O), 137.1 
(4°, ipso aromatic), 136.6 (4°, C-4), 131.2 (CH, C-3), 131.0 (4°, C-2), 128.6 (CH, 
Cbz/Bn phenyl), 128.5 (CH, Cbz/Bn phenyl), 128.1 (CH, Cbz/Bn phenyl), 128.0 (CH, 
Cbz/Bn phenyl) 127.9 (CH, Cbz/Bn phenyl), 127.6 (CH Cbz/Bn phenyl), 127.2 (CH, 
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C-5), 111.8 (CH, C-6), 78.9 (4°, C(CH3)3), 70.0 (CH2, benzylic Bn), 66.5 (CH2, 
benzylic Cbz), 42.3 (CH2 α Cbz), 40.8 (CH2 α Boc)  35.1 (CH2 β  Cbz), 30.6 (CH2 β  
Boc), 28.4 (CH3, Boc). 
 
ES-MS MH+ calcd for C30H37N2O5 505.26, found m/z 527.24 (MNa+), 505.35 
(MH+), 405.17 (M – Boc). 
 
Anal calcd C30H36N2O5. 0.5 H2O C 70.15, H 7.26, N 5.45. Found. C 70.09, H 7.10, N 
5.45 
 
FTIR: (KBr) 3360 (N-H), 3065, 3032, 2979, 2934, 1693 (C=O), 1687 (C=O), 1531, 
1453, 1274, 1255, 1223, 1130, 809, 733, 697 cm-1. 
 
Synthesis of N-(3-(2-tert-
butoxycarbonylaminoethyl)-4-
hydroxyphenethyl)-3, 4-
bis(pentyloxy)benzamide (118) 
 
2-(2-tert-Butoxycarbonylaminoethyl)-O-benzyl-N-benzyloxycarbonyltyramine 116 
(300 mg, 0.595 mmol) and Pd/C (40 mg) was stirred in 70 % EtOH: 30% EtOAc (15 
mL) under a H2 atmosphere (1 atm), at rt, for 24 h. The reaction was filtered through a 
Celite pad and concentrated in-vacuo to yield 80 mg (52%) of amine 117 as a 
hydroscopic tacky solid. 1H NMR showed the characteristic Cbz and Bn signals at δ 
7.43-7.22 to be absent. A solution of 3, 4-dipentoxybenzo ic acid 105 (80 mg, 0.27 
mmol) and 1,1 carbonyldiimidazole (46 mg, 0.29 mmol) was prepared in MeCN (7 
mL). The solid 117 from the hydrogenolysis reaction was added, without further 
purification or characterization, to this activated acid solution and the reaction was 
stirred at rt for 48 h. The solvent was reduced and the reaction taken up into EtOAc 
(20 mL), the organic was washed with water (1 x 10 mL), 2M KHSO4 (aq) (2 x 20 mL), 
and sat. NaHCO3 (aq) (2 x 20 mL). The organics were dried (MgSO4), and evaporated 
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to leave oil that was purified using preparative TLC (45% EtOAc: 55% hexane) to 
yield the title compound (66 mg, 20% overall yield from 2-(2-tert-
butoxycarbonylaminoethyl)-N-benzyloxycarbonyltyramine) as a colourless oil. A 
small portion was crystallised from EtOAc: Hexane to yield an analytically pure white 
solid. 
 
m.p. 141-142 °C 
 
1H NMR (CDCl3) δ 7.39 (1H, d, J 1.9 Hz, 2-H), 7.21 (1H, dd, J 8.3 & 1.9 Hz 6-H), 
6.93-6.80 (2H, m, aromatic), 6.43 (1H, br t, N-H amide), 5.09 (1H, br t, N-H 
carbamate), 4.00 (2H, t, J 6.6 Hz, O-CH2 (o)), 3.99 (2H, t, J 6.6 Hz, O-CH2 (p)), 3.60 
(2H, q, J 6.2 Hz, CH2-amide), 3.27 (2H, q, J 6.2 Hz, CH2-carbamate), 2.78 (4H, t, J 
6.4 Hz, 2 x CH2-Ph), 1.80 (4H, m, CH2 β  to ether), 1.48-1.37 (17H, m, Boc & alkyl 
chain) 0.93 (6H, m, CH3). 
 
13C NMR (CDCl3) δ 167.4 (4°, C=O amide) 156.9 (4°, C=O Boc), 153.8 (4°, C-O 
aromatic), 151.9 (4°, C-O aromatic), 148.9 (4°, C-O aromatic), 130.9 (CH, C-3 
tyramine), 130.1 (4°, C-4 tyramine), 128.1 (CH, C-5 tyramine), 126.9 (4°), 125.2 (4°), 
119.5 (CH, benzamide), 116.1 (CH, benzamide), 112.7 (CH, benzamide), 112.3 (CH, 
C-6 tyramine), 79.8 (4°, C(CH3)3), 69.3 (CH2, C-O), 69.2 (CH2, C-O), 41.5 (CH2 α 
amide), 41.1 (CH2-α-carbamate)  34.9 (CH2 β  amide), 31.1 (CH2-β-carbamate), 28.9 
(CH2), 28.8 (CH3, Boc), 28.4 (CH2), 28.2 (CH2), 22.4 (CH2), 14.0 (CH3). 
 
ES-MS MH+ calcd for C32H49N2O6 557.4, found m/z 579.4 (MNa+), 557.4 (MH+), 
457.2 (M – Boc). 
 
Anal calcd C32H48N2O6 C 69.04, H 8.69, N 5.03. Found. C 68.77, H 8.67, N 5.05 
 
FTIR: (KBr) 3386 (O-H), 3243 (N-H), 2956, 2918, 1688 (C=O), 1633 (C=O), 1509, 
1262, 1224, 1134, 1047, 819 cm-1. 
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Synthesis of N-(3-(2-aminoethyl)-4-
hydroxyphenethyl)-3,4-
bis(pentyloxy)benzamide hydrochloride (119) 
 
A solution of HCl in MeOH was prepared by the addition of AcCl (400 µL) to MeOH 
(5 mL). To this solution was added N-(3-(2-tert-butoxycarbonylaminoethyl)-4-
hydroxyphenethyl)-3, 4-bis(pentyloxy)benzamide 118 (50 mg, 0.090 mmol) and the 
reaction was stirred at rt for 4 h. The solvent was evaporated and the residue was 
crystallised from EtOAc: EtOH to yield the title compound as a white solid (19 mg, 
43%). The compound was not fully soluble in any common NMR solvent i.e.CDCl3; 
DMSO-d6, D2O, MeOD, MeCN-d3. 
 
m.p. 130 °C (dec.) 
 
1H NMR (DMSO-d6 & MeOD sample not fully soluble) δ 7.29 (2H, br s, aromatic), 
6.75 (1H, br s, aromatic), 6.73-6.50 (3H, m, aromatic), 3.60 (4H, br s), 3.30 (2H, br s), 
2.95 (2H, br s), 2.76-2.40 (4H, m), 1.40 (4H, br s), 1.05 (8H, m), 0.65 (6H, m). 
 
ES-MS MH+ calcd for C27H41N2O4 457.3, found m/z 457.3 (MH+) 
 
Anal calcd C27H43ClN2O5. H2O C 63.45, H 8.48, N 5.48. Found. C 63.44, H 8.38, N 
5.68 
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Labeling of N-(3-(2-aminoethyl)-4-
hydroxyphenethyl)-3, 4-
bis(pentyloxy)benzamide hydrochloride with 
BODIPY

 630/650-x, SE (121) 
 
A solution of N-(3-(2-aminoethyl)-4-
hydroxyphenethyl)-3,4-bis(pentyloxy)benzamide 
hydrochloride 119  (5.70 mg, 0.011 mmol) and Bodipy 630/650-X, SE 86 (4.12 mg, 
0.0062 mmol), was stirred at rt in the dark, in 1.5 mL of 30% MeCN: 70% pH 8.3 
NaHCO3 (aq) buffer for 1 h. The reaction was reduced in vacuo and the residue was 
partitioned between water and CHCl3. The aqueous phase was further extracted with 
CHCl3 (3 x 20 mL). The organic layers were combined, dried (MgSO4), and reduced. 
The resulting oil was purified using preparative TLC (10% MeOH: 90% CHCl3) to 
yield the title compound as a purple solid (3.16 mg, 51%). 
 
1H NMR (CDCl3) δ 8.41 (1H, br s, O-H phenol), 8.20 (1H, d, J 1.0 Hz, Bodipy), 7.62- 
7.55 (2H, m), 7.48 (1H, dd, J 1.0 & 5.0 Hz, Bodipy), 7.37 (1H, d, J 2.0 Hz, 2-H), 7.33 
(1H, br s), 7.21-7.18 (1H, m), 7.16 (1H, dd, J 8.3 & 1.9 Hz 6-H), 7.04-6.79 (11H, m), 
6.47 (1H, br t, N-H amide), 6.26 (1H, br t, N-H amide), 4.55 (2H, s, benzylic), 4.00 
(4H, t, J 6.6 Hz, O-CH2 (o) & (p)), 3.60 (2H, q, J 6.2 Hz, CH2-amide), 3.40-3.26 (4H, 
m), 2.78 (4H, t, J 6.4 Hz, CH2-phenol), 2.11 (2H, t, J 7.3 Hz, Bodipy) 1.82-1.20 (20H, 
m) 0.93 (6H, m, CH3-pentyl). 
 
ES-MS MH+ calcd for C56H67BF2N5O7S 1002.5 found m/z 1002.9 (MH+), 1024.5 
(MNa+) 
 
HPLC – gradient 35% → 100% MeCN in water over 30 min. Rt 19.62 min (89% 
using peak area) 
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Labeling of N-(3-(2-aminoethyl)-4-
hydroxyphenethyl)-3,4-
bis(pentyloxy)benzamide hydrochloride with 
dansyl chloride (120) 
 
A solution of N-(3-(2-aminoethyl)-4-hydroxyphenethyl)-3,4-bis(pentyloxy)benzamide 
hydrochloride 119 (5.7 mg, 0.011 mmol) and dansyl chloride (3.0 mg, 0.011), was 
stirred at rt in the dark, in 2 mL of 70% MeCN: 30% pH 8.3 NaHCO3 (aq) buffer for 12 
h. The reaction was reduced in vacuo and the residue was partitioned between water 
and CHCl3. The aqueous phase was fur ther extracted with CHCl3 (3 x 20 mL). The 
organic layers were combined, dried (MgSO4), and reduced. The resulting oil was 
purified using preparative TLC (7% MeOH: 93% CHCl3) to yield the title compound 
as a green oil (2.8 mg, 37%). 
 
1H NMR (CDCl3) δ 8.50 (1H, d, J 8.6 Hz, Dansyl), 8.21-8.10 (2H, m, Dansyl), 7.47 
(2H, t, J 7.3 Hz), 7.35 (1H, d, J 1.9 Hz, 2-H), 7.16-7.07 (2H, m), 6.87-6.77 (3H, m), 
6.65 (1H, d, J 8.1 Hz, 6.12 (1H, br t, N-H amide), 5.87 (1H, br s, O-H), 5.14 (1H, br t, 
N-H amide), 4.00 (4H, t, J 6.6 Hz, O-CH2 (o) & (p)), 3.60 (2H, q, J 6.2 Hz, CH2-
amide), 3.40-3.26 (4H, m), 2.78 (4H, t, J 6.4 Hz, CH2-phenol), 2.11 (2H, t, J 7.3 Hz, 
Bodipy) 1.82-1.20 (20H, m) 0.93 (6H, m, CH3-pentyl). 
 
ES-MS MH+ calcd for C39H52N3O6S 690.3 found m/z 690.2 (MH+) 
 
HPLC – gradient 35% → 100% MeCN in water over 30 min. Rt 18.92 min (95% 
using peak area) 
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Synthesis of N-(4-hydroxyphenethyl)-3,4-
bis(pentyloxy)benzamide (JTE2-3 (62)) 
 
A solution of 3,4-bis(pentyloxy)benzoic acid 105 (300 mg, 1 mmol) and 1,1-
carbonyldiimidazole (174mg, 1 mmol) was prepared in MeCN (30 mL). Tyramine 
(147mg, 1 mmol) was added to the reaction and was stirred at rt for 48 h. The solvent 
was reduced and the reaction taken up into EtOAc (20 mL), the organic was washed 
with water (1 x 10 mL), 2M KHSO4 (aq) (2 x 20 mL), and sat. NaHCO3 (aq)  (2 x 20 
mL). The organics were dried (MgSO4), and evaporated to leave oil that was purified 
by crystallizing from MeCN: water to yield the title compound as white needles (320 
mg, 77%). 
 
m.p. 135-136 °C Lit126 134-136 °C 
 
1H NMR (CDCl3) δ 7.34 (1H, d, J 2.0 Hz, 2-H), 7.14(1H, dd, J 2.0 & 8.3 Hz, 5-H), 
7.04 (2H, d, J 8.5 Hz, phenol aromatic), 6.81 (2H, d, J 8.5 Hz, phenol aromatic), 6.80 
(1H, d, J 8.3 Hz, 4-H), 6.53 (1H, s, OH), 6.17 (1H, br t, N-H amide), 4.03-3.97 (4H, 
m, O-CH2), 3.63 (2H, q, J 6.2 Hz, CH2-amide), 2.82 (2H, t, J 6.4 Hz, CH2-phenol), 
1.82-1.74 (4H, m, CH2-pentyl), 1.50-1.33 (8H, m, CH2-pentyl) 0.93 (6H, m, CH3-
pentyl). 
 
Lit126  1H NMR (DMSO-d6) δ 9.14 (1H, s), 8.33 (1H, t, J 5.4 Hz), 7.42-7.40 (2H, m), 
7.04-6.97 (3H, m), 6.68 (2H, d, J 8.4 Hz), 4.01-3.96 (4H, m), 3.45-3.32 (2H, m), 2.70 
(2H, t, J 7.4 Hz), 1.78-1.64 (4H, m), 1.49-1.26 (8H, m) 0.94-0.83 (6H, m). 
 
13C NMR (CDCl3) δ 167.5 (4°, C=O amide) 156.9 (4°), 151.9 (4°), 148.9 (4°), 130.1 
(4°), 129.8 (C-H), 126.8 (4°), 119.3 (CH, benzamide), 116.1 (CH, benzamide), 112.6 
(CH, benzamide), 112.3 (CH, tyramine), 69.3 (CH2, C-O), 69.1 (CH2, C-O), 41.5 
O
O
N
H
O OH
 214
(CH2 α amide), 34.9 (CH2 β  amide), 28.9 (CH2), 28.8 (CH3, Boc), 28.2 (CH2), 22.4 
(CH2), 14.0 (CH3). 
 
ES-MS MH+ calcd for C25H35NO4 413.3 found m/z 414.2 (MH+) 
 
Synthesis of 3-nitro-1-naphthoic acid (127)  
 
A mixture of 3-nitro-1, 8-naphthalic anhydride (20 g, 0.082 
mol), NaOH (11.2 g, 0.281 mol) in water (400 mL) was added to a suspension of 
HgOred (19.5 g, 0.090mol) in water (50 mL) and acetic acid (40 mL). The mixture 
which frothed vigorously, was then stirred and heated under reflux for 3 days. The 
suspension was then hot- filtered and the solid residue was air dried. The solid was 
then heated under reflux in conc. HCl(aq) (100 mL) and water (200 mL) for 4 h. Hot 
filtration gave the crude product, which was re-crystallized from hot acetic acid to 
give 3.85 g (22%) of the title compound as a cream coloured solid. 
 
m.p. 250-252 °C Lit 261 255-257 °C 
 
1H NMR (DMSO-d6) δ 13.89 (1H, br s, COOH), 9.22 (1H, d, J 2.4 Hz, 4-H), 8.93 
(1H, d, J 8.6 Hz, 5-H), 8.75 (1H, d, J 2.4 Hz, 2-H), 8.43 (1H, d, J 8 Hz, 8-H), 7.97-
7.89 (2H, m, aromatic). 
 
13C NMR (DMSO-d6) δ 166.1 (4°, C=O acid), 144.0 (4°), 135.1 (4°), 133.6 (4°), 
132.8 (4°), 131.5 (CH), 130.6 (CH), 128.8 (CH), 128.3 (CH), 126.3 (CH), 123.2 
(CH). 
 
ES-MS M- calcd for C11H7NO4 217.04, found m/z 217 (M-). 
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FTIR: (KBr) 3500 (O-H), 3068, 2641, 1701 (C=O), 1597, 1529, 1453, 1412, 1336, 
1287, 1253, 1203, 1102, 915, 796, 760, 687, 500 cm-1. 
 
Synthesis of 2-methyl-1-n-propylindole (125) 
 
Solid 2-methylindole (1 g, 0.008 mol) was added portion wise to a 
stirring slurry of NaH (0.2 g, 0.008 mol) in DMF (30 mLs) at 0 °C. To this red 
solution was added 1-bromopropane  (0.8 mL, 0.008 mol) and the reaction was stirred 
at rt for 4 h. The solvent was removed in vacuo and the residue was partitioned 
between EtOAc (50 mL) and water (50 mL). The organic layer was further washed 
with water (2 x 50 mL), dried (MgSO4) and reduced to yield the title compound 
(1.27g, 97%) as a yellow oil. 
 
1H NMR (CDCl3) δ 7.51 (1H, dd J 7.3 & 0.9 Hz, aromatic), 7.23 (1H, dd, J 7.1 & 1.1 
Hz, aromatic), 7.13-7.00 (2H, m, aromatic), 6.21 (1H, s, 3-H), 3.97 (2H, t, J 7.2 Hz, 
N-CH2), 2.38 (3H, s, CH3-indole) 1.73 (2H, sextet, J 7.4, CH2-propyl) 0.91 (3H, t, J 
7.4 Hz, CH3-propyl). 
 
13C NMR (CDCl3) δ 136.6 (4°), 136.4 (4°), 128.0 (4°), 120.2 (CH), 119.6 (CH), 119.1 
(CH), 109.0 (CH), 99.7 (CH), 44.6 (CH2-N-indole), 23.4 (CH2-propyl), 12.8 (CH3-
indole), 11.5 (CH3-propyl). 
 
AP-MS MH+ calcd for C12H16N 174.1, found m/z 173.9 (MH+). 
 
FTIR: (thin film) 3053, 2964, 2932, 2874, 2641, 1550, 1462, 1399, 1383, 1222, 769, 
745cm-1. 
 
N
 216
Synthesis of 2-methyl-3-(3-nitronaphthoyl)-1-n-
propylindole (128) 
 
3-Nitronaphthoyl chloride 127 was prepared by refluxing 3-
nitro-1-naphthoic acid in thionyl chloride for 4 h. The excess 
thionyl chloride was reduced in vacuo. 2-Methyl-1-n-propylindole (0.61 g, 3.5 mmol) 
and the freshly prepared 3-nitro naphthoyl chloride (1.03 g, 4.4 mmol) were dissolved 
in DCM (10ml) to give a red solution. Aluminium chloride (0.931g, 7.0 mmol) was 
gradually added to the reaction at r.t, before the reaction was heated to reflux for 30 
minutes. Sodium hydroxide was then added dropwise, until the reaction reached pH 
11, and it was filtered free of solids. The organic layer was separated and was washed 
with 1M sodium hydroxide (2 x 20 mL), brine (1 x 20 mL) and dried (MgSO4). The 
crude product was purified using flash chromatography (30% EtOAc: 70% hexane) to 
yield the title compound (0.24 g, 19%) as a yellow foam. 
 
1H NMR (CDCl3) δ 8.92 (1H, d, J 2.1 Hz, 4’-H), 8.30 (1H, J 2.3 Hz, 2’-H), 8.18-810 
(2H, m, aromatic), 7.70-7.55 (2H, m, aromatic), 7.34 (1H, d, J 8.2 Hz, aromatic), 
7.21-7.10 (1H, m, aromatic), 6.98-6.96 (2H, m, aromatic), 4.13 (2H, t, J 8.6 Hz, N-
CH2), 2.57 (3H, s, CH3-indole) 1.87 (2H, sextet, J 7.5, CH2-propyl) 1.01 (3H, t, J 7.4 
Hz, CH3-propyl). 
 
13C NMR (CDCl3) δ 190.5 (4°, C=O), 146.5 (4°), 144.7 (4°), 142.6 (4°), 136.3 (4°), 
132.9 (4°), 132.7 (4°), 128.3 (CH), 126.7 (4°), 126.1 (CH), 125.7 (CH), 122.6 (CH), 
122.4 (CH), 120.6 (CH), 118.5 (CH), 114.0 (4°), 109.8 (CH), 45.0 (CH2-N-indole), 
22.9 (CH2-propyl), 12.8 (CH3-indole), 11.5 (CH3-propyl). 
 
AP-MS M- calcd for C23H20N2O3 372.4, found m/z 372.1 (M-). 
 
Anal calcd C23H20N2O3 C 74.18, H 5.41, N 7.52 % Found. C 75.75, H 6.10, N 7.78 % 
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FTIR: (thin film) 3075, 2965, 2932, 2875, 2641, 1652 (C=O), 1603, 1530 (NO2), 
1504, 1455, 1412, 1333 (NO2), 1220, 1093, 760 cm-1. 
 
Synthesis of 3-(3-aminonaphthoyl)-2-methyl-1-n-
propylindole (129) 
 
A solution of 2-methyl-3-(3-nitronaphthoyl)-1-n-propylindole 
128 (240 mg, 0.886 mmol) and Pd/C (32 mg) in 70% EtOH: 
30% EtOAc (20 mL) was stirred at rt under a H2 atmosphere (1 atm) for 1 h. The 
reaction was filtered through a celite pad, concentrated in vacuo, and purified using 
preparative TLC (50% EtOAc:50% hexane) to yield the title compound as a pale 
yellow oil (147 mg, 66%). A small portion was crystallized from MeOH/ HCl to give 
the HCl salt as an analytical sample. 
 
1H NMR (CDCl3) δ 7.84 (1H, d, J 8.3 Hz, aromatic), 7.58 (1H, J 8.2 Hz, aromatic), 
7.25-7.20 (3H, m, aromatic), 7.19-7.08 (2H, m, aromatic), 7.05-6.95 (3H, d, J 8.2 Hz, 
aromatic), 4.03 (2H, t, J 7.3 Hz, N-CH2), 3.91 (2H, br s, NH2) 2.40 (3H, s, CH3-
indole) 1.76 (2H, sextet, J 7.5, CH2-propyl) 0.94 (3H, t, J 7.4 Hz, CH3-propyl). 
 
13C NMR (CDCl3) δ 193.1 (4°, C=O), 145.7 (4°), 143.5 (4°), 142.0 (4°), 136.1 (4°), 
135.4 (4°), 127.0 (4°), 126.6 (CH), 126.1 (4°), 125.4 (CH), 124.9 (CH), 123.3 (CH), 
122.2 (CH), 122.1 (CH), 121.3 (CH) 117.5 (CH), 114.7 (4°), 110.3 (CH), 109.4 (CH) 
44.8 (CH2-N-indole), 22.9 (CH2-indole), 12.5 (CH3-indole), 11.4 (CH3-propyl). 
 
ES-MS MH+ calcd for C23H23N2O 343.2, found m/z 343.0 (MH+). 
 
Anal calcd C23H23N2OCl C 72.91, H 6.12, N 7.39 % Found. C 72.72, H 6.16, N 7.13 
% 
 
N
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FTIR: (thin film) 3458 (NH2), 3354 (NH2), 3223 (NH2), 3051, 3006, 2965, 2932, 
2875, 2641, 1616 (C=O), 1600, 1508, 1416, 1220, 1087, 747 cm-1. 
 
Synthesis of 3-(3-N-tert-
butyloxycarbonylglycylaminonaphthoyl)-2-
methyl-1-n-propylindole (130) 
 
3-(3-Aminonaphthoyl)-2-methyl-1-n-propylindole 129 (86mg, 0.205 mmol), Nα-Boc-
glycine (38mg, 2.15 mmol), DCC (44mg, 2.15 mmol) and catalytic DMAP were 
dissolved in anhydrous DCM (4 mL). The reaction was stirred at rt for 12 h and then 
cool filtered and diluted with DCM (30ml). The organic layer was washed with 
KHSO4 (2×20 mL), NaHCO3 (2×20 mL), and brine (1×20 mL). The reaction was 
dried (MgSO4) and reduced in-vacuo to give a yellow solid. This was purified using 
preparative TLC (45% ethyl acetate: 55% hexane) to give 67.8mg (67%) of the title 
compound as a yellow oil.  
 
1H NMR (CDCl3) δ 8.90 (1H, br s, N-H amide), 8.28 (1H, br s, aromatic) 7.89 (1H, d, 
J 8.2 Hz, aromatic), 7.76 (1H, d, J 8.1 Hz, aromatic), 7.44-7.25 (5H, m, aromatic), 
7.18 (1H, t, J 7 Hz, aromatic), 7.02 (1H, t, J 7.2 Hz, aromatic), 4.03 (2H, t, J 7.3 Hz, 
N-CH2), 3.88 (2H, d, J 6.9 Hz, CH2-carbamate), 2.33 (3H, s, CH3-indole) 1.79 (2H, 
sextet, J 7.5, CH2-propyl), 1.42 (9H, s, CH3-Boc), 0.96 (3H, t, J 7.4 Hz, CH3-propyl). 
 
13C NMR (CDCl3) δ 193.1 (4°, C=O), 168.1 (4°, C=O Boc), 156.3 (4°, C=O Boc), 
146.4 (4°), 141.2 (4°), 136.2 (4°), 134.5 (4°), 128.2 (4°), 127.3 (4°), 126.6 (CH), 
126.8 (4°), 125.9 (CH), 124.9 (CH), 122.5 (CH), 122.4 (CH), 121.3 (CH), 119.2 (CH) 
118.6 (CH), 114.6 (4°), 109.6 (CH), 80.2 (4°, Boc), 44.8 (CH2-N-indole), 33.8 (CH2-
gly), 28.3 (CH3, Boc), 22.8 (CH2-propyl), 12.6 (CH3- indole), 11.4 (CH3-propyl). 
 
AP-MS MH+ calcd for C30H34N3O4 500.3, found m/z 500.1 (MH+). 
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FTIR: (thin film) 3307 (br, NH), 3055, 3007, 2973, 2931, 1685 (C=O Boc),1653 
(C=O), 1603, 1505, 1418, 1366 1244, 1092, 751 cm-1 
 
Synthesis of 3-(3-glycylaminonaphthoyl)-2-
methyl-1-n-propylindole hydrochloride (131) 
 
3-(3-N-tert butyloxycarbonyl-glycylaminonaphthoyl)-
2-n-propylindole 130 (58mg, 0.116 mmol) was 
dissolved in methanol (3 mL) and conc. HCl(aq) (3 mL), and the reaction was stirred at 
rt for 12 h. The reaction was reduced in-vacuo and the product was recrystallised from 
MeOH: acetonitrile to give 25mg (50%) of the title compound as a pale pink solid. 
 
m.p. 283°C (dec) 
 
1H NMR (MeOD) δ 8.41 (1H, d, J 1.8 Hz, aromatic) 7.90 (1H, d, J 8.2 Hz, aromatic), 
7.83 (1H, d, J 8.4 Hz, aromatic), 7.66 (1H, d, J 2.1 Hz aromatic), 7.53-7.30 (3H, m, 
aromatic), 7.20-7.12 (1H, m, aromatic), 7.10-7.05 (1H, m, aromatic), 6.99-6.90 (1H, 
m, aromatic), 4.21 (2H, t, J 7.3 Hz, indole N-CH2), 3.89 (2H, s, 1°amine-CH2), 2.45 
(3H, s, CH3-indole) 1.81 (2H, sextet, J 7.5, CH2-propyl), 0.94 (3H, t, J 7.4 Hz, CH3 -
propyl). 
 
13C NMR (MeOD) δ 195.1 (4°, C=O), 166.3 (4°, C=O amide), 149.0 (4°), 143.4 (4°), 
138.4 (4°), 136.8 (4°), 136.2 (4°), 129.6 (CH), 129.1 (4°), 128.7 (CH), 128.6 (4°), 
127.6 (CH), 126.4 (CH), 124.1 (CH), 123.7 (CH), 122.2 (CH), 120.2 (CH), 119.6 
(CH), 115.8 (4°), 111.7 (CH), 46.1 (CH2-N-indole), 42.7 (CH2-N-amine), 24.8 (CH2-
propyl), 12.6 (CH3-indole), 11.4 (CH3-propyl). 
 
AP-MS MH+ calcd for C25H26N3O2 400.2, found m/z 400.0 (MH+). 
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Anal calcd C25H26N3O2Cl.0.25 H2O C 67.79, H 5.69, N 9.49 % Found. C 68.12, H 
5.99, N 9.45 % 
 
FTIR: (KBr) 3168 (br, NH HCl salt), 2961, 2585 (amine HCl salt), 1688 (C=O Boc), 
1592, 1567, 1499, 1421, 1359 1263, 1091, 750 cm-1 
 
Synthesis of 3-(3-[N-(7-nitrobenz-2,1,3-
oxadiazol-4-ylglycyl)amino] naphthoyl)-2-
methyl-1-n-propylindole (132) 
 
A slolution of 3-(3-glycylaminonaphthoyl)-2-methyl-1-
n-propylindole HCl 131 (8 mg, 0.023 mmol) and NBD-F (2.85 mg, 0.0156 mmol) in 
pH 8.3 NaHCO3 (aq) buffer (0.5 mL) and MeCN (0.5 mL) were stirred at room 
temperature for 45 min giving an orange precipitate. The solid was filtered and 
washed with water. The solid was dried (35°C) to yield 4.0mg (46%) of the title 
product as an orange solid. 
 
m.p. 178 °C (dec.) 
 
1H NMR (DMSO-d6) δ 10.54 (1H, br s, aromatic), 9.45 (1H, br s, aromatic), 8.55 (1H, 
d, J 8.9 Hz, aromatic) 8.41 (1H, d, J not detectable, aromatic) 7.95 (1H, d, J 8.2 Hz, 
aromatic), 7.79 (1H, d, J 8.3 Hz, aromatic), 7.66 (1H, d, J 2.0 Hz aromatic), 7.60-7.48 
(2H, m, aromatic), 7.41-7.32 (1H, m, aromatic), 7.20-7.10 (1H, m, aromatic), 7.01-
6.92 (2H, m, aromatic), 6.47 (1H, m, aromatic), 4.45 (2H, br s, amide-CH2), 4.21 (2H, 
t, J 7.3 Hz, indole N-CH2), 2.45 (3H, s, CH3- indole) 1.81 (2H, sextet, J 7.2 Hz, CH2-
propyl), 0.91 (3H, t, J 7.3 Hz, CH3-propyl). 
 
ES-MS -ve calcd for C31H26N6O5 562.2, found m/z 561.1 (M-H) 
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FAB-MS (-ve mode) M- calcd for C31H26N6O5 562.1965 found 562.1962 
 
HPLC – gradient 35% → 100% MeCN in water over 30 min. Rt 13.64 min (91% 
using peak area) 
 
Synthesis of 2-methyl-3-(1-naphthoyl)-indole (134) 
 
A solution of 2-methylindole (0.50 g, 3.8 mmol) in EtOEt (7 mL) 
was added dropwise to a stirring solution of 3M 
methylmagnesium bromide in EtOEt (1.2 mL) at 0 °C. The reaction was allowed to 
reach rt. 1-naphthoyl chloride was freshly prepared by refluxing 1-naphthoic acid in 
thionyl chloride for 5 h and removing the excess thionyl chloride in vacuo. A solution 
of 1-naphthoyl chloride (0.62 g, 3.26 mmol) in ether (10 mL) was added to the 
magnesium indole salt and the reaction was stirred for 45 min at rt and 1.5 h at reflux.  
The reaction was quenched with the addition of sat. NH4Cl(aq) and was allowed to stir 
overnight to afford a fine precipitate. The solids were filtered from the reaction and 
the solid was refluxed in a solution of MeOH (12 mL), water (3 mL) and NaOH (200 
mg) for 2 h. The title compound was filtered from the reaction and dried to yield 
287mg (31%) of an off white solid. 
 
m.p. 221 °C Lit270 229-230 °C 
 
1H NMR (CDCl3 & DMSO-d6) δ 11.20 (1H, br s, N-H), 8.10-7.85 (3H, m, 
naphthalene), 7.53-7.28 (6H, m), 7.18-6.97 (2H, m, indole), 2.19 (3H, s, CH3). 
 
13C NMR (CDCl3 & DMSO-d6) δ 193.8 (4°, C=O), 146.6 (4°), 141.1 (4°), 135.6 (4°), 
134.0 (4°), 130.5 (4°), 129.9 (CH), 128.6 (CH), 127.9 (4°), 127.1 (4°), 126.6 (CH), 
125.8 (CH), 125.5 (CH), 125.2 (CH), 122.6 (CH), 122.1 (CH), 121.3 (CH), 115.0 
(4°), 111.4 (CH), 14.9 (CH3) 
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AP-MS MH+ calcd for C20H16NO 286.1, found m/z 286.2  (MH+). 
 
Anal calcd C20H15NO C 84.19, H 5.30, N 4.91 % Found. C 83.77, H 5.17 , N 4.70 % 
 
FTIR: (KBr) 3170 (N-H), 3105, 3053, 1595 (C=O), 1571, 1436, 1232, 1186, 887, 617 
cm-1 
 
Synthesis of 2-methyl 3-(1-naphthoyl)-1-n-
propylindole (JWH-015 (53)) 
 
A suspension of 2-methyl-3-(1-naphthoyl) indole 134 (100 mg, 
0.351 mmol), 1-bromopropane (75 µL, 0.848 mmol)) and 
K2CO3 (117 mg, 0.846 mmol) was refluxed in methyl ethyl ketone for 12 h. The 
reaction was filtered and reduced in vacuo. The residue was dissolved in MeCN: 
water and the crystals that formed (38 mg of 2-methyl 3-(1-naphthoyl) indole) were 
filtered. The mother liquor was reduced to dryness and the residue purified using 
preparative TLC to yield the title compound (42mg, 36% (59% based on recovered 
starting material) green oil (Rf 0.2 EtOAc: Pet Ether (1:10)). Attempted crystallization 
of the oil failed from a number of common solvent systems (i.e. EtOH: water, MeOH: 
water, MeCN: water, DMF: water, EtOAc: hexane and Acetone: water). 
 
1H NMR (CDCl3) δ 8.10 (1H, d, J 8.2 Hz), 7.95 (1H, d, J 8 Hz), 7.90 (1H, d, J 8.1 
Hz), 7.59-7.39 (4H, m), 7.31-7.12 (3H, m), 6.98 (1H, t, J 7.2 Hz), 4.07 (2H, t, J 7.4 
Hz, CH2-indole), 2.46 (3H, s, CH3-indole), 1.80 (2H, sextet (6), J 7.4 Hz, CH2-
propyl), 0.97 (3H, t, J 7.4 Hz, CH3-propyl). 
13C NMR (CDCl3) δ 193.4 (4°, C=O), 145.6 (4°), 140.5 (4°), 136.2 (4°), 134.4 (4°), 
129.9 (CH), 128.2 (CH), 127.1 (4°), 126.8 (CH), 125.7 (CH), 125.6 (CH), 125.1 
(CH), 122.2 (CH), 121.8 (CH), 114.9 (4°), 109.5 (CH), 44.8 (CH2-N-indole), 22.9 
(CH2-propyl), 12.55 (CH3-indole) 11.43 (CH3-propyl). 
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ES-MS MH+ calcd for C23H22NO 328.2 , found m/z 327.9  (MH+). 
Anal calcd C23H21NO.0.5 H2O C 82.11, H 6.59, N 4.16 % Found. C 82.11, H 6.49, N 
4.19 % 
 
8.2 Pharmacology 
 
Rat splenocyte membrane preparation 
 
Adult male Hooded Lister rats were killed by decapitation and spleens were removed, 
chopped with scissors and rapidly forced through a 70 µM pore size steel mesh with 
the plunger of a 5 mL syringe into ice-cold phosphate buffered saline (PBS) to 
produce a single cell suspension. The cells were pelleted by centrifugation, and 
erythrocytes were lysed with lysis buffer (0.017 M Tris, 0.144 M ammonium chloride, 
pH 7.2) for 3 mins. The cells were washed twice in PBS and resuspended in Tris 
buffer (50mM Tris, 100mM NaCl, 10mM MgCl2, pH 7.4). The cell suspension was 
homogenised with a glass/Teflon homogeniser. The homogenate was centrifuged at 
20,000 x g at 4 °C for 10 min and the pellet resuspended in Tris buffer. 
Homogenisation and centrifugation were repeated twice and the final pellet was 
resuspended in storage buffer (50mM Tris, 1mM EDTA, pH 7.4) to a protein 
concentration of 5 mg mL-1 for radioligand binding. 
 
hCB2 CHO cell membrane preparation 
CHO K1 cells stably transfected with the hCB2 receptor were kindly obtained from Dr 
Darren Smart (GlaxoSmithkline) and were grown in our own laboratories in 
Dubelcco’s modified Eagle’s medium (DMEM) containing 5% foetal calf serum,  2 
mM L-glutamine, 600 µg/mL Geneticin®, and 300 µg/mL Hygromycin B, in a Sanyo 
CO2 incubator (95% O2: 5% CO2) at 37 °C. Cells were passaged every 3-4 days, using 
trypsin to lift the cells, and resuspended in fresh media. Flasks were grown as above 
to confluence (3 days) and cells were harvested, by removing excess media, and 
collecting in ice cold PBS using a plastic cell scraper. The cells were washed twice in 
ice cold PBS. Cell disruption was performed using a Polytron hand held electric 
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homogeniser in Tris buffer (50mM Tris, 100mM NaCl, 10mM MgCl2, pH 7.4). The 
homogenate was centrifuged at 20,000 x g at 4 °C for 10 min and the pellet 
resuspended in Tris buffer. Homogenisation and centrifugation were repeated twice 
and the final pellet was resuspended in storage buffer (50mM Tris, 1mM EDTA, pH 
7.4) to a protein concentration of 5 mg mL-1 for radioligand binding or 2 mg mL-1 for 
[35S] GTP-γ-S binding and stored at -70 °C. 
 
hCB2 cell preparation for confocal microscopy 
The CHO K1 cells were grown as above except that upon confluence in T175 flasks 
cells were resuspended in 10 mL of DMEM. 0.5 mL of cell suspension was diluted in 
a further 10 mL of DMEM and 0.4 mL of this cell suspension was pipetted into 8 well 
glass bottomed plates. Incubation for 24 h gave plates of approximately 60-70 % 
confluence which were used in confocal microscopy experiments. 
 
hCB2 transient transfection and membrane preparation 
HEK-293T cells were grown in DMEM with 10% foetal bovine serum and high 
glucose. Cells were transiently transfected with pcDNA3 encoding CB2 using 
calcium phosphate precipitation and used for membrane preparation as described 
previously 271 Briefly, at 24 h post-transfection, cells were harvested, washed twice in 
PBS and resuspended in PBS with 0.1% v/v protease inhibitor cocktail (Sigma 
Chemical Co., St Louis, MO, U.S.A.). Cell disruption was performed with nitrogen 
cavitation at 750 psi for 5 min. Following removal of cell debris and nuclei by 
differential centrifugation, membranes were resuspended in buffer (25 mM Tris-HCl, 
pH 7.4, 5 mM MgCl2, 1 mM EDTA) + 7% sucrose. The membrane preparation was 
diluted to 0.6 mg ml-1 total protein concentration and stored at -70 °C. 
 
Radioligand binding in rat splenocyte and hCB2 CHO membranes 
Assay tubes were prepared in triplicate to a final volume of 1ml containing 0.3 nM 
[3H] CP 55,940 (Perkin-Elmer Life Sciences Inc., U.S.A.) and 250 µg membrane 
protein  and  diluted in Tris buffer (50 mM Tris.HCl, 2 mM EDTA, 5 mM MgCl2 also 
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containing 0.2 mgml_1 bovine serum albumin (BSA), pH7.4). Stock drugs were 
diluted in the same buffer containing 5 mg ml-1 BSA. Tubes were incubated for 90 
min at 30 °C. Specific binding was calculated by subtracting nonspecific binding 
(NSB, determined in the presence of 1 µM HU210 14). A Brandel cell harvester 
(Brandel Inc., Gaitherburg, MD, U.S.A.) was used to separate bound from unbound 
ligand and the former quantified by liquid scintillation counting.   Nonlinear regression 
analysis was carried out using Graphpad Prism3 (GraphPAD Software, San Diego, 
CA, U.S.A.). Ki values for the test compounds were determined from IC50 values 
using a KD of 0.59 nM for [3H] CP 55,940, using the Cheng–Prusoff equation. Results 
are presented as mean values, with a standard error of the mean (SEM) and 95 % 
confidence intervals. 
Radioligand binding in HEK-293T membrane preparations 
containing hCB2 receptors 
Radioligand binding assays were performed as previously described 271. Membrane 
preparations were incubated with 4 nM [3H] CP, 55,940 with varying concentrations 
of test compounds. NSB was determined with 1 µM CP 55,940 2. All conditions were 
prepared in triplicate. A Brandel cell harvester (Brandel Inc., Gaitherburg, MD, 
U.S.A.) was used to separate bound from unbound ligand and the former quantified 
by liquid scintillation counting. Results were analysed with Prism GraphPAD 
Software (GraphPAD Software, San Diego, CA, U.S.A.) as previously described193 
using the Cheng–Prusoff equation to determine Ki values with the KD value of 5.1 nM 
for CP 55,940 binding to hCB2 HEK 293T membrane preparations. 
[
35
S]GTP-γ-S membrane binding 
 
1 mL of CHO membrane containg the hCB2 receptor (see membrane preraration 
above) was preincubated with 100 mM GDP (ICN Biomedicals Inc., U.K.) and 1mM 
theophylline (Sigma, U.K.) in 15 mL of assay buffer (50mM Tris-HCl, 100mM 
NaCl,10mM MgCl2 containing 5mg mL-1 BSA, pH 7.4) for 20 min at 30 °C. Assay 
tubes were prepared in triplicate to a final volume of 1 mL and contained 0.5 mL of 
the preincubated membrane solution, 0.4 nM [35S]GTP-γ-S (Amersham, U.K.) and the 
appropriate concentrations of drug. The NSB was determined using 100 µM 
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nonradiolabelled GTP-γ-S 11 and 1 µM HU210 14 was included as a positive control. 
Tubes were incubated for 45 min at 30 °C. Free and bound [35S]GTP-γ-S were 
separated by rapid filtration (using filter mats presoaked in Tris buffer (pH 7.4) 
containing 5% BSA) and washed with ice-cold Tris buffer (pH 7.4). Data are 
presented as mean values of % basal binding ± SEM (where basal binding = 100%) 
for experiments performed in triplicate. Statistical analysis was performed by analysis 
of variance using Bonferroni post hoc tests using GraphPad Prism3. 
8.3 Molecular Modeling 
 
All aspects of the molecular modeling methodology relating to the absolute 
parameters used are fully discussed in the relevant chapters. The software used for the 
analysis is listed below and operated on a Silicon Graphics interface. 
 
Clustal W – sequence alignment (Version 1.81) 
Sybyl – molecular modeling platform (Tripos, St Louis, MO63144) 
Spartan PCPro – quantum mechanics software (Wavefunction Inc.) 
CHARMM – energy minimization and molecular dynamics234 
PROCHECK – Protein structure analysis software243 
Ligplot – Ligand-receptor analysis software245 
LIGBUILDER – De novo drug design software254 
8.4 Fluorescence confocal microcopy 
 
Images were taken using a Zeiss axiovert 100 with LSM510 confocal.  Fluorescence 
was obtained by using an appropriate laser excitation wavelength through a Plan-
apochromat 63x/1.4NA oil immersion objective and collecting emitted light through 
an appropriate long pass (LP) emission filter. Pinhole diameter was standardized to 1 
area unit.  
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